

INDEX

Page references in **bold face** refer to a major discussion of the entry. Positional and configurational designations in chemical names (e.g., 3-, α -, *N*-, *p*-, *trans*, D-, *sn*-) are ignored in alphabetizing. Numbers and Greek letters are otherwise alphabetical as if they were spelled out.

Note: Chapters 33–35, which are only available on our book companion website, www.wiley.com/college/voet, are separately indexed at this website.

- A
A77, 1116
AAA⁺ domain, 1184–1185
AAA⁺ family of ATPases, 1197, 1206
AAA⁺ proteins, 1197–1198
AADP⁺ (3-aminopyridine adenine dinucleotide phosphate), 1125
A antigen, 415
aaRSs, *see* Aminoacyl-tRNA synthetase
Abasic sites, 1218
Abbé refractometer, 156
AB blood type, 22
ABCA1 (ATP-cassette binding protein A1), 458
ABC transporters, **766–768**, 767F
Abe (abequose), 379F
Abelson, J., 1312, 1351
Abequose (Abe), 379F
A β (amyloid- β protein), 311–312
A β precursor protein (β PP), 311–312
Ab initio methods, 305
Abl, 708
A blood type, 22
ABO blood group system, 22, **414–415**
Abortive initiation, 1267–1268
Abrin, 1395T
Absolute configuration, 74–75
Absolute rate theory, 484–487
Absorbance:
 in Beer–Lambert law, 90
 of DNA and nucleic acids, 90, 92, 92F
Absorbance spectrum, 92
AC, *see* Adenylate cyclase
ac⁴C (*N*⁴-acetylcytidine), 1347F
ACAT, *see* Acyl-CoA:cholesterol acyltransferase
ACC (acetyl-CoA carboxylase), **962–964**
Accepted names, enzymes, 479
Acceptor, tRNA, 1346
Acceptor control, 862
Accessory pigments, 908–909
Accessory proteins:
 G proteins, 692
 GroEL/ES system, **294–302**
 peptidyl prolyl cis-trans isomerases, **292**
 protein disulfide isomerases, **290–292**, 290F, 291F
Accommodation, 1388
ACE (angiotensin converting enzyme), 547F
ACE inhibitors, 547F
Acetal, 520F
Acetaldehyde, *re* and *si* faces, 77F
Acetaminophen, 544–545, 544F, 1000
Acetate, as cholesterol precursor, 975F, 976–977
Acetate ion, 45, 45T, 48F
Acetic acid:
 creation in Miller-Urey experiments, 32T
 distribution curve, 48, 48F
 titration curve, 47, 47F
Acetimidiquinine, 544–545, 544F
Acetoacetate, 959, 960F
 decarboxylation, 510–511
 and degradation of leucine/lysine, 1040–1041
 and degradation of
 phenylalanine/tyrosine, 1043–1047
 degradation of tryptophan, 1041–1042
Acetoacetyl-CoA, 960
 α -Aceto- α -hydroxybutyrate, 1075
Acetolactate, 1075
Acetone, 959
 and cell wall lysis, 130
 dielectric constant and dipole moment, 43T
 protein solubility in, 134
Acetone, 679F
Acetonyl-CoA, 806–807
Acetylcholine (ACh), 527, **778–780**
Acetylcholine receptor (AChR), **780–781**, 780F
Acetylcholinesterase, **781–782**, 782F
 diffusion-limited, 490, 491
 inactivation by DIPE, 527
 Michaelis–Menten kinetic constants, 489T
Acetyl-CoA, 561, 561F
 in citric acid cycle, 789, 792–796, 792F, 795F, 816–819
 and degradation of leucine/lysine, 1040–1041
 and integration of pathways, 1090
 in ketogenesis, 960–961, 960F
 pyruvate carboxylase regulation, 873–874
Acetyl-CoA acetyltransferase, 960–961
Acetyl-CoA carboxylase (ACC), **962–964**
Acetyl-coenzyme A, *see* Acetyl-CoA
*N*⁴-Acetylcytidine (ac⁴C), 1347F
N-Acetyl-D-galactosamine, 392F
Acetyl-dihydrolipamide-E2, 795
N-Acetylglucosamine, *see* NAG
N-Acetylglutamate, 1025, 1029, 1070F, 1071
N-Acetylglutamate-5-semialdehyde, 1070F, 1071
N-Acetylglutamate synthase, 1029, 1070F, 1071
N-Acetylimidazolium, 513
 ϵ -*N*-Acetyllysine, 79F
N-Acetylmuramic acid, *see* NAM
N-Acetylneuraminic acid, *see* NANA
N-Acetylneuraminidate, 392F
Acetyl phosphate, 580, 607
Acetylsalicylic acid, 998
N-Acetylserine, 79F
O-Acetylserine, 1071
Acetyl transferase (AT), 967, 968
N-Acetylxylosamine (XylNAc) residue, 523
ACh, *see* Acetylcholine
AChR, *see* Acetylcholine receptor
Acids, **45**
 dissociation constants, 45–47, 46T
 polyprotic, **48–50**, 49F
Acid-base buffers, 48
Acid-base catalysis, **506–510**
Acid-base indicators, 51
Acid-base reactions, **45–47**
 and amino acids, **72–73**
 for protein assays, 131
 and standard state conventions, 60
Acid chain hypothesis, 446
Acidic solutions, 47
Acidosis, 955
Ackee fruit, 948
Ackers, G., 353
Aconitase, 789, 790F, **808–809**, 808F
cis-Aconitate, 789
ACP (acyl-carrier protein), 961
ACP synthase, 961
Acquired immune deficiency syndrome, *see* AIDS
Acridine orange, 157
Acromegaly, 685
Acrosomal protease, 525T
Acrylamide, 147, 147F
ACTH, *see* Adrenocorticotrophic hormone
Actin, 10, 10F, 301, 857
 in erythrocyte membranes, 413F, 414
 helical symmetry, 269
Actinomycin D, 79, 1272, 1272F
Action potentials, **775–777**, 775F, 776F
Activated complex, 485
Activation barrier, 486
Activators, 96, 351
Active, rolling mechanism (DNA unwinding), 1185–1186, 1186F
Active transport, 420, **747**
 ATP-driven, **758–768**
 ion-driven, **768–771**
Activity, 59–61
Activity coefficient, 61
Acute intermittent porphyria, 1056
Acute lymphoblastic leukemia, 1034
Acute pancreatitis, 537
Acyl-carnitine, 946
Acyl-carrier protein (ACP), 961
Acyl-CoA:cholesterol acyltransferase (ACAT), 455, 984
Acyl-CoA dehydrogenase, 948F

- Acyl-CoA dehydrogenase (AD), 947, 948
 Acyl-CoA oxidase, 958
 Acyl-CoA synthases, 945–946
 Acyl-dihydroxyacetone phosphate, 971
 1-Acyldihydroxyacetone phosphate, 1007
 Acyl-enzyme intermediate, 533
 2-Acylglycerol, 941
 1-Acylglycerol-3-phosphate acyltransferase, 971
 Acyl group transfer, 565
 Acyl phosphates, 580
 N-Acylsphingosine phosphocholine, 1008
 Acyltransferase (AT), 968
 AD, *see* Acyl-CoA dehydrogenase;
 Alzheimer's disease
 ADA, *see* Adenosine deaminase
 ada gene, 1216
 Adair, G., 348
 Adair constants, 349
 Adair equation, **348–349**
 Ada protein, 1216
 Adapter proteins, *see* APs
 Adaptive enzymes, 1261
 Adaptor, **705–711**, 709
 Adaptor hypothesis, 1345
 ADAR1, 1150–1151, 1150F
 and RNA editing, 1322–1323, 1323F
 ADAR2:
 and RNA editing, 1322, 1323F
 Addison's disease, 681
 Adducin, 412F–413F
 Ade, *see* Adenine
 Adenine, 18, **83**, 83T. *See also* Watson-Crick
 base pairs
 and genetic code, 100T, 1343T
 IR spectra of derivatives, 1155F
 modified nucleosides of, 1347F
 and point mutations, 1339–1340
 Adenine phosphoribosyltransferase
 (APRT), 1114
 Adenohypophysis, 682
 Adenosine, 83T, 578, 1130F
 Adenosine-3',5'-cyclic monophosphate,
see cAMP
 Adenosine-5'-(β -amino) diphosphate
 (AMPPN), 763, 763F
 Adenosine-5'-(β , γ -imido) triphosphate,
see AMPPNP
 Adenosine-5'-(β , γ -methylene) triphosphate
 (AMPPCP), 763, 763F, 764
 Adenosine-5'-phosphosulfate, 183
 Adenosine-5'-phosphosulfate (APS)
 kinase, 1072
 Adenosine deaminase (ADA), 1130F, 1131
 Adenosine diphosphate, *see* ADP
 Adenosine monophosphate, *see* AMP
 Adenosine triphosphate, *see* ATP
 S-Adenosylhomocysteine, 1034
 S-Adenosylmethionine, *see* SAM
 Adenyl-3',5'-uridyl-3',5'-cytidyl-3',5'-
 guanylyl-3'-phosphate, 84F
 Adenylate cyclase (AC), 653, **697–698**, 1286
 Adenylate kinase (AK), 582
 and glycolysis control in muscle,
 627–628, 628F
 X-ray structure of porcine, 254, 255F
 Adenylic acid, *see* AMP
 Adenylosuccinate, 1112
 Adenylosuccinate lyase (PurB), 1109F,
 1111, 1112
 Adenylosuccinate synthetase, 1112F
 Adenyltransferase, 1069, 1071
 ADH, *see* Alcohol dehydrogenase;
 Antidiuretic hormone
 Adhesins, 382
 Adipocytes, 388–389, 388F, 1096, 1097F
 Adiponectin, 1096, 1097F
 Adiponectin receptors, 1096
 Adipose tissue, 389
 brown, 860
 glucose uptake regulation in, 751F
 and other organs, 1091F, 1093
 A-DNA, 1146F, 1147F, **1148–1149**, 1148T, 1151
 AdoCbl, *see* 5'-Deoxyadenosylcobalamin
 AdoMet, *see* SAM
 ADP (adenosine diphosphate), 17, 82
 in Calvin cycle, 931
 in catabolism, 561, 561F
 in citric acid cycle, 816–817
 in glycolysis, 594F, 595
 in GroEL/ES system, 295–302
 RuvB binding of, 1231
 and thermodynamics of life, 578–583
 ADP/ATP carrier, 771
 ADP-glucose, 645
 ADP-glucose pyrophosphorylase, 931
 ADPNP, *see* AMPPNP
 ADP-ribosylated diphthalamide residue,
 eEF2, 1398
 ADP-ribosylation, 1398
 ADP-ribosylation factor, *see* ARF1
 Adrenal glands, 672F
 Adrenaline, *see* Epinephrine
 β -Adrenergic receptors, 664, 680
 Adrenocortical steroids, 680
 Adrenocorticotrophic hormone (ACTH),
 673T, 682–683
 Adrenoleukodystrophy (ALD), 767, 958
 β -Adrenoreceptors, 660, 680
 Adriamycin, 1169
 Adsorption chromatography, 132T, 135,
 143–144
 Adult-onset diabetes, 1102–1103
Aequorea victoria, 120
 Aerobes, 6. *See also specific organisms*
 Aerobic fermentation, 594F
 Aerobic metabolism, 864–865
 Aerobic oxidation, 594F
 Affinity chromatography, 132T
 ion exchange, 136
 metal chelation, 145
 mRNA, 158
 for proteins, 118, 141–143, 141F
 Affinity labeling, 527
 Aflatoxin B₁, 1225
 AFM (atomic force microscopy), 376
 Africa, sickle-cell anemia in, 188, 343
 African clawed toad, 1202
 African sleeping sickness, 799
 Agard, D., 456
 Agarose gel electrophoretogram, 106F
 Agarose gels:
 in affinity chromatography, 142, 142F
 in gel electrophoresis, 147–149
 in gel filtration chromatography,
 139, 140T, 141
 in ion exchange chromatography, 137
 AGC family of protein kinases, 730
 A⁺ gene, 1261–1262, 1264
 a gene (fruit fly), 25F
 Agglutinin, 366
 Aggrecan, 373–375, 373T, 374F
 Aging, telomere length and, 1210–1211
 Aglycone, 366
 AGO, *see* Argonaute
 Agonist, 539, 680
 Agouti related peptide (AgRP), 1099
 Agrin, 373T
Agrobacterium radiobacter, 106F
 AgRP (agouti related peptide), 1099
 AICAR, *see* 5-Aminoimidazole-4-
 carboxamide ribotide
 AICAR transformylase (PurH), 1109F, 1111
 AIDS (acquired immune deficiency
 syndrome), 123, **545–546**. *See also* HIV
 AIR, *see* 5-Aminoimidazole ribotide
 AIR carboxylase, 1109F, 1111
 AIR synthetase (PurM), 1109F, 1110
 AK, *see* Adenylate kinase
 AKAPs (A-kinase anchoring proteins), 714
 Akey, C., 424
 A-kinase anchoring proteins (AKAPs), 714
 Akt, *see* Protein kinase B
 Akt1/PKB α , 734
 Akt2/PKB β , 734
 Akt3/PKB γ , 734
 Ala, *see* Alanine
 ALA (δ -aminolevulinic acid), 1048
 ALAD (δ -aminolevulinic acid
 dehydratase), 1048
 Alanine:
 biosynthesis, 1067–1073
 degradation of, 1030–1034
 and degradation of tryptophan,
 1041–1042
 genetic codes for, 100T, 1343T
 half-life, 1413T
 α helix/ β sheet propensity, 302T, 304
 hydropathy scale for, 264T
 in Miller-Urey experiments, 32T
 in native unfolded proteins, 283
 nonessential amino acid, 1065T
 nonpolar side chain, 70
 Ramachandran diagram, 224F, 225
 structure and general properties, 68T, 71F
 (S)-Alanine, 76, 77F
 β -Alanine:
 creation in Miller-Urey experiments, 32T
 in pyrimidine catabolism, 1136
 L-Alanine, 76, 77F
 Alanine tRNA, 176, 1345
 AlaRS, 1351
 ALAS-1, 1056
 ALAS-2, 1056
 ALA synthase, 1056
 Ala-tRNA^{Cys}, 1359
 Albumin, 154F, 542, 677. *See also*
 Serum albumin
 Alcaptonuria, 569
 Alcohols:
 effect on protein denaturation, 265
 reactions to form hemiacetals and
 hemiketals, 361F
 Alcohol dehydrogenase (ADH), 479
 in fermentation, 618–619
 and methanol oxidation, 505
 molecular mass of, 140F
 stereospecificity of, 470–473
 Alcoholic fermentation, 470, 593–594,
616–619, 616F
 Alcohol:NAD⁺ oxidoreductase, 479
 ALD, *see* Adrenoleukodystrophy
 Aldehydes, hemiacetal formation of, 361F
 Aldehyde dehydrogenase, 447F
 Alditols, 364
 Aldohexoses, 360F
 Aldolase, 568
 binding to erythrocyte membrane, 412
 in glycolysis, 596F, **600–603**, 600F, 602F
 half-life, 1408T
 molecular mass determination by gel
 filtration chromatography, 140F
 sedimentation coefficient, 154F
 Aldol condensation, 568
 Aldol histidine, 239F

- Aldonic acids, 364
 Aldopentoses, 360F
 Aldoses, 360F, 361
 Aldose-ketose interconversion, 567, 567F
 Aldosterone, 681
 Aldotetroses, 360F
 Aldotrioses, 360F
 ALD protein, 958
 Aledronate, 679F
al gene (fruit fly), 25F
 Alignment score (AS), 196
 Alkaptonuria, 25–26, **1045–1047**
 1-Alkyl-2-acyl-
 sn-glycerophosphoethanolamine,
 1007, 1007F
 Alkylacylglycerophospholipids, 574, 1005,
 1007–1008
*O*⁶-Alkylguanine-DNA alkyltransferase,
 1216
*O*⁶-Alkylguanine residues, 1215, 1216
 1-Alkyl-*sn*-glycerol-3-phosphate, 1007
 Allantoic acid, 1134
 Allantoin, 1134
 Allantoinase, 1135F
 Alleles, **21**
 Allison, A., 187
 Allo forms (enantiomers), 75–76
 Allolactose, 97, 117
 1,6-Allolactose, 1261
 Allopurinol, 1135
 D-Allose, 360F
 Allosteric control:
 ATCase activity, 476–479
 gluconeogenesis, 878–879, 879F, 879T
 glycogen phosphorylase and glycogen
 synthase, **647–650**
 hemoglobin, **347–354**
 and metabolic flux, 620, 624
 D-*allo*-Threonine, 76, 76F
 L-*allo*-Threonine, 76, 76F
 Allotransplantation, 121
 Alloxanthine, 1135
 Allysine, 238
 Allysine aldol, 239F
 α₁ Adrenergic receptors, 680
 α₂ Adrenergic receptors, 680
 α/α Barrels, 982
 αα Motifs, 249–250, 249F
 α/β Barrels, 250, 252, 254, 300
 α/β Domains, 250, 300
 α Configuration, of nucleotides, 83
 α Domains, 249F
 α Helix, 226, 226F, 227F
 globular proteins, 246
 helix forms vs., 228F
 physical basis of, 304
 Ramachandran diagram, 224F
 and space filling, 281
 α-Ketoglutarate:ferredoxin reductase, 815
 α-MSH (α-melanocyte stimulating
 hormone), 1099
 α Oxidation, of fatty acids, 958–959, 959F
 α Particles, 572
 α Solenoid, 433
 α-Synuclein, 720
 α-Tocopherol, 866
 Alternative splicing, 1317–1318
 Altman, S., 1330
 D-Altrose, 360F
 Altschul, S., 201
 AluI, 105T, 106, 109
 Alumina, 144
 Alzheimer's disease (AD), 309, **311–312**,
 458–459, 720
Amanita phalloides (death cap), 1280
 α-Amanitin, 1280
amber codon, 1343
amber mutants, half-lives of, 1408
amber suppressor, 1362
 Ambros, V., 1326
 Ames, B., 1224
 Ames test, 1224–1225, 1225F
 Amethopterin, 492, 1129
 Amido black, 149F
 Amidophosphoribosyl transferase, 1108,
 1109F, 1114
 Amines, biosynthesis of, **1058–1062**
 α-Amino acids, 67, 67F, 70F
 D-Amino acids, 73–75, 79
 L-α-Amino acids, 75, 75F, 226
 L-Amino acids, 73–75, 75F, 78
 Amino acids, 15, 67–80. *See also*
 Protein sequencing
 acid-base properties, **72**
 as biosynthetic precursors, 1047–1064
 chemical synthesis of polypeptides,
 206–209
 classification and characteristics, **70–71**
 conformation angle distribution, 224F
 creation in Miller-Urey experiments,
 32T, 33
 defined, 67
 energy recovery by citric acid cycle, 789
 essential and nonessential, 1019, 1065T
 genetic code, 99, 100T, 1338–1345, 1343T
 hydropathy scale for side chains, 264T
 as metabolic fuels, 1095–1095
 as neurotransmitters, 782–783, 783F
 nomenclature, **72–73**
 nonstandard, **78–80**, 79F, 80F
 optical activity, **73–78**
 peptide bonds, **70**
 and phylogenetic tree, 6
 of proteins, 67–73, 68T–69T
 in protein synthesis, 98–100
 racemization, 116
 side chains as covalent catalysts, 511
 transport in blood, 973
 Amino acid biosynthesis:
 alanine, 1067–1073
 arginine, 1071
 asparagine, 1067–1073
 aspartate, 1067–1073
 citric acid cycle intermediates, 818
 cysteine, 1071–1072
 essential amino acids, **1072–1078**
 GCN2 regulates, 1400–1401
 glutamate, 1065–1071
 glutamine, 1067–1073
 glycine, 1071–1072
 histidine, 1078
 integration and interrelationships of, 1090
 isoleucine, 1075
 leucine, 1075
 lysine, 1072–1073, 1075
 methionine, 1072–1073, 1075
 nonessential amino acids, **1064–1072**
 ornithine, 1071
 phenylalanine, 1075–1078
 proline, 1071
 serine, 1071–1072
 threonine, 1072–1073, 1075
 tryptophan, 1075–1078
 tyrosine, 1075–1078
 valine, 1075
 Amino acid deamination, **1019–1020**
 oxidative, **1023–1025**
 transamination, **1020–1023**
 Amino acid metabolism, 561F. *See also*
 Urea cycle
 alanine, cysteine, glycine, serine, and
 threonine degradation, 1030–1034
 amino acids as metabolic fuels, 1094–1095
 arginine, glutamate, glutamine, histidine,
 and proline degradation, 1034
 asparagine and aspartate degradation, 1034
 biosynthesis of psychologically active
 amines, **1058–1062**
 deamination of amino acids, 1019–1025
 glucogenic and ketogenic amino acids,
 1029–1030
 heme biosynthesis, **1047–1058**
 heme degradation, **1056**
 integration and interrelationships with
 other pathways, 1090
 isoleucine, methionine, and valine
 degradation, 1034–1039
 leucine and lysine degradation, 1040–1041
 overview of common metabolic
 intermediates, 1029F
 phenylalanine and tyrosine degradation,
 1043–1047
 tryptophan degradation, 1041–1042
 and urea cycle, 1025–1029
 D-Amino acid oxidase, 1025
 L-Amino acid oxidase, 1025
 Amino acid residues, 70, 188, 302T
 Amino acid sequencing, *see* Protein
 sequencing
 Amino acid stem, tRNA, 1346
 Aminoacrylate, 1031
 Aminoacrylate-PLP Schiff base, 1078
 Aminoacylation, tRNA, 1345–1362
 Aminoacyl peptide, 170
 Aminoacyl site, *see* A site
 Aminoacyl-tRNA, 98, 1349, 1349F
 Aminoacyl-tRNA synthetase (aaRS), 99,
 1349–1359
 characteristics of, 1350F
 classes of, 1350–1351
 Class I, 1350–1354, 1350T, 1355F,
 1358, 1358F
 Class II, 1350–1351, 1350T, 1354–1355,
 1355F, 1358, 1358F
 and CysRS in archaeobacteria, 1359
 and Gln-tRNA^{Gln} formation, 1358–1359
 proofreading by, 1355–1358
 recognition by, 1351–1352, 1351F, 1352F
 γ-Aminobutyric acid (GABA), 79–80, 80F,
 783, 1049
 biosynthesis, 1058–1060
 α-Amino-β-chlorobutyrate, 1408
 Aminoglycosides, 1395
 Amino groups, 43F
 5-Aminoimidazole-4-carboxamide ribotide
 (AICAR), 1078, 1104, 1109F, 1111
 5-Aminoimidazole-4-(*N*-
 succinylcarboxamide) ribotide
 (SAICAR), 1109F, 1111
 5-Aminoimidazole ribotide (AIR),
 1109F, 1110
 β-Aminoisobutyrate, 1136
 α-Aminoisobutyric acid, 32T
 δ-Aminoleuvulinate synthase, 1048, 1049
 δ-Aminoleuvulinic acid (ALA), 1048
 δ-Aminoleuvulinic acid dehydratase
 (ALAD), 1048
 Aminomethyltransferase (AMT), 1032
 α-Amino-*n*-butyric acid, 32T
 Aminopeptidases, 166, 168, 168T
 Aminopeptidase M, specificity of, 168T
 Aminoprocollagen peptidase, 1403–1404
 β-Aminopropionitrile, 239, 276
 Aminopterin, 1129
 2-Aminopurine, *see* 2AP

- 3-Aminopyridine adenine dinucleotide phosphate (AADP⁺), 1125
 Amino sugars, 365
 Amino terminus, *see* *N*-terminus
 Amino transferases, 1020, 1136F
 Ammonia, 32, 33, 43T, 1025
 Ammonification, 1083
 Ammonium ion (NH₄⁺), 45, 45T, 47, 47F
 Ammonium persulfate, 146F
 Ammonium sulfate, 133F, 134
 Ammonotelic organisms, 1025
 Amoeba, 13F, 398T
 AMP (adenosine monophosphate), 83T
 in animal catabolism, 1130F
 and DNA ligase, 1187
 in glycogen metabolism, 648–650
 from IMP, 1112F
 synthesis of, **1111–1113**
 and thermodynamics of life, 578
 AMP deaminase, 1131
 AMP-dependent protein kinase (AMPK), 963
 and cholesterol biosynthesis, 989
 in fatty acid metabolism, 973, 975
 and glycogen synthase cascade, 660
 and hypoxia, 864
 and metabolic homeostasis, 1095–1097, 1097F
 and noninsulin-dependent diabetes, 1103–1104
 Amphibolic pathways, 789
 Amphipathic materials, 44
 Amphiphilic materials, 43–44
 Ampholytes, 67, 151, 151F
 Amphoteric substances, 67
 Ampicillin, 26, 107F, 111, 377F, **378**, 621
 AMPK, *see* AMP-dependent protein kinase
 AMPPCP, *see* Adenosine-5'-(β, γ-methylene) triphosphate
 AMPPN, *see* Adenosine-5'-(β-amino) diphosphate
 AMPPNP (adenosine-5'-(β, γ-imido) triphosphate), 609, 633, 768, 1231
 Amprenavir, 550F
amp^R gene, 107F, 111, 621
 AMT (aminomethyltransferase), 1032
 α-Amylase, 370, 469
 Amylin, 310
 Amylo-(1,4 → 1,6)-transglycosylase, 646, 667
 Amylo-1,6-glucosidase, 667
 β-Amyloid, 312
 Amyloids, 309–310
 Amyloid diseases, 310–311
 Amyloid fibrils, 309, 309F
 Amyloidosis, 309–310
 Amyloid plaques, 311–312, 458–459
 Amyloid-β protein (Aβ), 311–312
 Amylopectin, 369–370, 370F
 Amyloplast, 11F
 α-Amylose, 369, 369F
 Amytal, 831
Anabaena, 4F
 Anabolism, 17, 561–562
 Anaerobes, 6. *See also specific organisms*
 Anaerobic autotrophs, 814
 Anaerobic fermentation, 594F, **614–619**
 Anaerobic metabolism, 864–865
 Analbuminemia, 944
 Analytical ultracentrifuge, 154
 Anaphase, 20F, 21F
 Anaphase-promoting complex (APC), 1414
 Anaphylaxis, 1000
 Anaplerotic reactions, 818–819
 Anchoring proteins, 714
 Andersen's disease, 667
 Anderson, W. F., 122
 Androgens, 673T, 680, 991
 Anencephaly, 1035
 Anesthetics, neuronal membranes and, 398–399
 Anfinsen, C., 278
 Anfinsen cage, 298, 300
 Angelman syndrome (AS), 1251
 Angina pectoris, 686
 Angiosperms, 13F
 Angiotensin converting enzyme (ACE), 547F
 Angiotensin I, 547F
 Angiotensin II, 547F
 Angiotensinogen, 547F
 Anhydrides, formation of, 515T
 8-Anilino-1-naphthalenesulfonate (ANS), 287
 Animals, 7F, 12, 13F. *See also specific organisms*
 in carcinogenesis tests, 1224
 divergence, 192
 DNA polymerases, 1202–1205, 1202T, 1203T
 FAS-I, 965–967, 966F
 metabolic homeostasis, 1096–1101
 organ specialization, 1090–1095
 Animal cells, 7F
 Animalia, 12
 Anion channel, 412, 413F
 Anion exchangers, 135, 989–990
 Ankyrin, 413F, 414
 Ankyrin repeats, 414, 414F
 Annealing conditions, 93
 Anomeric carbon, 361
 Anomeric forms, cyclic sugars, **361–363**
 ANS (8-anilino-1-naphthalenesulfonate), 287
 Antagonist, 539, 680
 Antenna chlorophylls, 905–906, 906F
 Anterograde transport, 428
 Anthrax, 714–715
 Anthrax toxin, 714–715
 Antibiotics, protein synthesis inhibition and, 1395–1398
 Antibiotic-resistant transposons, 1242
 Antibodies, 131, 150. *See also* Monoclonal antibodies
 Anticodons, 98, 1330, 1346, 1389F
 Anticodon arm, 1346
 Anticodon stem-loop (ASL), 1394, 1394F
 Anti conformation, 1152F
 Antidiuretic hormone (ADH), 683
 Antifolates, 1129–1130
 Antigens, 376
 Antigenic groups, in bacterial cell walls, 378–379
 Antimycin, 831, 849
 Antioxidants, 865–866
 Antipain, 1409
 Antiparallel β pleated sheets, 224F, 229–230, 232
 Antiport, 758F
Antirrhinum, 22
 Antisense oligodeoxynucleotide, 1402–1403
 Antisense oligonucleotides, 1402–1403
 Antisense RNA, 1323, 1402
 Antisense strand, **1266**
 Antisnorkeling, 406
 2AP (2-aminopurine), 1339, 1339F
 AP1, 435–436
 AP2, 435–436, 436F
 AP3, 436
 AP4, 436
 Ap₅A, 628
 ApA, melting curve of, 1157F
 APC (anaphase-promoting complex), 1414
 AP endonuclease, 1218
 Aphidicolin, 1203
 Apical domain, 410
 ApoA-I, *see* Apolipoprotein A-I
 ApoA-II, *see* Apolipoprotein A-II
 Apocytochrome c, 448
 ApoE, *see* Apolipoprotein E
apoE4 gene, 312
 Apoenzyme, 473–474, 1023
 Apoferritin, 140F
 Apolipoproteins, **449–451**, 986
 Apolipoprotein A-I (apoA-I), 450–451, 450F, 450T, 451F, 458
 Apolipoprotein A-II (apoA-II), 450T, 458
 Apolipoprotein B-48, 450T, 452, 1322
 Apolipoprotein B-100, 449F, 450T, 452, 455, 1322
 Apolipoprotein C-I, 450T
 Apolipoprotein C-II, 450T, 451
 Apolipoprotein C-III, 450T
 Apolipoprotein D, 450T
 Apolipoprotein E (apoE), 312, 450T, 453, 455–456, 456F
 Apolipoprotein E2, 458–459
 Apolipoprotein E3, 458, 459
 Apolipoprotein E4, 458, 459
 Apomyoglobin, 173F, 284, 289
 Apoproteins, **449–451**
 Apoptosis, 717
 Apparent dissociation constants, 348
 Appetite control, 1098, 1099, 1100F
 Applied Biosystems, 184
 Aβ precursor protein, 311–312
 APRT (adenine phosphoribosyltransferase), 1114
 AP (adapter protein), 435–436, 436F
 APS/Cbl complex, 738
 AP sites, 1218
 APS (adenosine-5'-phosphosulfate) reductase, 1072
 Aptamers, 214, 1300
 Apurinic sites, 1218
 Apyrase, 183
 Apyrimidinic sites, 1218
 AQP0, 756
 AQP1, 756–757, 757F, 787
 AQP12, 756
 Aquaglyceroporins, 756
 Aquaporins, 399F, **756–757**, 757F, 787
 Aqueous solutions, 40–50
 acids, bases, and buffers, 45–50
 hydrocarbon transfer in, 262–264, 263T
 nucleotide base stacking in, 1156–1157
 polyprotic acids, 48–50
 and properties of water, 40–45
araBAD operon, 1287, **1291–1294**, 1292F, 1293F
Arabidopsis thaliana, 177T, 182, 1410F
 Arabinose, glucose and, 1286
 D-Arabinose, 360F
 L-Arabinose, 1291–1294
 AraC, 1292–1294
 Arachidic acid, 387T
 Arachidonate, 994
 Arachidonic acid, 387T, 994–997, 995F
*araI*₁, 1292
*araO*₂, 1292
 Arber, W., 104
 Archaea, 6, 7F, 13F, 192
 Archaeal introns, 1307T
 Archaeobacteria, 6, 1359
Archaeoglobus fulgidus, 177T
 Arcuate nucleus, 1099
 AREs (AU-rich elements), 1327
 ARF1 (ADP-ribosylation factor), 434–435, 435F, 695–696

- ARF GAP, 437
 ARF nucleotide-binding site opener (ARNO), 434
 Arg, *see* Arginine
 Arginine:
 biosynthesis, 571F, 1071
 degradation, 1034
 as essential amino acid, 1065T
 genetic codes for, 100T, 1343T
 α helix/ β sheet propensity, 302T
 isoelectric point, 72
 location in globular proteins, 246
 side chains, 71, 264T
 specific rotation, 74
 structure and general properties, 69T
 trypsin-catalyzed cleavage, 170
 Argininosuccinase, **1028**
 Argininosuccinate synthetase, **1028**
 Argonaute (AGO), 1324, 1325, 1325F
 ArgRS, 1352
 A-RNA, 1151
 ARNO (ARF nucleotide-binding site opener), 434
 Arnold, E., 1208
 Arnold, W., 906
aroH operon, 1297
 Aromatic amino acid decarboxylase, 1060
 ar/R constriction, 756
 Arrhenius, A., 45
 Arsenate, 636
 Arsenic, 799, 822
 Arsenicals, 799
 Arsenite, 799
 ARSs, *see* Autonomously replicating sequences
 Arteriosclerosis, 456–458
 Arthropods, 13F
 AS, *see* Alignment score; Angelman syndrome
 Ascobolus, 13F
 Ascorbic acid (vitamin C), 236, **364–365**, 364F
 A-side transfer, 472
 A (aminoacyl) site, 98F, 1373, 1385, 1387
 ASL, *see* Anticodon stem-loop
 Asn, *see* Asparagine
 Asp, *see* Aspartic acid
 L-Asparaginase, 1034
 Asparagine:
 biosynthesis, 1067–1073
 degradation, 1034
 genetic codes for, 100T, 1343T
 in globular proteins, 246–247
 half-life, 1413T
 α helix/ β sheet propensity, 302T
 as nonessential amino acid, 1065T
 side chains, 71, 264T
 structure and general properties, 69T
 Asparagine synthetase, 1068
 Aspartame, 1087
 Aspartate, 71. *See also* Aspartic acid
 biosynthesis, 1067–1073
 degradation, 1034
 half-life, 1413T
 as nonessential amino acid, 1065T
 Aspartate aminotransferase, 876, 877F
 Aspartate transcarbamoylase, *see* ATCase
 Aspartic acid:
 degradation, 1034
 genetic codes for, 100T, 1343T
 in globular proteins, 246
 α helix/ β sheet propensity, 302T
 isoelectric point, 72
 in Miller-Urey experiments, 32T
 side chains, 71, 264T
 structure and general properties, 69T
 Aspartic proteases, 546–549, 548F
 Aspartokinase, 1072, 1075T
 β -Aspartyl-AMP, 1068
 Aspartyl phosphate, 759
 Aspartyl- β -phosphate, 1075
 Aspirin, 994, 998, 999F
 Aspirin-triggered *epi*-lipoxins (ATLs), 1004
 AspRS, tRNA^{Asp} and, 1354–1355, 1354F, 1355F
 Asp-tRNA^{Asn}, 1358
 Assembly factors, 1365
 Astbury, W., 233
 Asthma, 680
 Asx, 68T, 73. *See also* Asparagine; Aspartic acid
 Asymmetric centers, 74–76
 Asymmetric PCR, 116
 AT, *see* Acetyl transferase
 AT-AC introns, 1319
 AT-AC spliceosome, 1319
 Ataxin-1, 1252
 ATCase (aspartate transcarbamoylase), 475F, 478F
 allosteric control, 476–479
 feedback inhibition, 474–479
 in UMP synthesis, 1115F, 1116
 X-ray structure, 476F
 Atheromas, 456
 Atherosclerosis, 456–458
 Atherosclerotic plaques, 240, 457F
 ATLs (aspirin-triggered *epi*-lipoxins), 1004
 Atomic fluctuations, 307, 308
 Atomic force microscopy (AFM), 376
 Atorvastatin, 990, 991F
 ATP (adenosine triphosphate), 82, 559, 586.
 See also Electron transport; Oxidative phosphorylation; Photosynthesis
 and aerobic vs. anaerobic metabolism, 864–866
 in ATCase feedback inhibition, 475
 in Calvin cycle, 931
 in catabolism, 561, 561F
 in citric acid cycle, 789, 816–817, 819
 consumption of, 582–583
 coupled reactions with, 579F
 and DNA ligase, 1188
 effect on hemoglobin oxygen binding, 330
 in electron transport chain, 823–824, 824F, 828, 829
 formation, 582–583
 in gluconeogenesis, 877–878
 in glycogen metabolism, 648–649
 in glycolysis, 593, 594F, 595, 600, 608–610, 613
 in GroEL/ES system, 294, 298–300
 in mitochondria, 9
 in nitrogen fixation, 1082
 overview of roles, 17
 in oxidative phosphorylation, 845–863, 846F
 photorespiration dissipates, 935
 in photosynthesis, 902, 926
 production control for, 863–864, 863F
 in protein folding, 300
 source of free energy for metabolic pathways, 561F
 sources of, during exercise, 1092F
 structure, 578F
 and thermodynamics of life, 578–583
 in transcription, 95–96, 1265
 turnover rate, 583
 and vesicle fusion, 444–445
 ATP/ADP carrier, 448
 ATP-ADP translocator, 448, 768, **771**
 ATPases:
 A-, F-, P-, and V-types, 758
 (Ca²⁺)-ATPase, **762–764**
 (H⁺-K⁺)-ATPase, **764–765**
 (Na⁺-K⁺)-ATPase, **758–762**
 and molecular chaperones, 293
 ATP-cassette binding protein A1 (ABCA1), 458
 ATP-citrate lyase, 818, 968
 ATP-driven active transport, **758–768**
 ATP mass action ratio, 862
 ATP α S, 698
 ATP γ S, 294, 444–445, 1204F
 ATP sulfurylase, 183, 1072
 Atractyloside, 771
 Attenuation, 1296–1299
 Attenuator, 1297–1299
 A-type ATPases, 758
 AU-AC introns, 1307T, 1319
 AU-AC spliceosome, 1319
 AUG (codon), 1343
 AU-rich elements (AREs), 1327
 Aurora, 1402
 Autocrine hormones, 671
 Autoimmune disorders, 688
 cyclosporin A for, 292
 multiple sclerosis, 777
 and type 1 diabetes, 1102
 Autolysis, 131
 Autonomously replicating sequences (ARSs), 109, 1205
 Autophagic vacuoles, 1409
 Autophosphorylation, 670, 700
 Autoradiography, **94–95**, 95F, 148, 572
 of sequencing gels, 177–178, 178F
 Autosomes, 23
 Autotrophs, 5
 Auxilin, 436
 Auxotrophic mutants, 570
 Avery, O., 86
 Avidin, 577, 873
 Avogadro's number, 53T
 Axial groups, in sugars, 363
 Axon, 771
 5-Azacytosine (5-AzaC) residue, 1249
 Azaserine, 80, 80F, 1142
 3'-Azido-3'-deoxythymidine (AZT; zidovudine), 546, 1207
 Azidomet, 135F
Azotobacter vinelandii, 1080F–1081, 1341
 AZT, *see* 3'-Azido-3'-deoxythymidine
 Azurin, 135F
 B
 Babcock, G., 844
 Baboons, xenotransplantation with, 121
 BAC-ends (sequence-tagged connectors), 181
 Bacilli, 4
Bacillus, 4F
Bacillus subtilis, 376, 377F, 1284
Bacillus thuringiensis (Bt), 122
 Bacitracin, 888–889, 889F
 Backside attack, 514F
 BACs (bacterial artificial chromosomes), 108–109, 113, 114, 181
 Bacteria. *See also* specific organisms
 conjugation of, 1262–1264, 1262F
 divergence of, 192
 DNA base composition, 84
 DNA size, 94T
 and eukaryotic protein production, 118
 fatty acids of, 387
 genetic regulation of sugar transport, 765T, 766, 767F

- Bacteria (*Contd.*)
 genetics of, 26
 glutamine synthetase regulation, 1069F
 glycogen synthase, 645
 glycoproteins of, 375–379
 homologous recombination in, 1225
 microfossil, 29F
 phylogenetic tree for, 7F
 in prokaryotic classification, 6
 RNAP, 96, 1265–1266
 self-compartmentalized proteases of, 1419–1420
 spores of, *see* Spores
 virulence of, 375
- Bacterial artificial chromosomes, *see* BACs
- Bacteriochlorophyll *a* (BChl *a*), 135F, 903, 904F
- Bacteriochlorophyll *b* (BChl *b*), 903, 904F, 916
- Bacteriophages, **27**, 1190
 DNA, 86–88
 RNAP, 1265
- Bacteriophage λ :
 cloning vector, 108, 108F, 111F
 DNA size, 94T
 electron micrograph, 108F
 helix–turn–helix motif, 1288
 template binding, 1264
- Bacteriophage 434, helix–turn–helix motif, 1288, 1289F
- Bacteriophage M13:
 cloning vector, 108, 108F
 replication, **1190**, 1190F
- Bacteriophage MS2, sequencing, 176
- Bacteriophage P1, Cre recombinase, 1243–1244
- Bacteriophage P22, 1288
- Bacteriophage Φ X174:
 genetic map, 1344, 1344F
 Pol I, 1177
 replication, **1190–1193**, 1192F
 template binding, 1266
- Bacteriophage SP01, 1284
- Bacteriophage T2, 1264, 1265F
 attachment to *E. coli*, 87F
 DNA, 94F, 94T
 in Hershey–Chase experiment, 87, 87F
- Bacteriophage T4, 27F, 28, 1264, 1265F
 cloning vector, 109
 DNA size, 94T
 FC0 mutation, 1340
 template binding, 1266
- Bacteriophage T5, attachment of, 86F
- Bacteriophage T6, 94T, 1263F
- Bacteriophage T7, in chain-terminator method, 179
- Bacteriopheophytin *b* (BPheo *b*), 910–911
- Bacteriorhodopsin (BR), **850–851**, 851F
 membrane structure, 402–403, 403F
- Baculovirus vectors, 108
- Baker, D., 305, 306, 310
- Baker's yeast, *see* *Saccharomyces cerevisiae*
- Balch, W., 437
- Baldwin, R., 285, 287
- Baltimore, D., 545, 1207
- Bamacan, 373T
- BamHI, 105T
- Ban, N., 966–968
- B antigen, 415
- Banting, F., 575, 1102
- Barber, J., 916
- Barford, D., 722, 723
- Barnett, J., 750
- Barrels:
 α/α , 982
 α/β , 250, 252, 254, 300
 β , 231F, 448–449
 Swiss roll, 252, 253F
 TIM, 252, 254F, 300
 up-and-down β , 251–252
- Barré-Sinoussi, F., 545
- Basal cells, 16F
- Basal laminae, 373
- Basal level, 1261
- Bases, **45–47**. *See also* Nucleotide bases
 and buffers, 48
 nucleic acid, *see* Nucleic acid bases
 Base-catalyzed hydrolysis, RNA, 85, 85F
- Base excision repair (BER), 1216, 1218
- Base flipping, 1215
- Basement membranes, 373
- Base pairs, 18, **84**, 1154–1156. *See also* Watson–Crick base pairs
 association constants for formation, 1155T
 complementary, 89
 non-Watson–Crick, 1154–1156, 1154F
 and recombination, 28
- Base stacking, in B-DNA, 89
- Basic helix–loop–helix/leucine zipper (bHLH/Zip), 987
- Basic Local Alignment Search Tool, *see* BLAST
- Basic solutions, 47
- Basolateral domain, 410
- Bassham, J., 927
- Batrachotoxin, 777
- Battersby, A., 1053
- Baumeister, W., 1414
- Bax, A., 656
- B blood type, 22
- BBP (branch point-binding protein), 1312, 1314
- BChl *a*, *see* Bacteriochlorophyll *a*
- BChl *b*, *see* Bacteriochlorophyll *b*
- BCKDH kinase, 1039
- BCKDH phosphatase, 1039
- BCM7, 534–535
- Bcr, 718
- B-DNA, 88F, **1145–1148**, 1146F, 1147F
 conversion to Z-DNA, 1149F
 structure of ideal, 1148T
 three-dimensional structure, 89F
 Watson–Crick structure, **88–90**
- Beadle, G., 26, 570
- Becker, J., 1002
- Beckmann, R., 422, 424
- Bed volume, in gel filtration chromatography, 138
- Beer–Lambert law, 90
- Begg, G., 171
- Behenic acid, 387T
- Beinert, H., 834
- Benign tumors, 703
- Benner, S., 472
- Benson, A., 927
- Benzamidine, 556
- Benzene, 43, 43T
- Benzer, S., 28
- Benzoic acid, 945
- BER, *see* Base excision repair
- Berg, P., 109, 1350
- Berger, J., 1167–1168, 1188, 1195, 1275
- Bergström, S., 994
- Beriberi, 474T, **617–618**
- Berman, H., 236, 1287
- Bernal, J. D., 241, 331
- Berry, E., 838, 840
- Berzelius, J., 469
- Best, C., 575
- Best, G., 1102
- β_1 -Adrenergic receptors, 690
- β_2 -Adrenergic receptors, 690
- β -Adrenergic receptor kinase (β ARK), 697
- $\beta\alpha\beta$ Motif, 249, 249F
- β ARK (β -Adrenergic receptor kinase), 697
- β -Arrestins, 697
- β Barrel, 231F, 448–449
- β Bends, 232, 233F
- β_c , 717–718
- β Cells, pancreatic, *see* Pancreatic β cells
- β Clamp, Pol III, 1182–1183, 1183F
- β Configuration, nucleotides, 83
- β Domains, 249–254, 249F
- β Hairpin motif, 249, 249F
- β Helix, 314
- β -Horseshoe, GyrA intein, 1407
- β -Lactamase, 378
- β Oxidation, fatty acids, 945, **947–950**, 958
- β Particles, 572
- β Pleated sheets, **229–232**, 229F–232F
 globular proteins, 246
 propensities and classifications of amino acid residues for, 302T
 Ramachandran diagram, 224F
 and space filling, 281
- β PP (A β precursor protein), 311–312
- β -Propeller, 692
- β Ribbons, 1290–1291
- β Sandwich, 251
- Beta structures, proteins, **229–232**, 229F–232F
- β Subunit, Pol III, 1182–1183
- b* gene (fruit fly), 25F
- BglI, 105T
- BglIII, 105T
- BH₄ (5,6,7,8-tetrahydrobiopterin), 686, 1043–1044
- bHLH/Zip (basic helix–loop–helix/leucine zipper), 987
- Bi Bi reactions, 498–499
- Bibliome, 576
- Bicyclic cascade, 650, 651F
- Bidirectional replication, 1174, 1176
- Bienert, H., 808
- Bifurcated hydrogen bond, 261
- Bilayers, *see* Lipid bilayers
- Bile acids, 941, 992, 993F
- Bile pigments, 1056
- Bile salts, 941, 943–944, 989–990, 992–993
- Bilins, 909
- Bilirubin, 1056
- Bilirubin diglucuronide, 1056, 1057
- Bilirubin UDP-glucuronosyltransferase, 1056
- Biliverdin, 1056
- Bimolecular reactions, 483
- Binding modules, **705–711**
- Binding specificity, protein purification and, 132
- Bioavailability, 542
- Biochemical literature, **34–36**
- Biochemical review publications, 35T
- Biochemistry, **14–19**
 biological structures, 14–17, 16F
 defined, 3
 expression and transmission of genetic information, 18–19
 genetics review, 19–28
 metabolic processes, 17
- Bioethics, 123
- Bio-Gel A, 139
- Bio-Gel P, 139
- Biogenic amines, 782
- Bioinformatics, **194**
 globular proteins, 256–259
 phylogenetic tree construction, 203–205, 203F

- sequence alignment, 195–203
sequence databases, 194–195
Biological evolution, 29, 30F
Biological membranes, *see* Membranes
Biological structures, 14–17, 16F
Biopterin, 1043
BIOSIS Previews, 35
Biosynthesis, 561
Biotin, 473T, 577, 857, 873
Biotin carboxylase, 963
Biotin carboxyl-carrier protein, 963
Biotinyllysine, 873
Bipolar disorder, 736
Bishop, M., 705
1,3-Bisphosphoglycerate, *see* 1,3-BPG
2,3-Bisphosphoglycerate, *see* 2,3-BPG
Bisphosphoglycerate mutase, 596F, 611, 611F
2,3-Bisphosphoglycerate phosphatase, 596F, 611
Bisphosphonates, 679, 679F
Bisubstrate enzyme reactions, **497–501**, 498F
Bisulfite ion, 1249
Bisulfite sequencing, 1249
Black, J., 764
Blackburn, E. H., 1210
Black mouth, 342
Blaese, M., 122
BLAST (Basic Local Alignment Search Tool), 201, 202F
Blastocyst, 1250
Blobel, G., 420, 424, 1371
Bloch, K., 961, 975, 976
Block, S., 1273
Blood, 973
ABO blood groups system, 22, **414–415**
buffering, 48
universal donors/recipients, 466
Blood–brain barrier, 542, 783
Blood clotting factors, recombinant, 119
Blood glucose, 638, **661–664**, 1094
Blood groups, 22, **414–415**
Blood group determinants, 414–415
Blood plasma, 323–324
Blood vessels, 235
BLOSUM45 substitution matrix, 201
BLOSUM62 substitution matrix, 201, 203
Blow, D., 527
Blue-green algae, *see* Cyanobacteria
Blundell, T., 549
Blunt ends, 106
Blunt end ligation, 1188
Boat conformation, 363, 363F
BOC-amino acid, 206
BOC (*tert*-Butyloxycarbonyl) group, 206–208
Bohm, A., 1303
Bohr, C., 328
Bohr, N., 329
Bohr effect, hemoglobin, 328–329, 328F, **329**, 340
Boltzmann, Ludwig, 55
Boltzmann constant (k_B), 53T, 55, 486
Bonaparte, N., 799
Bone, 235, 540
Bongrekic acid, 771
Boniva, 679F
BoNT/A, 442
BoNT/G, 442
Borhani, D., 451
Boron, 31
Borsook, H., 1408
Botulinus toxin, 780
Botulism, 442, 1340
Bovine 20S proteasome, 1417
Bovine pancreatic ribonuclease A, 470.
See also RNAse A
acid-base catalytic mechanism, 508–510, 509F
physical constants, 153T
Bovine pancreatic trypsin inhibitor, *see* BPTI
Bovine papillomavirus, E1 protein, 1184–1185, 1185F
Bovine somatotropin (bST), 119
Bovine spongiform encephalopathy (BSE), 312, 315
Box C/D snoRNAs, 1329
Box H/ACA snoRNAs, 1329
Boyer, H., 107
Boyer, P., 612, 845, 856, 857
1,3-BPG (1,3-bisphosphoglycerate), 580, 596F, 607, 609
2,3-BPG (2,3-bisphosphoglycerate):
in glycolysis, 610
and hemoglobin oxygen binding, **329–331**, 329F–331F, 340–341
BPheo *b* (bacteriopheophytin *b*), 910–911
B protein, 1314
BPTI (Bovine pancreatic trypsin inhibitor), 308–309, **533**, 533F
BR, *see* Bacteriorhodopsin
Brachet, J., 1260
Bradykinin, 208
Bragg, L., 331
Bragg, W., 331
Brain, metabolic relationships, 1090–1091, 1091F
Branch, phylogenetic trees, 203–204, 203F
Branched-chain α -keto acid dehydrogenase, 1039
Branching enzyme, 646, 667
Branch migration, 1226, 1230–1234
Branch points, phylogenetic trees, 203–204, 203F
Branch point-binding protein, *see* BBP
Brändén, C.-I., 256, 929
Branton, D., 408
Braunstein, A., 1021
BRCA1, 1236
BRCA2, 1236
Breaker, R. R., 1300, 1318
Breast cancer, 119–120, 1236
Breathing motions, 306
Breathnach, R., 1305
Brenner, S., 1264, 1340, 1341
Brewer's yeast, 617F
Briggs, G. E., 488
Brij 30, 399F
Brij 35, 399F
Brinster, R., 86
British anti-lewisite, 822
Brittle bone disease, 240
Brodsky, B., 236
Bromide ion, 45T
5-Bromo-4-chloro-3-hydroxyindole, 110
5-Bromo-4-chloro-3-indolyl- β -D-galactoside (X-gal), 110
Bromohydroxyacetone phosphate, 604
5-Bromouracil, 1339, 1339F
Bronsted, J., 45
Bronsted acid, 45
Bronsted base, 45
Brouillette, C., 451
Brown, A., 323, 488
Brown, D., 1283
Brown, M., 452, 453, 987
Brown adipose tissue, 860
Brown algae, 13F
Browner, M., 1001
Brown fat, 860
Brownian ratchet, 428, 1280
Bruice, T., 514, 515
Brünger, A., 441, 444
Brush border cells, 38, 768
BSE, *see* Bovine spongiform encephalopathy
B-side transfer, 472
bST (bovine somatotropin), 119
Bt (*Bacillus thuringiensis*), 122
Bt corn, 122
5-BU, *see* 5-Bromouracil
Bubonic plague, 722
Buchanan, J., 1107
Buchner, E., 470, 593
Budding yeast, *see* *Saccharomyces cerevisiae*
Buffers, **47–48**
Buffer capacity, 51
Bugg, C., 656
Bundle-sheath cells, 936
 α -Bungarotoxin, 781
Burley, S., 1303, 1378
Burns, J., 620
Burst phase, in protein folding, 286
Butryl-ACP, 965
tert-Butyloxycarbonyl (BOC) group, 206–208
Butyrylcholinesterase, 782
bw gene (fruit fly), 25, 25F
Bypass DNA polymerases, 1222
C
C1 domain, 730–731
C2 domain, 727, 730–731
C3G, 737F
C₄ cycle, 934–937, 936F
CA1P (2-carboxyarabinitol-1-phosphate), 930
Ca²⁺, *see* Calcium ion
Ca²⁺-binding protein, 678
(Ca²⁺)-ATPase, **762–764**
CABP (2-carboxyarabinitol-1,5-bisphosphate), 930, 930F
CACCC box, 1282
cacophony pre-mRNA (*Drosophila melanogaster*), 1322
Caenorhabditis elegans:
genome sequencing, 177T, 182
miRNA, 1326
sense RNA injection for, 1323
trans-splicing in, 1320
Cahn, R., 76
Cahn-Ingold-Prelog system, **76–77**
N⁵-CAIR, 1111
CAIR (carboxyaminoimidazole ribotide), 1109F, 1111
Cairns, J., 1173, 1181
Calcineurin (CaN), 724–725
Calcitonin, 673T, 677, 678
Calcium ion (Ca²⁺), 45T, 805, 816–817
Calcium metabolism, **677–678**
Calmodulin (CaM), 655–658, 688, 764
Calmodulin-dependent protein kinase I (CaMKI), 658
Calmodulin-dependent protein kinase II (CaMKII), 699
Calnexin (CNX), 427, 885–887, 886F, 887F
Caloric restriction, 1101
Calorie (unit), 53, 53T
Calpain, 736
Calreticulin (CRT), 427, 885–887, 886F
Calvin, M., 927, 930
Calvin cycle:
control of, 932–934
free energy changes from, 933T
net reaction, 931

- Calvin (*Contd.*)
 in photosynthesis, 927–934, 929F
 stoichiometry of, 931
 CaM, *see* Calmodulin
 CAM (Crassulacean acid metabolism), 937
 Cambillau, C., 941
 Camels, erythrocyte membranes, 414
 CaMKI (calmodulin-dependent protein kinase I), 658
 CaMKII (calmodulin-dependent protein kinase II), 699
 cAMP (adenosine-3',5'-cyclic monophosphate), 653
 and AraC, 1292
 and blood glucose control, 661
 and catabolite repression, 1286
 controlling fatty acids with, 861
 and eicosanoid mediation, 993
 and integration of metabolic cycles, 1089
 cAMP-dependent protein kinase (CAPK), 653
 cAMP-phosphodiesterases (cAMP-PDEs), 698
 cAMP receptor protein (CRP), 1286
 cAMP response element (CRE), 879
 Campothecin, 1170
 CaN (calcineurin), 724–725
 Cancer. *See also related topics, e.g.:*
 Carcinogenesis
 and cell cycle, 1202
 cell metabolism, 864–865
 and chaperone proteins, 720
 and DNA methylation, 1251
 and gene therapy, 123
 role of glycoproteins in, 381
 and telomeres, 1211–1212
 thymidylate synthesis inhibition, 1129–1130
 and tyrosine kinase-based signaling, **703–705**
Canis familiaris (dog), genome sequencing, 177T
 Cantor, C., 158
 CAP, *see* Catabolite gene activator protein;
 Cbl-associated protein
 cap-0, 1302
 cap-1, 1302
 cap-2, 1302
 Cap binding protein, eIF4E, 1378
 Capillary electrophoresis (CE), 152
 CAPK (cAMP-dependent protein kinase), 653
 Capping, of telomeres, 1210
 Capping enzyme, 1302, 1302F
 19S Caps, 1411F
 Capsids, 26
 Caps structure, 1302, 1302F
 Capsule, bacterial, 4
 Carbamates, 329, 1025
 N-Carbamoylaspartate, 475
 Carbamoyl aspartate, in UMP synthesis, 1115F, 1116
 Carbamoylation, hemoglobin, 340
 Carbamoyl phosphate, 475, 1025–1028, 1115F
 Carbamoyl phosphate synthetase (CPS), **1025–1028**
 Carbamoyl phosphate synthetase I (CPS I), 1116
 Carbamoyl phosphate synthetase II (CPS II), 1115F–1116
 Carbanions, 563, 563F, 568–569, 569F
 Carbocation, 563, 563F
 Carbodiimides, 207
 Carbohydrates, **359**. *See also* Glycoproteins;
 Monosaccharides; Oligosaccharides;
 Photosynthesis; Polysaccharides
 analysis of, **366–367**
 in collagen, 238
 energy recovery from, 789
 Fischer convention for, 360–361
 functional groups of, 43
 glycoprotein, 380–381
 low carbohydrate diets, 1106
 from photosynthesis, 5
 Carbohydrate metabolism, 561F
 Carbohydrate microarrays, 383
 Carbohydrate recognition markers, 439
 Carbon, properties of, 29, 31
 Carbon–carbon bonds, breaking and making, 562–563, **567–569**, 568F
 Carbon dioxide:
 in Calvin cycle, 927, 931
 compensation point in plants, 935–936
 in photosynthesis, 901, 903, 935–937
 transport by hemoglobin, **328–329**
 Carbonic anhydrase:
 diffusion-limited, 490
 metal ion catalysis, 511–513, 512F
 Michaelis–Menten kinetic constants, 489T
 tertiary structure, 246F
 Carbon monoxide, heme group and, 324
 Carbon monoxide dehydrogenase, 954
 Carbonylcyanide-*p*-trifluoromethoxyphenylhydrazine (FCCP), 860
 Carboxyaminoimidazole ribotide, *see* CAIR
 2-Carboxyarabinitol-1,5-bisphosphate, *see* CABP
 2-Carboxyarabinitol-1-phosphate (CA1P), 930
 Carboxyatractyloside (CATR), 771
 γ -Carboxyglutamate, 79F
 γ -Carboxyglutamic acid, 79
 Carboxy-hemoglobin, solubility and ionic strength of, 133F
 Carboxyl groups, 43F
 Carboxyl terminus, *see* C-terminus
 Carboxyltransferase, 963
 Carboxymethyl-cellulose ion exchangers, *see* CM-cellulose ion exchangers
 Carboxymethyl-CoA, 806
 Carboxymethylcysteine, 607
 Carboxymyoglobin, 1057
 Carboxypeptidases, 165–166, 168T
 Carboxypeptidase A, 168T, 231F, 254F, 473
 Carboxypeptidase B, 168T
 Carboxypeptidase C, 168T
 Carboxypeptidase Y, 168T
 Carboxyphosphate, 873, 1025
 Carboxyprocollagen peptidase, 1403–1404
 Carboxypropyl-CoA, 955
 Carcinogens, 1202, 1224–1225
 Carcinogenesis, 1224
 Cardiac glycosides, 761–762, 761F
 Cardiolipin, 389T, 398T, 1005, 1006F
 Cardiotonic steroids, 761–762
 Carell, T., 1215
 Carnitine, 946
 Carnitine palmitoyltransferase I, 946, 975
 Carnitine palmitoyltransferase II, 946
 β -Carotene, 122, 908, 976
 Carotenoids, 905F, 907–909
 Carrager, B., 437
 Carriers, 745, 748
Carsonella ruddii, 177T
 CART (cocaine and amphetamine-regulated transcript), 1099
 Cartilage, 235, 240T, **375**
 Caruthers, M., 211
 Casein, 150
 β -Casein, 534
 κ -Casein, 547
 Casein kinase 1, 660
 Casein kinase 2, 660
 CASP (Critical Assessment of Structure Prediction), 305
 Caspersson, T., 1260
 Cassette exons, 1318
 Cassette mutagenesis, 119–120
 Catabolism, 17, 561–562, 561F
 purine ribonucleotides, **1130–1134**
 pyrimidine ribonucleotides, **1136**
 Catabolite gene activator protein (CAP), 654
 and AraC, 1292
 and catabolite repression, 1286–1288, 1287F
 Catabolite repression, 766, **1285–1288**
 Catalase, 10, 866, 935
 heme group in, 324
 horse liver, 153T
 Michaelis–Menten kinetic constants, 489T
 molecular mass of, 140F
 sedimentation coefficient, 154F
 Catalysis, free energy of reaction for, 487, 487F
 Catalysts, 469
 Catalytic constant, 490
 Catalytic triad, 529
 Cataplerosis, 1090
 Cataplerotic reactions, 818
 Cataracts, and galactose, 633
 Cate, J., 1366
 Catechol, 680, 1059
 Catecholamines, 680, 1058–1060
 Catenation, 1163, 1163F
 CATH (Class, Architecture, Topology, and Homologous superfamily), 256T, 258
 Cathepsins, 1408–1409
 Cathepsin D, 439, 547
 Cathepsin E, 547
 Cathepsin K, 540
 Cation exchangers, 135–136
 CATR (carboxyatractyloside), 771
 Cattle, *see* Cow
 Caveolae, 411
 Caveolins, 411
 C $_{\alpha}$ backbone, 244–245
 Cbl-associated protein (CAP), 737F
 CBP, *see* CREB-binding protein
 CCA-adding polymerase, 1331
 CCAAT box, 1282
 CCAAT/enhancer-binding protein α (C/EBP α), 572
 c-Cbl, 1412–1413, 1412F
 CCdA-p-Puro, 1383, 1383F
 C chain, proinsulin, 280–281, 280F
 CCHL (cytochrome *c* heme lyase), 448
 CCK, *see* Cholecystokinin
 CCT chaperonins, 301–302, 301F
 CCVs, *see* Clathrin-coated vesicles
 CD, *see* Circular dichroism
 Cdc6, 1206–1207
 Cdc7, 1205
 Cdc18, 1206–1207
 Cdc45, 1205
 CDKs (cyclin-dependent protein kinases), 1202, 1206–1207, 1414
 cDNA:
 depositing on DNA chips, 212–213
 and PCR, 116
 reverse transcriptase, 1207–1208
 CDP-diacylglycerol, 1004–1005
 CD spectroscopy, 284–285, 285F
 Cdt1, 1206, 1207
 CE (capillary electrophoresis), 152

- C/EBP α (CCAAT/enhancer-binding protein α), 572
 Cech, T., 1306–1308
 Celebrex, 543, 1000
 Celecoxib, 999–1000
 Celera Genomics, 181–182
 Cells, **3**, 16F. *See also* Prokaryotes
 eukaryote, 7F
 human, 12F
 plant, 11F
 prokaryotic, 4F
 Cell cycle, **1202**, 1202F. *See also* Apoptosis
 Cell division:
 meiosis, 21F
 mitosis, 20F
 in mitosis, 1202
 Cell growth, 1202, 1211
 Cell membranes, 4, 4F, 7F. *See also* Plasma membranes
 Cellobiose, 367, 367F
 Cellophane, 141
 Cell proliferation, 1202. *See also* Cancer
 Cell sorters, 575
 Cellular immunity, 292
 Cellulase, 369
 Cellulose, 11, 359, **367–369**, 368F
 Cellulose-based ion exchangers, 137–138, 137F
 Cell walls, 4
 plant cells, 11, 11F
 prokaryotes, 4F
 Central dogma of molecular biology, 95, 95F, 1260
 Centrifugation:
 differential, 130
 ultra-, 132T, **152–156**, 159
 Centrioles, 7F
 Centromeres, 20, 24F, 109
 Ceramides, 390, 1008–1009
 Cerebrosides, 391, 1008–1010, 1009F, 1010F
 Ceruloplasmin, 140F
 Cesium chloride, 156, 156F
 CETP (cholesteryl ester transfer protein), 458
 Cetuximab, 720
 Cetyltrimethylammonium bromide (CTAB), 399F
 CE website, *see* Combinatorial extension of optimal pathway
 C-extein, 1407
 CF₁CF₀ complex, 926
cf gene (fruit fly), 25, 25F
 CFI (cleavage factor I), 1302
 CFII (cleavage factor II), 1302
c-fos proto-oncogene, 705
 CFTR (cystic fibrosis transmembrane regulator) protein, 427–428
 CFTs (channel-forming toxins), 416–418
 CG, *see* Chorionic gonadotropin
c gene (fruit fly), 25F
 cGMP, 687
 cGMP-dependent protein kinase, 687
 cGMP-phosphodiesterase (cGMP-PDE), 692
 CGN, *see* Cis Golgi network
 Chagas-Cruz disease, 799
 α Chain, hemoglobin, 193, 194
 β Chain, hemoglobin, 193, 194
 δ Chain, hemoglobin, 194
 ϵ Chain, hemoglobin, 194
 γ Chain, hemoglobin, 194
 ζ Chain, hemoglobin, 194
 Chain elongation:
 protein synthesis, 1372–1373, 1379–1388
 RNAP, 1270–1272, 1270F, 1271F
 Chain initiation:
 codons for, 1343
 protein synthesis, 1373–1379
 RNAP, 1267–1269
 Chain termination:
 protein synthesis, 1391–1395
 RNAP, 1271F, 1273–1275
 Chain-terminator method, 176. *See also* Sanger method
 Chair conformation, 363, 363F, 519F
 Chalfie, M., 120
 Chamberlin, M., 1273
 Chambon, P., 1305
 Chang, G., 767
 Changeux, J.-P., 349
 Channel formers (ionophores), 748
 Channel-forming membrane proteins, **416–418**
 Channel-forming toxins (CFTs), 416–418
 Channeling, 794, 1028, 1075
 Ca²⁺ channels, 772
 Chaotropic ions, 266
 Chaperone proteins, 293–302, 720
 role in secretory pathway, 421F, 427–428
 Chaperonins, 293
 CHAPS (detergent), 399F
 Chargaff, E., 84, 86, 88
 Chargaff's rules, 84, 85, 88
 Charge relay system, 536
 Charges, of amino acid side chains, 71
 Charge shielding, 513
 Charge transfer complex, 803–804, 804F
 Chase, M., 87
 CHCRs, *see* Clathrin heavy chain repeats
 Checkpoint, in cell cycle, 1202
 C Helix, 242F
 Chemical carcinogens, 704–705
 Chemical coupling hypothesis, 845
 Chemical damage, DNA susceptibility to, 1214F
 Chemical equilibria, *see* Equilibrium
 Chemical evolution, 29, 30F, **31–33**, 185–194
 and gene duplication, 192–194
 and neutral drift, 188–192
 rates for proteins, 191F, 192
 and sickle-cell anemia, 185–188
 Chemical kinetics:
 elementary reactions, **483**
 reaction rates, **483–484**
 and spontaneous processes, 54
 transition state theory, **484–487**
 Chemical logic, **563–565**
 Chemical mutagenesis, 1339–1340
 Chemical mutagens, 1181, 1339–1340
 Chemical potential, 58, 744
 Chemical protons, 843
 Chemical synapses, 778
 Chemical synthesis:
 of genes, 118
 of oligonucleotides, 209–214
 of polypeptides, 205–209
 Chemiluminescence, 183
 Chemiosmotic hypothesis, 846
 Chemokines, 717
 Chemolithotrophs, 5
 Chemotaxis, 717
 Chemotrophs, 559
 Cheng, X., 1248
 Chenodeoxycholate, 992
 Chickens:
 cancer viruses, 704–705
 embryonic development, 14F
 lactate dehydrogenase H, 153T
 ovalbumin, 1304, 1304F, 1305F
 as source of proteins for purification, 130
 triose phosphate isomerase, 231F, 252, 254F
 Chicken foot (Holliday junction), 1234
 Chimeric vector, 104
 Chimpanzees, 116, 177T
 Chipman, D., 523
 Chiral centers, 74–76
 Chirality, 74, 78, 225–226
 Chiral organic synthesis, 78
 Chi sequences, 1230
 Chi structures, 1228
 Chitin, 369, 369F
 Chiu, W., 301
 Chl, *see* Chlorophyll
 Chl *a*, *see* Chlorophyll *a*
 Chl *b*, *see* Chlorophyll *b*
 Chloramphenicol, 107, 1395T, 1396F, **1397**
 Chloride ion, 45T
 Chlorocruorins, 325
 Chloroform, 43T, 144
 Chlorophyll (Chl), 12, 403, **903–912**. *See also* Photosynthesis
 absorption spectrum, 905F
 electronic states, 905F
 Chlorophyll *a* (Chl *a*), 903, 904F, 905F, 908, 916, 917
 Chlorophyll *b* (Chl *b*), 903, 904F, 905F, 908
 Chloroplasts, 11F, 13F
 photorespiration in, 935
 photosynthesis site, 11–12, **901–903**
 Chloroquine, 1058, 1409
 Cholate, 992
 Cholecalciferol-25-hydroxylase, 678
 Cholecystokinin (CCK), 673T, 675
 Cholera toxin (CT), 694–697, 1398
 Cholesterol, **392–393**, 393F
 and dietary EPA, 1002–1003
 excretion of, 993
 fluidity of, 398
 and LDL, 449F
 in membranes, 398T, 400F
 metabolism of, 975, **984–987**
 synthesis of, 1096
 takeup by LDL, 453–455
 transport of, 452F, 456
 utilization of, **991–993**
 Cholesterol 7 α -hydroxylase, 993
 Cholesterol biosynthesis, 975–976
 citric acid cycle intermediates, 818
 control of, 989–991
 HMG-CoA in, **976–977**
 HMG-CoA reductase in, 987–989
 lanosterol in, **982–984**, 985F
 and LDL receptor activity, 989–991
 pyrophosphomevalonate decarboxylase in, **977–978**
 squalene formation, **978–982**, 979F
 Cholesteryl esters, 393, 449F, 984, 986
 Cholesteryl ester hydrolase, 466
 Cholesteryl ester transfer protein (CETP), 458
 Cholesteryl stearate, 393
 Cholestyramine, 990
 Choline, 389T, 390, 779
 Choline acetyltransferase, 779
 Cholinergic synapses, 778–780
 Chondroitin-4-sulfate, 371F, 372
 Chondroitin-6-sulfate, 371F, 372
 Chorionic gonadotropin (CG), 132, 673T, 684
Chorthippus parallelus, 24F
 Chou, P., 302, 303
 Chou–Fasman method, 302–303
 Chromate, 1075, 1076F, 1077F
 Chromatids, 20, 24, 24F
 Chromatin, 7F, 8
 Chromatogram, 144

- Chromatographic separations, 135
 affinity chromatography, 118, 141–143
 gel filtration chromatography, 138–141
 ion exchange chromatography, 135–138
 nucleic acids, **157**
 proteins, **135–146**
- Chromatophores, 902
- Chromogenic substrates, 110
- Chromophore, 402, **908**
- Chromosomal theory of inheritance, 22–26
- Chromosomes, 4, **19–20**, 19F
 bacterial artificial, *see* BACs [bacterial artificial chromosomes]
 in meiosis, 21F
 in mitosis, 20F
 multiforked, 1195, 1195F
 number of, in eukaryotes, 19T
 of prokaryotes, 4
 recombination of, *see* Recombination
 replication of, *see* DNA replication
 sex, 22–23
 and telomere capping, 1210
 yeast artificial, *see* YACs (yeast artificial chromosomes)
- Chromosome walking, 114, 114F, 180
- Chronic myelogenous leukemia (CML), 718
- Chyle, 451
- Chylomicrons, 449, **451–452**, 944
 and cholesterol biosynthesis, 986
 properties, 449T
 transport in blood, 973
- Chylomicron remnants, 451–452, 986
- Chymosin, 547
- Chymotrypsin, 470, 525, 525T, 529T, 565
 active sites, 529F, 531F
 catalytic mechanism, **531–537**
 gene duplication, 194
 kinetics and catalytic group, 525–527
 Michaelis–Menten kinetic constants, 489T
 proenzymes, 538
 X-ray structure, 527–529, 528F
- α -Chymotrypsin, 153T, 538, 538F
- π -Chymotrypsin, 538, 538F
- Chymotrypsinogen, 140F, 264F, 527, 538, 538F
- CIC channels, 755–756, 755F
- Ciechanover, A., 1410
- Cilia, 10
- Ciliates, 7F, 13F
- Cimetidine, 764
- Ciprofloxacin (Cipro), 1167, 1170, 1395
- Circular dichromism (CD), 284–285, 285F
- cI repressor, 1288
- Cis-acting elements, 1264
- Cis cisternae, 428, 429F
- Cis configuration, 28, 388
- Cis Golgi network (CGN), 428, 429F
- Cis-SNARE complex, 444–445
- Cis-splicing, 1320
- Cisternae, 428
- Cisternal maturation, 428
- Cisternal progression, 428
- Cis-trans test, 28, 28F
- Cistrons, 28, 1264, 1340
- Citrate:
 in citric acid cycle, 789, 790F
 glycolysis inhibition, 863–864
 and metabolic cycles, 1088–1089
- Citrate condensing enzyme, 806
- Citrate synthase, 568, 621
 in citric acid cycle, 789, 790F, **806–808**, 806F, 807F, 815–816
- Citric acid cycle, 561F, **789–820**
 acetyl-CoA synthesis, 792–805
 aconitase, 789, 790F, **808–809**, 808F
 amphibolic functions, 789, 817–819, 818F
 citrate synthase, 789, 790F, **806–808**, 806F, 807F, 815–816
 coupling to glycolysis, 594F
 electron-transport chain, 824F
 energy-producing capacity, 813
 enzymes of, **806–815**
 evolution of, 814–815
 fumarase, 790F, 791, **812–813**, 812F
 integration of, 813–814, 1090
 isocitrate dehydrogenase, 789, **809–810**, 809F, 815–816
 α -ketoglutarate dehydrogenase, 789, **810**, 815–816
 malate dehydrogenase, 790F, 791, **813**
 net reaction, 791
 overview, 789–792, 790F
 oxaloacetate in, 873F
 pathways using intermediates, 818, 872F
 pyruvate dehydrogenase complex, **792–800**, 804–805, 805F
 rate-controlling reactions of, 815–816
 regulation, 815–817, 816F
 replenishing intermediates of, 818–819
 succinate dehydrogenase, 791, **811–812**, 812F
 succinyl-CoA synthetase, 791, **810–811**, 811F
- Citrulline, 80, 80F, 571F, 1028
- L-Citrulline, 686
- Citryl-CoA, 807
- CJD, *see* Creutzfeldt-Jakob disease
- Claisen ester cleavage, 949–950
- Claisen ester condensation, 568
- Clamp loader, 1196–1198, 1197F
- Clans, of Pfam families, 258
- Clardy, J., 1116
- Clark, B., 1380
- Class, Architecture, Topology, and Homologous superfamily, *see* CATH
- Class I aaRSs (aminoacyl-tRNA synthetases), 1350–1351, 1350T, 1355F, 1358, 1358F
 X-ray structure of, 1352–1354
- Class I promoters, 1286
- Class I release factors, 1391–1392
- Class II aaRSs (aminoacyl-tRNA synthetases), 1350–1351, 1350T, 1355F, 1358, 1358F
 X-ray structure of, 1354–1355
- Class II major histocompatibility complex (MHC) proteins, 1102
- Class II promoters, 1286–1287
- Class III promoters, 1287
- Classical thermodynamics, 587
- Classification number, 470
- Clathrates, 262F, 263
- Clathrin, 430–439
- Clathrin barrel, 437F
- Clathrin-coated vesicles (CCVs), 431–439, 431F, 433F, 434F
- Clathrin heavy chain repeats (CHCRs), 432F, 433
- Clathrin heavy chains, 430, 432, 432F
- Clathrin light chains, 430, 432, 432F, 433F
- Claude, A., 1362
- Clausius, R., 56
- Cl[−] channels, **755–756**, 755F
- Cleavage and polyadenylation specifying factor (CPSF), 1302–1303
- Cleavage factor I, 1302
- Cleavage factor II, 1302
- Cleavage sites, type II restriction enzymes, 105, 105T
- Cleavage stimulating factor (CstF), 1302–1303
- Cleland, W. W., 498, 536
- Clinical trials, 542–543
- Clones, 104, 113–114
- Cloning, *See also* Molecular cloning
 directional, 117, 117F
 molecular, *see* Molecular cloning
 shotgun, 113
- Cloning vectors (vehicles), 104, **106–109**
- Clore, M., 656
- Closed complexes, 1268
- Closed conformations:
 KlenTaq1, 1179–1180, 1179F
 Rep helicase, 1186
- Closed systems, 52
- Clostridium botulinum*, 442, 1340
- Clotting, *see* Blood clotting
- Cloverleaf structure, 1329–1330, 1329F, 1346F
- ClpA, 1419
- ClpP, 531, 531F, 1419, 1419F
- Clp protease, 1419
- ClpX, 1419
- CLUSTAL, 201–202, 202F, 205, 304
- Cmc (critical micelle concentration), 394
- CM-cellulose ion exchangers, 137–138, 141
- CML (chronic myelogenous leukemia), 718
- CMP (cytidine monophosphate), 83T, 1136F
- CMV (cytomegalovirus), 1403
- Cn3D, 256T, 258
- CNBr, *see* Cyanogen bromide
- CNX, *see* Calnexin
- CO₂ compensation point, 935–936
- CoA, *see* Coenzyme A
- Coagulation, *see* Blood clotting
- Coated pits, 454, 454F
- Coated vesicles, 428–439, 429F
- Coatomer, 430
- Cobalamin coenzymes, 473T, 474T
- Cobalt ion, 1158
- Cobratoxin, 781
- Cocaine and amphetamine-regulated transcript (CART), 1099
- Cocci, 4
- Cochaperone proteins, 293
- Cockayne syndrome (CS), 1218
- Cocoonase, 525T
- Coding strand, 1266
- Codominant traits, 22, 23F
- Codons, 95F, 98–101, **1338**, 1343T
 anticodon interactions with, 1389F
 frequently used, 1360
 nonsense suppressors, 1362, 1362T
 triplet, 1340–1341
- Coelenterates, 13F
- Coenzymes, **473–474**, 473T, 474T
 biosynthesis of flavin, **1138**
 biosynthesis of nicotinamide, **1136–1138**
 as covalent catalysts, 511
- Coenzyme A (CoA), 82, 473T, 795T. *See also* Acetyl-CoA
 biosynthesis, **1138–1139**
 discovery, 791–792
- Coenzyme B₁₂, 954–955, 954F
- Coenzyme Q (CoQ; ubiquinone):
 electron-transport chain coenzyme, 829–830, 836F
 in oxidative phosphorylation, 848–849
- Coenzyme Q: Cytochrome c oxidoreductase (Complex III), 840–841, 840F
- Coenzyme QH*, 836F
- Coenzyme QH₂, 836F, 848–849
- Coenzyme Q reductase, 834–835, 837–840
- Cofactors, 473

- Cohen, P., 1025
 Cohen, S., 107
 Cohesive ends, 105. *See also* Sticky ends
 Coil conformation, **230, 232**
 Coiled coil structure (keratin), 234, 235F
 Cointegrate, 1239–1240, 1239F–1241F
 Cold denatured proteins, 284
 Cold-labile proteins, 130
 Colicins, 418
 Colicin E3, 1375
 Colipase, 941–942, 941F
 Coliphage, 1190
 Collagen, 78, 163, **235–240**
 assembly, 1405
 diseases associated with, 240
 isoelectric point, 134T
 Ramachandran diagram, 224F
 sedimentation coefficient, 154F
 Collagen $\alpha 1$ (I), 236F
 Collagen fibrils, 237–240, 237F, 239F, 240T
 Collective motions, 307, 308
 Collins, F., 181
 Collman, J., 328
 Collodion, 141
 Colony hybridization, 113–114, 114F
 Colony-stimulating factors, 119
 Combinatorial chemistry, 541
 Combinatorial extension of optimal pathway, 256T, 258
 Comparative modeling, 304–305
 Compare 3D, 258
 Competitive-binding studies, 674–675
 Competitive inhibition, **493–494**, 494F, 747
 Complementary base pairing, 18, 89
 Complementation group, 27
 Complementation tests, 24–25, 25F, 27
 Complement C1, 525T
 Complement C9, 1317
 Complement system-mediated reactions, 121
 Complex I (NADH dehydrogenase, NADH: coenzyme Q oxidoreductase), 832T, **834–837**, 836F–837F, 845
 Complex II (Succinate dehydrogenase, succinate: coenzyme Q oxidoreductase) 493, 947
 in citric acid cycle, 791, **811–812**, 812F
 and electron transport, 832T, **837–840**, 839F, 845
 Complex III (Coenzyme Q: Cytochrome *c* oxidoreductase, cytochrome *bc_L*), 832T, **840–841**, 840F, **847–850**, 849F, 912
 Complex IV (Cytochrome *c* oxidase, COX), 153T, 188, 584, 832T, **841–845**, 842F, **851–852**, 851F, 852F
 Complex V (proton-translocating ATP synthase), *see* F_1F_0 -ATPase
 Complex oligosaccharides, 888
 Complex systems, 736–738
 Complimentary DNA, *see* cDNA
 Composite transposons, 1237, 1237F
 α -Conarachin, 140F
 Concanavalin A, 230, 231F, 246F, 249F, 366
 Concanavalin B, 153T
 Concentration, free energy and, 58, 61
 Concentration cells, 586
 Concerted general acid-base catalyzed reaction, 507
 Condensation reactions, for peptide bonds, 70F
 Condensing enzyme, 965
 Conformational coupling hypothesis, 845
 Conformation maps, 223–225
 Congenital erythropoietic porphyria, 1056
 Conjugate acid, 45
 Conjugate base, 45
 Conjugate redox pair, 584
 Conjugation, 1225
 Connective tissues, 235
 Connexins, 415, 416
 Connexin 26 (Cx26), 416, 417F
 Connexons, 415–416
 Conservatively substituted positions, 188
 Conservative replication, 90
 Constitutive enzymes, 1261
 Constitutive heterochromatin, 182
 Constitutive mutation, 1262
 Contact inhibition, 381, 703, 1202
 Contigs, 180
 Contour lengths, 94
 Controlled rotation, 1166, 1166F
 Convergent evolution, **317**
 Cooley's anemia, 219
 Coomassie brilliant blue, 149, 411
 Cooper, J., 1048
 Cooperative binding, 326
 Cooperative process, 92
 Cooperman, B., 1122
 Coordinate expression, of enzymes, 1264
Copia, 1246
 COPII protein, 429F, 430, 437–439, 437F, 439F
 COPI protein, 429F, 430, 437
 Coproporphyrinogen I, 1056
 Coproporphyrinogen oxidase, 448, 1053
 CoQ, *see* Coenzyme Q
 Cordycepin, 1270
 Core enzyme, 1265, 1267, 1269
 Corepressor, 1297
 Core promoter element, 1282
 Core proteins, 373
 Corey, R., 221, 229
 Cori, C., 595, 651, 880
 Cori, G., 595, 651, 880
 Cori cycle, **880**, 880F
 Cori's disease, 667
 Corn:
 Bt corn, 122
 chloroplast, 902F
 and pellagra, 474
 transposons, 1236, 1244
 CORN crib mnemonic, for handedness of amino acids, 75, 75F
 Cornea, collagen fibrils in, 240T
 Cornish-Bowden, A., 623
 Cornynephage b, 1397
 Corpeus luteum, 683
 Correlated invariants, 1346
 Correlated spectroscopy (COSY), 243
 Corrin, 954
 Cortex, 679
 Corticosterone, 680
 Corticotropin-releasing factor (CRF), 673T, 682
 Cortisol, 680
 Cosmid vectors, 108
 Cosmid walking, 181
Cos site, 108
 COSY (correlated spectroscopy), 243
 Coulomb (unit), 53T
 Coulomb's law, 42, 259
 Coumadin, 543F
 Coumarin, 1167
 Coupled reactions, **60–61**, 131
 Coupling, translational, 1398
 Covalent catalysis, **510–511**
 Covalent modification, 624
 gluconeogenesis, 878–879
 glycogen metabolism, **650–651**
 Cow. *See also related topics e.g.:* Bovine pancreatic ribonuclease A
 20S proteasome, 1417
 cellulose digestion, 369
 mad cow disease, 312, 315
 as source of proteins for purification, 130
 COX, *see* Complex IV
 Cox, M. M., 1234
 COX-1, 998, 999
 COX-2, 998, 999
 COX-2 inhibitors, 999–1000, 999F
 COX-3, 1000
 Coxibs, 999
 Cozymase, 594
 CP43 subunit (PsbC), of photosystem, 916
 CP47 subunit (PsbB), of photosystem, 916
 CP-320473, 982
 CPDs (cyclobutane pyrimidine dimers), 1214–1215
 CPE (cytoplasmic polyadenylation element), 1402
 CPE-binding protein (CPEB), 1402, 1402F
 CpG islands, 1249
 cPLA₂ (cytosolic phospholipase A₂), 727
 Cpn10, 294
 Cpn60, 294
 CPS (carbamoyl phosphate synthetase), **1025–1028**
 CPS I (carbamoyl phosphate synthetase I), 1116
 CPS II (carbamoyl phosphate synthetase II), 1115F–1116
 CPSF (cleavage and polyadenylation specifying factor), 1302–1303
 Craik, C., 530
 Cramer, W., 920
c-Ras proto-oncogene, 705, 708–709
 Crassulacean acid metabolism (CAM), 937
 Cravatt, B., 404
 CRE (cAMP response element), 879
 Creatine, 1092
 Creatine kinase, 505, 570, 571F, 583
 CREB, *see* CRE binding protein
 CREB-binding protein (CBP), 283–284, 283F
 CRE binding protein (CREB), 283–284, 283F, 879
 Cre recombinase, 1243–1244, 1245F, 1259
 Cretinism, 677
 Creutzfeldt-Jakob disease (CJD), 312, 314, 315
 CRF, *see* Corticotropin-releasing factor
 Crick, F., 88, 95, 236, 1146, 1173, 1260, 1340, 1341, 1345, 1360
 Cristae, 9, 824, 825F
 Critical Assessment of Structure Prediction (CASP), 305
 Critical micelle concentration (cmc), 394
 Critical nucleus, 347F
 CrkII, 737F
 Crocodiles, blood oxygen utilization, 357
 Crofts, A., 840
 Crop plants, 122. *See also* Corn; Rice
 Cro protein, 1288, 1289F
 Crossing-over, 20, 24, 24F, 1226–1228
 Cross-linking agents, 270–271, 270F
 Cross- β spines, 310–311
 Crotoxin, 153T
 CRP (cAMP receptor protein), 1286
 CRT, *see* Calreticulin
 Cryo-electron microscopy (cryo-EM), 301, 1365–1366
 in citric acid cycle research, 798
 in secretory pathway research, 422–426, 422F, 423F, 425F
 Cryptic branch site, 1306
 Cryptic splice sites, 1318
 α Crystallin, 140F
 γ -B Crystallin, 252, 253F

- Crystallization, protein, 134–135, 241–243
 Crystallographic symmetry, 270
 Crystal proteins, 122
 CS (Cockayne syndrome), 1218
 CsA, *see* Cyclosporin A
 c-*Src* gene, 705, 706
 CstF (cleavage stimulating factor), 1302–1303
 CT, *see* Cholera toxin
 CTAB (cetyltrimethylammonium bromide), 399F
 CTD (C-terminal domain), 1277, 1286–1288
 CTD (C-terminal domain) kinases, 1277
 CTD (C-terminal domain) phosphatases, 1277
 C-terminal domain, *see* CTD
 C-terminus, 73
 in protein sequencing, 165–168
 in protein synthesis, 1371–1373
 CTP (cytidine triphosphate), 475F
 in ATCase feedback inhibition, 475
 synthesis of, **1118–1119**
 in transcription, 96, 1265
 CTP synthetase, 1118
 C-Type cytochromes, 316, 316F, 317F
 Cud chewing, 369
 Cul1, 1412, 1413F
 Cullin family, 1412, 1421
 Curare, 781
 Curie (Ci), 591
 Curry, S., 944
 Curved arrow convention, 564
 Cusack, S., 1381
 Cushing's syndrome, 681, 743
 Cut-and-paste transposition mechanism, 1237–1239, 1238F
 Cx26, *see* Connexin 26
 Cyanate, Hb and, 340
 Cyanide, 831
 β -Cyanoalanine, 80, 80F
 Cyanobacteria, 5–6, 7F, 12, 13F
 Cyanogen bromide (CNBr), 142, 170–171
 Cyanosis, 342
 3',5'-Cyclic AMP, *see* cAMP
 Cyclic AMP response element-binding protein, *see* CREB-binding protein (CBP)
 Cyclic cascade, 647–650
 Cyclic depsipeptide, 748
 3',5'-Cyclic GMP, *see* cGMP
 2',3'-Cyclic nucleotides, 508
 Cyclic processes, 53
 Cyclic symmetry, of proteins, 268, 268F
 Cyclins, 214F, 1202
 Cyclin-dependent protein kinases, *see* CDKs
 Cyclobutane pyrimidine dimers (CPDs), 1214–1215
 Cyclobutylthymine dimer, 1214–1215, 1214F
 Cyclohexane, conformations of, 363, 363F
 Cycloheximide, 1395T, 1396F
 Cyclooxygenase (COX), 406, 997
 Cyclopentanoperhydrophenanthrene, 392
 Cyclophilin, 724F, 725
 Cyclopropane, 398
 Cyclosome, 1414
 Cyclosporin A (CsA), 292–293, 724
 Cyglar, M., 886
 Cys, *see* Cysteine
 CysRS, in archaeobacteria, 1359
 Cystathione, 1034
 Cysteine:
 amino groups, 208F
 biosynthesis, 1071–1072
 degradation, 1030–1034
 disulfide bonds, 71, 71F, 168–169
 and fluorescence resonance energy transfer, 286
 genetic codes for, 100T, 1343T
 α helix/ β sheet propensity, 302T
 as nonessential amino acid, 1065T
 side chains, 71, 208F, 264T
 structure and general properties, 69T
 Cysteine proteases, 1417
 Cysteinyl-adenylate, 1359
 Cystic fibrosis, 122–123, 427–428
 Cystic fibrosis transmembrane regulator (CFTR) protein, 427–428
 Cystine, 71. *See also* Cysteine
 disulfide bond cleavage in protein sequencing, 168–169
 stereoisomers, 76, 76F
 D-Cystine, 76, 76F
 L-Cystine, 76, 76F
 meso-Cystine, 76, 76F
 Cys-tRNA^{Cys}, 1359
 Cyt, *see* Cytosine
 Cytidine, 83T, 1136F
 Cytidine deaminase, 1136F, 1322
 Cytidine monophosphate, *see* CMP
 Cytidine triphosphate, *see* CTP
 Cytidylic acid, *see* CMP
 Cytochalasin B, 769
 Cytochrome *a*, **838**, 838F
 Cytochrome *b*, **838**, 838F, 1408T
 Cytochrome *b*₅, 401–402, 402F, 971
 Cytochrome *b*₆, 920
 Cytochrome *b*₆f complex, 915, 920–921, 921F
 Cytochrome *b*₅₅₉, 916
 Cytochrome *b*₅₆₂, 250F, 251
 Cytochrome *bc*₁, *see* Complex III
 Cytochrome *b*_H, 838
 Cytochrome *b*_L, 838
 Cytochrome *c*, 16F, **188–189**, **838**, 838F, 841–843
 amino acid sequence, 186T–187T, 189F, 196F
 evolution of, 189, 191F, 316, 317F
 folding of, 284, 289, 289F
 half-life, 1408T
 isoelectric point, 134T
 molecular mass, 140F
 phylogenetic tree, 189, 190F
 physical constants of, 153T
 sedimentation coefficient, 154F
 visible absorption spectrum, 838F
 X-ray structure of, 247F
 Cytochrome *c*₁, 838F, 840, 848
 Cytochrome *c*₂, 912
 Cytochrome *c* heme lyase (CCHL), 448
 Cytochrome *c* oxidase (COX), *see* Complex IV
 Cytochrome *c* reductase, 188
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 543–545
 in fatty acid oxidation, 959
 in heme biosynthesis, 1055
 polymorphic, 545
 X-ray structure, 543F
 Cytochrome P450 reductase, 686
 Cytochrome *f*, 914–915, 915F, 920
 Cytochrome P450:
 detoxification reactions, 1225
 and drug metabolism, 54

- Death-inducing signal complex, *see* DISC
 5-Deazaflavin, 1215
 6dEB (6-deoxyerythronolide B), 968
 Debranching enzyme, 370, 639, **642–643**, 667
 DEBS (deoxyerythronolide B synthase), 968
 Decamethonium ion, 788
 Decapping enzyme, 1327
 Decay, of DNA, 116–117
 Decoding, 1379
 Decorin, 373T
 de Duve, C., 9
 Deep View, 257
 Deformylase, 1374
 Degeneracy, of genetic code, 99, 1338, 1341, 1343–1344, 1360–1361
 Dehydroascorbic acid, 364
 L-Dehydroascorbic acid, 364F
 7-Dehydrocholesterol, 678
 Dehydrogenases, 318, 498
Deinococcus radiodurans, 1259
 Deisenhofer, J., 294, 403, 453, 840, 910
 de Lange, T., 1213
 Deletion mutations, 1340
 DeLucia, P., 1181
 Dematin, 412
 Denaturation:
 of DNA, 90–93, 92F
 of proteins, *see* Protein denaturation
 Denaturation temperature, 57
 Denatured proteins, 57
 Denitrification, 1083
 Denitrifying bacteria, 6
De novo methods, 305
 Density gradients, 155
 3'-Deoxyadenosine, 1270
 5'-Deoxyadenosylcobalamin (AdoCbl), 954–955, 954F
 Deoxycytidine deaminase, 1124
 6-Deoxyerythronolide B (6dEB), 968
 Deoxyerythronolide B synthase (DEBS), 968
 Deoxygenated hemoglobin (deoxyHb), 329, 331
 and BPG, 341, 341F
 structure, 331–333, 334F–335F
 Deoxygenated hemoglobin S (deoxyHbS), 343–344, 343F–347F
 DeoxyHb, *see* Deoxygenated hemoglobin
 DeoxyHbS, *see* Deoxygenated hemoglobin S
 Deoxynucleoside triphosphates, *see* dNTPs
 Deoxynucleotides, **82–83**
 2-Deoxy-PIP₂, 728
 Deoxyribonucleic acid, *see* DNA
 Deoxyribonucleotides, **82–83**, 82F,
 1119–1130. *See also specific nucleotides*
 Deoxy-D-ribose, 18
 β-D-2-Deoxyribose, 365
 2'-Deoxyribose, **1119–1126**
 2'-Deoxy-D-ribose, 83
 Deoxyribosomes, 1308
 Deoxy sugars, 365
 Deoxythymidine, 83T, 1136F
 Deoxythymidine monophosphate (dTMP), 83T, 1127–1128
 Dephospho-CoA kinase, 1138, 1139F
 Dephospho-CoA pyrophosphorylase, 1138, 1139F
 Depsipeptides, 1272
 Dermatan sulfate, 371F, 372
 Dermatosparaxis, 1404
 Desamido NAD⁺ (nicotinate adenine dinucleotide), 1138
 Desaturases, **969–971**
 de Saussure, T., 901
 Desensitization, 697
 Destruction box, 1414
 Detergents, 262, 265, 399F
 Detergent-resistant membranes (DRMs), 411
 Deubiquitinating enzymes, *see* DUBs
 Deuterium, *see* Hydrogen exchange
 de Vos, A., 684
 Dextran gels, 137, 139, 140T, 141
 α-Dextrinase, 370
 Dextrins, 370
 Dextrorotatory molecules, 74
 D forms (amino acids), 74–76
d gene (fruit fly), 25F
 DGLA (dihomo-γ-linolenic acid), 994
 DH (β-hydroxyacyl-ACP dehydrase), 965
 DHA (4,7,10,13,16, 19-Docosahexenoic acid), 387T, 971
 DHAP, *see* Dihydroxyacetone phosphate
 Dhe-Paganon, S., 1250
 DHF, *see* Dihydrofolate
 DHFR, *see* Dihydrofolate reductase
 DHODH, *see* Dihydroorotate dehydrogenase
 Diabetes insipidus, 743
 Diabetes mellitus, 310, **1102–1104**, 1409.
 See also Insulin
 1,2-Diacylglycerol, 941
 Diacylglycerol (DAG), 661, 994
 Diacylglycerol acyltransferase, 971
 Diacylglycerol lipase, 994
 Diacylglycerophospholipids, 1004–1005, 1005F
 Diagonal plot, 196
 Dialysis, 117, 132T, 141, 141F
 Diaminopimelic acid, 123, 377F
 Diastase, 469
 Diastereomers, 75–76
 Diatoms, 13F
 Diatomaceous earth, 144
 6-Diazo-5-oxo-L-norleucine (DON), 1142
O-diazoacetyl-L-serine, 1142
 Diazotrophs, 1080
 Dicer (RNase), 1324
 3-(3,4-Dichlorophenyl)-1,1-dimethylurea (DCMU), 915
 Dickens, F., 892
 Dickerson, R., 89, 529, 1148
 Dicyclohexylcarbodiimide (DCCD), 207–208
N,N'-Dicyclohexylurea, 207
 Didanosine, 1208
 2',3'-Didehydro-3'-deoxythymidine, 1208
 2',3'-DideoxyCTP (ddCTP), 1178–1180
 2',3'-Dideoxycytidine (ddC), 1208
 2',3'-Dideoxyinosine (ddI), 1208
 Dideoxy method, 176. *See also*
 Sanger method
 2',3'-Dideoxynucleoside triphosphate (ddNTP), 177
 Dielectric constants, 42–43, 43T
 2,4-Dienoyl-CoA reductase, 952
 3,5-2,4-Dienoyl-CoA reductase, 952
 Diethylaminoethyl cellulose ion exchangers, *see* DEAE-cellulose ion exchangers
 Diethyl ether, 43T, 144, 398
 Diethylpyrocarbonate, 312–313, 313F
 Diet-induced thermogenesis, 1099–1100
 Differential centrifugation, 130
 Diffusion coefficient, 745
 Diffusion-controlled limit, 490
 Digalactosyl diacylglycerol, 902
 Digitalis, 539, 761–762, 761F
 Digitoxin, 761–762
 Dihedral angles, 222–225
 Dihedral symmetry, of proteins, 268, 268F
 Dihomo-γ-linolenic acid (DGLA), 994
 7,8-Dihydrobiopterin, 1043–1044
 Dihydroceramide, 1009
 Dihydroceramide reductase, 1009
 Dihydrofolate (DHF), 445, 492, **1062**, 1127
 Dihydrofolate reductase (DHFR), 300, 445, 492, 1044, 1062, 1129–1130
 Dihydrolipoamide, in citric acid cycle, 794–795, 795F
 Dihydrolipoamide dehydrogenase, 796
 Dihydrolipoyl dehydrogenase, 792, 801–804, **801–814**, 802F, 804F
 Dihydrolipoyl transacetylase (E2), 792, 793F, **795–797**, 796F, 797F
 Dihydrolipoyl transsuccinylase (E2o), 810
 Dihydroorotase, 1115F, 1116, 1118
 Dihydroorotate, 1115F, 1116
 Dihydroorotate dehydrogenase (DHODH), 1115F, 1116
 Dihydropteridine reductase, 1044
 Dihydrosphingosine, 391F, 1009
 Dihydrouracil, 1136F
 Dihydrouracil dehydrogenase, 1136F
 Dihydrouridine (D), 1346, 1347F
 Dihydroxyacetone, 361, 361F
 Dihydroxyacetone phosphate (DHAP), 596F, 600–603, 929, 944F
 Dihydroxyacetone phosphate acyltransferase, 971
 1α,25-Dihydroxycholecalciferol (1,25(OH)₂D), 678, 679
 3,4-Dihydroxyphenylalanine, *see* L-DOPA
 Dihydroxythymine, 1136F
 Diimine, 1082
 Diisopropylphosphofluoridate (DIPF), 526–527
 Diketogulonic acid, 364
 L-Diketogulonic acid, 364F
 Diketopiperazine, 243F
 Dill, K., 262, 281, 287
 Dimers, 267
 Dimethoxytrityl (DMTr) protecting group, 210F, 211
*N*⁶-*N*⁶-Dimethyladenosine, 1156–1157
 Dimethylallyl pyrophosphate, 977
 1-Dimethylamino-naphthalene-5-sulfonyl chloride, *see* Dansyl chloride
 5,6-Dimethylbenzimidazole (DMB), 954
N,N-Dimethylformamide, *see* DMF
*N*²,*N*²-Dimethylguanosine (m₂G), 1347F
 Dimethylxaloacetate, 511
 Dimethylsuberimide, 270, 270F
 Dimethyl sulfate (DMS), 1267
 Dimethyl sulfoxide, *see* DMSO
dinB gene, 1222
 2,4-Dinitrofluorotoluene base, 1177
 2,4-Dinitrophenol (DNP), 860
 Dinoflagellates, 13F
 Dintzis, H., 1371
 Dinucleotide-binding fold, 256
 Dioldehydrase, 1018
 Dipeptides, 70, 70F
 DIPF (diisopropylphosphofluoridate), 526–527
 Diphosphatidylglycerol, 389T
 1,3-Diphosphoglycerate, 607
 2,3-Diphosphoglycerate (DPG), 329
 Diphthalamide residue, eEF2, 1398
 Diphtheria, 1397–1398
 Diphtheria toxin (DT), 123, 153T, 1395T, **1397–1398**
Diplococcus pneumoniae, 85
 Diploid cells, 24F
 Diploid genome, 182
 Diploid number, 19
 Dipolar ions, 70
 Dipole-dipole interactions, 260–261, 260F

- Dipole moment, 39, 43T
 Dipyrromethane, 1053
 Directional cloning, 118, 118F
 Direct transposition, 1237–1239
 Disaccharides, **367**
 Disc electrophoresis, 148, 148F, 149F
 Discontinuous pH electrophoresis, 148, 148F
 Discriminator base, 1351F
 Disorder, entropy and, 54–57
 Dissociation constant (K_a):
 and acid strength, 45–47, 46T
 and pH, 47
 of polyprotic acids, 49–50
 Distal histidine, in hemoglobin, 332, 340
 Distance-based tree-building, 205
 Distance matrix, 204–205
 Distributive enzymes, 1177
 Disulfide bonds:
 cysteine, 71, 71F
 insulin, 165F
 interchange reaction, 280F
 keratin, 235
 in native proteins, 292
 in protein sequencing, 168–169, 172, 184
 and protein stability, 264–265
 Divergent evolution, 254, **317**
 Dixon, J., 736
 DL3, 714
 D-loops, 1213
 DM (myotonic dystrophy), 1252
 DMB (5,6-dimethylbenzimidazole), 954
 DMF (*N,N*-dimethylformamide), 134, 262
 DMS (dimethyl sulfate), 1267
 DMSO (dimethyl sulfoxide), 43T, 134, 262
 DNA (deoxyribonucleic acid), 3, 18, 1145.
 See also related topics, e.g.: DNA repair
 A-DNA, 1146F, 1147F, **1148–1149**,
 1148T, 1151
 B-DNA, 1145–1148, *see* B-DNA
 as carrier of genetic information, **85–88**
 and central dogma of molecular biology,
 95, 1260
 chemical structure, **84–85**
 cloning, *see* Molecular cloning
 complementary base pairing, 18
 decay of, 116–117
 denaturation and renaturation, 90–93,
 92F, 93F
 double helical structure, **1145–1148**
 fractionation, 156–159
 frictional ratio, 155
 junk, 1317
 mutation of, *see* Mutations
 in nucleus, 8–9
 replication, 18F, 90, 101–104, 102F
 sedimentation coefficients, 154F
 semiconservative replication, 1173–1174
 semidiscontinuous replication,
 1175–1176, 1175F
 size, 94–95
 structure, 18F
 supercoiled, **1158–1170**
 transcription, 95–98
 X-ray diffraction, 88F
 Z-DNA, 1146F, 1147F, 1148T, **1149–1151**
 DnaA boxes, 1194, 1195
dnaA gene, 1196
 DnaA protein, 1194–1195, 1206
dnaB gene, 1182T
 DnaB helicase, 1191, 1193–1194
 DNA-binding domain, 705
 DnaB protein, 1206
 in prokaryotic replication, 1190, 1190T,
 1191, 1195, 1199
 in unwinding of DNA, 1183, **1184**, 1184T
 DNA chips, *see* DNA microarrays
 DnaC protein, 1190, 1190T, 1195, 1206
 DNA Data Bank of Japan (DDBJ), 195T
 DNA-directed DNA polymerases, *see* DNA
 polymerases
 DNA-directed polymerases, 1173. *See also*
 DNA polymerases
dnaG gene, 1176
 DNA glycosylases, 1218
 DnaG protein, 1190T
 DNA gyrase, 1166–1169, **1174–1175**,
 1190, 1195
 DnaJ, 293
 DnaK, 293
 DNA ligase, 103, 103F, 1176
 in DNA replication, **1187–1188**,
 1188F, 1189F
 in mismatch repair, 1220
 DNA ligase IV, 1224
 DNA methylation, **1246–1252**
 DNA methyltransferase, 104, 105
 DNA microarrays, **211–213**, 211F, 212F,
 213F
dnaN gene, 1182T
 DNA photolyases, 1214–1215, 1215F
 DNA polymerase, 101–103, 102F,
 1173–1174, 1174F
 bypass, 1222
 error-prone, 1222
 eukaryotic, 1202–1205, 1203T
 intercalating agents inhibit, 1272
 nucleotidyl transferase mechanism, 1180F
 in PCR, 114–115
 properties of selected animal, 1203T
 replication fidelity, 1200–1201, 1201F
 RNA-directed, 95F, 116
 and semidiscontinuous replication,
 1175–1176
 and TERT, 1210
 T7 DNA polymerase, 179
 DNA polymerase α (pol α), 1202–1203
 DNA polymerase β (pol β), 1205
 DNA polymerase γ , *see* Pol γ
 DNA polymerase δ , *see* Pol δ
 DNA polymerase ϵ , *see* Pol ϵ
 DNA polymerase ζ , *see* Pol ζ
 DNA polymerase η , *see* Pol η
 DNA polymerase ι , *see* Pol ι
 DNA polymerase κ , *see* Pol κ
 DNA polymerase I (Pol I), 103, 103F,
 1176–1181
 in bacteriophage ϕ X174 replication, 1191
 in bacteriophage M13 replication, 1190F
 error correction, 103–104
 error rate, 1220
 as A family polymerase, 1202
 in gene manipulation, 109
 role in recombination repair, 1234
 in site-directed mutation, 119
 T. thermophilus, 1179F
 use in nucleic acid sequencing, 177–179
 DNA polymerase II (Pol II), **1181**, 1181T
 as B family polymerase, 1202
 role in SOS repair, 1222
 DNA polymerase III (Pol III), 103, **1182–1183**
 as C family polymerase, 1202
 error correction, 103–104
 role in mismatch repair, 1220
 DNA polymerase IV (Pol IV), 1182, 1222
 DNA polymerase V (Pol V), 1182, 1222
 DNA polymerase A family, 1202, 1205
 DNA polymerase B family, 1202
 DNA polymerase C family, 1202
 DNA polymerase D family, 1202
 DNA polymerase X family, 1202
 DNA polymerase Y family, 1202
dnaQ gene, 1182T
 DNA recombination, *see* Recombination
 DNA repair, **1213–1225**
 and carcinogen identification, 1224–1225
 direct damage reversal, 1214–1216
 double-strand break repair, **1223–1224**
 excision repair, **1216–1219**
 mismatch repair, **1220**
 and Pol I, 1181
 and replication fidelity, 1200–1201
 and SOS response, 1221–1223
 DNA replicase, 1182
 DNA replication, 18–19, 1145, **1173–1174**.
 See also related topics, e.g.: DNA ligase
 enzymes for, 1176–1189
 in eukaryotes, **1201–1213**
 in meiosis, 21F
 in mitosis, 20F
 overview, 1173–1176
 in prokaryotes, 1173, **1190–1201**, 1200F
 semiconservative nature of, 90, 91F,
 1173–1174
 semidiscontinuous, 1175–1176, 1175F
 telomeres, 1209–1213
 unwinding, 1183–1187
 and viruses, 27
 DNA–RNA hybrids, 96, 1151, 1151F
 DNase I, 1181
 DNA sequencing:
 automated, 179–180
 genome sequencing, 180–182
 Sanger method, 176–180
 sequence databases, 194–195
 DNA topoisomerases, 1176
 DnaT protein, 1190, 1190T
 DNA unwinding elements (DUEs), 1194
dnaX gene, 1182T
 DNMT1, 1250
 DNMT3a, 1250
 DNMT3b, 1250
 DNP (2,4-dinitrophenol), 860
 dNTPs (deoxynucleoside triphosphates):
 in chain-terminator method, 177–179
 in DNA replication, 101, 1170, 1174F
 and replication fidelity, 1200–1201
 Docking proteins, 420, 710
 4,7,10,13,16,19-Docosahexenoic acid,
 see DHA
 Dodecyltriethylammonium bromide
 (DTAB), 399F
 Dodson, E., 1216
 Dogs:
 fatty acid experiments with, 945
 number of chromosomes, 19T
 Dolichol, 883, 883F
 Dolichol-P-mannose, 884
 Dolichol-PP-oligosaccharide synthesis,
 884F, 885
 Domains:
 of life, 6
 of proteins, **247**, 281
 Domain swapping, 718
 Dominant traits, 20–22
 DON (6-Diazo-5-oxo-L-norleucine), 1142
 Donnan equilibrium, 787
 Donohue, J., 88
 Dopamine, 80, 80F, 783, 1058–1060
 Dopamine β -hydroxylase, 1060F
 Dopamine receptors, 689
 Dot matrices, sequence alignment using,
 196–197, 197F
 Dot plot, 196
 Double blind tests, 542–543
 Double-displacement reactions, 499

- Double helical structure, of DNA, **88–90**
 Double-reciprocal plot, 490, 490F, 494F–496F, 499F, 500F
doublesex (dsx) pre-mRNA (*Drosophila melanogaster*), 1318
 Double-sieve mechanism, 1356
 Double-strand breaks, *see* DSBs
 Double-stranded DNA, *see* dsDNA
 Double-stranded RNA, *see* dsRNA
 Double-stranded RNA-activated inhibitor (DAI), 1400
 Double-stranded RNA-activated protein kinase (PKR), 1400
 Doublié, S., 1303
 Doubly wound sheets, 254, 255F
 Douce, R., 1032
 Doudna, J., 1324
 Down mutations, 1266
 Down's syndrome, 312
 Doxorubicin, 1169, 1170
 DPG (2,3-diphosphoglycerate), **329**
dp gene (fruit fly), 25F
 Dpo4, 1222, 1222F
 Drew, H., 89, 1148
 Driving force, 587
 drk protein, 709
 DRMs (detergent-resistant membranes), 411
 Drosha, 1325
Drosophila melanogaster, 23F
 alternative splicing, 1318, 1319F
 cacophony pre-mRNA, 1322
 chromosome number, 19T
 complementation test, 25F
 DNA, 94, 94T, 95F
 Dscam protein, 1318
 genetic experiments, 23–26
 genetic map, 25F
 genome sequencing, 113, 177T, 182
 mitochondria, 1344T
 per gene, 120F
 26S proteasome, 1411F
 replication, 1176F, 1202, 1205F
 RNA interference, 1324
 spliceosomes, 1312F
 transposons, 1244, 1246
 ubiquitin, 1409
 Drugs, 78, 396, 968
 Drug design, **539**
 cytochromes P450, 543–545
 discovery techniques, **539–541**
 HIV protease and its inhibitors, **545–551**
 pharmacology, **542–545**
 structure-based, 541
 Drug discovery, **539–541**
 Drug–drug interactions, 544
 Druker, B., 719
 DSBs (double-strand breaks), 1223–1224, 1235F
 Dscam protein, 1318
 dsDNA (double-stranded DNA), 18F
 detection by electrophoresis, 158, 158F
 Klentaq1, 1180
 replication, 102–103, 1174
 from semiconservative replication, 90
 dsRNA (double-stranded RNA), 85, 1323
 DSX-F protein, 1318
 DSX-M protein, 1318
dsx (doublesex) pre-mRNA (*Drosophila melanogaster*), 1318
 DT, *see* Diphtheria toxin
 DTAB (dodecyltriethylammonium bromide), 399F
 dTMP, *see* Deoxythymidine monophosphate
 DUBs (deubiquitinating enzymes), 1417–1418, 1420–1421
 Ducruix, A., 709
 DUEs (DNA unwinding elements), 1194
 Dunathan, H., 1033
 Dunn, M., 1078
 Duplex DNA, 90, 1159F. *See also* dsDNA (double-stranded DNA)
 dUTP, 1218
 dUTP diphosphohydrolase (dUTPase; dUTP pyrophosphate), 1126
 Dutton, L., 841
 Dutzler, R., 755
 du Vigneaud, V., 205
 Duydens, L., 909
 Dwarfism, 685
 Dyad axes, 89F
 Dynamic mutations, 1251–1252
 Dynammin, 436
 Dynamite, 743
 Dynein, 440
 Dystrophin, 1305
 E
 E1, *see* Pyruvate dehydrogenase; Ubiquitin-activating enzyme
 E1b, 799
 E1 (Enzyme I), of PTS system, 765
 E1o, *see* α -Ketoglutarate dehydrogenase
 E1p, 799
 E1 protein:
 of bovine papillomavirus, 1184–1185, 1185F
 and Rho factor, 1275–1276
 E2, *see* Dihydrolipoyl transacetylase; Ubiquitin-conjugating enzyme
 EIIA, of PTS system, 765, 767F
 EIIB, of PTS system, 765
 EIIC, of PTS system, 765
 EII, of PTS system, 765
 E2o (dihydrolipoyl transsuccinylase), 810
 E3, *see* Ubiquitin-protein ligase
 E3a, 1413, 1414
 E3b, 799
 E3 binding protein (E3BP), 798
 E3o, 799
 E3p, 799
 E4P, *see* Erythrose-4-phosphate
 E6-associated protein (E6AP), 1414
 E6 protein, 1414
E. coli, 4–5, 4F. *See also* Bacteriophages; *specific genes*
 χ^{1776} strain, 123
 Ada protein, 1216
 ampicillin resistant, 26
 aspartokinase isoenzymes, 1075T
 BAC replication in, 109
 and bacteriophages, 27F, 28, 86F, 87, 87F, 1340
 biological structures, 14, 15F
 carbamoyl phosphate synthetase, 1027–1028
 catabolite repression, 1285–1288
 CCA-adding polymerase, 1331
 chromosome replication, 1195
 cloning of, 104
 DNA conservation experiments, 90, 91F
 DNA ligase, 1188, 1188F, 1189F
 DNA methylation, 1247
 DNA of humans vs., 8–9
 DNA repair, 1214
 DNA replication, 102F–104F, 103, 104
 DNA size, 94T
 elongation cycle, 1380F
 enzyme induction, 1260–1264
 fMet, 1374
 genome sequencing, 113, 177T
 GroEL/ES system, 294–302
 heat shock proteins, 293, 294
 homologous recombination, 1228–1230
 inclusion bodies, 117, 117F
 internal structure, 5F
 isocitrate dehydrogenase, 817
lac operon, 97, 97F
 membrane of, 398T
 mismatch repair, 1220, 1220F
 molecular composition, 5T
 multiforked chromosomes, 1195, 1195F
 nonsense suppressors, 1362, 1362T
 nucleotide excision repair, 1217
 Pol I, 1176–1181, 1181T
 Pol I Klenow fragment, 1178F
 Pol II, 1181, 1181T
 Pol III, 1181T, 1182–1184, 1182T, 1183F
 Pol IV, 1182
 Pol V, 1182
 pre-mRNA splicing, 1312
 primase, 1188–1189, 1189F
 promoters, 1266, 1267F
 pUC18 cloning vector, 107, 107F, 111
 pyrimidine synthesis regulation, 1118F
 pyruvate dehydrogenase complex, 792, 793F
 RecBCD, 1231, 1231F
 replication, 1174F, **1192–1200**, 1193F
 replication in, 1183–1187, 1184T
 replication rate, 1174–1175
 replisome, 1196F
 Rho factor, 1276F
 ribosome complements, 1363T
 ribosomes, 367F, 1363–1365, 1363F–1366F, 1370–1371
 RNAP, 1265–1266
 RNA primers, 1176
 RNAP subunits, 1277T
 RuvABC in, 1231
 semidiscontinuous replication, 1175
 shuttle vectors, 118
 σ factors, 1284
 simultaneous transcription and translation, 1283F
 as source of proteins for purification, 130
 termination pathway in ribosomes, 1391F
Ter sites and *oriC* locus, 1199F
 thymine dimer effect, 1214–1215
 topoisomerase III Y328F mutant, 1163–1165, 1164F
 TPP-sensing riboswitch, 1300, 1300F
 transcription in, 1271–1273, 1273F, 1284–1301
 translation in, 1375F, 1376F
 tRNA genes, 1330
 two-dimensional gel electrophoresis of, 152F
 type II restriction enzymes, 105T
 UV absorbance spectra of nucleic acids and DNA, 92F
 E54K mutation, 1239
 Ealick, S., 1116
 Early endosome antigen 1 (EEA 1), 734, 735F
early genes, 1284
 Eaton, W., 346, 353
 4E-BP1, 1401
 4E-BP2, 1401
 4E-BP3, 1401
 Ebright, R., 1286, 1287
 EBS (epidermolysis bullosa simplex), 235
 Echinoderms, 13F
 Eck, M., 716, 721
 Eclipsed conformation, 222, 223F
 EcoRI, 105, 105F, 105T, 106
 EcoRII, 105T

- EcoRV, 105–106, 105F, 105T, 109
 ECS (editing site complementary sequence), 1323F
 Ectodomains, 453, 684
 ED₅₀, 539
 Edema factor (EF), anthrax, 715
 Edidin, M., 408
 Editing:
 of DNA chain, 1170, 1201
 of tRNA, 1355–1358
 Editing site complementary sequence (ECS), 1323F
 Editosome, 1321–1322
 Edman, P., 165, 171
 Edman degradation, 165, 167F, 171, 172, 174
 Edman's reagent, 165, 167F
 EDTA (ethylenediaminetetraacetic acid), 157
 EEA 1, *see* Early endosome antigen 1
 eEF1A, 1388, 1389F
 eEF1B, 1388
 eEF1B α , 1388, 1389F
 eEF1B β , 1388
 eEF2, 1388, 1398, 1405
 EF, *see* Edema factor; Elongation factor
 EF1A, 1379
 EF1B, 1379
 EF2, 1385–1386
 Effectors, 348, 442, 625T, 688
 EF-G, 1375T, **1385–1388**, 1386F
 EF hands, 656
 Efstradiadis, A., 1306
 EF-Ts, 1375T, 1379, 1381–1382, 1382F
 EF-Tu, 1375T
 in chain initiation, 1382F, 1386, 1386F, 1388
 and Gln-tRNA^{Gln}, 1358
 and initiator tRNA, 1380–1381, 1381F
 and translational accuracy, 1390–1391
 Egelman, E., 1228
 EGF, *see* Epidermal growth factor
 EGF receptor, 699
 EH, *see* Enoyl-CoA hydratase
 E Helix, 242F
 EHK (epidermolytic hyperkeratosis), 235
 Ehlers-Danlos syndromes, 240, 1404
 Eicosanoid metabolism, 993–997
 for leukotrienes and lipoxins, 996F,
 1000–1004
 for prostaglandins, prostacyclins, and
 thromboxanes, 996F, **997–1000**
 Eicosanoid receptors, 689
 5,8,11,14,17-Eicosapentaenoic acid, *see* EPA
 8,11,14-Eicosatrienoic acid, 994
 eIF1A, 1376
 eIF2, 1376, 1399–1401
 eIF2 α , 1399–1401
 eIF2B, 1379, 1399
 eIF2 α kinases, 1399
 eIF2 phosphatase, 1399
 eIF3, 1376
 eIF4A, 1378
 eIF4B, 1365, 1379
 eIF4E, 1378, 1399, 1401
 eIF4F, 1378
 eIF4G, 1327, 1378
 eIF4H, 1379
 eIF5, 1379
 eIF5B, 1379
 eIF n , 1376, 1378
 80S subunit (ribosome), 1370T, 1371, 1371F
 Einstein (unit), 903
 Eisenberg, D., 310, 929, 1068, 1315
 EJC (exon junction complex), 1326–1327
 Eklund, H., 934, 1119, 1122
 Elastase, 525, 525T, 529T
 gene duplication, 194
 proenzymes, 538
 specificity, 169T
 X-ray structure, 528F, 530, 534–535, 535F
 Elasticity coefficient, 622
 Elastin, 240, 529
 Electrical synapses, 778
 Electric fish, 779–780
 Electroblothing, 111
 Electrochemical cells, 584, 584F
 Electrochemical potential, 745
 Electromotive force (emf), 584
 Electron acceptor, 584
 Electron density, 241
 Electron density maps, 241–242, 242F
 Electron donor, 584
 Electronic complementarity, Watson–Crick
 base pairs, 1155–1156
 Electron pairs, acids/bases and, 45
 Electron paramagnetic resonance (EPR), 911
 Electron paramagnetic spectroscopy, 911
 Electron spin resonance (ESR) spectroscopy, 911
 Electron-transfer flavoprotein (ETF), 948
 Electron-transfer reactions, 586
 Electron transport, 188, 386, 823, **828–845**.
 See also Oxidative phosphorylation
 and acyl-CoA reoxidation, 948
 Coenzyme Q: Cytochrome *c*
 oxidoreductase, 832T, 840–841, 841F
 components of, **833–845**
 cytochrome *c* oxidase, 832T,
 841–845, 842F
 inhibitor studies, 831, 831F
 in mitochondria, **823–828**
 NADH: Coenzyme Q reductase, 832T,
 834–835
 net reaction, 824F, 829–830, 829F
 P/O ratio, 831–833, 833F
 in purple photosynthetic bacteria,
 909–913, 913F
 reduction potentials of components in
 testing mitochondria, 832T
 rigid coupling of phosphorylation and
 oxidation, 831–833
 sequence of, **829–833**
 thermodynamics, **828–829**
 two-center, in photosynthesis, 913–925
 Electron tunneling, 841
 Electrophiles, 563–564, 563F
 Electrophilic catalysis, 510
 Electrophoresis, 132T
 capillary, 152
 gel, 147–150
 isoelectric focusing, 150–152
 nucleic acids, **158–159**
 paper, 146–147
 proteins, **146–152**
 SDS–PAGE, 150
 Electrophoretic mobility, 146
 Electroplaques, 779, 779F
 Electrospray ionization (ESI), 172
 Electrostatic forces, protein stability and,
 259–261
 Elements, periodic table, 31F
 Elemental composition, humans, 29T
 Elementary reactions, **483**
 11S regulator, 1418–1419
 Elimination reactions, **566–567**, 567F
 Elion, G., 1130
 ELISA, *see* Enzyme-linked immunosorbent
 assay
 Ellis, J., 293
 Elongases, **969–971**
 Elongation factor (EF), 422–423,
 1375T, **1379**
 Elution, in ion exchange chromatography, 136
 Embden, G., 595
 Embden–Meyerhoff–Parnas pathway, 595.
 See also Glycolysis
 EMBL Nucleotide Sequence Database,
 195T
 Embryogenesis, 1250–1251, 1401
 Embryological development, 14F
 Embryonic stem cells, 121
 Emergent properties, 738
 Emf (electromotive force), 584
 Enantiomers, 74–76, 74F
 Endergonic processes, 57
 End groups, amino acid, 165–168
 Endo, T., 446
 Endo conformation, 1153, 1153F
 Endocrine glands, 671, 672F
 Endocrine hormones, 671
 Endocrine system, 672F
 Endocytosis, 8, 433, 454F, 986, 986F
 Endoglycosidases, 366
 Endonucleases, 1160, 1407–1408. *See also*
 Restriction endonucleases
 Endopeptidases, 169–170, 169T, 194
 Endopeptidase Arg-C, 169T
 Endopeptidase Asp-N, 169T
 Endopeptidase Glu-C, 169T
 Endopeptidase Lys-C, 169T
 Endoplasmic reticulum (ER), 7F, 9, 11F
 metabolic functions, 562T
 rough, *see* Rough endoplasmic reticulum
 secretory pathway in, 420–424
 smooth, *see* Smooth endoplasmic reticulum
 β -Endorphin, 673T, 685
 Endosomes, 455F
 Endothelial NOS (eNOS), 686–688
 Endothelium, 686
 Endothermic processes, 53
 Endotoxins, 688
 δ -Endotoxins, 122
 End point, of titration, 51
 Enediolate anion, 567
 Energy, **53**
 conservation of, 52–54
 and evolution, 34
 metabolic processes, 17
 for prokaryotes, 5–6
 Energy barrier, to free rotation of
 polypeptide backbone, 222–223
 Energy coupling, 845
 Energy metabolism strategies, 1088–1090
 Energy-rich bonds, 580
 Energy-rich compounds, *see* High-energy
 compounds
 Energy surface, in landscape theory, 287
 Energy transduction, 587, 845
 Engelman, D., 1365
 Englander, W., 285
 Englemann, T., 901
 Enhancers, 1282–1283, 1337
 Enolase, 567, 596F, **612–613**, 613F
 Enolate, 568, 569F
 Enol forms, of nucleotide bases, 88
 Enol phosphates, 580
 5-Enolpyruvylshikimate-3-phosphate
 synthase (ESPS-synthase), 1075
 eNOS (endothelial NOS), 686–688
 Enoyl-ACP reductase (ER), 965
 Enoyl-CoA hydratase (EH), 947, 947F,
 948, 958
 Enoyl-CoA isomerase, 950
 3,2-Enoyl-CoA isomerase, 952
 Enteropeptidase, 537

- Enthalpy, **53–54**
 Entner–Doudoroff pathway, 636–637
 Entropy, **55–57**
 of peptidyl transferase reaction, 1384–1385
 and protein folding, 284, 287
 and temperature, 56F
 unitary entropy change, 263T
 env, 1246
 Enzymatic interconversion, *see* Covalent modification
 Enzymes, 4, 163, **469–479**. *See also specific enzymes*
 activity control, 474–479
 allosteric control, 476–479
 in assays, 131
 catalytic activity of, 243
 chemical catalysis vs., 469
 coenzymes, **473–474**
 for DNA replication, 1176–1189
 DNA replication error repairing, 103–104
 feedback inhibition control for, 475
 geometric specificity, **472–473**
 as globular proteins, 241
 historical perspective, 469–470
 for liposome delivery, 396
 nomenclature, **479**
 one gene-one enzyme maxim, 26
 processive and distributive, 1177
 selective catalysis by, 588–589
 stereospecificity, **470–472**
 substrate specificity, **470–473**, 470F
 Enzyme I (EI), of PTS system, 765
 Enzyme catalysis. *See also* Drug design
 acid–base catalysis, **506–510**
 covalent catalysis, **510–511**
 electrostatic catalysis, **512**
 lysozyme, **517–525**
 metal ion catalysis, **511–512**
 and preferential transition state binding, **515–516**, 516F
 and proximity/orientation effects, **512–515**
 serine proteases, **525–537**
 zymogens, **537–538**
 Enzyme Commission, 470
 Enzyme induction, 1260–1264
 Enzyme inhibition, **493–496**
 Enzyme kinetics, 482, 487–492
 bisubstrate reactions, **497–501**
 competitive inhibition, **493–494**
 data analysis, **490–491**
 and flux control coefficient, 621–622
 Haldane relationship, **491–492**
 Michaelis–Menten kinetics, **488–491**, 496–497, 501–503
 mixed inhibition, **495–496**
 pH effects, **496–497**
 reversible reaction, **491–492**
 uncompetitive inhibition, **495**
 Enzyme-linked immunosorbent assay (ELISA), **131–132**, 132F
 Enzyme-substrate complex, 470F, **488**
 Enzymology, 469
 EPA (5,8,11,14,17-eicosapentaenoic acid), 387T, 971, 994, 1002–1003
 Epidermal growth factor (EGF), 453–454, 997, 1317
 Epidermal growth factor (EGF) receptor, 699
 Epidermis, 16F
 Epidermolysis bullosa simplex (EBS), 235
 Epidermolytic hyperkeratosis (EHK), 235
 Epigenetic genome changes, 1249–1250
 Epigenetic reprogramming, 1250–1251
 Epimers, 361
 Epimerization, 567
 Epinephrine, 673T, **679–680**
 in fatty acid metabolism regulation, 973
 in glycogen metabolism regulation, 660
 synthesis, 1058–1060
 Epithelial cells, 373, 410
 Epitopes, 205
 EPO, *see* Erythropoietin
 Epoxy-activated agarose, 142, 143F
 2',3'-Epoxy-ATP, 1180
 EPR (electron paramagnetic resonance), 911
 E protein, 1314
 Equatorial groups, in sugars, 363
 Equilibrium, 55, **58–61**, 587
 Equilibrium constants, 45–47, 58–59, 58T
 Equilibrium density gradient ultracentrifugation, 90, 91F, 155, 156, 159
 Equilibrium thermodynamics, 587–588
 Equivalence point, 48
 ER, *see* Endoplasmic reticulum; Enoyl-ACP reductase
 Erabutoxin, 781
 ERAD process, 427
 Erbitux, 720
 eRF1, 1392
 eRF3, 1392
 Ergocalciferol, 678
 Ergosterol, 393, 678
 ERKs (extracellular-signal-regulated kinases), 713
 Ernst, O., 694
 ERp57, 886
 Error catastrophe, 587
 Error correction:
 in DNA replication, 103–104
 in RNA replication, 1281, 1281F
 Error-prone DNA polymerases, 1222
 Erythromycin, 1395T, 1396F
 Erythrocyte ghosts, 325
 Erythrocytes, 324–325
 heme synthesis regulation, 1055–1056
 and sickle-cell anemia, 185–188, 185F, **343–347**
 Erythrocyte glucose transporter, 746–748, 746F, 747F
 Erythrocyte membranes, **411–414**, 411F
 and blood groups, **414–415**
 composition, 398T
 freeze-etch micrograph, 410F
 glycophorin A, 401F
 Erythromycin A, 968, 969F
 Erythropoietic protoporphyria, 1055
 Erythropoietin (EPO), 119, 123, 717
 D-Erythrose, 360F
 Erythrose-4-phosphate (E4P), 636, 896, 929
 D-Erythrulose, 361F
 Escherich, T., 4
Escherichia coli, *see E. coli*
 ESEs, *see* Exonic splicing enhancers
 ESI (electrospray ionization), 172
 ESI-MS, 173
 E (exit) site, 1373, 1385, 1387
 ESPS-synthase (5-enolpyruvylshikimate-3-phosphate synthase), 1075
 ESR (electron spin resonance) spectroscopy, 911
 Essen, L.-O., 1215
 Essential amino acids, 1019, 1065T, **1072–1078**
 Essential fatty acids, 971
 ESSs (exonic splicing silencers), 1306
 Esters, rates of reaction and motional freedom, 515T
 β-Estradiol, 681
 Estrogens, 458, 673T, 680, 991
 ESTs (expressed sequence tags), 181
 ETF (electron-transfer flavoprotein), 948
 ETF:ubiquinone oxidoreductase, 837, 948
 Ethanol, 783. *See also* Yeast alcohol dehydrogenase
 dielectric constant and dipole moment, 43T
 from Entner–Doudoroff pathway, 636, 637F
 from fermentation, 616
 prochiral atoms of, 77F
 protein solubility in, 134
 Ethanolamine, 389T, 390, 1004
 Ethics, of gene therapy, 123–124
 Ethidium ion, 157, 1161–1162, 1162F
 Ethyl-CoA, 874
 Ethylenediaminetetraacetic acid (EDTA), 157
 Ethylene glycol, 265
 O⁶-Ethylguanine residues, 1216
 N-Ethylmaleimide (NEM), 440–441
 Ethylnitrosurea, 1340
 Etoposide, 1169, 1170
 Eubacteria, 6, 192
 Euchromatin, 182
 Eukarya, 6, 7F
 Eukaryotes, 3, **6–14**
 cellular architecture, 8–12
 chromosome number, 19T
 citric acid cycle in, 789
 DNA, 86, 88, 94T
 DNA methylation, 1248–1251
 DNA replication, **1201–1213**
 evolution of, 13F, 34
 genome sequencing, 176
 glucose transporters, 751
 introns of, 1316
 metabolic pathway location, 562
 mismatch repair, 1220
 mRNA posttranscriptional modification, 1302–1327
 nuclear pores of, 1327
 nucleotide excision repair, 1217
 phylogeny and differentiation, 12–14
 polypeptide synthesis, 1376–1379, 1388, 1392
 RecA-like proteins, 1230
 ribosomes, 1369–1371
 rRNA processing, 1328–1329
 secretory proteins, 421F
 translational in, 1376–1379, 1377F
 translation in, 1398–1402
 transposons, 1244–1246
 Eukaryotic gene expression:
 in bacteria vs. eukaryotic cells, 118–119
 and colony hybridization, 114
 and mRNA lifetime, 101
 posttranscriptional modification, 97–98
 RNAP, 96, 1276–1283
 transcriptional initiation, 96
 European corn borer, 122
 Evans, M., 262
 Evans, R., 1104
 Even-chain fatty acids, 945F
 Evolution, **29**, 30F. *See also* Chemical evolution; Mutations
 of citric acid cycle, 814–815
 convergent and divergent, 252, 254, **317**, 531
 and divergence of kingdoms, 192
 of protein structures, 316–318
 and transposition, 1242
 Evolutionary distance, 189
 Evolutionary tree, 13F
 Excinuclease, 1217
 Excision repair, **1216–1219**
 Excitatory synapses, 778
 Exciton transfer, 905

- Exclusion limit, in gel filtration chromatography, 138
- Exercise, ATP for, 1092F
- Exergonic processes, 57
- Exit site, *see* E site
- Exo conformation, 1153, 1153F
- Exocrine gland, 675
- Exocytosis, 8, 440F, 751–752
- Exoglycosidases, 366
- Exons, 98, **1304–1305**
cassette, 1318
and protein modules, 1317
splicing, 1305–1308
- Exonic splicing enhancers (ESEs), 1306, 1314
- Exonic splicing silencers (ESSs), 1306
- Exon junction complex (EJC), 1326–1327
- Exon skipping, 1314
- 3' → 5' Exonuclease, 103–104, 104F
Pol I, 1177, 1180–1181
and reverse synthesis of DNA, 1200–1201, 1201F
- 5' → 3' Exonuclease, 103, 103F
in chain-terminator method, 177
Pol I, 1177, 1181
- Exonuclease I, 1220
- Exonuclease VII, 1220
- Exopeptidases, 165–166, 168T
- Exosomes, 1327, 1327F
- Exothermic processes, 53
- Expressed sequences, 97, **1304**
- Expressed sequence tags (ESTs), 181
- Expression, *see* Gene expression
- Expression platform, 1300–1301
- Expression profile, 213
- Expression vector, 117
- Exteins, **1405**, 1406F, **1407**
- Extensive quantities, 61
- External nodes, phylogenetic trees, 203, 203F
- Extracellular-signal-regulated kinases (ERKs), 713
- Extrinsic membrane proteins, 400
- Ex vivo* gene therapy, 122
- Eyring, H., 484
- F
- F1,6P, *see* Fructose-1,6-bisphosphate
- F₁F₀-ATPase (Complex V, proton-translocating ATP synthase), 758, **852–859**, 865
- FIP, *see* Fructose-1-phosphate
- F2,6P, *see* Fructose-2,6-bisphosphate
- fC (5-Fluorocytosine) residue, 1248
- F6P, *see* Fructose-6-phosphate
- FAAH, *see* Fatty acid amide hydrolase
- Fab New hemoglobin fragment, 251F
- Fabry's disease, 1013T
- Facilitated diffusion, 420, **750–752**
- Factor IX, 1317
- Factor X, 1317
- Facultative anaerobes, 6
- FAD (flavin adenine dinucleotide), 82, 790F
biosynthesis, 1138
in catabolism, 561F
in citric acid cycle, 791, 794, 795T
reactions of, 565, 566F
- FADH• (flavin adenine dinucleotide, radical form), 565F
- FADH₂ (flavin adenine dinucleotide, fully reduced form), 565F
in catabolism, 561F
in citric acid cycle, 789, 790F, 791, 819
in electron-transport chain, 823, 824F, 828, 829
- FAD pyrophosphorylase, 1138
- FAICAR (5-formaminoimidazole-4-carboxamide ribotide), 1109F, 1111
- Familial amyloid polyneuropathy, 310
- Familial Creutzfeldt–Jakob disease, 314
- Familial hypercholesterolemia (FH), 456–457, 466, 989
- Familial type III hyperlipoproteinemia, 459
- Faraday (unit), 53T, 584
- Farber's lipogranulomatosis, 1013T
- Farnesyl group, 406, 838
- Farnesyl pyrophosphate (FPP), 978, 979F
- Farnesyl pyrophosphate synthase, 978
- FAS, *see* Fatty acid synthase
- Fasman, G., 302, 303
- Fast-twitch muscle fibers, 619
- Fat, *see* Adipose tissue
- Fats, 940. *See also* Triacylglycerols
- Fatal familial insomnia (FFI), 314
- Fat cells, *see* Adipocytes
- Fat-soluble vitamins, 474, 993
- Fatty acids, **386–388**
activation, **945–946**, 946F
in citric acid cycle, 789
essential, 971
glycogen vs., 638
and insulin resistance, 1102, 1103F
names of, 387T
transport in blood, 973
- Fatty acid amide hydrolase (FAAH), 404–406, 405F
- Fatty acid anions, 44, 44F
- Fatty acid biosynthesis, 964F
acetyl-CoA carboxylase, **962–964**
carbon–carbon bond formation, 965F
citric acid cycle intermediates, 818
elongases and desaturases, **969–971**
fatty acid synthase, **964–968**
mitochondrial acetyl-CoA transport, **968–969**
and other pathways, 1089–1090
regulation, 974F
triacylglycerol synthesis, **971–973**, 972F
- Fatty acid oxidation, **945**
and AMP-dependent protein kinase, 1096
glycolysis inhibition, 864
hormonal regulation, 973–975, 974F
minor pathways, **958–959**
odd-chain fatty acids, **952–957**
and other pathways, 1089–1090
β oxidation, **947–950**, **958**
regulation, **973–975**, 974F
and transport, 946–947, 946F
unsaturated fatty acids, **950–952**
- ω – 3 Fatty acids, 1003
- ω – 6 Fatty acids, 1003
- Fatty acid synthase (FAS), 568, 962, **964–968**
- Fatty acylated proteins, 407
- Fatty acyl-CoA, 947F
- Fatty acyl-CoA desaturases, 970–971, 971F
- Fatty streak lesions, 458
- Favism, 897
- FBLD (fragment-based lead discovery), 541–542
- F-box, 1412, 1413F
- F-box protein family, 1412
- FBP, *see* Fructose-1,6-bisphosphate
- FBPase, *see* Fructose-1,6-bisphosphatase
- FBPase-2 (fructose bisphosphatase-2), 663
- FC0 mutation (phage T4), 1340
- FC1 mutation (phage T4), 1340
- FC2 mutation (phage T4), 1340
- FC3 mutation (phage T4), 1340
- FC4 mutation (phage T4), 1340
- FC5 mutation (phage T4), 1340
- FCCP (carbonylcyanide-*p*-trifluoromethoxyphenylhydrazone), 860
- F⁺ cell, 1262–1263
- F[−] cell, 1262–1263
- Fd, *see* Ferredoxin
- FDP (fructose-1,6-diphosphate), 600
- FdUMP (5-fluorodeoxyuridylate), 1127–1129
- Feathers, 233
- Feedback inhibition, 474–479, 620, 623–624
- Feher, G., 910
- Feigon, J., 1212
- Female sex hormones, 681
- FeMo-cofactor, 1081–1082
- Fen (fenfluramine), 543
- FEN-1 (flap endonuclease-1), 1207
- Fenfluramine (fen), 543
- Fenn, J., 172
- Fen-phen, 543
- Fe-protein, 1080–1082
- Fermentation, 6, 469–470, 593–594
alcoholic, 593–594, **616–619**
energetics, 619
homolactic, 593, **614–616**
- Ferns, 13F
- Ferredoxin (Fd), 835, 835F, 934F
- Ferredoxin-NADP⁺ reductase (FNR), 924, 924F
- Ferredoxin-thioredoxin reductase (FTR), 933–934, 934F
- Ferritin, 140F, **381**
- Ferrochelatase, 1055
- Fe–S cluster, *see* Iron–sulfur clusters
- Fesik, S., 707
- Fetal hemoglobin, 193–194, 331
- Fetulin, 140F
- F factor, 1262–1263
- F' factor, 1263
- Ffh polypeptide, 422
- FFI (fatal familial insomnia), 314
- FGAM, *see* Formylglycinamide ribotide
- FGAM synthetase (PurL), 1109F, 1110
- FGAR, *see* Formylglycinamide ribotide
- FGF, *see* Fibroblast growth factor
- FH, *see* Familial hypercholesterolemia
- Fibrillarlin, 1329
- Fibrils, 238–240
- Fibrin, 191, 310
- Fibrinogen, 191
in amyloid diseases, 310
frictional ratio, 155
isoelectric point (human), 134T
molecular mass, 140F
physical constants (human), 153T
solubility, 133F, 134
- Fibrinogen amyloidosis, 310
- [Glu¹]Fibrinopeptide B, 175F
- Fibrinopeptides, 190, 191F
- Fibroblasts, 9F, 454F, 1211–1212
- Fibroblast growth factor (FGF), 375, 700
- Fibroblast interferon, 1399
- Fibromodulin, 373T
- Fibronectin, 684
- Fibrous proteins, 226, **232–240**. *See also*
Collagen; Keratin
collagen, **235–240**
keratin in, **233–235**, 234F
- Fick's first law of diffusion, 745
- Fields, S., 705
- Fiers, W., 176
- 50S subunit (ribosome), 1363T, 1366–1368, 1368F, 1371, 1384F
- Fight or flight response, 664
- Filamentaceous bacteriophage M13, 108, 108F
- Fillingame, R., 853

- Filmer, D., 352
 Fingerprinting, 147, 174
 Finishing, 181
 Fink, G., 1245
 Finzel, B., 1151
 Fire, A., 1323
 FirstGlance, 256T, 257
 First law of thermodynamics, **52–54**
 First-order rate equation, 483–484
 First-order reactions, 483, 484F
 Fischer, A., 123
 Fischer, E., 70, 75, 352, 360, 470, 651, 722
 Fischer convention, **75–76**
 Fischer projections, 75, 75F
 Fish, embryonic development of, 14F
 Fission yeast, *see Schizosaccharomyces pombe*
 Fitzgerald, P., 549
 5' end, of nucleic acids, 84
 FK506, 292–293
 FK506 binding protein (FKBP12), 292, 293, 724–725
 FKBP12-rapamycin-associated protein (FRAP), 737F
 Flagella, 4, 4F, 10
 Flagellates, 7F
 Flagellin, 10, 1243, 1388
 FLAP, *see* 5-lipoxygenase-activating protein
 Flap endonuclease-1 (FEN-1), 1207
 Flatworms, trans-splicing in, 1320
 Flavin, 566
 Flavin adenine dinucleotide, *see* FAD
 Flavin adenine dinucleotide, fully reduced form, *see* FADH₂
 Flavin adenine dinucleotide, radical form (FADH•), 565F
 Flavin coenzymes, 473T, **1138**
 Flavin mononucleotide, *see* FMN
 Flavin mononucleotide, radical form, *see* FMNH•
 Flavin mononucleotide, reduced form, *see* FMNH₂
 Flavobacteria, 7F
 Flavodoxin, 135F
 Flavokinase, 1139F
 Flavoprotein, 801
 Flavoprotein dehydrogenase, 828, 828F
 Flavr Savr tomato, 1403
 Fleming, A., 376
 Fletterick, R., 433, 530, 640
 Flipases, 420
 Flip-flop, 396, 419–420
fljA gene, 1243
fljB gene, 1243
fljC gene, 1243
 Fluid mosaic model, of membranes, **408–411**
 9-Fluorenylmethoxycarbonyl (Fmoc) group, 207
 Fluorescamine, 149
 Fluorescence, 286, 904–905
 Fluorescence recovery after photobleaching (FRAP), 396–397, 396F
 Fluorescence resonance energy transfer (FRET), 284, 286, 286F, 299, 300
 Fluoroacetyl-CoA, 809
 Fluorochlorobromomethane, enantiomers, 74F
 Fluorocitrate, 809
 (2*R*,3*R*)-2-Fluorocitrate, 809
 5-Fluorocytosine (¹³C) residue, 1248
 5-Fluorodeoxyuridine, 1129
 5-Fluorodeoxyuridylylate (FdUMP), 1127–1129
 Fluorophore, 396
 5-Fluorouracil, 1129
 Flurbiprofen, 998
 Flux, 589, 593, 619, 745
 Flux control coefficient, 620–622
 fMet, *see* *N*-Formylmethionine
 fMet-tRNA^{Met}_f, **1373–1374**, 1376
 FMN (flavin mononucleotide), 686, 834, 836F, 1138
 FMNH• (flavin mononucleotide, radical form), 836F
 FMNH₂ (flavin mononucleotide, reduced form), 836F
 Fmoc (9-fluorenylmethoxycarbonyl) group, 207
FMRI gene, 1251, 1252
 FMR protein (FMRP), 1251
 FNR, *see* Ferredoxin-NADP⁺ reductase
 Foam cells, 457
 Fodor, S., 212
 Folate, **1062**
 Folds, 249F, 250–251
 Folding-trap mechanism, 448
 Foldons, 289, 289F
 Fold recognition, 305
 Folic acid, 474T, 1062
 Follicle-stimulating hormone (FSH), 673T, 683
 Following substrate, 498
 Fomivirsen (Vitravene), 1403
 Fontecilla-Camps, J., 941
 Food, energy content of, 941T
 Footprinting, 1267
 Forespore, 1284
 Fork-junction promoter DNA fragment, 1268
 Formaldehyde, 505
 Formamide, 43T
 5-Formaminoimidazole-4-carboxamide ribotide, *see* FAICAR
 Formate dehydrogenases, 1361
 Formic acid, 32T
N-Formiminoglutamate, 1034
*N*⁵-Formimino-tetrahydrofolate, 1034, 1062
 Formylglycinamide ribotide (FGAR), 1109F, 1110
 Formylglycinamidine ribotide (FGAM), 1109F, 1110
N-Formylmethionine (fMet), 79, 79F, 1373–1374
N-Formylmethionine-tRNA^{Met}_f (Met-tRNA^{Met}_f), **1373–1374**
 Formylmethionyl-tRNA, 1063
*N*¹⁰-Formyl-tetrahydrofolate, 1062
 Forskoln, 698
 Förster, T., 286
 Förster distance, 286
 48S Initiation complex, 1379
 40S subunit (ribosome), 1370T
 43S Preinitiation complex, **1376–1377**
 Fos, 713, 737F
 Fosamax, 679F
 Fossil fuels, 901
 Fossil record, 29, 192
 Foster, S., 376
 4-Helix bundle, 241, 250F
 454 Life Sciences, 182
 454 sequencing system, 182–184, 183F
 4-Helix bundle, of SNAREs, 441–442
 4.4₁₆ Helix, 228
 Fowler's solution, 799
 Fowlpox virus, 94T
 F pili, 1262
 FPP, *see* Farnesyl pyrophosphate
 F protein, 1314
 Fractional saturation, 325
 Fractionation, 132, **156–159**
 Fragile X syndrome, **1251–1252**
 Fragment-based lead discovery (FBLD), 541–542
 Frame, 1341
 Frameshift mutations, 1222, 1341
 Frameshift suppressors, 1362
 Franceschii, F., 1376
 Frank, H., 262
 Frank, J., 422, 1365, 1371, 1388
 Franklin, B., 393–394
 Franklin, R., 88
 FRAP (FKBP12-rapamycin-associated protein), 737F
 Free energy, **57–58**
 and concentration, 58, 61
 and enzyme catalysis, 537
 and equilibrium constants, 58T
 membrane transport, 744
 and protein folding, 284, 287
 standard state, **58–60**
 unitary Gibbs free energy change, 263T
 Free energy of activation, 486, 487
 Free energy of formation, 59–60, 59T
 Freeman, H., 921
 Freeze-etch technique, 408–410, 409F
 Freeze-fracture technique, 408–410, 409F
 French press, 130
 FRET, *see* Fluorescence resonance energy transfer
 Frey, P., 536
 Frictional coefficient, 146, 155
 Frictional ratio, 155
 Fridovich, I., 865
 Frogs, chromosome number of, 19T
 Fromme, P., 922
 Fructofuranose, 361
 β-D-Fructofuranose, 362F
 β-Fructofuranosidase, 488
 Fructokinase, 630
 Fructose, 361, 361F, 362F, 630–631, 631F
 Fructose-1,6-bisphosphatase (FBPase), 582, 630, 877, 933F
 and glycolysis, 593, 594F, 629
 and metabolic cycles, 1088–1089
 Fructose-1,6-bisphosphate (FBP; F1,6P), 479, 596F, 600
 Fructose-1,6-diphosphate (FDP), 600
 Fructose-1-phosphate, 630
 Fructose-1-phosphate aldolase, 630
 Fructose-2,6-bisphosphate (F2,6P), 627, 663–664
 Fructose-6-phosphate (F6P), 582, 582F
 and erythrose-4-phosphate, 636
 in glycolysis, 596F, 598–600
 Fructose bisphosphatase-2 (FBPase-2), 663
 Fructose intolerance, 630
 Fruit flies, *see Drosophila melanogaster*
 Frydman, J., 301
 FSH, *see* Follicle-stimulating hormone
 FTR, *see* Ferredoxin-thioredoxin reductase
 FtsY, 423
 F-type ATPases, 758
 F-type H⁺-ATPase, 852, 854F
 L-Fucose, 365
 Fumarase, 481, 567, 947
 in citric acid cycle, 790F, 791, **812–813**, 812F
 diffusion-limited, 490
 Michaelis–Menten kinetic constants, 489T
 molecular mass, 140F
 Fumarate, 493, 947
 in citric acid cycle, 790F, 791, **811**
 degradation of phenylalanine and tyrosineto, 1043–1047
 hydration, 481
 Fumarate hydratase, 812–813

- Functional groups:
 in Cahn–Ingold–Prelog system, 76
 hydrogen bonding, 43F
 p*K* values of, 72
- Fungi, 7F, 12, 13F
 divergence of, 192
 FAS-I, 967–968, 967F
- Furan, 361
- Furanoses, 361
- Furey, W., 616
- Furylfuramide, 1225
- Fusidic acid, 1395T, 1396F
- Fusion pore, 442, 443F
- Fusion proteins, 118, 431
- Futai, M., 857
- Futile cycle, 629
- Fyn, 708, 715
- FYVE domains, 734, 735F
- G**
- G₀ phase, **1163**, 1206
- G_α, *see* Transducin
- G1,6P (glucose-1,6-bisphosphate), 642
- G1P, *see* Glucose-1-phosphate
- G₁ phase, **1202**, 1205, 1206F
- G, *see* Free energy
- G₂ phase, **1202**, 1206
- G6P, *see* Glucose-6-phosphate
- G6Pase, *see* Glucose-6-phosphatase
- G6PD, *see* Glucose-6-phosphate dehydrogenase
- G6P translocase, 661
- G_{A2} ganglioside, 1011
- GABA, *see* γ-Aminobutyric acid
- Gab-1 (Grb2-associated binder-1), 738
- gag, 1245
- Gag-pol polyprotein, 546
- Gag polyprotein, 546
- Gal, *see* Galactose
- Galactitol, 633
- Galactans, 366
- Galactocerebrosides, 391, 1009–1010
- Galactocerebroside-3-sulfate, 1010
- Galactokinase, 631
- D-Galactosamine, 365
- D-Galactose, 110, 360F, 361, 392F
- Galactose (Gal):
 and glucose in *E. coli*, 1286
 in glycolysis, 630–633, 632F
- Galactose-1-phosphate uridylyltransferase, 631
- Galactosemia, 632–633
- β-Galactosidase, 107F, 110, 366, 367
 in enzyme induction, 1261–1262
 molecular mass, 140F
 sequencing, 165
- Galactoside permease, 769. *See also* Lactose permease
- 1-β-Galactosylceramide, 1010
- Galactosyl diacylglycerol, 902
- Galactosyltransferase, 882
- D-Galacturonic acid, 364
- Gallo, R., 545
- Gallus gallus*, genome sequencing of, 177T
- GalNAc transferase, 890
- Gametes, 20
- γ Complex, Pol III, 1182
- Gamma radiation, 572
- γδ Resolvase, 1239–1241, 1241F
- γδ Transposon, 1239–1241, 1241F
- Gangliosides, 392, 392F, 1008
 biosynthesis, 1010–1011, 1011F
- GAP, *see* Glyceraldehyde-3-phosphate; GTPase-activating protein
- GAP-containing inositol phosphatase (GIP), 735
- GAPDH, *see* Glyceraldehyde-3-phosphate dehydrogenase
- Gap junctions, membranes, **415–416**, 416F
- Gap penalties, 201
- GAPs, **705–711**
- GAR (glycinamide ribotide), 1109F
- Garavito, M., 997
- Garrod, A., 25–26
- GAR synthetase (PurD), 1109F, 1110
- GAR transformylase (PurN), 1109F, 1110
- Gas constant, 53T
- Gas–liquid chromatography (GLC), 366
- Gassman, P., 536
- Gastric inhibitory peptide (GIP), 673T, 675
- Gastric mucosa, 764–765
- Gastrin, 673T, 675
- Gastroesophageal reflux disease (GERD), 764
- Gastrointestinal hormones, **675–676**
- Gastrula, 1250
- GatA subunit of Glu-Adt, 1358
- GatB subunit of Glu-Adt, 1358
- GatC subunit of Glu-Adt, 1358
- Gated pore, 750–751
- Gating, of ion channels, 771–775
- Gaucher's disease, 1013T
- Gay-Lussac, J., 469
- GC (guanylate cyclase), 687
- GC box, 1282
- GCN2, 1400–1401
- GCN4, 1400–1401
- GCPR kinases (GRKs), 697
- G-CSF (granulocyte colony-stimulating factor), 717
- G_{D3} ganglioside, 1011
- GDH, *see* Glutamate dehydrogenase
- GDI, *see* GDP dissociation inhibitor; Guanine nucleotide dissociation inhibitor
- GDP (guanosine diphosphate):
 in citric acid cycle, 790F, 791
 and EF-Tu, 1380–1381, 1381F
 in secretory pathway, 420, 423–424
 in vesicle formation, 434–435, 437
- GDP dissociation inhibitor (GDI), 441
- GEFs, *see* Guanine nucleotide exchange factors
- Geiger counting, 572
- Gelatin, 236
- Gel electrophoresis:
 for measuring supercoiling, 1162
 of nucleic acids, **158–159**, 158F, 179
 of proteins, 132T, 147–150, 148F
 pulsed-field, 158–159, 159F
 for restriction maps, 106, 106F
 two-dimensional, 152, 152F
- Gel filtration chromatography, **138–141**, 139F, 157, 169
- Geminin, 1206–1207
- GenBank, 195T
- Genes, **21–22**. *See also* Chromosomes; DNA and bacterial conjugation, 1262–1264
 chemical synthesis, 118
 duplication of, **193–194**, 317–318
 fruit fly experiments, 22–25
 liposome delivery, 396
 manipulation, **109–111**
 one gene-one enzyme maxim, 26
 reporter, 120–121, 120F
 self-splicing, 1306–1308
 sex linked, 24
 and tetranucleotide hypothesis, 85
- Gene A protein, 1191, 1193
- Gene expression, 25–26, 95–104, 95F
 DNA replication, 101–104
- eukaryotic, *see* Eukaryotic gene expression overview, 18–19, **95–101**
 prokaryotic, *see* Prokaryotic gene expression and RNAi, 1325–1326
 transcription, 95–98
 translation, 95, 98–101
- General acid catalysis, 506–507
- General base catalysis, 507
- General import protein (GIP), 446
- General recombination, 1225
- Gene sequence databanks, 195T
- Gene splicing, 97–98, 1305. *See also* Spliceosomes
 alternative splicing, 1317–1318
 cis- and trans-splicing, 1319–1320
 exons, 1305–1308
 pre-mRNAs, 1312
 role of splicing-associated factors, 1312, 1314
 self-splicing genes, 1306–1308
 significance of, 1316–1317
- Gene therapy, **122–124**, 991
- Genetic anticipation, 1251
- Genetic code, 87, 88, **1338–1345**
 briefly summarized, 1421
 deciphering, 1341–1343
 mitochondrial deviations from ideal, 1344T
 nature of, 1343–1344
 nonuniversality of, 185, 1344–1345
 standard, **1343T**
 in translation, 99, 100T
- Genetic control, metabolic flux and, 624
- Genetic crosses, 20, 21F
- Genetic diseases, 26, 112–113, 122–123. *See also specific diseases*
- Genetic engineering, 104. *See also* Molecular cloning; Recombinant DNA technology
- Genetic information, 18–19. *See also* Genes
- Genetic maps, 24, 25F
- Genetic mutations, *see* Mutations
- Genetic recombination, 1225
- Genetics, **19–28**. *See also specific topics*
 bacterial, 26
 chromosomal theory of inheritance, 22–26
 chromosomes, **19–20**
 Mendelian inheritance, **20–22**
 viral, 26–28
- Genome, 8–9, 94, 1173. *See also* Human genome
- Genome Analyzer, 184
- GenomeNet, 195T
- Genome sequencing, 176, 177T, **180–185**, 180F
- Genomes OnLine Database (GOLD), 195T
- Genomic imprinting, 1251
- Genomic libraries, **113–114**
- Genotypes, 21–22, 22F
- Genitic acid, 173
- Geometric complementarity, of Watson–Crick base pairs, 1154–1155
- Geometric specificity, enzymes, **472–473**
- George III, King of England, 1056
- Geranylgeraniol, 903
- Geranylgeranyl groups, 406
- Geranyl pyrophosphate, 978–979
- GERD (gastroesophageal reflux disease), 764
- Gerhart, J., 475
- Gerlt, J., 536
- Germ cells, 19, 20, 21F
- Germ plasm theory, 19

- Gerstmann–Sträussler–Schneiker (GSS) syndrome, 314
- GFP (green fluorescent protein), 120–121, 120F, 121F
- GGAs, 436
- GH, *see* Growth hormone
- Ghrelin, 1099
- Giardia intestinalis*, 1324, 1324F
- Gibbs, J. W., 57
- Gibbs free energy, **57–60**, 58T. *See also* Free energy
- Gierasch, L., 294
- Gigantism, 685
- Gilbert, W., 1284
- Gilman, A., 690
- GIP, *see* GAP-containing inositol phosphatase; Gastric inhibitory peptide; General import protein
- Girvin, M., 853
- GK, *see* Glucokinase
- GKRP (glucokinase regulatory protein), 662
- GLA, *see* γ -Linolenic acid
- GLC (gas–liquid chromatography), 366
- GlcNAc, *see* NAG
- Gleevec, 719–720
- Gln, *see* Glutamine
- GlnRS, 1352–1354, 1353F, 1355F
- Gln-tRNA^{Gln}, 1358–1359, 1359F
- Globins, 193–194, 193F, 324
- Globin fold, 251
- Globosides, 1008, 1010–1011, 1011F
- Globular proteins, **241**
 α helix in, 226
 β pleated sheets in, 230
hierarchical organization, **281–282**, 281F
nonrepetitive structures in, **230–233**
structural bioinformatics, **256–259**
tertiary structure, **245–256**
X-ray and NMR structure, **241–245**
- γ -Globulins, 134T, 140F
- Glu, *see* Glutamic acid
- Glu-AdT, *see* Glu-tRNA^{Gln} amidotransferase
- Gluathione peroxidase, 897
- Glucagon, 140F, 660, 673T, 973
- Glucans, 366
- Glucocerebrosides, 391, 1010
- Glucocorticoids, 673T, 680, 991, 1090
- Glucocorticoid hormone response element (GRE), 879
- Glucocorticoid receptor, 879
- Glucogenic amino acids, 1029–1030, 1090, 1095
- Glucogenesis, 359
- Glucokinase (GK), 597, 662–664
- Glucokinase regulatory protein (GKRP), 662
- Gluconeogenesis, 562, 571, **871–880**
and AMP-dependent protein kinase, 1096
and citric acid cycle, 818
and Cori cycle, **880**
gluconeogenesis pathway, **872–878**
and glycolysis, 595, 878F
and other pathways, 1088–1089
regulation of, **878–879**
and starvation, 1101
stimulation by FBPase-1, 664
- Gluconic acid, 364
- 1,5-Gluconolactone, 642
- D-Glucono- δ -lactone, 364F
- Glucopyranose, 361
- α -D-Glucopyranose, 362F
- β -D-Glucopyranose, 362F, 363F
- D-Glucosamine, 365
- Glucose, 565F. *See also* Blood glucose; Electron-transport chain
complete oxidation of, 823
and *E. coli*, 1285–1286, 1286F
in Entner–Doudoroff pathway, 636, 637F
membrane permeability coefficients, 747T
mutarotation of, 507–508
and noninsulin-dependent diabetes, 1103F
transport in blood, 973
- Glucose-1,6-bisphosphate (G1,6P), 642
- Glucose-1-phosphate (G1P), 370, 631, 639, 932
- Glucose-6-phosphatase, 877
- Glucose-6-phosphatase (G6Pase), 661, 666, 1088–1089
- Glucose-6-phosphate (G6P), 565F, 638–639
as energy-rich compound, 580
in Entner–Doudoroff pathway, 637F
in glycolysis, 596F, 597–598
and metabolism, 1089, 1094
- Glucose-6-phosphate dehydrogenase (G6PD), 894, 894F, 897–898
- Glucose-6-phosphate isomerase, 598
- D-Glucose, 359–362, 362F, 392F
- L-Glucose, 360
- α -D-Glucose, 363F, 507
- β -D-Glucose, 507
- Glucose-alanine cycle, 878, 1022–1023
- Glucose-dependent insulinotropic polypeptide, 675
- Glucose-fatty acid cycle, 864
- Glucose metabolism, 567
- Glucose transport:
ATP-driven active, **758–768**
in erythrocytes, 746–748, 746F, 747F
and facilitated diffusion, **750–752**, 750F, 751F
ion-driven active, **768–771**
maltoporin in, **749–750**
in muscle and fat, 751F
- α -Glucosidase, 370
- α -1,4-Glucosidase deficiency, 666
- Glucosidase II, 886
- 1- β -Glucosylceramide, 1009–1010
- D-Glucuronic acid, 364
- D-Glucurono- δ -lactone, 364F
- GluProRS, 1351
- GLUT1, 751
- GLUT2, 662, 751
- GLUT3, 751
- GLUT4, 661, 737F, 751
- GLUT4 storage vesicles, 751
- GLUT5, 751
- GLUT12, 751
- Glutamate, 71. *See also* Glutamic acid
biosynthesis, 1065–1071
degradation, 1034
and nitrogen fixation, 1080
as nonessential amino acid, 1065T
Glutamate-5-phosphate, 1070F, 1071
Glutamate-5-semialdehyde, 1034, 1070F, 1071
Glutamate-aspartate aminotransferase, 1022
Glutamate-aspartate carrier, 827–828
Glutamate dehydrogenase, 266
Glutamate dehydrogenase (GDH), 153T, 818, 1020, **1023–1033**, 1024F
Glutamate receptor pre-mRNA, 1322
Glutamate synthase, 934, 1065–1067
- Glutamic acid, *see also* Glutamate
degradation, 1034
genetic codes for, 100T, 1343T
in globular proteins, 246
half-life, 1413T
 α helix/ β sheet propensity, 302T
isoelectric point, 72
in Miller–Urey experiments, 32T
in native unfolded proteins, 283
in PEST proteins, 1413
side chains, 71, 264T
structure and general properties, 69T
- Glutaminase, 1023, **1025–1027**, 1034
- Glutamine:
amino group, 208F
biosynthesis, 1067–1073
degradation, 1034
and *E. coli* nonsense suppressor, 1362T
genetic codes for, 100T, 1343T
in globular proteins, 246–247
half-life, 1413T
 α helix/ β sheet propensity, 302T
in native unfolded proteins, 283
as nonessential amino acid, 1065T
side chains, 71, 208F, 264T
structure and general properties, 69T, 71F
- Glutamine amidotransferase, 1025–1027, 1066–1067, 1078
- Glutamine PRPP aminotransferase (PurF), 1108, 1111
- Glutamine synthetase, 269F, 591, 1023, 1029, 1068–1071
- γ -Glutamyl cycle, 1061, 1061F
- γ -Glutamyl cyclotransferase, 1061
- γ -Glutamylcysteine synthetase, 1061
- Glutamyl group, 73T
- γ -Glutamyl kinase, 1070F, 1071
- γ -Glutamylphosphate, 1068
- γ -Glutamyltransferase, 1001
- γ -Glutamyl transpeptidase, 1061
- Glutaraldehyde, 270, 270F
- Glutaredoxin, 1124
- Glutathione, 142
- Glutathione (GSH), 544–545, 544F, 803, **1060–1062**
Glutathione disulfide (GSSG), 803
Glutathione peroxidase, 866, 1003, 1060F
Glutathione reductase (GR), 801, 803, 1060F
Glutathione-S-transferase, *see* GST
Glu-tRNA^{Gln}, 1358
Glu-tRNA^{Gln} amidotransferase (Glu-AdT), 1358, 1359F
Glu-tRNA^{Glu}, 1358
- Glx, 68T, 73. *See also* Glutamic acid; Glutamine
- Gly, *see* Glycine
- Glycans, 365–366
- Glyceraldehyde, 75, 75F
- D-Glyceraldehyde, 75, 75F, 360F, 361
- L-Glyceraldehyde, 75, 75F, 76, 77F
- Glyceraldehyde-3-phosphate, 636
from Calvin cycle, 927–929, 931
in Entner–Doudoroff pathway, 637F
in glycolysis, 595, 596F, 600–603
topological diagram, 254F
- Glyceraldehyde-3-phosphate dehydrogenase (GAPDH):
domains, 248, 249F
and erythrocyte membrane, 412
in glycolysis, 596F, **607–608**, 607F, 608F
half-life, 1408T
molecular mass, 140F
(S)-Glyceraldehyde, 76, 77F
- Glyceraldehyde kinase, 630
- Glycerate, 935
- L-Glycero-D-mannoheptose, 379F
- Glyceroglycolipids, 1004
- Glycerol, **364**, 388, 389T
- Glycerol-3-phosphate, 580, 828, 828F
- sn-Glycerol-3-phosphate, 389, 389F
- Glycerol-3-phosphate acyltransferase, 971

- Glycerol-3-phosphate dehydrogenase, 828, 828F, 944
- Glycerolipids, 1004F
- Glycerol kinase, 630, 766, 944
- Glyceroneogenesis, 971, 973, 1093
- Glycerophosphate shuttle, 828, 828F
- Glycerophospholipids, **389–390**, 389F, 394–395, **1004–1008**
- N*⁶-β-Glyceryl lysine, 601
- Glycidol phosphate, 604
- Glycinamide ribotide (GAR), 1109F
- Glycine:
- biosynthesis, 1071–1072
 - as chemical messenger, 79–80
 - conjugates of, 993, 993F
 - degradation, 1030–1034
 - electrostatic influences, 72
 - genetic codes for, 100T, 1343T
 - half-life, 1413T
 - α helix/β sheet propensity, 302T, 304
 - in heme biosynthesis, 1048
 - isoelectric point, 72
 - in Miller–Urey experiments, 32T
 - in native unfolded proteins, 283
 - as nonessential amino acid, 1065T
 - optical activity, 74
 - steric hinderance, 224–225, 224F, 225F
 - structure and general properties, 68T
 - titration curve, 72, 72F
- Glycine cleavage system, 1031–1033
- Glycine decarboxylase multienzyme system, 1031–1033
- Glycine synthase, 1031–1033
- Glycocalyx, 381, 414, 414F
- Glycoconjugates, 359
- Glycoforms, 380
- Glycogen, 359, **370**, 370F, 638
- fatty acids vs., 638
 - particle fabrication, 646–647
- Glycogen branching, **646–647**
- Glycogen breakdown, **638–644**
- glycogen debranching enzyme, 370, 639, **642–643**, 667
 - glycogen phosphorylase, **639–641**
 - and other pathways, 1089
 - phosphoglucomutase, 639, **642**
- Glycogen debranching enzyme, 370, 639, **642–643**, 667
- Glycogenin, 380, 645–646, 646F
- Glycogen metabolism, **638–668**
- blood glucose maintenance, **661–664**
 - control of, **647–666**
 - covalent modification in, **650–651**
 - glycogen breakdown, **638–644**
 - glycogen phosphorylase bicyclic cascade, **651–660**
 - glycogen storage diseases, **666–668**
 - glycogen synthase bicyclic cascade, **660**
 - glycogen synthesis, **644–647**
 - stress response, **664–665F**
 - thermodynamics, 643–644
- Glycogen phosphorylase, 370, **639–641**
- allosteric control, 479, **647–650**
 - bicyclic cascade, **651–660**
 - covalent modification, 1405
 - deficiency, 667
- Glycogen storage diseases, **666–668**
- Glycogen synthase, **644**, 645, **647–650**
- Glycogen synthase kinase-3 (GSK3), 660
- Glycogen synthesis:
- glycogen branching, **646–647**
 - glycogen synthase, **644**
 - and other pathways, 1089
 - UDP-glucose pyrophosphorylase, **644**
- Glycolate, 935
- Glycolate oxidase, 935
- Glycolate phosphatase, 935
- Glycolic acid, 32T
- Glycolipids, 359, 381, 398T, 400F
- Glycolipid metabolism, 1004
- glycerophospholipids, **1004–1008**
 - sphingoglycolipids, **1008–1013**
 - sphingophospholipids, **1008–1009**
- Glycolysis, 569, **593–634**. *See also* Electron-transport chain; Fermentation
- aerobic, 864
 - aldolase, 596F, **600–603**
 - and AMP-dependent protein kinase, 1096
 - anaerobic, 614–619, 864
 - and citrate, 863–864
 - effectors of nonequilibrium enzymes, 625T
 - electron-transport chain, 824F
 - enolase, 596F, **612–613**
 - and fatty acid oxidation, 864
 - fermentation, **614–619**
 - and free energy changes, 625T
 - fructose utilization, 630–631
 - galactose utilization, 630–633, 632F
 - and gluconeogenesis, 878F
 - glyceraldehyde-3-phosphate dehydrogenase, 596F, **607–608**
 - hexokinase, 596F, **597–598**
 - mannose utilization, 630, 633, **633**, 633F
 - and metabolic regulation and control, **619–630**
 - net reaction, 594F, 595
 - and other pathways, 1088
 - overview of, **595–596**, 596F
 - phosphofructokinase, 596F, **600**, 625–627, 626F, 630
 - phosphoglucose isomerase, 596F, **598–600**
 - phosphoglycerate kinase, 596F, **608–610**
 - phosphoglycerate mutase, 596F, **610–612**
 - pyruvate kinase, 596F, **613–614**
 - for rapid ATP production, 619
 - regulation in muscle, **624–630**
 - triose phosphate isomerase, 596F, **603–606**
- Glycomes, 382–383
- Glycomics, **382–383**, 578
- Glycone, 366
- Glycophorin A, 400–401, 401F, 413F
- Glycoproteins, 359, **373**
- in bacterial cell walls, 375–379
 - biosynthesis, **880–892**
 - formation, 101
 - glycomics, **382–383**
 - proteoglycans, **373–375**
 - structure and function, **379–382**
- Glycoprotein carbohydrates, **380–381**
- Glycosaminoglycans, **370–372**
- Glycosidases, 364
- Glycosides, 363
- Glycosidic bonds, 83, **363–365**, 880–881, 883F
- Glycosphingolipids (GSLs), 391, 1004
- Glycosylation, 101
- Glycosylceramides, 1009–1010
- Glycosyl-enzyme intermediate, 522
- Glycosyl group transfer, 565
- Glycosylphosphatidylinositol (GPI), 407–408, 408F, 890–892, 891F
- Glycosylphosphatidylinositol (GPI) membrane anchors, 882, 891F
- Glycosyltransferases, 881, 1010
- Glyoxylate, 935
- Glyoxylate cycle, **880**, 881F
- Glyoxylate pathway, 10
- Glyoxylic acid, 1135F
- Glyoxysome, 10, 880
- Glyphosate, 1075
- G_{MI} Gangliosidosis, 1013T
- G_{M2}-activator protein, 1011, 1012F
- GM-CSF, *see* Granulocyte-macrophage colony-stimulating factor
- GM-CSF receptor, 717–718, 718F
- GMP (guanosine monophosphate), 83T, **1111–1113**, 1112F, 1130F
- GMPPNP (guanosine-5'-(β,γ-imido) triphosphate), 710–711
- GMP synthase, 1112F
- GMRα, 717–718
- GnRF, *see* Gonadotropin-releasing factor
- Goiter, 677
- GOLD (Genomes OnLine Database), 195T
- Gold, L., 213
- Goldberg, J., 434, 438, 1223
- Golden rice, 122, 122F
- Goldman equation, 775
- Goldsmith, E., 713
- Goldstein, J., 452, 453, 987
- Golgi, C., 9
- Golgi apparatus, 7F, 9, 11F. *See also* Post-translational modification
- metabolic functions, 562T
 - vesicle formation, **428–440**
 - vesicle fusion, **440–445**
- Golgi network, 428, 429F
- Golgi stack, 428, 429F
- Gonadotropin-releasing factor (GnRF), 673T, 683
- Gonadotropins, 683
- Gonads, 680, 681
- Goodman, M., 1222
- Google Scholar, 35
- Gorter, E., 395
- Gouaux, E., 417
- Gourse, R., 1266
- Gout, **1134–1135**, 1142
- GPCRs, *see* G-protein-coupled receptors
- GPI, *see* Glycosylphosphatidylinositol
- GPI-linked proteins, 407–408, 408F
- GPI membrane anchors, *see* Glycosylphosphatidylinositol membrane anchors
- G-protein-coupled receptors (GPCRs), 689, 993
- G proteins, 407, 423, 688, 692, 695F, 1314, **1376**, 1395
- G-quartets, 1212–1213, 1212F
- GR, *see* Glutathione reductase
- Gradient elution, 137
- Gram, C., 6
- Gramicidin A, 79, 748, 787
- Gram-negative bacteria, 6, 376, 376F, 403
- Gram-positive bacteria, 6, 7F, 13F, 376, 376F, 398T
- Gram stain, 6
- Grana, 902
- Granulocyte colony-stimulating factor (G-CSF), 717
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 381, 717. *See also* GM-CSF receptor
- Granulocytes, 381
- GRASP (Graphical Representation and Analysis of Surface Properties), 259
- Gray, H., 841
- Grb2, 708, 709
- Grb2-associated binder-1 (Gab-1), 738
- GRE (glucocorticoid hormone response element), 879
- GreA, 1281
- GreB, 1281, 1282
- Greek key motif, 249F, 250
- Green algae, 13F, 19T
- Greenberg, G. R., 1108

- Green fluorescent protein, *see* GFP
 Green photosynthetic bacteria, 6
 Green revolution, 122
 Green sulfur bacteria, 923
 Greider, C., 1210
 Grendel, F., 395
 GRF, *see* Growth hormone-releasing factor;
 Guanine nucleotide releasing factor
 GRIF (growth hormone release-inhibiting
 factor), 683
 Griffith, F., 86
 Griffith, J., 1213
 Grindley, N., 1240
 GRKs (GPCR kinases), 697
 gRNAs (guide RNAs), 1321, 1321F, 1324
 GroEL/ES system, **293–302**, 295F–297F, 307,
 307F, 352
 Gronenborn, A., 656
 Ground substance, 371
 Group I chaperonins, 293
 Group I introns, 1306–1309, 1307T,
 1309F, 1310F
 Group II chaperonins, 293, 301–302
 Group II introns, 1307T, 1308
 Group III introns, 1307T
 Group transfer reactions, **564–565**, 564F
 Group translocation, **765–766**
 Growth hormone (GH), 86, 571, 683. *See*
 also Human growth hormone
 Growth hormone release-inhibiting factor
 (GRIF), 683
 Growth hormone-releasing factor (GRF),
 673T, 683
 Grunberg-Manago, M., 1341
 G-segment, of DNA, 1169
 GSH, *see* Glutathione
 GSH synthetase, 1061
 GSK3 (glycogen synthase kinase-3), 660
 GSLs, *see* Glycosphingolipids
 GSSG (glutathione disulfide), 803
 GSS (Gerstmann–Sträussler–Schneiker)
 syndrome, 314
 GST (glutathione-S-transferase), 142,
 1001, 1060F
 GT (UDP-glucose:glycoprotein
 glucosyltransferase), 886
 GTP (guanosine triphosphate):
 in citric acid cycle, 789, 790F, 791
 and EF-Tu, 1380–1381
 gluconeogenesis, 877–878
 hydrolysis of, 1394–1395
 in secretory pathway, 420, 423–424
 in transcription, 96, 1265
 in vesicle formation, 436, 437
 in vesicle fusion, 441
 GTPase:
 in secretory pathway, 423
 in vesicle formation, 434–437
 in vesicle fusion, 441
 GTPase-activating protein (GAP), 423, 437,
 692, 1376
 GTP-binding factor, 1395
 GTPγS, 436F, 692
 Gua, *see* Guanine
 GU-AG introns, 1307T
 Guanidinium ion, 117, 169, 284
 Guanidino group, 580
 Guanine, 18, 83, **83**, 83T. *See also*
 Watson–Crick base pairs
 and genetic code, 100T, 1343T
 IR spectra of, 1155F
 modified nucleosides of, 1347F
 and point mutations, 1339–1340
 in purine catabolism, 1130F
 tautomeric forms, 88F
 Guanine-7-methyltransferase, 1302
 Guanine deaminase, in purine
 catabolism, 1130F
 Guanine nucleotide dissociation inhibitor
 (GDI), 692
 Guanine nucleotide exchange factors
 (GEFs), 423, 434, 692, **705–711**, 1379
 Guanine nucleotide releasing factor
 (GRF), 692
 Guanosine, 83T, 1130F
 Guanosine binding site, 1310F
 Guanosine diphosphate, *see* GDP
 Guanosine monophosphate, *see* GMP
 Guanosine triphosphate, *see* GTP
 Guanylate cyclase (GC), 687
 Guanylic acid, *see* GMP
 Guide RNAs, *see* gRNAs
 Guillemin, R., 683
 D-Gulose, 360F
 GW1516, 1104
 Gymnosperms, 13F
 Gypsy moth, 122
 GyrA, 1166–1169
 GyrA intein, 1407, 1407F
 Gyrase, 1166. *See also* DNA gyrase
 GyrB, 1166–1168, 1168F
 H
 H, *see* Enthalpy
 H1, 1243
 H1 gene, 1243
 H2, 1243
 H2 gene, 1243
 H₂PO₄, *see* Hydrogen phosphate ion
 H₃PO₄ (phosphoric acid), 49F
 Haber, F., 1083
 Haber process, 1083
 HAD (3-L-hydroxyacyl-CoA
 dehydrogenase), 947, 947F, 948, 958
 Hadju, J., 534
 HaeII, 105T
 HaeIII, 105T, 109
 Haecel, E., 12
Haemophilus influenzae, 176, 177T
 Hair, **233–235**, 275
 Haldane, J. B. S., 32, 488
 Haldane relationship, **491–492**
 Hales, S., 901
 Half cell, 584
 Half-chair conformation, 519F, 1153
 Half-life, 484
 Half reactions, 585–586
 Half-time, 484
Haloarcula marismortui, 1365, 1368
 Halobacteria, 6, 398T, 402
 Halophiles, 7F
 Hamm, H., 692
 Hammerhead ribozymes, **1310–1311**, 1311F
 Hanson, R., 571, 879
 H antigen, 415
 Haploid cells, 24F
 Haploid genomes, 182
 Haploid number, 19
 Haplotype, 106
 Harden, A., 594
 Hard water, 465
 Harrison, S., 424, 431, 433, 716, 725, 1288
 Hartl, U., 300
 Hartley, B., 525
 Hasemann, C., 663
 Hatch, M., 936
 Haworth, N., 366
 Haworth projection formulas, **361**, 362F
 Hb, *see* Hemoglobin
 HbA, *see* Hemoglobin A
 Hb Bibba, 342
 Hb Boston, 342, 343F
 Hb Bristol, 342
 Hb Cowtown, 358
 HbE, 342
 Hb Hammersmith, 342
 Hb Harlem, 344
 Hb Hyde Park, 358
 Hb Kansas, 343
 Hb KorleBu, 344–345
 HbM, 342
 Hb Memphis, 345, 358
 Hb Milwaukee, 342, 343F
 HbM Iwate, 342
 Hb Philly, 342
 Hb Rainer, 357
 Hb Riverdale-Bronx, 358
 HbS, *see* Hemoglobin S
 Hb Savannah, 342
 Hb Yakima, 343
 HCR (heme-controlled repressor), 1399
 HD gene, 1252
 HD (Huntington's disease), 1252
 HDL (high density lipoprotein), 449, 449T,
 451, 456, 458
 HDPR (6-hydroxy-1,6-dihydropurine
 ribonucleoside), 1132
 Heart, 625T, 816, 817, 1093
 Heart attack, 456, 865
 Heartburn, 764
 Heart muscle, 1092
 Heat, 53
 Heat-labile enterotoxin (LT), 696
 HEAT repeats, 722–723
 Heat shock locus UV, *see* HsIUUV
 Heat shock proteins, 293, 294. *See also*
 Molecular chaperones
 Heat shock protein 10 (Hsp10), 294
 Heat shock protein 40 (Hsp40), 293
 Heat shock protein 60 (Hsp60), 294F
 Heat shock protein 70, *see* Hsp70
 Heat shock protein 90, *see* Hsp90
 Heavy chains, clathrin, 430
 HECT domain, 1410
 Heinrich, R., 620
 Heinz bodies, 342
 Helical structures, **225–229**, 225F
 collagen triple helical structure,
 236–238, 237F
 Helical symmetry, proteins, 269, 269F
 Helicases, 1163, 1176, **1183–1187**
 Helicase II, 1217
 Heliozoans, 13F
 Helix:
 α, **226–227**
 basic helix–loop–helix/leucine
 zipper, 987
 C, 242F
 DNA as, **88–90**, 88F
 E, 242F
 4-helix bundle, 241, 250F
 H, 248F
 interwound, 1160, 1160F
 left-handed, 224F, 225F, 1149–1151
 π, 224F, 228
 and pitch of protein, 225
 right-handed, 224F–226F
 superhelix, 433, 1158–1160, 1162
 3₁₀, 224F, 226, 228
 3.6₁₃ (α), 226, 227F
 toroidal, 1160, 1160F
 Helix-capping position, 262
 Helix–turn–helix (HTF) motif, 1240,
 1288–1290, 1289F, 1290F
 Helper T cells, 545–546

- Hemagglutinin, 380
 β -Hematin, 1058
Hematocrit, 324
Heme *a*, 839F
Heme *b*, 839F. *See also* Iron-protoporphyrin IX
Heme b_{562} (heme b_H), 838
Heme b_{566} (heme b_L), 838
Heme *c*, 839F
Heme c_i (heme *x*), 920
Heme-controlled repressor (HCR), 1399
Heme group, **324–325**, 574, 574F
 biosynthesis, **1047–1058**
 degradation, **1056**
Heme oxygenase, 1056
Heme-regulated inhibitor (HRI), 1399, 1399F
Hemerythrin, 325
Heme *x* (heme c_i), 920
Hemiacetals, **361**, 520F
Hemifusion, 442, 443F
Hemiketals, **361**
Hemin, 1055
Hemmings, E., 116
Hemocyanin, 153T, 325
Hemoglobin:
 abnormal, **341–347**
 affinity for CO, 1056–1057
 allosteric regulation, **347–354**
 α and β chains, 332T–333T
 and Bohr effect, 328–329, 328F, **329**, 340
 BPG and oxygen binding of, **329–331**, 329F–331F, 340–341
 carbon dioxide transport, **329**
 conformational fluctuations, 306, 306F
 cooperativity, 352–354
 and distal histidine residue, 340
 and erythrocyte membrane, 412
 function, **323–331**
 gene duplication, 193–194
 heme group, **324–325**
 Hill plot, 327F
 as “honorary enzyme,” 323
 hydrogen exchange for, 309F
 isoelectric point (human), 134T
 isolation, 129
 lamprey, 135F
 molecular pathology, **342–343**
 optimal sequence alignment for, 197F
 oxygen binding, **325–328**, 334–339
 Perutz mechanism, **334–340**
 rate of evolution, 191, 191F
 and sickle-cell anemia, 81, 185–188, **343–347**
 solubility of, 133F
 in Southern blotting, 112
 structure and mechanism, 267F, **332–341**
Hemoglobin A (HbA), 175F, **186**
Hemoglobin E, 342
Hemoglobin F, *see* Fetal hemoglobin
Hemoglobinopathies, **342–343**
Hemoglobin S (HbS), 175F, **186–188**, 277, **343–347**
 α -Hemolysin, 416–418, 418F
 Hemolytic anemia, 185, 342, 343
Hemophilia, 119
Hemozoin, 1058
Henderson, R., 402
Henderson–Hasselbalch equation, **47–48**, 72
Hendrickson, W., 702
Hen egg white (HEW) lysozyme, 275–276, 276T, 470, **517–525**, 517F, 518F, 524F
Henri, V., 488
Henry’s law, 61
Henseleit, K., 791, 1025
Heparan sulfate, 373
Heparin, 371F, 372–373, 372F, 375, 700
Hepatitis B vaccine, 119
Hepoxilins, 1000
Heptahelical receptors, 689
Heptoses, 360F
HER2 receptor, 119–120
Herbivores, cellulose digestion by, 369
Herceptin, 119–120
Hereditary elliptocytosis, 414
Hereditary nonpolyposis colorectal cancer (HNPCC), 1220
Hereditary ovalocytosis, 414
Hereditary spherocytosis, 414
Hermit crabs, chromosome number, 19T
Herriott, R., 86
Hers, H.-G., 663
Hers’ disease, 667
Hershey, A., 87
Hershey–Chase experiment, 87F
Hershko, A., 1410
(15*R*)-HETE ([15*R*]-hydroxyeicosatetraenoic acid), 1004
(15*S*)-HETE ([15*S*]-hydroxyeicosatetraenoic acid), 1003
Heterocysts, 1083
Heterogeneous nuclear ribonucleoprotein (hnRNP), 1314
Heterogeneous nuclear RNA (hnRNA), 1304
Heterogeneous nucleation, 346, 347F
Heterokaryon, 408
Heterolytic bond cleavage, 563, 956
Heteropolysaccharides, 365–366
Heterotrimeric G proteins, 688–689
 adenylate cyclases, **697–698**
 G protein-coupled receptors (GPCRs), **689–690**
 phosphodiesterases, **688–689**
 structure and function, **690–697**
Heterotrophs, 6
Heterotropic allosteric effect, 348, 351, 351F, 354
Heterozygous genotypes, 21–22
Heuristic algorithms, 201
Heuser, J., 444
HEW, *see* Hen egg white lysozyme
1-*O*-Hexadec-1'-enyl-2-acetyl-*sn*-glycero-3-phosphocholine, 1008
Hexane, 43, 43T, 144
Hexokinase (HK), 565
 in gluconeogenesis, 872
 in glycolysis, 596F, **597–598**
 mannose utilization, 633
Hexokinase D, 662
Hexokinase IV, 662
Hexosaminidase A, 123, 1011, 1012F
Hexosaminidase B, 1013
Hexoses, 360F
Hexose monophosphate (HMP) shunt, 892.
 See also Pentose phosphate pathway
Hfr cells (high frequency of recombination), 1263
hGH, *see* Human growth hormone
hGHbp (human growth hormone binding protein), 684
HGPR (hypoxanthine-guanine phosphoribosyltransferase), 1114
H Helix, 248F
HIC, *see* Hydrophobic interaction chromatography
Hidden Markov models (HMMs), 202
High-altitude adaptation, 330–331, 330F, 357
High density lipoproteins, *see* HDL
High-energy compounds, 580–581. *See also* specific compounds
High frequency of recombination (Hfr) cells, 1263
High-mannose oligosaccharides, 888
High-performance liquid chromatography, *see* HPLC
High potential iron-sulfur proteins, *see* HIPs
High-throughput screening, 541
HI/HA, *see* Hyperinsulinism/hyperammonemia
Hihydrosphingosine, 390
Hill, A., 326
Hill, C., 1419
Hill, R., 903
Hill constant, 327
Hill equation, **326–328**, 348
Hill plot, 327–328, 327F
Hill reaction, 903
HindIII, 105T
Hin DNA invertase, 1243
hin gene, 1243
Hinnie, 1251
HIPs (high potential iron-sulfur proteins), 202F, 281F
Hippuric acid, 945
His, *see* Histidine
his operon, 1299, 1299T
His tag, 145, 857
Histamine, 80, 80F, 783, 1058, 1059
Histamine receptors, 689
Histidine:
 biosynthesis, 1078
 degradation, 1034
 as essential amino acid, 1065T
 genetic codes for, 100T, 1343T
 in globular proteins, 246
 α helix/ β sheet propensity, 302T
 and hemoglobin, 332, 341
 isoelectric point, 72
 side chains, 71, 264T
 structure and general properties, 69T
Histidinodehydroxymerodesmosine, 239F
Histones, 78, 134T
Histone H4, 190–191
Histrionicatoxin, 781
Hitchings, G., 1130
HIV (human immunodeficiency virus), 208–209, 1207
HIV-1, 545–546, 545F
 polyproteins of, 546, 546F
 protease of, 208–209, 546, 548–551, 548F
 reverse transcriptase of, 1207–1209, 1209F
HIV-2, 545
HIV protease:
 of HIV-1, 208–209, 546, 548–551, 548F
 inhibitors of, **545–551**
 and polyproteins, 1404
HK, *see* Hexokinase
(H^+ - K^+)-ATPase, 764–765
HMG-CoA, 960, **976–977**, 1040–1041
HMG-CoA lyase, 960
HMG-CoA reductase, **977**, 987–989
HMG-CoA reductase kinase (RK), 989
HMG-CoA synthase, 960, 976
HMIT, 751
HMMs (hidden Markov models), 202
HMP (hexose monophosphate) shunt, 892.
 See also Pentose phosphate pathway
HNPCC (hereditary nonpolyposis colorectal cancer), 1220
hnRNA (heterogeneous nuclear RNA), 1304
hnRNP (heterogeneous nuclear ribonucleoprotein), 1314

- HO₂• 865
 Hoagland, M., 1345
 Hodgkin, A., 776
 Hodgkin, D. C., 241, 331
 Hofmeister, F., 70
 Hofmeister series, 266
 Hofmeyr, J.-H., 623
 Hofrichter, J., 346
 Hol, W., 696, 792, 1165
hola gene, 1182T
holB gene, 1182T
holC gene, 1182T
holD gene, 1182T
holE gene, 1182T
 Holley, R., 176, 1345
 Holliday, R., 1226
 Holliday junction, 1226, 1226F, 1233F
 in recombination repair, 1234–1236
 and RuvABC, 1230–1234
 Holoenzymes, 473, 722, 1265. *See also* Pol III
 holoenzyme; RNAP holoenzyme
 Homeostasis, **619–620**, 1096–1101
 Homing endonuclease, 1407–1408
 Hominy grits, 481
 Homocitrate, 1081–1082
 Homocysteine, 80, 80F, 1034
 Homocysteine methyltransferase, 1037
 Homogeneous nucleation, 346, 347F
 Homogenizer, 130
 Homogentisate, 1045, 1047F
 Homogentisate dioxygenase, 1045
 Homogentisic acid, 25, 569
 Homolactic fermentation, 593, **614–616**
 Homologous end-joining, 1235–1236, 1235F
 Homologous pairs, 19
 Homologous proteins, **188–192**, **194–196**
 Homologous recombination, 1222,
 1225–1236, 1227F
 Homology modeling, 304–305
 Homolytic bond cleavage, 563, 956
Homo neandertalensis, 116
 Homopolypeptides, 205
 Homopolysaccharides, 365–366
Homo sapiens, 14, 116. *See also* Humans
 Homoserine, 759
 Homotropic allosteric effect, 348,
 350–351, 354
 Homozygous genotypes, 21–22
 Honig, B., 259
 Hood, L., 181
 Hoogsteen geometry, 1154
 Hooke, R., 3
 Hop diffusion, 411, 411F
 Hopene, 983
 Horecker, B., 892
 Hormones, **671–674**, 673T. *See also*
 Glucagon; Insulin
 assays for, 131
 in brown fat, 860–862, 861F
 for calcium metabolism, **677–678**
 classification, 671, 672F
 epinephrine and norepinephrine,
 679–680
 for fatty acid metabolism, 973–975, 974F
 gastrointestinal, **675–676**
 growth, **684–685**
 hypothalamus and pituitary, **682–683**,
 1099, 1100F
 menstrual cycle control, **683–684**
 nitric oxide, **685–688**
 opioid peptides, **685**
 pancreatic islet, **675**
 quantitative measurements, **674–675**
 steroid, **680–682**
 thyroid, **676–677**
 Hormone-sensitive triacylglycerol lipase,
 861, 944, 973
 Horn, 233, 234
 Horowitz, N., 3, 34
 β-Horseshoe, GyrA intein, 1407
 Horwich, A., 294, 297, 298
 Host organism, 104
 Host-specific modifications, 104
 Hough, E., 1044
 Housekeeping genes, 1282
 HpaII, 105T, 1249
 (15S)-HPETE ([15S]-hydroperoxyeicosa-
 tetraenoic acid), 1003
 5-HPETE, *see* 5-
 Hydroperoxyeicosatetraenoic acid
 12-HPETE, *see* 12-
 Hydroperoxyeicosatetraenoic acid
 15-HPETE, *see* 15-
 Hydroperoxyeicosatetraenoic acid
 HPETEs (hydroperoxyeicosatetraenoic
 acids), 1000
 HPK1, 714
 HPLC (high-performance liquid
 chromatography), 145–146, 157, 171, 366
 HPR, of PTS system, 765
 H-protein, 1031
 HPV (human papillomavirus), 1414
 H-Ras, 709
 HRI, *see* Heme-regulated inhibitor
 Hsc70, 436
 HsIU caps, 1419
 HsIUUV (heat shock locus UV), 1419, 1420F
 HsIUUV protease, 1419
 HsIV subunit, 1419–1420, 1420F
 Hsp10 proteins, 294
 Hsp40 proteins, 293
 Hsp60 proteins, 294F
 Hsp70 proteins, 293, 421F, 445
 Hsp90 proteins, 293, 720
 HTH, *see* Helix–turn–helix motif
 HU, 1195
 Hubbard, S., 700
 Huber, R., 403, 653, 806, 910, 1414, 1415,
 1419, 1420
 Hugging dimer, 1050
 Human cells, 12F
 Human cytomegalovirus protease, 531
 Human genome, 176, 177T, 1402
 Human genome project, 181–182
 Human Genome Sequencing Consortium,
 181, 182
 Human growth hormone (hGH), 119, 250F,
 251, 259F, **684–685**
 Human growth hormone binding protein
 (hGHbp), 684
 Human growth hormone receptor, **684–685**
 Human immunodeficiency virus, *see* HIV
 Human papillomavirus (HPV), 1414
 Humans, 16F. *See also* *Homo sapiens*
 apoB, 1322
 BBP, 1314F
 biological structures, 14
 c-Cbl-UbcH7-ZAP-70 complex, 1412F
 chromosome number, 19T
 cloning, 1251
 Cul1-Rbx1-Skp1-F-box^{Skp2} complex, 1412F
 cytochrome c, 196F
 DNA repair, 1214
 DNA size, 94T
 E. coli DNA vs., 8–9
 elemental composition, 29T
 embryonic development, 14F
 evolutionary divergence of, 116
 fuel reserves for, 1101T
 genomic libraries, 113
 hormones, 673T
 Pot1, 1213
 RFLPs of, 106
 Skp1-Skp2 complex, 1412
 telomere length, 1211
 transposons, 1244, 1246
 ubiquitin, 1409
 UDG, 1219F
 Hünefeld, F., 323
 Hunger, 1098, 1099
 Huntington, 1252
 Huntington's disease (Huntington's
 chorea), 1252
 Hurley, T., 646
 Hurwitz, J., 1265
 Huxley, A., 776
 Hwang, P., 431
 Hyaluronan, **371–372**
 Hyaluronate, 371F, 372, 372F
 Hyaluronic acid, **371–372**, 375
 Hyaluronidase, 372
 Hybridization, 93
 Hybrid oligosaccharides, 888
 Hybridoma, 131
 Hybrid proteins, 118
 Hyde, C., 1076
 Hydrated ions, 43
 Hydrazine, 166, 168
 Hydrazinolysis, 166, 168
 Hydrochloric acid, 46
 Hydrocortisone, 680
 Hydrodynamic volume, 155
 Hydrogen, in Miller-Urey experiments, 32
 Hydrogen bonding:
 in base pairs, 84, 89, 1156
 in collagen triple helical structure, 237F
 and enzyme substrate specificity, 470F
 in functional groups, 43F
 in α helix, 227F
 in HIV protease-1, 549F
 low-barrier vs. short, strong, **535–536**
 in β pleated sheet, 229–230, 229F
 in proteins, **261–262**
 and tRNA tertiary structure, 1348–1349
 in water, 41–42, 41F
 Hydrogen exchange, **285–286**, 309F
 Hydrogen ions, 60
 Hydrogen peroxide, 10
 Hydrogen phosphate ion (H₂PO₄[−]),
 47, 47F
 Hydrogen sulfide, 324
 Hydrolases, 479T
 Hydrolysis, base-catalyzed, 85, 85F
 Hydronium ion, 45, 45F, 46
 Hydropathies, 264, 264T, 304
 5-Hydroperoxyeicosatetraenoic acid
 (5-HPETE), 996F, 997, 1000
 12-Hydroperoxyeicosatetraenoic acid
 (12-HPETE), 996F, 997, 1000
 15-Hydroperoxyeicosatetraenoic acid
 (15-HPETE), 996F, 997, 1000
 Hydroperoxyeicosatetraenoic acids
 (HPETEs), 1000
 (15S)-Hydroperoxyeicosatetraenoic
 acid([15S]-HPETE), 1003
 Hydrophilic materials, 42
 Hydrophobic bonding, 264
 Hydrophobic collapse, 286–287
 Hydrophobic effect, **262–264**
 Hydrophobic forces, 44
 and enzyme substrate specificity, 470F
 in integral membrane proteins, 406
 in nucleic acid bases, 1156–1157
 and protein stability, **262–264**
 and reverse turns, 304

- Hydrophobic interaction chromatography (HIC), 132T, 145
- Hydrophobic interactions, 44
- Hydrophobic materials, 42
- Hydropyrimidine hydratase, 1136F
- Hydroxide ions, 45, 45T, 46, 688
- 6-Hydroxy-1,6-dihydropurine ribonucleoside (HDPR), 1132
- 8-Hydroxy-7,8-dimethyl-5-deazariboflavin, 1215
- β -Hydroxyacyl-ACP dehydrase (DH), 965
- 3-L-Hydroxyacyl-CoA, 947, 947F
- 3-L-Hydroxyacyl-CoA dehydrogenase, *see* HAD
- 3-Hydroxyanthranilate, 1042
- Hydroxyapatite, 540, 677
- Hydroxyapatite chromatography, 144, 157
- β -Hydroxybutyrate, 831
- D- β -Hydroxybutyrate, 959
- D- β -Hydroxybutyrate dehydrogenase, 960
- α -Hydroxybutyric acid, 32T
- 25-Hydroxycholecalciferol, 678
- (15R)-Hydroxyecosatetraenoic acid ([15R]-HETE), 1004
- (15S)-Hydroxyecosatetraenoic acid ([15S]-HETE), 1003
- Hydroxyethylthiamine pyrophosphate, 616–617
- 3-Hydroxykynurenine, 1041–1042
- Hydroxylamine, 312–313
- point mutations caused by, 1340, 1340F
- prion reactivation with, 312–313, 313F
- Hydroxyl groups, 43F
- Hydroxyl radical, 325, 865
- 5-Hydroxylysine (Hyl), 78, 79F, 236
- Hydroxymethylbilane, 1053
- Hydroxymethylbilane synthase, 1053
- 5-Hydroxymethylcytosine residue, 1247
- Hydroxymethylglutaryl-CoA, *see* HMG-CoA
- p-Hydroxyphenylpyruvate, 1045, 1047F
- p-Hydroxyphenylpyruvate dioxygenase, 1045
- 4-Hydroxyproline (Hyp), 78, 79F, 236
- 3-Hydroxyproline, 236
- Hydroxypyruvate, 935
- 8-Hydroxyquinone, 1119
- 5-Hydroxytryptophan, 1046, 1060
- Hydroxyurea, 347, 1119
- Hyl (5-hydroxylysine), 236
- Hyp (4-hydroxyproline), 236
- Hyperacute rejection, 121
- Hyperammonemia, 1023, 1025
- Hypercholesterolemia, 456–457, 466, 989–991
- Hyperchromic effect, 92
- Hyperglycemia, 1102, 1103
- Hyperhomocysteinemia, 1034–1035
- Hyperinsulinism/hyperammonemia (HI/HA), 1023, 1025
- Hyperlysinemia, 1041
- Hyperlysinuria, 1041
- Hyperphenylalaninemia, 1045
- Hypertension, 547F
- Hyperthermophiles, 266
- Hyperthyroidism, 677
- Hypervariable position, 188
- Hyperventilation, 357
- Hypoglycemia, 666
- Hypoglycin A, 948, 948F
- Hypothalamus, 672F, 682
- hunger signal transmission, 1099
- integration of signals, 1099, 1100F
- leptin expression, 1098
- Hypothyroidism, 677
- Hypotonic solutions, 130
- Hypoxanthine, 127, 1108, 1130F, 1135, 1339–1340
- Hypoxanthine–guanine phosphoribosyltransferase (HGPRT), 1114
- Hypoxia, 331, 864
- Hypoxic, 324
- I
- i^6 A, *see* N^6 -Isopentenyladenosine
- IAPP (islet amyloid polypeptide), 310–311, 311F
- I κ B α , 1414
- Ibandronate, 679F
- Ibuprofen, 78, 78F
- IC₅₀, 539
- ICATs, *see* Isotope-coded affinity tags
- Ice, 41–42, 41F
- I-cell disease, 439
- Icosahedral symmetry, 268, 268F
- IDL (intermediate density lipoproteins), 449, 449T, 986, 1322
- D-Idose, 360F
- IEF (isoelectric focusing), 150–152
- IF, *see* Initiation factor
- IF-1, 1375–1376, 1375T
- IF₁ protein, 865
- IF-2, 1375–1376, 1375T
- IF-3, 1375–1376, 1375T
- I-FABP (intestinal fatty acid-binding protein), 943–944, 944F
- I gene, 1262
- IgG, *see* Immunoglobulin G
- IHF (integration host factor), 1195
- IHP (inositol hexaphosphate), 330
- I κ B kinase (IKK), 1420
- IL-1, *see* Interleukin-1
- IL-3 receptors, 717
- IL-5 receptors, 717
- Ile, *see* Isoleucine
- IleRS, 1352, 1356–1357, 1357F
- Illegitimate recombination, 1236
- Illumina system, 184
- ilv* operon, 1299, 1299T
- Image reconstruction, 1363F
- Imatinib, 719
- Imidazole, 513
- β , γ -Imido nucleoside triphosphate, 1275
- Aminoaceticpropionic acid, 32T
- Iminodiacetic acid, 32T
- Immobilized pH gradients, 151
- Immune electron microscopy, 1365
- Immune system, 1132
- Immunoaffinity chromatography, 143
- Immunoblotting, 149–150, 150F
- Immunochemical procedures, 131–132
- Immunofluorescence, 408
- Immunoglobulins, 163
- Immunoglobulin fold, 251, 251F
- Immunoglobulin G (IgG), 154F, 282, **380**
- Immunophilins, 292, 724
- IMP (inosine monophosphate), 1108
- animal catabolism pathway, 1130F
- conversion to AMP or GMP, 1112F
- synthesis, **1108–1111**, 1109F
- IMP cyclohydrolase (PurJ), 1109F, 1111
- IMP dehydrogenase, 1112F
- IMS, *see* Intermembrane space
- Inactivation, of ion channels, 774–775
- Inactivators, 494
- Inborn errors of metabolism, 26
- Inclusion bodies, 117, 117F
- Indels, *see* Insertion/deletion mutations
- Independent assortment, 21–22, 22F
- Independent segregation, 23F
- Indinavir, 550F, 551
- Indirect readout, 1290
- Indole-3-glycerol phosphate, 1075
- Indolepropanol phosphate (IPP), 1078
- Induced-fit hypothesis, 352
- Induced-fit model, of allosteric interactions, 352
- Inducers, 97, 97F, 1261
- Inducible enzymes, 1261
- Inducible NOS (iNOS), 686–688
- ine suffix, 73
- Infarction, 456
- Inflammatory response, 993, 1003–1004
- Influenza virus neuraminidase, 466
- Ingen-Housz, J., 901
- Ingold, C., 76
- Ingram, V., 186
- Inheritance, 20–26
- Inherited diseases, *see* Genetic diseases
- Inhibition, of enzymes, *see* Enzyme inhibition
- Inhibitors, 351, 492
- Inhibitory synapses, 778
- Initial velocity, 489
- Initiating codon, 100–101, 100T
- 48S Initiation complex, 1379
- Initiation factor (IF), 1375–1376, 1375T
- Inorganic pyrophosphatase, 582, 946
- iNOS (inducible NOS), 686–688
- Inosine, 1130F, 1347F
- Inosine monophosphate, *see* IMP
- Inosine triphosphate, *see* ITP
- myo*-Inositol, 364, 389T
- Inositol-1,4,5-triphosphate, *see* IP₃
- Inositol hexaphosphate (IHP), 330
- Inositol polyphosphate 1-phosphatase, 736
- Inositol polyphosphate 3-phosphatases, 736
- Inositol polyphosphate phosphatases, 734–736
- Insects, mutation rate of, 192
- Insertion/deletion mutations (indels), 196, 1340
- Insertion sequences (IS), 1236
- In situ* gene therapy, 122–123
- In situ* hybridization, 113–114, 114F
- InsR, *see* Insulin receptor
- Insulin, 164–165, 165F, 673T, **1099**
- affinity chromatographic isolation, 142
- in fatty acid metabolism regulation, 974
- in glycogen metabolism regulation, 660
- glycogen synthase kinase-3 inhibition, 660
- isoelectric point, 134T
- and passive-mediated glucose transport, 751–752
- pyruvate dehydrogenase phosphatase activation, 805
- recombinant human, 119
- renaturation, 280–281
- sequencing of bovine, 165F
- Insulin-dependent diabetes, 1102, 1400
- Insulinlike growth factor II receptor, 890
- Insulin receptor (InsR), 142, 699–703, 737F
- Insulin receptor substrate (IRS), 710, 1103
- Insulin resistance, 1103, 1103F
- Insulin signaling system, 736–738
- Insulin-stimulated protein kinase, 659–660
- Integral membrane proteins, 399–406
- Integrase, 545, 1245
- Integration host factor (IHF), 1195
- Intein Database, 1407
- Inteins, **1405–1407**, 1406F
- Intensive quantities, 61
- Intercalating agents, 1160–1162, 1272
- Intercalation, 157
- Interfacial activation, 941
- Interferons, **1399–1400**, 1400F

- Intergenic suppressors, 1362
 Interleukins, 657, 671, 717
 Interleukin-1 (IL-1), 671, 1414
 Interleukin-1 β -converting enzyme, *see* ICE
 Interleukin-2, 671
 Intermediates, reaction, 483
 Intermediate density lipoproteins, *see* IDL
 Intermediate filaments, 10–11
 Intermembrane space (IMS), 9, 446, 448
 Internal conversion, 904
 Internally compensated molecules, 76
 Internal nodes, phylogenetic trees, 203–204, 203F
 Internal resolution site, 1237
 Internal ribosome entry site (IRES), 1379
 Interphase, 20F, 21F
 Intervening sequences, 97, **1304**
 Interwound helix, 1160, 1160F
 Intestinal fatty acid-binding protein, *see* I-FABP
 Intragenic suppressors, 1340
 Intrasteric mechanism, 658
 Intrinsic dissociation constants, 348
 Intrinsic factor, 956
 Intrinsic membrane proteins, *see* Integral membrane proteins
 Intrinsic proteins, 399–406
 Intrinsic terminators, 1273–1275, 1273F
 Intronic splicing enhancers (ISEs), 1306
 Intronic splicing silencers (ISSs), 1306
 Introns, 98, **1304–1305**
 AU-AC, 1319
 Group I, 1306–1309, 1307T
 Group II, 1307T, 1308
 in prokaryotes vs. eukaryotes, 1316
 types of, 1307T
 Invariant residues, 188
 Invertase, 367, 488
 Inverted micelles, 51
 Invert sugar, 367
In vivo gene therapy, 123
 Iodoacetic acid, 168–169
 Ions, solvation of, 43F
 Ion-driven active transport, **768–771**
 Ion exchange, 135
 Ion exchange chromatography, 132T, **135–138**, 136F, 157
 Ion exchangers, 137–138, 138T
 Ionic charge, protein purification and, 132
 Ionic interactions, 259–260, 1158
 Ionic mobility, 44–45, 45T
 Ionic strength, 133–134, 133F
 Ionization constants, 47, 49–50, 49F, 502–503
 Ionizing radiation, 1214
 Ionophores, **748–749**, 748F
 Ion pair, 259–260, 260F
 IP₃ (inositol-1,4,5-triphosphate), 661, 665, 725–726
 IP₃ receptor, 726
 IPP (indolepropanol phosphate), 1078
 IPTG (isopropylthiogalactoside), 117, 621, 1261, 1295
 IRES (internal ribosome entry site), 1379
 Iron, in heme biosynthesis, 1056
 Iron-protoporphyrin IX, 316, 316F, 324, 838, 904F. *See also* Heme *b*
 Iron–sulfur clusters, 808F, 809, 834–835
 Iron–sulfur protein (ISP), 840
 Irreversible thermodynamics, 587
 IRS, *see* Insulin receptor substrate
 IS (insertion sequences), 1236
 IS1, 1236, 1236T
 IS2, 1236, 1236T
 IS4, 1236T
 IS5, 1236T
 Ischemia, 325, 864
 IS elements, 1236
 ISEs (intronic splicing enhancers), 1306
 Islet of Langerhans, 675
 Islet amyloid polypeptide, *see* IAPP
 Isoaccepting tRNAs, 1351
 Isoalloxazine, 566
 Isocaudamers, 128
 Isocitrate, 789, 790F, **809**
 Isocitrate dehydrogenase, 568, 789, **809–810**, 810F, 815–816
 Isocitrate lyase, 880
 Isoelectric focusing (IEF), 132T, 150–152
 Isoelectric point (pI), 72, 134, 134T, 150
 Isoelectric precipitation, 134
 Isoflurane, 398–399
 Isoforms, 543
 Isoionic point, 81
 Isolated systems, 52
 Isolation, protein, **129–133**
 Isoleucine:
 biosynthesis, 1075
 chiral centers, 76, 77F
 degradation, 1034–1039
 as essential amino acid, 1065T
 genetic codes for, 100T, 1343T
 in globular proteins, 246
 half-life, 1413T
 α helix/ β sheet propensity, 302T
 in native unfolded proteins, 283
 side chains, 70, 264T
 stereoisomers, 77F
 structure and general properties, 68T
 (2S,3S)-Isoleucine, 76, 77F
 Isomaltose, 367, 367F
 Isomerases, 479T
 Isomerization, **567**
 N⁶-Isopentenyladenosine (i⁶A), 976, 1347F
 Isopentenyl pyrophosphate, 977, 977F, 978F
 Isopentenyl pyrophosphate isomerase, 978, 978F
 Isopeptide bond, 1409
 Isoprene, 406, 975
 Isoprenoids, 976–977, 976F
 Isoprenoid groups, 406
 Isoprenylation site, 406
 α -Isopropylmalate, 1075
 Isopropylthiogalactoside, *see* IPTG
 Isoproterenol, 680
 Isopycnic ultracentrifugation, 156, 157F
 Isoschizomers, 127–128
 Isotonic saline solution, 161
 Isotopes, 573T
 Isotope-coded affinity tags (ICATs), 577–578, 577F
 Isotope effects, 572
 Isotope studies, 500–501, **572–575**
 Isotope tests, 813–814
 Isozymes, 202F, 277, 543
 ISP (iron–sulfur protein), 840
 ISSs (intronic splicing silencers), 1306
 Iterative annealing model (GroEL/ES system), 299–300
 ITP (inosine triphosphate), 1273
 Iwata, S., 838, 916

 J
 Jacob, F., 1262, 1264–1265
 Jaenisch, R., 1251
 Jaffe, E., 1050
 Jahn, R., 441, 444
 JAK (Janus kinase), 718
 JAK1, 718
 JAK2, 718
 JAK3, 718
 JAK4, 718
 JAK–STAT pathway, 717–718
 Jamaican vomiting sickness, 948
 James, M., 523
 Jansonius, J., 403
 Janus, 283
 Janus kinase (JAK), 718
 Jap, B., 840
 Jaundice, 1056
 Jefferson, T., 116
 Jelly roll, 252, 253F
 Jencks, W., 515
 JIP-1, *see* JNK interacting protein-1
 Jmol, 256T, 257
 JNK, 714
 JNK interacting protein-1 (JIP-1), 714, 743
 Johnson, A., 424
 Johnson, L., 640, 658
 Joliet, P., 917
 Jones, M. E., 1117
 Jorgensen, R., 1323
 Joshua-Tor, L., 1184
 Joule (unit), 53, 53T
 Jpred3 algorithm, 304
 Jun, 705, 713, 737F
 Junk DNA, 1317
 Juvenile-onset diabetes, 310, 1102

 K
 K_M (Michaelis constant), 489
 K_a, *see* Dissociation constant
 Kaback, R., 770
 Kacser, H., 620
 Kahn, R., 1104
 Kaiser, D., 109
 Kaiser, T., 450
 Kalckar, H., 578
 Kallikrein, 525T
 Kamen, M., 813, 903
 Kaplan, N., 791
 Kaptein, R., 1295
 Karplus, M., 307, 857
 Kauzmann, W., 264
 kb (kilobase pairs), 95
 k_B, *see* Boltzman constant
 K⁺ channels, **752–755**, 753F, 754F
 KDEL receptors, 440
 KDO (2-keto-3-deoxyoctanoate), 379F
 Ke, H., 725
 Keilin, D., 838
 Kelvin temperature scale, 53T
 Kendrew, J., 246, 331
 Kennedy, E., 419, 823, 946
 Kent, S., 209
 K_{eq}, *see* Equilibrium constant
 Keratan sulfate, 371F, 372, 373
 Keratin, 10–11, 10F, **233–235**
 α Keratins, 233–235, 234F
 β Keratins, 233–235
 2-Keto-3-deoxy-6-phosphogluconate, 637F
 2-Keto-3-deoxy-D-arabinoheptulosonate-7-phosphate, *see* DAHP
 2-Keto-3-deoxyoctanoate (KDO), 379F
 2-Keto acid dehydrogenases, 799
 Ketoacidosis, 961, 1102
 β -Ketoacyl-ACP reductase (KR), 965
 β -Ketoacyl-ACP synthase (KS), 965
 β -Ketoacyl-CoA, 947F, 949F
 β -Ketoacyl-CoA thiolase, *see* KT
 3-Ketoacyl-CoA transferase, 961
 α -Ketoadipate, 1042
 α -Ketobutyrate, 1034, 1075
 Keto-enol tautomerization, 506–507, 507F

- Keto forms, of nucleotide bases, 88
Ketogenic amino acids, 1029–1030, 1090, 1094
 α -Ketoglutarate, 789, 809, 1034, 1067F
 α -Ketoglutarate dehydrogenase (E1 α), 789, 799, **810**, 815–816
 α -Ketoglutarate dehydrogenase complex, 799
Keto groups, hydrogen bonding in, 43F
 α -Ketoisovalerate, 1075
 α -Ketoisovalerate dehydrogenase, 1039
Ketones, 361F
Ketone bodies, **959–961**, 973, 1095, 1101
Ketonogenesis, 959–961
Ketopentose, 360
Ketoses, 360F, 361, 361F
Ketosis, 961
3-Ketosphinganine, 1008
3-Ketosphinganine reductase, 1009
3-Ketosphinganine synthase, 1008
KF (Klenow fragment), 177, **1177–1178**, 1178F, 1180–1181
KFERQ proteins, 1409
Khorana, H. G., 209, 211, 1342
Kidneys, 871, 1091F, 1095
Kidney stones, 1134
Kieselguhr, 144
Kilobase pairs (kb), 95
Kim, J.-J., 948
Kim, K. K., 1151
Kim, P., 282
Kim, S., 1346
Kim, S.-H., 840
Kinases, 513, 581, **597**
Kinemages, 257
Kinesin, 440
Kinetics:
chemical, 54, **482–486**
enzyme, **487–492**
membrane transport, **745–757**
Kinetic barrier, 486
KiNG, 256T, 257
King, J., 289
Kinosita, K., Jr., 857, 1271
Kirchhausen, T., 431
Kjeldgaard, M., 1381, 1388
Kleinschmidt procedure, 94F
Klenow fragment, *see* KF
Klentaq1, 1178–1180, 1223
Klinefelter's syndrome, 682
Klug, A., 1346, 1363
KNF model, of allosteric interactions, 352
Knockout mice, 121, 572
Knoop, F., 572, 791, 945
Knowles, J., 565
Kohda, D., 446
Kok, B., 917
Kool, E., 1177
Kornberg, A., 1116, 1176, 1194, 1195, 1281
Kornberg, R., 1277–1278
Kornfeld, S., 884, 888
Koshland, D., 352, 513, 514, 621, 817
Kossiakoff, A., 684
KR (β -ketoacyl-ACP reductase), 965
Krabbe's disease, 1013T
K-Ras 4A, 709
K-Ras 4B, 709
Krauss, N., 922
Kraut, J., 534
Krebs, E., 722
Krebs, H., 651, 791, 1025
Krebs cycle, 789. *See also* Citric acid cycle
Kreevoy, M., 536
KS (β -ketoacyl-ACP synthase), 965
KT (β -ketoacyl-CoA thiolase), 947, 947F, 948, 949F
Ku, 1223–1224, 1223F
Ku70, 1223
Ku80, 1223
Kuhn, H., 1001
Kühne, F. W., 470
Kunitz, M., 470
Kunkel, T., 1205
Kurisu, G., 924
Kuriyan, J., 706, 710, 720, 1125, 1182, 1196, 1197, 1204
Kuru, 312
Kushmerick, M., 863
Kv1.2 channels, 773, 773F, 774F
Kv channels, **772–774**
 K_w (ionization constant of water), 47
Kwashiorkor, 1087
Kynureninase, 1042
L
lacI gene, 107F, 621, 1264
S-lac-NAD⁺, 614, 615F
lac operators, 1284–1285, 1285F, 1294
lac operon, 97, 97F, 1261–1262, 1294
lac promoter, 117, 621, 1266, 1294
lac repressor, 97, 107F, 117, 621, 1263–1264
allosterically important residues, 1296
isolation of, 129
in prokaryote transcription control, **1284–1285**
structure, 1294–1296, 1296F
 α -Lactalbumin, 882
 β -Lactamase, 1237
Lactase, 367
Lactate:
converting to oxaloacetate, 872F
in Cori cycle, 880
from fermentation, 594, 594F, **614–619**
transport in blood, 973
Lactate dehydrogenase, *see* LDH
Lactate dehydrogenase H, 153T
Lactic acid, 32T
D-Lactic acid, 365
 β -Lactoglobulin, 133F, 134
Lactoperoxidase, 140F
Lactose, **367**, 367F, 631
and glucose, 1286
metabolism in *E. coli*, 97
synthesis, 882
Lactose intolerance, 367
Lactose permease, 766, **768–771**, 769F, 770F, 1261
Lactose synthase, 883F
Lactosyl ceramide, 1010
lacZ gene, 107F, 120, 1294
lacZ' gene, 107F, 110, 111
LADH, *see* Liver alcohol dehydrogenase
Lagging strand synthesis, 103, 103F, 1175, 1175F, 1190–1191
Lake, J., 1365
Lamarck, Jean Baptiste de, 19
Lamarckism, 19
 λ integrase, 1243–1244
Lamprey, hemoglobin of, 194
Lander, E., 181
Landick, R., 1273
Lands, W., 1005
Landscape theory, of protein folding, **287–289**, 288F
Landsteiner, K., 414–415
Lanosterol, **982–984**, 985F
Lanosterol synthase, 982
Lanzilotta, W., 1055
Large calorie (Cal), 53, 53T
Large-T antigen, SV40, 1211
Lariat structure, 1306, 1306F
late genes, 1284
Lateral diffusion, 396
Lathyrism, 238–239
 α -Latrotoxin, 780
Lattman, E., 282
Lauric acid, 387T
Lavoisier, A., 823, 901
LBHBs (low-barrier hydrogen bonds), **536**
LCa (clathrin light chain), 430, 432, 432F
LCA2 (Leber's congenital amaurosis 2), 123
LCAT, *see* Lecithin-cholesterol acyltransferase
LCb (clathrin light chain), 430, 432, 432F
Lck, 715
LD₅₀, 539
LDH (lactate dehydrogenase):
half-life, 1408T
in homolactic fermentation, 614–615, 615F
isozymes, 277
molecular mass, 140F
X-ray structure of dogfish, 254, 255F, 256
LDL (low density lipoproteins), 449, 449F
and apoB-100, 1322
and atherosclerosis, 458
as cholesterol carrier, 449F
cholesterol takeup by, 453–455
properties, 449T
LDL receptors (LDLR), 453–457, 453F, 454, 1317
and apoB-100, 1322
and atherosclerosis, 456–457
and cholesterol homeostasis, 989–991, 990F
and endocytosis mediation, 986, 986F
L-DOPA, 1046, 1059–1060F
Lead compounds (drug discovery), 539
Leader sequence, 1297–1298
Leading strand synthesis, 102–103, 1175, 1175F, 1190–1193
Leading substrate, 498
Lead poisoning, 1134
Leaves, phylogenetic trees, 203, 203F
Leberman, R., 1381–1382
Leber's congenital amaurosis 2 (LCA2), 123
Le Châtelier's principle, 59
Lecithins, 389T, 390
Lecithin-cholesterol acyltransferase (LCAT), 450T, 452, 453F
Lectins, 366, 885
Leder, P., 1342
Lederberg, J., 1262
Leflunomide, 1116
Left-handed helix, 225F, 1149–1151
Left-handed α helix, 224F
Leghemoglobin, 219, 1083
Lehninger, A., 823, 946
Leloir, L., 631, 883
Leloir pathway, 631
Lennarz, W., 291
Leptins, 1096–1099, 1101
Leptin-E100, 1098F
Lesch-Nyhan syndrome, 1114, 1135
Leslie, A., 853, 857, 865
let-7 gene, 1326
Lethal factor (LF), anthrax, 715
Letsinger, R., 211
Leucine, 26
basic helix-loop-helix/leucine zipper, 987
biosynthesis, 1075
degradation, 1040–1041
as essential amino acid, 1065T
genetic codes for, 100T, 1343T
in globular proteins, 246
half-life, 1413T

- α helix/β sheet propensity, 302T
- inserted by *E. coli* nonsense suppressor, 1362T
- in native unfolded proteins, 283
- side chains, 70, 264T
- specific rotation, 74
- structure and general properties, 68T
- Leucine aminopeptidase, 168T
- Leucine-rich repeats (LRRs), 1412
- Leuconostoc mesenteroides*, 139
- Leu-enkephalin, 673T, 685
- Leukocytes, 85
- Leukocyte elastase, 533
- Leukocyte interferon, 1399
- Leukotrienes, 993
 - arachidonic acid precursor, 995–997
 - biosynthesis, **1000–1002**, 1002F, 1060F
 - series-5, 1003
- Leukotriene A₄ (LTA₄), 1000
- Leukotriene B₄ (LTB₄), 1001
- Leukotriene C₄ (LTC₄), 1001
- Leukotriene D₄ (LTD₄), 1001
- Leukotriene E₄ (LTE₄), 1001
- Leukotriene receptors, 689
- leu* operon, 1299T
- Leupeptin, 556
- Levine, P., 83
- Levinthal, C., 284, 287
- Levinthal paradox, 284
- Levitt, M., 523
- Levorotatory molecules, 74
- Lewis, G., 45
- Lewis, M., 1294
- Lewis acids, 45, 511
- Lewis bases, 45
- Lewisite, 822
- LexA, 1221–1222, 1228
- lexA* gene, 1221
- LF (lethal factor), anthrax, 715
- L forms (amino acids), 74–76
- LH, *see* Luteinizing hormone
- LHC-II, 908–909, 909F
- LHCs, *see* Light-harvesting complexes
- Licensing, *see* Pre-replicative complex (Pre-RC)
- Lienhard, G., 515
- Life, 3–37
 - and biochemical literature, 34–36
 - and biochemistry, 14–19
 - chiral molecules and, 78
 - defined, 3
 - divergence of major kingdoms, 192
 - eukaryotes, 6–14
 - evolutionary tree, 13F
 - and genetics, 19–28
 - origin of, **28–34**
 - prokaryotes, 3–6
 - and thermodynamics, 52, **586–589**
 - and water's properties, 40, 41
- Life Science Directory, 194–195
- LigA, 1187
- Ligament, 235
- Ligands:
 - Adair equation, **348–349**
 - in affinity chromatography, 142, 142F
 - Hill equation for binding, **326–328**
- Ligand-gated binding, 606
- Ligand-gated channels, 771–772
- Ligases, 479T
- Light absorption, 903–909
- Light chains, clathrin, 430
- Light-harvesting complexes (LHCs), 906–909, 908F
- Light reactions, photosynthesis, **902–926**
 - electron transport in purple bacteria, 909–913
 - light absorption, 903–909
 - photophosphorylation, 925–926
 - two-center electron transport, 913–925
- Lignin, 369
- Lignoceric acid, 387T, 958
- Lilijas, A., 1385
- Lima, C., 1327
- Limit dextrins, 385
- Limited proteolysis, 170
- lin-4* gene, 1326
- LIN-14 protein, 1326
- Linear concentration gradients, 137F
- Linear gradient elution, 137
- Linear polymers, 70
- LINES (long interspersed nuclear elements), 1246, 1249
- Lineweaver–Burk plot, **490**, 490F, 494F–496F, 499F, 500F
- Linked genes, 24
- Linkers, in gene manipulation, 109–110, 110F
- Linking number, 1158, 1162
- Link proteins, 375
- Linoleic acid, 386, 387F, 387T, 950F, 971
- α-Linolenic acid, 387F, 387T, 971, 994
- γ-Linolenic acid (GLA), 387T, 994
- Lipase, 153T, 941–942, 941F
- Lipids, 15, 16F. *See also related topics. e.g.:*
 - Fatty acids
 - and acid-base groups, 48
 - aggregates of, **393–399**
 - biosynthesis, 818, 973
 - classification, **386–393**
 - fluidity, 388, 397–399
 - metabolism, 561F
 - in thylakoid membrane, 902
- Lipid bilayers, 44F, 395F, 397F. *See also* Membranes
 - dynamics, 396–399, 397F
 - fluidity, 397–399
 - liposomes, **395–396**
 - micelles, **394–395**, 394F
 - phospholipid diffusion, 396F
- Lipid-linked membrane proteins, **406–408**
- Lipid metabolism, 561F, **940–944**
 - cholesterol, **975–993**
 - eicosanoid, **993–1004**
 - fatty acid biosynthesis, **961–973**
 - fatty acid oxidation, **945–959**
 - ketone bodies, **959–961**
 - phospholipids and glycolipids, **1004–1013**
 - regulation of fatty acid metabolism, **973–975**
- Lipidomics, 578
- Lipid-soluble vitamins, 474
- Lipid storage disease, 1011, 1013
- Lipid-water interfaces, 940–941
- Lipinski, C., 542
- Lipinski's rule of five, 542
- Lipitor, 990–991, 991F
- Lipmann, F., 578, 791, 892
- Lipoamide, in citric acid cycle, 794, 795F
- Lipogenesis, 1096
- Lipoic acid, 473T, 794, 795T
- Lipolysis, 1096
- Lipopolysaccharides, 378
- Lipoproteins:
 - characteristics of major classes, 449T
 - dysfunctions, 456–459
 - function, **451–456**
 - structure, **449–451**
- Lipoprotein lipase (LPL), 450T, 451, 943
- Liposomes, 122, **395–396**
- Lipoxins (LXs), 993, **1003–1004**
- 15-*epi*-Lipoxin A₄ (15-*epi*-LXA₄), 1004
- Lipoxin A₄ (LXA₄), 1003F, 1004
- Lipoxin receptors, 689
- 5-Lipoxygenase (5LO), 1000
- 12-Lipoxygenase (12LO), 1000
- 15-Lipoxygenase (15LO), 1000, 1001
- Lipoxygenase-1, 1001
- 5-Lipoxygenase-activating protein (FLAP), 1001, 1002, 1002F
- Lipoyllysyl arm, dihydrolipoyl dehydrogenase, 797
- Lipscomb, W., 476
- Liquid scintillation counting, 572
- Literature search, 34–35
- Lithgow, T., 445
- Lithium ion, 45T, 1158
- Liver:
 - AMP-dependent protein kinase in, 1096, 1097F
 - and cholesterol biosynthesis, 987
 - citric acid cycle in, 816, 817
 - fructose utilization in, 630–631
 - glucokinase in, 597
 - gluconeogenesis in, 871
 - glycogen storage in, 638–639, 667–668
 - half-lives of enzymes in, 1408T
 - heme synthesis regulation, 1055–1056
 - and other organs, 1091F, 1093–1094
 - rat liver cytoplasmic ribosomes, 1370T
 - stress response of, 665F
- Liver alcohol dehydrogenase (LADH), 472, 505, 618–619
- Liver glycogen synthase deficiency, **668**
- Liverworts, 13F
- Living systems, rise of, 33–34
- LKB1, 1096
- 5LO (5-lipoxygenase), 1000
- 12LO (12-lipoxygenase), 1000
- 15LO, *see* 15-Lipoxygenase
- Local energy maxima, 289
- Local mediators, 671
- Lock-and-key hypothesis, 470
- Loewenstein, W., 416
- Logan, D., 1385
- Log odds, 198
- Log odds substitution matrix, 198
- Lohman, T., 1186
- Lon, 1419
- London dispersion forces, 260–261, 261F
- Longevity, and caloric restriction, 1101
- Long interspersed nuclear elements, *see* LINES
- Long terminal repeats (LTRs), 1245–1246
- Long-term regulation, of fatty acid metabolism, 973
- Loop conformation, **230**, **232**
- Looped rolling circle replication, 1191–1193, 1192F
- Lopez, A., 717
- Lord, R., 1155
- Lorimer, G., 300
- Lovastatin, 990, 991F
- Low-barrier hydrogen bonds (LBHBs), 536
- Low density lipoproteins, *see* LDL
- Lowenstein, J., 1132
- Lowe syndrome, 735
- Lowry, T., 45
- loxP* gene, 1244
- LPL, *see* Lipoprotein lipase
- L-protein, 1032
- LRRs (leucine-rich repeats), 1412
- LT (heat-labile enterotoxin), 696
- LTA₄ (leukotriene A₄), 1000

- LTB₄ (leukotriene B₄), 1001
 LTC₄ (leukotriene C₄), 1001
 LTC₄ synthase, 1001
 LTD₄ (leukotriene D₄), 1001
 LTE₄ (leukotriene E₄), 1001
 LTRs (long terminal repeats), 1245–1246
 Lu, P., 1294
 Luciferase, 183
 Luciferin, 183
 Ludwig, M., 1036, 1037, 1125
 Lührmann, R., 1314, 1315
 Luisi, B., 800
 Lungfish, 94T
 Luteinizing hormone (LH), 154F, 673T, 683
 LXA₄, *see* Lipoxin A₄
 15-*epi*-LXA₄ (15-*epi*-lipoxin A₄), 1004
 LXs, *see* Lipoxins
 Lyases, 479T
 Lycopenes, 905F, 907
 Lydon, N., 719
 Lynen, F., 791
 Lyophilization, 141
 Lys, *see* Lysine
 Lysate, 130
 Lysidine, 1347F, 1352
 Lysine:
 amino group, 208F
 biosynthesis, 1072–1073, 1075
 degradation, 1040–1041
 and *E. coli* nonsense suppressor, 1362T
 as essential amino acid, 1065T
 genetic codes for, 100T, 1343T
 half-life, 1413T
 α helix/β sheet propensity, 302T
 isoelectric point, 72
 in native unfolded proteins, 283
 side chains, 71, 208F, 264T
 structure and general properties, 69T
 trypsin-catalyzed cleavage, 170
 Lysis, 27, 130
 Lysogenic mode, 1243
 Lysolecithin, 452
 Lysophosphatidic acid, 971
 Lysophospholipase A₂, 942
 Lysophospholipids, 942
 Lysosomal protease, 525T
 Lysosomes, 7F, 9–10, **1408–1409**
 metabolic functions, 562T
 in secretory pathway, 420, 421F
 and vesicle formation, 428–440
 and vesicle fusion, 440–445
 Lysozyme, 470, 479, **517**
 in amyloid diseases, 310–311
 and bacterial cell walls, 376
 catalytic mechanism, **520–525**, 521F
 covalent intermediate of, 524F
 hen egg white, 275–276, 276T, 470,
 517–525, 517F, 518F
 isoelectric point, 134T
 for protein solubilization, 130
 structure, **517–520**
 substrate interactions with, 510F
 transition state, 523F
 Lysozyme amyloidosis, 310
 LysRS, 1351
 Lysyl group, 73T
 Lysyl hydroxylase, 240, 1405
 Lysyl oxidase, 238, 240
 Lytic mode, 1243
 α-Lytic protease, 525T
 D-Lyxose, 360F
- M**
 m¹A (1-Methyladenosine), 1347F
 m³C (Methylcytidine), 1347F
 m⁴C (N⁴-Methylcytosine) residue, 1246
 m⁵C-MTase, *see* 5-Methylcytosine
 methyltransferase
 m⁵C (5-Methylcytosine) residue, 1246
 m⁶A (N⁶-Methyladenine), 1246
 M6P/IGF-II receptor, 890
 m⁷G, *see* N⁷-Methylguanosine
 m⁷GDP, 1378
 m²G (N²,N²-Dimethylguanosine), 1347F
 MacKinnon, R., 751, 752, 755, 774
 MacLeod, C., 86
 Macrocytes, 1064
 Macrofibrils, 234, 234F
 α₂-Macroglobulin, 154F
 Macromolecular mimicry, 1386
 Macromolecules, 15, 16F, 17, 257
 Macrophages, 381, 457, 671
 Macrophage colony-stimulating factor
 (M-CSF), 717
 Macroscopic dissociation constants, 348
 Mad cow disease, 312, 315
 Magnesium ion, 45T, 1158, 1308–1309
 Maintenance methylation, 1249–1251, 1249F
 Maize, *see* Corn
 Major facilitator superfamily (MFS), 751
 Major groove, in DNA 90, 1145
 Major histocompatibility complex (MHC)
 proteins, 1102
 Malaria, 187–188, 343, 898, 1058
 Malate, 790F, 791, **813**, 936
 L-Malate, 481, 947
 Malate-aspartate carrier, 827, 827F
 Malate dehydrogenase, 876, 947
 in citric acid cycle, 790F, 791, **813**
 molecular mass, 140F
 Malate dehydrogenase, decarboxylating, 956
 Malate-α-ketoglutarate carrier, 827
 Malate synthase, 880
 Malathion, 527
 MALDI (matrix-assisted laser
 desorption/ionization), 172–173
 Male sex hormones, 681
 Malic enzyme, 956
 Malignant transformation, 1211–1212
 Malignant tumors, 381, 703. *See also* Cancer
 Malonate, 493, 791, **811**
 Malonic semialdehyde, 1136F
 Malonyl/acetyl-CoA-ACP transacylase
 (MAT), 964
 Malonyl-CoA, 961, 1136F
 Malonyl/palmitoyl transferase (MPT), 967
 Maltodextrins, 749
 Maltotriose, 640F
 Maltoporin, **749–750**, 749F
 Maltose, 367, 367F
 Maltose binding protein, 300
 Maltose phosphorylase, 501
 Maltotriose, 370
 Mammals. *See also specific types*
 cloning, 1251
 CpG methylation, 1249
 cytoplasmic adenylation of mRNAs, 1402
 DNA base composition, 84
 energy metabolism strategies, **1088–1090**
 genomic imprinting, 1251
 glycogen synthase, 645
 homolactic fermentation, **614–615**
 isoprenoid metabolism, 976F
 keratin, 232–233
 LDL-receptor mediated endocytosis,
 986, 986F
 mitochondrial DNA replication,
 1207, 1207F
 mitochondrial deviations from
 ideal, 1344T
 mRNAs, 1302
 mutation rate, 192
 myoglobin, 324
 POH1, 1418
 signal recognition particles, 422
 snoRNAs, 1329
 Mammalian target of rapamycin (mTOR),
 734, 738
 Man, *see* Mannose
 Manganese ion, 1158
 Maniatis, T., 1306
 Manley, J., 1312
 Mannose, 630, 633, 633F, 747T
 D-Mannose, 360F, 361
 Mannosidase, 366
 D-Mannuronic acid, 364
 Map-based genomic sequencing,
 180–181, 181F
 MAP (mitogen-activated protein) kinase,
 712–714
 MAP kinase kinase (MKK), 713
 MAP kinase kinase kinase (MKKK), 713
 MAP-kinase signaling cascades, **712–714**
 Maple syrup urine disease (MSUD), 1039
 Margolic acid, 1018
 Margoliash, E., 189
 Margulis, L., 9
 Marmur, J., 93
 Mars, 39
 Martin, A., 144
 Martius, C., 791
 Mas37, 449
 Masking, of mRNA, 1401–1402
 Massey, V., 801
 Mass spectrometry, *see* MS
 Mast cells, 372
 MAT (malonyl/acetyl-CoA-ACP
 transacylase), 964
 Matrix, 9, 445, 448, 824, 825F
 Matrix-assisted laser desorption/ionization
 (MALDI), 172–173
 Matrix-associated regions, *see* MARs
 Matrix processing peptidase (MPP), 447
 Matrix protein 1, *see* M1
 Matrix space, 9
 Mattevi, A., 1066
 Matthaei, H., 1341, 1343
 Matthews, B., 282
 Matthews, D., 1128
 Matthews, R., 1036, 1037
 Maturity-onset diabetes, 310, 1102–1103
 Maximal velocity (*V*_{max}), 489
 Maximum likelihood (ML) tree-building
 criteria, 205
 Maximum parsimony (MP) tree-building
 criteria, 205
 Mayer, R., 901
 Mb, *see* Myoglobin
 MBD (methyl-CpG binding domain), 1249
 MCAD (medium-chain acyl-CoA
 dehydrogenase), 948
 McArdle's disease, 644, 667
 McCarty, M., 86
 McClintock, B., 1236
 McDermott, A., 604, 606
 Mcm2, 1205
 Mcm3, 1205
 Mcm4, 1205
 Mcm5, 1205
 Mcm6, 1205
 Mcm7, 1205
 Mcm10, *see* DDK
 MCM complex, 1205, 1206
 MCPA-CoA (methylenecyclopropylacetyl-
 CoA), 948, 948F

- M-CSF (macrophage colony-stimulating factor), 717
- Mdm10, 449
- MDPK (myotonic dystrophy protein kinase), 1252
- MDR (multidrug resistance) transporter, 766–767
- Mechanism-based inhibitors, 1128
- Mechanosensitive channels, 772
- Medial cisternae, 428, 429F
- Mediated membrane transport, **745–748**
- Medium-chain acyl-CoA dehydrogenase (MCAD), 948
- MedLine, 35, 195
- Medulla, 679
- Megaloblastic anemia, 474T
- Meiosis, **20**, 21F, 24F, 1224
- Meister, A., 1061
- MEK, 713
- MEKK1, 714
- Melanin, 1046
- α -Melanocyte stimulating hormone (α -MSH), 1099
- Melezitose, 385
- Mello, C., 1323
- Melting curve:
 - DNA, 93, 93F
 - proteins, 265F
- Melting temperature (T_m):
 - DNA, 93, 93F
 - proteins, 265
- Memapsin 2, 547
- Membranes:
 - assembly and protein targeting, **418–449**
 - and blood groups, **414–415**
 - composition of, 398T
 - Donnan equilibrium for, 787
 - of erythrocytes, **411–414**, 411F
 - fluid mosaic model, **408–411**
 - function of, 386
 - gap junctions, **415–416**
 - lipid distribution in, **419–420**
 - secretory pathway, **420–428**
 - vesicle formation, **428–440**
 - vesicle fusion, **440–445**
- Membrane potential, 447, **745**
- Membrane proteins, **399–406**
 - channel-forming, **416–418**
 - integral, **399–406**
 - lipid-linked, **406–408**
- Membrane transport:
 - ABC transporters, **766–768**
 - action potentials, **775–777**
 - aquaporins, **756–757**
 - ATP–ADP translocator, **771**
 - ATP-driven active, **758–768**
 - Ca^{2+} -ATPase, **762–764**
 - Cl^- channels, **755–756**
 - general scheme, 747F
 - group translocation, **765–766**
 - and $(\text{H}^+ - \text{K}^+)$ -ATPase, **764–765**
 - ion-driven active, **768–771**
 - in ionophores, **748–749**
 - K^+ channels, **752–755**
 - kinetics of mediated transport, **746–748**
 - lactose permease, **769–770**
 - malto porin, **749–750**
 - mediated, **745–748**
 - Na^+ -glucose symport, **768–769**
 - $(\text{Na}^+ - \text{K}^+)$ -ATPase, **758–762**
 - and neurotransmission, **771–784**
 - nonmediated, **745–746**
 - passive-mediated glucose transport, **750–752**
 - thermodynamics of, **744–745**
 - voltage-gated ion channels, **771–775**
- Menaquinone, 910
- Mendel, G., 20–22
- Mendelian inheritance, **20–22**, 107F
- Menstrual cycle control, **683–684**
- Menten, M., 488
- 2-Mercaptoethanol, 168
- 6-Mercaptopurine, 1142
- Merozygote, 1263
- Merrifield, B., 206, 208
- Mertz, J., 109
- Meselson, M., 90, 1173, 1264
- Meso form, 76
- Mesophiles, 266
- Mesophyll cells, 904
- Mesosomes, 4, 4F
- Messenger RNA, *see* mRNA
- Met, *see* Methionine
- Metabolic adaptation, 1102–1104
- Metabolic control, **619–621**
- Metabolic control analysis, **620–624**
- Metabolic flux, 620, 624
- Metabolic homeostasis, **619–620**, 1096–1101
- Metabolic inhibitors, 569
- Metabolic pathways, 14, 17, **559–562**
 - and carbon–carbon bonds, **567–569**, 568F
 - in cells, 560F
 - chemical logic, **563–565**
 - eliminations, isomerizations, and rearrangements, **566–567**
 - energy metabolism, **1088–1090**
 - evolution, 34
 - group transfer reactions, **564–565**
 - interorgan specialization, **1090–1095**
 - organelles in, 562T
 - organic reaction mechanisms, **562–569**
 - oxidations and reductions, **565–566**
- Metabolic regulation, 619
- Metabolic syndrome, 1104
- Metabolism, 559. *See also specific types of metabolism*
 - cancer cells, 864–865
 - experimental study of, **569–575**
 - inborn errors of, 26
 - isotope studies of, **572–575**
 - metabolic inhibitors, growth studies, and biochemical genetics, **569–572**
 - organs, cells, and subcellular organelles in, **575**
 - oxidation–reduction reactions, **584–586**
 - phosphate compound thermodynamics, **578–583**
 - systems biology, **576–578**
 - and thermodynamics of life, **586–589**
- Metabolites, 559
- Metabolite carrier proteins, 448
- Metabolome, 576
- Metabolomics, **578**
- Metabolons, 595, 817
- Metachromatic leukodystrophy, 1013T
- Metal-activated enzymes, 511
- Metal chelation affinity chromatography, 145
- Metal ion catalysis, **511–512**
- Metalloenzymes, 511
- Metaphase, 20F, 21F
- Metastasis, 703
- Metazoa, 12, 1202, 1206–1207
- Met-enkephalin, 673T, 685
- Methane, 32, 42
- Methanococcus*, 7F
- Methanococcus jannaschii*, 424, 425F
- Methanogens, 6
- Methanol, 43T, 505
- Methemoglobin (metHb), 324, 342
- Methemoglobinemia, 342
- Methemoglobin reductase, 324–325
- $\text{N}^5, \text{N}^{10}$ -Methenyltetrahydrofolate, *see* MTHF
- Methionine:
 - biosynthesis, 1072–1073, 1075
 - degradation, 1034–1039
 - as essential amino acid, 1065T
 - genetic codes for, 100T, 1343T
 - in globular proteins, 246
 - half-life, 1413T
 - α helix/ β sheet propensity, 302T
 - in native unfolded proteins, 283
 - side chains, 70, 264T
 - structure and general properties, 68T
- Methionine sulfone, 1066
- Methionine synthase, 955, 1037
- Methionyl-tRNA synthetase (MetRS), 100, 1352
- Methotrexate, 445, 492–493, 1129
- 9-Methyladenine, 1156F
- N^6 -Methyladenine (m^6A) residue, 1246
- 1-Methyladenosine (m^1A), 1347F
- N*-Methylalanine, 32T
- Methylamine methyltransferase, 1361
- Methyl arachidonyl fluorophosphonate, 405F
- ω -*N*-Methylarginine, 79F
- α -Methylaspartate, 1033F
- Methylation analysis, 366
- Methylcobalamin, 1037
- Methyl-CpG binding domain (MBD), 1249
- β -Methylcrotonyl-CoA carboxylase, 962
- Methylcytidine (m^3C), 1347F
- N^4 -Methylcytosine (m^4C) residue, 1246
- 5-Methylcytosine methyltransferase (m^5C -MTase), 1247–1248, 1247F
- 5-Methylcytosine (m^5C) residue, 1246
- N^6 -Methyl-dA, 85
- 5-Methyl-dC, 85
- α - β -Methylene-ADP, 1108F
- N,N'*-Methylenebisacrylamide, 147, 147F
- Methylenecyclopropylacetyl-CoA, *see* MCPA-CoA
- $\text{N}^5, \text{N}^{10}$ -Methylene-tetrahydrofolate, 1031, **1062**
- $\text{N}^5, \text{N}^{10}$ -Methylene-tetrahydrofolate reductase (MTHFR), 1035–1037
- Methyl-D-glucosides, 363F
- Methylglyoxal, 606
- O^6 -Methylguanine residue, 1216
- N^7 -Methylguanosine (m^7G), 1302, 1347F
- 3-Methylhistidine, 79F
- Methylmalonic aciduria, 955
- Methylmalonic semialdehyde, 737F
- Methylmalonyl-CoA, 1136F
- L*-Methylmalonyl-CoA, 567
- (*S*)-Methylmalonyl-CoA, 952, 952F, 953
- Methylmalonyl-CoA mutase, 567, 953–956, 954F, 955F, 957F
- Methylmalonyl-CoA racemase, 953
- Methyl-*p*-nitrobenzene sulfonate, 536–537
- N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG), 1215–1216
- Methylphosphonate, 1402
- O^2 -Methylribose, 1328
- Methyl silicones, 31
- N^5 -Methyl-tetrahydrofolate, 1034, 1062
- Methyl thiocyanate, 170
- 4-Methylumbelliferyl- β -D-*N*-acetylglucosamine, 1011
- 5-Methyluracil, *see* Thymine
- N*-Methylurea, 32T
- MetJ, 1290
- Metmyoglobin (metMb), 324
- Metmyoglobin reductase, 325
- met* repressor, 1290–1291, 1291F

- MetRS, *see* Methionyl-tRNA synthetase
 Met-tRNA^{Met}, 1373–1374
 Met-tRNA^{Met}_i, 1376, 1401
 Metzler, D., 1021
 Mevacor, 990, 991F
 Mevalonate, 977
 Mevalonate-5-phosphotransferase, 977
 Mevalonolactone, 987
 Mevinolin, 990
 Meyerhof, O., 595
 Mfd protein, 1218
 MFS (major facilitator superfamily), 751
 Mge1, 447
 MHC (major histocompatibility complex) proteins, 1102
 M.HhaI, 1248, 1250
 M.HhaI DNA methyltransferase, 1248F
 mHsp70, 447
 Mice:
 cancer cells, 382F
 carcinogenesis tests, 1224
 genome sequencing, 176, 177T
 injection with transformed pneumococci, 86
 knockout, 121
 liver membrane composition, 398T
 monoclonal antibodies from, 119
 obese and diabetic, 1098–1099
 telomere length, 1211–1212
 transgenic, 86, 86F, 121F
 Micelles, 44, 44F, 51, **394–395**, 394F
 Michaelis, L., 488
 Michaelis complex, 488
 Michaelis constant (K_M), 489
 Michaelis–Menten equation, **488–491**, 488F
 Michaelis–Menten kinetics:
 derivations, 501–503
 for enzymes, 489T
 inhibition, 493–496
 pH dependence, 496–497
 Michel, H., 403, 840, 907, 910
 Microbodies, 10
 Microdomains, 410
 Microfibrils, 234, 234F
 Microfilaments, 10
 Microheterogeneity, 373
 MicroRNAs (miRNAs), 1325–1326
 Microscopic dissociation constants, 348
 Microscopic ionization constants, 49, 50
 Microsomes, 154F, 883, **1362**
 Microsporidiae, 7F
 Microtubules, 10
 Microvilli, 38
middle genes, 1284
 Miescher, F., 85
 Migration rate (paper chromatography), 144
 Miles, E., 1076
 Miller, C., 774
 Miller, S., 32–33
 Miller–Urey experiments, 32T
 Milstein, C., 420
 Mineral acids, 46
 Mineralcorticoids, 673T, 680, 991
 Minor groove, in DNA, 90, 1145
 Minot, G., 956
 miRBase database, 1326
 miRNAs (microRNAs), 1325–1326
 Mismatch repair, **1220**, 1220F
 Missense suppressors, 1362
 Mitchell, P., 846
 Mitochondria, 7F, **9**, 11F, 16F, **823–828**, 825F.
 See also Electron-transport chain
 acetyl-CoA transport in, **968–969**
 anatomy, 824, 825F
 citric acid cycle in, 809, 815
 cytoplasmic shuttle systems, 827–828
 fatty acid transport in, 946–947, 946F
 gluconeogenesis in, 876–877, 877F
 heme biosynthesis in, 1054
 lipid composition of beef heart membrane, 398T
 membranes of, 853F
 metabolic functions of, 562T
 mouse liver, 833F
 photorespiration in, 935
 protein importing in, 445, 446F
 protein targeting in, **445–449**
 sedimentation coefficient, 154F
 transport systems, 824–828, 826F
 wobble pairings of tRNA, 1361
 Mitochondrial carrier family, 771
 Mitochondrial DNA, *see* mtDNA
 Mitochondrial electron-transport chain, *see* Electron-transport chain
 Mitochondrial import stimulation factor (MSF), 445
 Mitochondrial inner membrane, 398T
 Mitochondrial outer membrane, 398T
 Mitochondrial trifunctional protein, 948–949
 Mitogens, 1202, 1401
 Mitogen-activated protein (MAP) kinase, 712–714
 Mitosis, **20**, 20F, 1202
 Mitotic spindle, 10, 20, 1202
 Mixed inhibition, **495–496**, 496F, 502
 Mixed triacylglycerols, 388
 MJ33, 943
 MK-591, 1001–1002, 1002F
 MK0886, 1001
 MKK (MAP kinase kinase), 713
 MKK4, 714
 MKK7, 714
 MKKK (MAP kinase kinase kinase), 713
 MKKK kinase (MKKKK), 714
 ML (maximum likelihood tree-building criteria), 205
 MLCK (myosin light chain kinase), 656
 MLK3, 714
 MMDb, *see* Molecular Modeling Database
 MNNG (*N*-methyl-*N'*-nitro-*N*-nitrosoguanidine), 1215–1216
 Mobile genetic elements, 1225–1236
 Mobile loop, GroES system, 294, 307F
 Mobile phase, 135
 Mobility, 45–46, 45F, 45T, 745
 Modrich, P., 1220
 Modulator, 348
 MoFe-protein, 1080–1081
 Mohammadi, M., 701
 Molar extinction coefficient, 90
 Molecular archeology, 116
 Molecular biology, 95, 95F, 1260
 Molecular chaperones, 290, **293–302**.
 See also Chaperone proteins
 Molecular clock, 192
 Molecular cloning, **104–124**
 cloning vectors, **106–109**
 gene manipulation, **109–111**
 gene therapy, **122–123**
 genomic libraries, **113–114**
 and nuclear sequencing, 176
 and polymerase chain reaction, **114–117**
 protein production, **117–121**
 and protein purification, 130
 restriction endonucleases, **104–106**
 social, ethical, and legal considerations, 123, 124F
 Southern blotting, **111–113**
 transgenic organisms, **121–123**
 Molecular disease, **185–187**
 Molecular dynamics simulation, 307–308, 308F, 397
 Molecular ionization constants, 49–50
 Molecularly, reactions, 483
 Molecular mass, $5n$
 by gel filtration chromatography, 138, 139, 140F
 in protein sequencing, 169
 by SDS-PAGE, 150, 151F
 Molecular Modeling Database (MMDb), 256T, 258
 Molecular sieve chromatography, 138
 Molecular size, protein purification and, 132
 Molecular weight, $5n$
 Molecular weight cutoff, 141
 Mollusks, 13F
 Molten globule, 287
 Molybdopterin complex (Mo-pt), 1132
 Mondragón, A., 1164–1165, 1331
 Monera, 6
 Monoclonal antibodies, 119–120, 131–132, 143
 Monocyclic cascade, 650
 Monod, J., 349, 1262, 1264–1265
 Monogalactosyl diacylglycerol, 902
 Monooxygenases, 543
 Monoprotic acids, 49
 Monosaccharides, **359–363**. *See also* specific Monosaccharides
 Monosodium glutamate (MSG), 1064
 Monotopic proteins, 404, 426
 Montagnier, L., 545
 Moody, P., 1216
 Moore, P., 1365, 1366, 1383
 Mo-pt (molybdopterin complex), 1132
 Moras, D., 1357
 Morgan, T. H., 23, 24
 Morikawa, K., 1199, 1231
 Morpheesins, 1050
 Mosses, 13F
 Most Representative NMR Structure in an Ensemble, 256T
 Mother cell, 1284
 Motifs, 249–251
 Mouse, *see* Mice
 Moving boundary electrophoresis, 146
 Mozzarella, A., 353
 MPA (mycophenolic acid), 1112
 M phase, **1202**, 1206
 MPP (matrix processing peptidase), 447
 MPT (Malonyl/palmitoyl transferase), 967
 MP (maximum parsimony) tree-building criteria, 205
 Mre11 complex, 1224
 mRNA (messenger RNA), 1145, 1260, **1264–1265**
 affinity chromatographic isolation, 158
 base pairing with 16S rRNA, 1374–1375
 degradation, 1327
 and enzyme induction, 1260–1264
 masking and cytoplasmic polyadenylation, 1401–1402
 methylation, 1320
 posttranscriptional modification, 1302–1327
 reading of, 1342–1343, 1342F, 1372
 transport of, 1326–1327
 MS (mass spectrometry), 169, 172–174, 172F, 366
 MsbA, 767–768, 767F
 MSF (mitochondrial import stimulation factor), 445
 MSG (monosodium glutamate), 1064
 α -MSH (α -melanocyte stimulating hormone), 1099
 MS/MS, *see* Tandem mass spectrometry

- mSos, 709
 MspI, 105T
MspI, 1249
 MSUD (maple syrup urine disease), 1039
 MTase, 1247–1248
 mtDNA, 116, 1207, 1207F
 MTHF (N^5,N^{10} -methenyltetrahydrofolate), 1129, 1215
 MTHFR (N^5,N^{10} -methylene-tetrahydrofolate reductase), 1035–1037
 mtHsp70, 447
 mTOR, *see* Mammalian target of rapamycin
 Mtr3, 1327
 Mucin, 381, 890, 890F
 Mucopolidosis II, 439
 Mucopolysaccharides, 371
 Mucus, 381
 Mule, 1251
 Müller-Hill, B., 1284, 1294
 Mullis, K., 114
 Multicellular organisms, 12, 34, 1202.
 See also specific organisms
 Multidrug resistance (MDR) transporter, 766–767
 Multienzyme complexes, 792, 794
 Multiforked chromosomes, 1195, 1195F
 Multipass transmembrane proteins, 426
 Multiple sclerosis, 777
 Multiple sequence alignment, 201–203
 Munc18, 441
 Mupirocin, 1356, 1356F
 Murein, 376
 Murine eIF4e, 1378F
 Murphy, W., 956
 Musacchio, A., 708
 Muscarine synapses, 778
 Muscarinic synapses, 778
 Muscle, 10
 AMP-dependent protein kinase in, 1096, 1097F
 anaerobic glycolysis in, 615
 citric acid cycle for, 792, 817
 fibrous proteins, 232
 free energy changes of glycolysis in, 625T
 fructose utilization in, 630
 glucose uptake regulation in, 751F
 glycogen storage in, 638–639, 667
 glycolysis regulation in, 624–630
 and other organs, 1091–1093, 1091F
 slow and fast-twitch fibers, 619
 Muscle fatigue, 615, 1092–1093
 Muscle glycogen synthase deficiency disease, 668
 Muscular dystrophy, 1252
 Mutagens, 104, 570
 Mutagenesis, 119–120, 1224–1225, 1225F
 Mutarotation, 362–363, 507–508
 Mutase, 610
 Mutations:
 in DNA replication, 102
 dynamic, 1251–1252
 and evolution, 18–19, 185
 nonsense, 1362
 point, **192**, 1339–1340
 random nature of, 195
 rates of, 192
 up and down, 1266
 and viruses, 27, 27F
 MutH, 1220
 MutL, 1220
 MutS, 1220
 MWC model, of allosteric interactions, 349–351
 Myasthenia gravis, 781
 Myc, 713, 737F
Mycobacterium leprae, 1234
Mycobacterium tuberculosis, 177T
Mycobacterium xenopi, 1407, 1407F
 Mycophenolic acid (MPA), 1112
Mycoplasma, 4F
Mycoplasma genitalium, 177T
Mycoplasma hominis, 94T
 Mycoplasmas, 6
 Myelin, 398T, 777
 Myelination, 777–778, 778F
 Myelin membrane, 398T
 Myeloma, 131
 Myoadenylate deaminase deficiency, 1132
 Myocardial infarction, 456, 865
 Myoglobin (Mb), 323, **331–332**, 332F
 α and β chains of, 332T–333T
 conformation of, 306F
 electron density map, 242F
 ESI-MS spectrum, 173, 173F
 gene duplication, 193–194
 α helix, 227F
 H helix, 248F
 Hill plot, 327F
 isoelectric point, 134T
 mobility, 308F
 in molecular dynamics simulation, 308F
 molecular mass, 140F
 nitric oxide detoxification by, 325
 oxygen binding by, 325–326, 326F
 physical constants of, 153T
 sequence alignment, 197F
 solubility in ammonium sulfate solution, 133F
 tertiary structure, 245–246
 X-ray structure, 241F, 245F
 Myokinase, 627. *See also* Adenylate kinase (AK)
 Myosin, 10, 301
 Myosin light chain kinase (MLCK), 656
 Myotonic dystrophy (DM), 1252
 Myotonic dystrophy protein kinase, 1252
 Myristic acid, 387T, 407
 Myxobacteria, 13F
 Myxothiazol, 849

 N
 Na⁺, *see* Sodium ion
N-Acetylneuraminic acid, *see* NANA
 Na⁺ channels, 772, 776–777
 NAD⁺ (nicotinamide adenine dinucleotide), 82, 471F, 791
 790F, 766F
 biosynthesis, 1137F, 1138
 in catabolism, 561F
 in citric acid cycle, 794, 795T
 and DNA ligase, 1187
 domains, 248
 in glycolysis, 585, 594F
 in glyoxylate cycle, 880
 in oxidation-reduction reactions, 565
 and yeast alcohol dehydrogenase, 471–472
 NADD, 471
 NADH (nicotinamide adenine dinucleotide, reduced form):
 766F, 766F
 in catabolism, 561F
 in citric acid cycle, 789, 791, 819
 as electron-transfer coenzyme, 586
 in electron-transport chain, 823, 824F, 828, 829
 in fatty acid oxidation, 950
 in glycolysis, 585, 594F
 in oxidation-reduction reactions, 565
 and yeast alcohol dehydrogenase, 471–472
 NADH:Coenzyme Q reductase, *see* Complex II
 NADH-cytochrome *b₅* reductase, 971
 NADH dehydrogenase, *see* Complex I
 NADH-dependent dehydrogenases, 472
 NAD⁺ kinase, 1137F, 1138
 NADP⁺ (nicotinamide adenine dinucleotide phosphate), 471F, 473, 931, 1137F
 NADPH (nicotinamide adenine dinucleotide phosphate, reduced form):
 in Calvin cycle, 931
 in metabolic pathways, 561, 561F
 and photorespiration, 935
 in photosynthesis, 902, 926
 and yeast alcohol dehydrogenase activity, 471F
 NADPH-P450 reductase, 543–545
 NAD⁺ pyrophosphorylase, 1137F, 1138
 NAG (*N-Acetylglucosamine*), 365, 371, 376, 377F
 lysozyme catalytic mechanism, 517–520, 517F, 522–525
 in peptidoglycan, 377F
 rates of hydrolysis, 518T
 X-ray structure of, 518F
 NAG- β (1 \rightarrow 4)-2-deoxy-2-fluoro- β -D-glucopyranosyl fluoride (NAG2FGlcF), 524
 Nagai, K., 1314, 1315
 Na⁺-glucose symport, **768–769**, 768F, 769F
 Nails, 233, 234, 275
 Nakamura, Y., 1394
 (Na⁺-K⁺)-ATPase ((Na⁺-K⁺) pump), **758–762**, 761F
 NAM (*N-acetylmuramic acid*), 365, 365F, 376, 377F
 lysozyme catalytic mechanism, 517, 517F, 519–520, 522–525
 rates of hydrolysis, 518T
 NANA (*N-acetylneuraminic acid*), 365, 365F, 1010
 NAS, *see* Normalized alignment score
 Nathans, D., 105
 National Center for Biotechnology Information (NCBI), 35, 201
 Native chemical ligation, 209, 209F
 Native form (DNA), 88
 Native proteins, 221, 264
 crystalline, 243
 folding into, 278
 free energy, 57
 unfolded forms, **283–284**, 284F
 Natural selection, *see* Evolution
 Navia, M., 549, 724
 NCBI, *see* National Center for Biotechnology Information
 NDB, *see* Nucleic Acid Database
 NDP, *see* Nucleoside diphosphate
 Neandertals, 116
 Nearest-neighbor analysis, 127
 NEDD8, 1421
 Needleman, S., 199
 Needleman-Wunsch sequence alignment algorithm, 199–201, 200F
 Negative allosteric effect, 348
 Negative design, of proteins, 305
 Negatively cooperative binding, 327
 Negative regulator, 1286
 Neighbor-joining (N-J) method, for phylogenetic tree construction, 204
 Nelfinavir, 550F
 Nelson, N., 923
 NEM (*N-ethylmaleimide*), 440–441
 Nematodes, 13F, 1320. *See also* *Caenorhabditis elegans*

- Némethy, G., 352
 NEMO subunit, 1420
 NEM-sensitive fusion protein,
 see NSF protein
 N-end rule, 1413
 NER, *see* Nucleotide excision repair
 Nernst, W., 584
 Nernst equation, 584
 Nernst–Planck equation, 745
 Nerve growth factor (NGF), 717
 Nerve transmission, 440F
 Nervonic acid, 387T
 Nested primers, 116
 Neuberger, C., 595
 Neupert, W., 445
 Neural tube defects, 1035
 Neurocan, 373T
 Neurofibrillary tangles, 311, 312
 Neuroglobin, 325
 Neurohypophysis, 683
 Neurons, 12F
 Neuronal membranes, anesthetics and,
 398–399
 Neuronal NOS (nNOS), 686–687, 687F
 Neuropeptides, 783–784
 Neuropeptide Y (NPY), 1099
Neurospora, 13F, 26
Neurospora crassa, 1319, 1320F, 1344T
 Neurotoxins, 442, 442F, 776–777
 Neurotransmission:
 action potentials, **775–777**
 voltage-gated ion channels, **771–775**
 Neurotransmitters, 527, **778–784**
 amino acids as, 80
 synthesis of, 1058–1060
 in vesicles, 440
 Neurotransmitter receptors, **778–784**
 Neutral drift, **188–192**
 Neutral fats, 388
 Neutral solutions, 47
 Neutrophils, 688
 Newsholme, E., 629, 973
 New variant Creutzfeldt–Jakob disease
 (nvCJD), 315
 N-extein, 1406F, 1407
 NFAT₁, 724
 NF- κ B (nuclear factor κ B), 1414
 NGF (nerve growth factor), 717
 NH₄⁺, *see* Ammonium ion
 NHEJ (nonhomologous end-joining),
 1223–1224, 1224F
N^ω-hydroxyl-L-arginine (NOHA), 686, 686F
 Niacin, 474
 Niacinamide, 474
 Nicholls, A., 259
 Nicholson, G., 408
 Nick translation, 1181, 1187
 Nicotinamide, 474T, 1137F
 Nicotinamide adenine dinucleotide,
 see NAD⁺
 Nicotinamide adenine dinucleotide, reduced
 form, *see* NADH
 Nicotinamide adenine dinucleotide
 phosphate, *see* NADP⁺
 Nicotinamide adenine dinucleotide
 phosphate, reduced form, *see* NADPH
 Nicotinamide coenzymes, 471F, 473T,
 1136–1138
 Nicotinamide mononucleotide, *see* NMN
 Nicotinamide phosphoribosyltransferase,
 1137F, 1138
 Nicotinate, 1137F
 Nicotinate adenine dinucleotide (desamido
 NAD⁺), 1138
 Nicotinate mononucleotide, 1137F, 1138
 Nicotinate phosphoribosyltransferase, 1136,
 1137F, 1138
 Nicotine, 778
 Nicotinic acid, 474
 Nicotinic synapses, 778
 NIDDM, *see* Noninsulin-dependent diabetes
 Niemann–Pick disease, 1013T
 Nierhaus, K., 1373, 1388
 Nigericin, 869
 NIH shift, 1045
 19S caps, 1414, 1417
 19S regulator, 1414
 Nirenberg, M., 1341–1343
 Nitrate ion, 324
 Nitrate reductase, 1083
 Nitric acid, 46
 Nitric oxide (NO), 324
 binding to heme group, 324
 detoxification by myoglobin, 324
 hormonal roles, **685–688**
 Nitric oxide synthase, 685–687
 Nitrification, 1083
 Nitroacetic acid, 857
 Nitrite, 1340
 Nitrite ion, 324
 Nitrite reductase, 934, 1083
 3-Nitro-2-(*S*)-hydroxypropionate, 812
 Nitrocellulose, 111, 113
 Nitrogen, 31
 Nitrogenase, 1080–1082
 Nitrogen cycle, 1083, 1083F
 Nitrogen excretion, 1134–1135
 Nitrogen fixation, 5–6, **1078–1083**
 Nitrogen-fixing bacteria, 1080–1082
 Nitrogen mustard, 1340
 Nitrogenous bases, 83. *See also* Nucleic
 acid bases
 Nitroglycerin, 686
p-Nitrophenolate ion, 513, 525–526
p-Nitrophenylacetate, 513, 525–526, 526F
 Nitrosamines, 1340
 Nitrosoheme, 687
 Nitrous acid, 1339, 1340F
 N–J method, for phylogenetic tree
 construction, 204
N-Linked glycoproteins, 882–889
N-Linked oligosaccharides, 374F, 379–380,
 379F, 881, 888F
 synthesis of glycoproteins from, 882–889
 NLS (nuclear localization signal), 1414
 NMN (nicotinamide mononucleotide),
 1137F, 1138, 1187
 NMR spectroscopy:
 interpretation of structures, 243–244
 for metabolism studies, 569, 572
 with pulsed H/D exchange, 285–286
 nNOS, *see* Neuronal NOS
 NO, *see* Nitric oxide
 Nodes of Ranvier, 777
 NOESY, *see* Nuclear Overhauser effect
 spectroscopy
 NOHA, *see* *N^ω*-hydroxyl-L-arginine
 Noller, H., 1364, 1366, 1387, 1388, 1392, 1394
 Nomenclature:
 amino acid, 72–73
 enzymes, **479**
 Nomura, M., 1365
 Noncompetitive (mixed) inhibition,
 495–496, 496F, 502
 Nonconjugate flow, 587
 Noncooperative binding, 327
 Nonequilibrium thermodynamics, 587
 Nonessential amino acids, 1019,
 1064–1072, 1065T
 Nonhomologous end-joining, *see* NHEJ
 Noninsulin-dependent diabetes (NIDDM),
 310, 1102–1104, 1103F
 Nonketonic hyperglycinemia, 1032–1033
 Nonmediated membrane transport,
 745–746
 Nonpolar amino acids, 70–71
 Nonreceptor tyrosine kinases (NRTKs), 715
 Nonsense codons, 1343
 Nonsense mutations, 1362
 Nonsense suppression, 1362
 Nonshivering thermogenesis, 629,
 860–861
 Nonstandard amino acids, **78–80**, 79F, 80F
 Nonsteroidal anti-inflammatory drugs
 (NSAIDs), 994, 995, 998–999, 999F
 Nonviral retrotransposons, 1246, 1246F
 Noonan syndrome, 721
 Norepinephrine, 673T, **679–680**, 1046
 controls fatty acids in brown fat, 861
 role in fatty acid metabolism regulation, 973
 role in glycogen metabolism regulation, 660
 synthesis from tyrosine, 1058–1060
 Normalized alignment score (NAS),
 196, 198F
 Northern transfer (Northern blot), 113
 Northrop, J., 470
 NO synthase (NOS), 685–687
 Novobiocin, 1167, 1169, 1170, 1175
 NPCs (nuclear pore complexes), 1327
 NPY (neuropeptide Y), 1099
 NPY/AgRP cell type, 1099
 N-Ras, 709
 NRTKs (nonreceptor tyrosine kinases), 715
 NSAIDs, *see* Nonsteroidal anti-
 inflammatory drugs
 nSec1, 433F, 442–444
 NSF (NEM-sensitive fusion) protein, 441,
 444–445, 444F, 445F, 1159
 nt (nucleotides), 1175
 N-terminal nucleophile (Ntn) family,
 1066, 1417
N-terminus (amino acids), 73, 165,
 1371–1373
 Ntn family, *see* N-terminal nucleophile family
 NTPase, 1275–1276
 NTPs, *see* Nucleoside triphosphates
 Nuclear envelope, 9
 Nuclear factor κ B (NF- κ B), 1414
 Nuclear localization signal (NLS), 1414
 Nuclear membrane, 7F, 9
 Nuclear Overhauser effect spectroscopy
 (NOESY), 243, 244F
 Nuclear pore complexes (NPCs), 1327
 Nucleases, 101
 Nucleation, 346, 347F
 Nuclei, in landscape theory of protein
 folding, 287–289, 288F
 Nucleic acids, 15, 82–95. *See also*
 DNA; RNA
 and amino acid sequence, 70
 base pairing, 1154–1156
 base stacking, 1156–1157
 as buffer components, 48
 chemical structure, 84–85, 84F
 dietary, 1130
 and DNA function, 85–88
 and DNA structure, 88–95
 double-helical structures, **1145–1148**
 evolution, 33
 functional groups, 43
 hydrophobic forces, 1157–1158
 and nucleotides, 82–84
 oligonucleotide synthesis, 209–213
 organization of, 163–164
 polymeric organization, 17F

- sedimentation coefficients, 154F
 stability of, 1151–1158
 sugar-phosphate chain conformation, 1152–1154
 supercoiled DNA, **1158–1170**
- Nucleic acid bases, **82–83**. *See also* Nucleotide bases
 Chargaff's rules for, 84, 85
 modification of, 85
 names, structures, and abbreviations, 83T
 tautomeric forms of, 88, 88F
 UV absorbance spectra, 92F
- Nucleic Acid Database (NDB), 256T, **257**
- Nucleic acid fractionation, **156–159**
- Nucleic acid sequencing, **176**, 180–182
 amino acid sequencing contrasted, 184–185
 genome sequencing, 180–184
 Sanger method, 176–180
- Nuclei scaffolding, 287
- Nucleoid, 4, 4F
- Nucleolus, 7F, 9, 11F, 1328
- Nucleophiles, 563, 563F, 564
- Nucleophilic catalysis, 510–513
- Nucleoplasmin, 293
- Nucleoporins, 1327
- Nucleosidases, 1130
- Nucleosides, **82–83**, 83T
 Nucleoside-5'-phosphate, 83
 Nucleoside diphosphate (NDP), 582, 1125
 Nucleoside diphosphate kinases, 582, 644, 1113
- Nucleoside monophosphate kinases, 1113
- Nucleoside phosphorylases, 1130
- Nucleoside triphosphates, 82
- Nucleoside triphosphates (NTPs), 95–96, 582
- Nucleosomes, 291–293
- Nucleotidase, 1130F, 1136F
- 3'-Nucleotide, 83
- 5'-Nucleotide, 83
- Nucleotides, 15, 18, **82–83**
 defined, 82
 degradation, **1130–1136**
 names, structures, and abbreviations, 83T
 as units, 1175
- Nucleotide bases. *See also* Nucleic acid bases
 in aqueous solution, 1156–1157
 ionic interactions, 1158
 in prebiotic conditions, 33
- Nucleotide coenzyme biosynthesis, **1136–1139**
- Nucleotide excision repair (NER), 1216–1218, 1217F
- Nucleotide metabolism, **1107–1140**
 biosynthesis of nucleotide coenzymes, 1136–1139
 degradation of nucleotides, 1130–1136
 deoxyribonucleotide formation, 1119–1130
 purine ribonucleotide synthesis, 1107–1114
 pyrimidine ribonucleotide synthesis, 1114–1119
- Nucleotide sugars, 882F
- Nucleus, 3, **8–9**. *See also* DNA replication;
 animal cell, 7F
 metabolic functions, 562T
 plant cell, 11F
 transport of mRNA from, **1326–1327**
- NutraSweet (aspartame), 1087
- nvCJD (new variant Creutzfeldt-Jakob disease), 315
- Nyborg, J., 1380, 1381, 1388
- Nylon, 111
- O
- O-antigens, 85, **378–379**
- Obesity, 629, 862, 1093, 1096–1099, 1104
- OB folds, 1213
- Obligate aerobes, 6
- Obligate anaerobes, 6
- O blood type, 22
- OB-R protein, 1098
- Ochoa, S., 791, 1341, 1342
- ochre codon, 1343
- ochre mutants, 1408
- ochre suppressor, 1362
- O^c mutation, 1264
- OCRL, 735
- Octahedral symmetry, proteins, 268, 268F
- Octanoyl-CoA, 948
- Oculocerebrorenal dystrophy, 735
- ODCase, *see* OMP decarboxylase
- Odd-chain fatty acids, 945F, **952–957**
- O'Donnell, M., 1182, 1196, 1197, 1222
- OEC (oxygen-evolving complex), 916
- OE (outside end) sequences, 1237, 1238F
- OGDH (2-Oxoglutarate dehydrogenase), 799
- O⁺ gene, 1264
- Ogston, A., 814
- 1, 25(OH)2D (1 α , 25-Dihydroxycholecalciferol), 678
- Oils, 387, 393–394, 394F
- Okazaki, R., 1175
- Okazaki fragments, **1174–1176**, 1187, 1219
 in *E. coli* replication, 1193F, 1194, 1198
 eukaryotes, 1207
- Oleate, 44F
- Oleic acid, 386, 387F, 387T, 950F
- (2', 5')-Oligoadenylate synthetase (2,5A synthetase), 1400
- Oligomers, 267, 270–271, 271F
- Oligomycin B, 870
- Oligomycin sensitivity conferring protein, *see* OSCP
- Oligonucleotides, 209–214, 1402–1403
- Oligonucleotide adaptors, 110F
- Oligonucleotide probes, 112–113, 113F
- Oligopeptides, 70
- Oligosaccharides, **359**
 biosynthesis, **880–892**
 N- and O-linked, 374F, 379–380, 379F
 in plasma membranes, 400F
 synthesizing, 382–383
- Oligosaccharyltransferase, *see* OST
- O-Linked glycoproteins, 890–892
- O-Linked oligosaccharides, 374F, **379–381**, 380F, 881
 synthesis of glycoproteins from, 890–892
- ω oxidation, fatty acids, 959
- ω protein, 1163. *See also* Topoisomerase I
- Omeprazole, 765
- 2'-O'-methyltransferase, 1302
- OMP, *see* Orotidine-5'-monophosphate
- Omp85, 449
- OMP decarboxylase (ODCase), 1115F, 1116–1117
- OmpF porin, 403–404, 405F
- Oncogenes, 705–711
- One gene-one enzyme maxim, 26
- One gene-one polypeptide maxim, 26
- One-intermediate model, of reversible enzyme reactions, 491
- Ontogeny, phylogeny and, 12
- Oocytes, mRNA masking and, 1401
- opal codon, 1343
- opal suppressor, 1362
- Oparin, A., 32
- Open complex, 1267–1268
- Open conformation:
 of Klentaq1, 1179–1180, 1179F
 of Rep helicase, 1186
- Open reading frames (ORFs), 182, **304**
- Open β sheets, 251, 254–256
- Open systems, 52, 587, 588F
- Open-X conformation, 1227F
- Operators, 97
- Operator constitutive mutation, 1264
- Operon, 1262
- Opiate receptors, 685
- Opsin, 689, 694
- Optical activity, **73–78**
- Optical density, in Beer–Lambert law, 90
- Optical isomers, 75
- Optical traps, 1273–1274
- Optical tweezers, 1274, 1274F
- Oral rehydration therapy, 768
- ORC (origin recognition complex), 1205–1207
- Orc1, 1205
- Orc2, 1205
- Orc3, 1205
- Orc4, 1205
- Orc5, 1205
- Orc6, 1205
- Order, probability of, 55F
- Order–disorder transition, 397, 397F
- Ordered Bi Bi reactions, 498–500
- Ordered mechanisms, 498
- Order of reaction, 483
- ORFs, *see* Open reading frames
- Organs, 16F, **1090–1095**. *See also specific organs*
- Organelles, 16F, 562T
- Organic arsenicals, 799
- Organic compounds, synthesizing, 32F
- Organic reaction mechanisms, **562–569**
- Organic solvents, 134
- Organisms, 16F, 192. *See also specific organisms*
- Organ perfusion, 575
- oriC locus, 1194–1195, 1194F, 1199F
- Orientation effects, enzyme catalysis by, **512–515**
- Origin-independent replication restart, 1235
- Origin recognition complex, *see* ORC
- Ornithine, 80, 80F, 571F, 1028, 1071
- Ornithine- δ -aminotranferase, 1070F, 1071
- Ornithine decarboxylase, 1408T
- Ornithine transcarbamoylase, **1028**
- Ornithorhynchus anatinus*, 177T
- Orotate, 1115F, 1116
- Orotate phosphoribosyl transferase, 1115F, 1116
- Orotic acid, 1114
- Orotic aciduria, 1118–1119
- Orotidine-5'-monophosphate (OMP), 1115F, 1116–1117
- Orthologous proteins, 194
- Orthophosphate (P_i), 578
- Orthophosphate cleavage, 582
- OSCP (oligomycin sensitivity conferring protein), 855, 870
- Osmotic coefficient, 1156, 1157F
- Osmotic lysis, 130
- OST (oligosaccharyltransferase), 885–886, 885F
- Osteoarthritis, 240
- Osteoblasts, 540, 677–678
- Osteoclastoma, 540
- Osteoclasts, 540, 677–678
- Osteocytes, 12F
- Osteogenesis imperfecta (brittle bone disease), 240

- Osteoglycin, 373T
 Osteomalacia, 677–678
 Osteoporosis, 540, 678–679, **1400**
 Ouabain, 761–762, 761F
 Outer membrane, 6
 Outgroups, 204
 Outside end sequences, *see* OE sequences
 Ovalbumin, 134T, 140F, 1304, 1304F, 1305F
 Ovarian cancer, 1236
 Ovaries, 672F
 Overproducers, 117
 Ovomucoid, 140F
 Oxa1, 448
 Oxalic acid, 49
 Oxaloacetate, 947
 in citric acid cycle, 791, 814
 synthesis of, 872F, 1034, 1067F
 Oxalosuccinate, 789, 809
 Oxidants, 584
 Oxidation, 583
 Oxidation-reduction reactions, 364–365,
 565–566, 584–586
 Oxidative deamination, **1023–1025**, 1340F
 Oxidative phosphorylation, 386, 561F,
 845–862
 and ATP synthesis, **852–859**
 control of, **862–863**
 and electron-transport chain, 823, 829,
 831–833
 energy coupling hypothesis for, **845–846**
 and glycolysis, 594F
 and other pathways, 1090
 proton gradient generation, **846–852**
 uncoupling, **859–862**, 860F
 Oxidizing agent, 584
 Oxidizing atmosphere, 32
 Oxidoreductases, 479T
 Oxidoreduction reactions, 583
 2,3-Oxidosqualene, 982, 983f
 Oxidosqualene cyclase, 983F, 984F
 2,3-Oxidosqualene cyclase, 982, 983
 2-Oxoacid dehydrogenase family, 799
 2-Oxoglutarate dehydrogenase
 (OGDH), 799
 Oxonium ion, 520
 5-Oxoprolinase, 1061
 5-Oxoproline, 1062
 Oxyanion hole, 534
 Oxygen:
 adaptation of life to, 34
 partial reduction of, 865
 production of, 914–920, 934–937
 transport of, 56, 323–234, 329
 Oxygenated hemoglobin (oxyHb), 325, 329,
 332, 333F–335F
 Oxygenated myoglobin (oxyMb), 325
 Oxygen binding, by hemoglobin, **325–328**
 and BPG, **329–331**, 329F–331F
 cooperativity, 334–340, 351–354
 free energy and saturation curves, 339F
 Oxygen debt, 880
 Oxygen electrode, 830, 830F
 Oxygen-evolving complex (OEC), 916
 Oxygen tension, 325
 oxyHb, *see* Oxygenated hemoglobin
 OxyLuciferin, 183
 oxyMb (oxygenated myoglobin), 325
 Oxytocin, 205, 673T, 683
Oxytricha nova, 1212, 1212F
- P
 P1 plasmids, 1259
 p44 subunit, 1218
 p51, 1208–1209, 1209F
 p53, 1211, 1414
 p66, 1208–1209, 1209F
 p85, PI3K subunit, 732
 p101, PI3K subunit, 733
 p150, PI3K subunit, 733
 P680, 916–917
 P700, 922–923
 P870, 909
 P960, 912
 PA (protective antigen), anthrax, 715
 PA26, 1418–1419, 1418F
 PA28, 1418
 PA700, 1414
 Pääbo, S., 116
 PAB II (poly(A)-binding protein II), 1303
 PABP (poly(A)-binding protein),
 1303, 1304F
 Pace, N., 1331
 Pacific Biosciences, 184
 Packing density, 247
 PAF (platelet-activating factor), 1008
 PAGE (polyacrylamide gel electrophoresis),
 147–148. *See also* SDS-PAGE
 PAH (phenylalanine hydroxylase), 1043
 Pai, E., 1133
 Pain, prostaglandins and, 993–994
 Pairwise alignment, 196, 201
 PaJaMo experiment, 1236F, 1262–1263
 Palade, G., 9, 1362
 PALA (*N*-(phosphonacetyl)-L-aspartate),
 476–477
 Palindromes, 105, 106
 Palmitate, 44F
 Palmitic acid, 386, 387T, 407
 Palmitoleic acid, 387T
 1-Palmitoleoyl-2,3-dioleoyl-glycerol, 940
 1-Palmitoleoyl-2-linoleoyl-3-stearoyl-
 glycerol, 388
 Palmitoyl-ACP, 965
 Palmitoyl thioesterase (TE), 965
 PAM (presequence translocase-associated
 motor), 447
 PAM-1 matrix, 198
 Pam16, 447
 Pam17, 447
 Pam18, 447
 PAM-250 log odds substitution matrix,
 198–199, 199F, 201, 203
 PAM units (Percentage of Accepted point
 Mutations), 189, 197–199
 Pancreas, 672F
 Pancreatic δ cells, **675**
 Pancreatic acinar cells, 12F, 525
 Pancreatic α cells, **675**, 973
 Pancreatic β cells, 661, **675**, 973, 1102–1103
 Pancreatic cancer, 1236
 Pancreatic DNase, 157
 Pancreatic DNase I, 1160
 Pancreatic islet hormones, **675**
 Pancreatic phospholipase A₂, 942–943,
 942F, 943F
 Pandit, Jayvardhan, 982
 Pangenesis, 19
 Pangenesis, 19
 Pantothenate, 474T, 1138, 1139F
 Pantothenate kinase, 1138, 1139F
 Pantothenic acid, 792
Pan troglodytes, 177T
 PAP (poly(A) polymerase), 1302, 1303F
 Paper chromatography, 132T, 144–145, 144F
 Paper electrophoresis, 146–147, 147F
 PapG-protein, 382
 PAPS (3'-phosphoadenosine-5'-
 phosphosulfate), 1010, 1072
 Parabiosis, 1096–1099
 Paracrine glands, 671
 Parallel β pleated sheets, 224F, 229–230
 Paralogous proteins, 194
 Parathion, 527
 Parathyroid, 672F
 Parathyroid hormone (PTH), 673T, 677
 Pardee, A., 475, 1262
 Parent DNA, 1174F
 Parker, M., 718
 Parkinson's disease, 309, 720, 1059, 1060
 Parnas, J., 595
 Parodi, A., 883
 Paromomycin, 1395T, 1396F, **1397**, 1397F
 Partial molar free energy, 58
 Partial specific volume, 153
 Partition coefficient, 144, 540, 745–746
 PAS (periodic acid-Schiff's reagent),
 411–412
pas (primosome assembly site), 1190
 Passenger RNAs, 1324
 Passive-mediated transport, 745, **750–752**
 Pastan, I., 1286
 Pasteur, L., 469, 593, 619, 864
 Pasteur effect, 619, 864, 1088
 Patel, D., 1300, 1324
 Path dependence, 53
 Pauling, L., 185–186, 221, 226, 229,
 515, 1355
 Pavletich, N., 736, 1412, 1413
 PBG (porphobilinogen), 1048
 PBGS, *see* Porphobilinogen synthase
 P bodies, 1325
 PbRCs (purple photosynthetic bacteria
 RCs), 909
 PC, *see* Plastocyanin
 PCC, *see* Protein-conducting channel
 P-cluster, 1081
 PCNA (proliferating cell nuclear antigen),
 1204, 1204F, 1206
 PCR, *see* Polymerase chain reaction
 PDB, *see* Protein Data Bank
 PDBid, 256–257
 PDC, *see* Pyruvate decarboxylase; Pyruvate
 dehydrogenase multienzyme complex
 PDGFR (platelet-derived growth factor
 receptor), 699
 PDI (protein disulfide isomerase), 280,
 290–292, 290F, 291F
 PDK-1 (phosphoinositide-dependent
 protein kinase-1), 731
 PDZ domain, 708
 PE, *see* Phosphatidylethanolamine
 Pearl, L., 1234
 Peas, 19T, 20–22
 PEG (polyethylene glycol), 1132
 PEG-ADA, 1132
 Pellagra, 474, 1138
 Penetrance, of diseases, 1251
 Penicillin, **377–378**, 377F, 378F, 1395
 Penicillinase, 378
 Penicillinoic acid, 378F
 Pentoses, 82–83, 360F
 Pentose phosphate pathway, **892–898**, 893F,
 1090
 PEP, *see* Phosphoenolpyruvate
 PEP carboxykinase (PEPCK), 818, 1089
 in gluconeogenesis, 872–873, 876, 876F, 879
 PEP carboxylase, 1408T
 PEPCK, *see* PEP carboxykinase
 Pepsin, 134T, 169T, 470, 547, 547F
 Pepsinogen, 675
 Peptidases, 79
 Peptides, 70. *See also* Polypeptides
 mass spectrometry of, 172–175, 172F
 in protein sequencing, 169–171
 release of, 1392–1394

- Peptide-*N*⁴-(*N*-acetyl-β-D-glucosaminyloxy) asparagine 253F, 252F
- Peptide-*N*⁴-(*N*-acetyl-β-D-glucosaminyloxy) asparagine amidase F, 252
- Peptide bonds, **70**, 99F, 222, 1384–1385
- Peptide group, **221–225**
- cis*-Peptide group, 222F
- trans*-Peptide group, 222F
- Peptide mapping, 174–175, 175F
- Peptide recognition particle (prp73), 1409
- Peptide units, 70
- Peptidoglycan, 376
- Peptidoglycan *N*-acetylmuramoylhydrolase, 479
- Peptidoleukotrienes, 1000, 1001
- Peptidomimetics, 550–551
- Peptidyl-L-amino acid hydrolase, 470
- Peptidyl homoserine lactone, 170
- Peptidyl prolyl *cis-trans* isomerases (PPIs), 290, **292**
- Peptidyl site, *see* P site
- Peptidyl transferase, 1382, 1383, 1383F, 1385F
- Peptidyl-tRNA, 98F, 1373, 1391
- Percentage of accepted point mutations, *see* PAM units
- Perchloric acid, 46
- per* gene, 120F
- Perham, R., 796, 800
- Periodic acid-Schiff's reagent (PAS), 411–412
- Periodic table of elements, 31F
- Peripheral proteins, 400
- Peripheral subunit-binding domain (PSBD), 796, 800, 800F
- Periplasmic space, 117, 378
- PERK (PKR-like endoplasmic reticulum kinase), 1400
- Perlecan, 373T
- Permeability coefficient, 745, 747T, 775
- Permeases, 745
- Permethylated analysis, 366
- Permissive conditions, 27
- Pernicious anemia, 474T, 956–957, 1064
- Peroxisomal β oxidation, fatty acids, **958**
- Peroxisomes, 10, 562T, 935, 958F. *See also* Amino acid metabolism; Glyoxylate pathway
- Peroxisome proliferator-activated receptor γ (PPARγ), 1104
- Peroxynitrite, 688
- Pertussis toxin (PT), 697, 1398
- Perutz, M., 331, 341, 1252
- Perutz mechanism, **334–340**
- Petsko, G., 308
- 6PF-2-K (phosphofructokinase-2), 663–664
- Pfam, *see* Protein families
- Pfanner, N., 445
- PFGE, *see* Pulsed-field gel electrophoresis
- PFK, *see* Phosphofructokinase
- PFK-2 (phosphofructokinase-2), **663–664**
- PFK-2/FBPase-2, 663
- Pfu* DNA polymerase, 114
- 2PG, *see* 2-Phosphoglycerate
- 3PG, *see* 3-Phosphoglycerate
- PG (polygalacturonase), 1403
- PGAs, 994
- PGE₂, 997
- PGEs, 994
- PGF_α, 994
- PGF_β, 994
- PGFs, 994
- PGF_{2α}, 997
- PGG₂, 997
- PGH₂, 997
- PGH synthase (PGHS), 997–999, 997F, 999F
- PGI, *see* Phosphoglucose isomerase
- PGI₂, *see* Prostacyclin I₂
- PGK, *see* Phosphoglycerate kinase
- P-glycoprotein, 766–767
- PGM, *see* Phosphoglycerate mutase
- PGs, *see* Prostaglandins
- pH, **47–48**
- and biochemical standard state, 60
- and buffers, 48
- in disc electrophoresis, 148
- immobilized pH gradients, 150
- in ion exchange chromatography, 136
- and isoelectric focusing, 150, 151
- and Michaelis–Menten kinetics, **496–497**
- and protein denaturation, 265
- and protein solubility, 133F, 134
- and protein stabilization, 130–131
- Phages, *see* Bacteriophages
- Pharmacodynamics, 539
- Pharmacogenomics, 545
- Pharmacokinetics, 542
- Pharmacology, 539, **542–545**
- Phase variation, 1243, 1243F
- PHAS-I, 1401
- PHAS-II, 1401
- PH (pleckstrin homology) domain, 435, 708, 729
- Phe, *see* Phenylalanine
- pheA* operon, 1299T
- Phen (phentermine), 543
- Phenolphthalein, 51
- Phenotypes, 21–22, 22F
- Phenoxazine ring system, 1272
- Phentermine (phen), 543
- Phentolamine, 680
- Phenylacetic acid, 945
- Phenylacetic acid, 945
- Phenylalanine:
- aromatic ring flipping and protein core mobility, 308–309
- biosynthesis, 1075–1078
- degradation, 570, 570F, 1043–1047
- as essential amino acid, 1065T
- genetic codes for, 100T, 1341–1342, 1343T
- in globular proteins, 246
- half-life, 1413T
- α helix/β sheet propensity, 302T
- in native unfolded proteins, 283
- Ramachandran diagram, 225
- side chains, 70–71, 264T
- structure and general properties, 68T, 71F
- Phenylalanine hydroxylase (PAH), 1043
- Phenylethanolamine *N*-methyltransferase, 1060F
- 2-Phenylethyl boronic acid, 556
- Phenylisothiocyanate, *see* PITC
- Phenylketonuria (PKU), 569–570, 948, **1045–1047**
- β-Phenylpropionate, 527
- Phenylpyruvate, 570, 1045
- Phenylthiocarbonyl (PTC), 165
- Phenylthiohydantoin (PTH), 165
- Pheophytin *a* (Pheo *a*), 916
- Pheromones, 671–672, 976
- PheRS, 1351
- Philadelphia chromosome, 718
- Phillips, D., 252, 517, 519, 521–524
- Phillips, S., 1290, 1291
- PhK, *see* Phosphorylase kinase
- Phlorizin, 768
- PHLPP protein phosphatase, 732
- pH meter, 47
- PhoE porin, 403–404
- Phosphagens, 583
- Phosphatase, 140F
- 5-Phosphatase II, 735
- Phosphate, 578
- Phosphate carrier, 448, 826
- Phosphate compound thermodynamics, **578–583**
- Phosphatidic acid phosphatase, 971
- Phosphatidic acids, 389, 389T, 398T
- Phosphatidylcholine, 389T, 398T
- Phosphatidylethanolamide: serine transferase, 1004
- Phosphatidylethanolamine (PE), 389T, 398T, 419
- Phosphatidylglycerol, 389T, 398T, 1004, 1006F
- Phosphatidylglycerol phosphate, 1005
- Phosphatidylinositol (PI), 891F
- Phosphatidylinositol (PtdIns), 389T, 398T, 732, 1004–1006, 1006F
- Phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P₂), 435, 665, 725
- Phosphatidylserine, 389T, 398T, 1004, 1005F
- Phosphinothricin, 1068
- 3'-Phosphoadenosine-5'-phosphosulfate, *see* PAPS
- 3'-Phosphoadenosine-5'-phosphosulfate (APS) reductase, 1072
- Phosphoanhydride bond, 578
- Phosphoarginine, 580
- Phosphocholine, 1004
- Phosphocreatine, 570–571, 580, 583, 1092
- (2',5')-Phosphodiesterase, 1400
- Phosphodiesterases, 176, 653, **688–689**
- Phosphodiester groups, 84
- Phosphodiester method, of oligonucleotide synthesis, 209, 211
- Phosphoenolpyruvate (PEP), 581F, 596F, 612, 872
- Phosphoenolpyruvate carboxykinase, *see* PEP carboxykinase
- Phosphoenolpyruvate carboxykinase (PEPCK), 571
- Phosphoenolpyruvate-dependent phosphotransferase (PTS) system, 765, 765F
- Phosphoester bond, 578
- Phosphoethanolamine, 1004
- Phosphofructokinase (PFK), 667
- allosteric control, 479
- binding to erythrocyte membrane, 412
- in gluconeogenesis, 872
- in glycolysis, 596F, **600**, 625–627, 626F, 627F, 630
- and integration of pathways, 1088
- Phosphofructokinase-2 (PFK-2), 663–664
- Phosphoglucokinase, 642
- Phosphoglucomutase, 632, 639, **642**
- 6-Phosphogluconate, 637F, 894, 894F
- 6-Phosphogluconolactonase, 894
- 6-Phosphoglucono-δ-lactone, 894
- Phosphoglucose isomerase (PGI), 596F, **598–600**, 599F
- Phosphoglycerate kinase (PGK), 596F, **608–610**, 609F
- Phosphoglycerate mutase (PGM), 596F, **610–612**, 610F
- 2-Phosphoglycerate (2PG), 594–595, 610
- 3-Phosphoglycerate (3PG), 594–595, 608
- Phosphoglycerides, **389–390**
- Phosphoglycohydroxamate, 603
- 2-Phosphoglycolate, 603, 934–935
- Phosphoguanidines, 580, 581F
- 3-Phosphohydroxypyruvate, 1070F, 1071
- Phosphoimager, 111
- Phosphoinositide 3-kinases (PI3Ks), 732–734
- Phosphoinositide 4-kinases (PIP4Ks), 732
- Phosphoinositide 5-kinases (PIP5Ks), 732

- Phosphoinositide cascade, **725–738**
 inositol polyphosphate phosphatases, 734–736
 phosphoinositide 3-kinases, 732–734
 phospholipases C, 727–730
 protein kinases C, 730–732
 second messengers, 725–727
- Phosphoinositide-dependent protein kinase-1 (PDK-1), 731
- Phosphoinositol, 994
- Phospholipases, 408, 410
- Phospholipase A₂, 942–943, 942F, 943F, 994, 1017
- Phospholipase C, 664, 706, 725, **727–730**, 728F, 994
- Phospholipase C-β (PLC-β), 690, 692
- Phospholipase C-γ, 706
- Phospholipids, 400F, 410F, 419–420
- Phospholipid exchange proteins, 420
- Phospholipid metabolism, 1004
 glycerophospholipids, **1004–1008**
 sphingoglycolipids, **1008–1013**
 sphingophospholipids, **1008–1009**
- Phospholipid translocases, 420
- Phosphomannose isomerase, 633
- Phosphomevalonate kinase, 977
- N-(Phosphonacetyl)-L-aspartate (PALA), 476–477
- Phosphopantetheine transferase, 961
- Phosphopantetheine transferase (PPT), 967
- Phosphopantothenoylcysteine decarboxylase, 1138, 1139F
- Phosphopantothenoylcysteine synthetase, 1138, 1139F
- Phosphopentose epimerase, 929
- Phosphoprotein phosphatase-1 (PP1), 651, 658–660
- Phosphoprotein phosphatase-2A, 963
- Phosphoramidite method, of
 oligonucleotide synthesis, 210F, **211**
- β-5-Phosphoribosylamine (PRA), 1108, 1109F, 1111
- 5-Phosphoribosyl-α-pyrophosphate (PRPP), 1078, 1108, 1109F, 1114
- 5-Phosphoribosylpyrophosphate synthetase, 1108
- Phosphoribulokinase, 927
- Phosphoric acid (H₃PO₄), 49F
- Phosphorothioate oligonucleotides, 1402
- Phosphorus, 31
- Phosphorylase, *see* Glycogen phosphorylase
- Phosphorylase kinase (PhK), 651, 655, 658, 667, 670
- Phosphoryl groups, 578
- Phosphoryl group-transfer potentials, 578–579
- Phosphoryl group-transfer reactions, 565, 565F, 578–579
- O-Phosphoserine, 79F
- Phosphotyrosine-binding (PTB) domain, 707
- Photoautotrophs, 5–6
- Photooxidation, 905
- Photophosphorylation, 582, 912–913, **925–926**
- Photoprotective agents, 976
- Photoreactivating enzymes, 1214–1215
- Photorespiration, **934–937**, 935F
- Photosynthesis, 5–6, 559, **901**. *See also* Calvin cycle
 carbohydrates product of, 359
 chloroplasts as site of, 11–12, **901–902**
 dark reactions, 902, **926–937**
 electron transport in purple bacteria, **909–913**
 evolution, 34
 light absorption, **903–909**
 light reactions, **902–926**
 membrane process, 386
 photophosphorylation, **925–926**
 photorespiration and C₄ cycle, **934–937**
 two-center electron transport, **913–925**
- Photosynthetic bacteria, 6
- Photosynthetic reaction center (PRC), 905
 integral membrane proteins, 403, 404F
 purple bacteria, 909–911, 909F, 911F
- Photosystem I (PS I), **913–925**, 922F, 923F, 925F
- Photosystem II (PS II), **913–925**, 918F, 925F
- Phototrophs, 559
- Phycobiliproteins, 909
- Phycocyanin, 905F, 909
- Phycocyanobilin, 909
- Phycoerythrin, 905F, 909
- R-Phycoerythrin, 140F
- Phycoerythrobilin, 909
- Phylloquinone, 922
- Phylogenesis, 6
- Phylogenetic trees, **6**, 7F, 13F
 and bioinformatics, 203–205, 203F
 and protein sequencing, 189, 190F
- Phylogeny, eukaryotes, 12–14
- Phytanic acid, 958
- Phytanic acid storage syndrome, 959
- Phytanoyl-CoA hydroxylase, 958
- Phytol, 903
- PI, *see* Phosphatidylinositol
- pI, *see* isoelectric point
- P_i (orthophosphate), 578
- PI3Ks (phosphoinositide 3-kinases), 732–734
- PIC (preinitiation complex), 1376–1377
- Pickart, C., 1417
- Picket-fence Fe-porphyrin complexes, 328, 328F
- Picot, D., 920
- Pigs, 121, 130
- π Helix, 224F, 228
- Pili, 4, 4F
- Pilkis, S., 663
- Ping Pong reactions, **498–499**, 499F, 501
- PIP₂, *see* Phosphatidylinositol 4,5-bisphosphate
- PIP4Ks (phosphoinositide 4-kinases), 732
- PIP5Ks (phosphoinositide 5-kinases), 732
- PIR (Protein Information Resource), 195T
- PISA (Protein Interfaces, Surfaces and Assemblies), 256T
- Pisum sativum*, 20
- PITC (phenylisothiocyanate), 165, 167F
- Pitch, of helix, 89, 225
- Pituitary, 672F, 682
- PK, *see* Pyruvate kinase
- pK, 47
 of amino acid ionizable groups, 68T–69T, 70
 and pH, 48
 of polyprotic acids, 49–50
 of weak acids, 46T
- PKA, *see* Protein kinase A
- PKB, *see* Protein kinase B
- PKC, *see* Protein kinase C
- PKR (double-stranded RNA-activated protein kinase), 1400
- PKR-like endoplasmic reticulum kinase (PERK), 1400
- PKU, *see* Phenylketonuria
- Placebo, 542
- Planck's constant, 903
- Planck's law, 903
- Plants, 7F, 12, 13F. *See also* Photosynthesis
 C₃ and C₄, 936
 cell structure of, 11, 11F
 divergence from other kingdoms, 192
 glycogen synthase, 645
 glyoxylate cycle, **880–881**
 mitochondrial deviations from ideal, 1344T
 mutation rate, 192
 transgenic, 122
- Plantae, 12
- Plant cells, 11, 11F
- Plant medicines, 539
- Plaques, 27
- Plasma glucose, 1103F
- Plasmalogens, 390, 574, 1005, 1007–1008, 1007F
- Plasma membranes, 4. *See also* Cell membrane
 composition, 398T
 of eukaryotes, 8, 11F
 of prokaryotes, 4F
 schematic diagram, 400F
 secretory pathway, **420–428**
 sedimentation coefficient, 154F
 vesicle formation, **428–440**
 vesicle fusion, **440–445**
- Plasmids, 106–108, 1228F, 1262, 1262F
- Plasmid-based cloning vectors, 106–108
- Plasmin, 525T
- Plasminogen, 458
- Plasmodesma, 11F
- Plasmodium falciparum*, 177T, 188, 898, 1058
- Plastids, 901
- Plastocyanin (PC), 916, 921–922, 921F
- Plastoquinol (QH₂), 915
- Plastoquinone (Q), 915
- Platelet-activating factor (PAF), 1008
- Platelet-derived growth factor receptor (PDGFR), 699
- PLC-β, *see* Phospholipase C-β
- Pleckstrin, 735
- Pleckstrin homology domain, *see* PH domain
- Pleurodeles waltl*, 1271F
- P-loop, 710
- PLP, *see* Pyridoxal-5'-phosphate
- Pmf (proton-motive force), 846
- PMP (pyridoxamine-5'-phosphate), 1020
- Pneumococci, S and R form, 86, 86F
- PNP, *see* Purine nucleoside phosphorylase
- POH1, 1418
- Point mutations, **192**, 1339–1340
- Point symmetry, 267
- pol, 1246
- Pol α (DNA polymerase α), 1202–1203
- Pol α/primase, 1203, 1206, 1207
- Pol β (DNA polymerase β), 1205
- Pol γ (DNA polymerase γ), 1202, 1205
- Pol δ (DNA polymerase δ), 1202–1207, 1203F
- Pol ε (DNA polymerase ε), 1202, 1205, 1206
- Pol ζ (DNA polymerase ζ), 1205, 1223
- Pol η (DNA polymerase η), 1205, 1223
- Pol ι (DNA polymerase ι), 1205, 1223
- Pol κ (DNA polymerase κ), 1205, 1223
- Pol I, *see* DNA polymerase I; RNAP I
- Pol II, *see* DNA polymerase II; RNAP II
- Pol III, *see* DNA polymerase III; RNAP III
- Pol III core, 1182, 1198, 1222
- Pol III holoenzyme, 1182, 1183F, 1190, 1191
 in *E. coli* replication, 195, 1193F, 1194
 in SOS repair, 1222
- Pol IV, *see* DNA polymerase IV
- Pol V, *see* DNA polymerase V
- Pol V mutasome, 1222
- POLA, *see* Pol α
- Polarimeter, 74, 74F
- Polarity, 132, 1398
- Polar side chains, amino acid, 71
- POLB, *see* Pol β
- polC* gene, 1182T

- polC* mutants, 1182
 POLD1, *see* Pol δ
 POLE, *see* Pol ϵ
 POLG, *see* Pol γ
 POLH, *see* Pol η
 POLI, *see* Pol ι
 Poliomyelitis, 1404
 POLK, *see* Pol κ
 Polubiquitin, 1404
 Poly(A), 1157F, 1302–1303
 Poly(A)-binding protein, *see* PABP
 Poly(A)-binding protein II (PAB II), 1303
 Polyacrylamide gel, 139, 140T, 147, 147F
 Polyacrylamide gel electrophoresis, *see* PAGE
 Polyadenylation, 1401–1402
 Polyadenylic acid [poly(A)] tail, 97
 Poly(A) polymerase, *see* PAP
 Poly(A) (polyadenylic acid) tail, 97
 Poly(AUAG), 1343
 Polybrene, 171
 Polycistronic mRNA, 1264
 Polycythemia, 343
 Polydispersity, 375
 Polyelectrolytes, 136
 Polyethylene glycol (PEG), 1132
 Polygalacturonase (PG), 1403
 Polyglycine, 205, 224F, 228–229, 229F
 Poly(GUAA), 1343
 Polyketide biosynthesis, 968, 969F
 Polylinkers, 107
 Polylysine, 205
 Polymerase chain reaction (PCR), **114–117**, 115F, 212–213
 Polymerase switching, 1204
 Polymorphic enzymes, 545
 Polynucleotides, 84, 209–213. *See also*
 Nucleic acids
 Polymavirus, 94T, 1172
 Polyoxyethylene-*p*-isooctylphenyl ether, 399F
 Polyoxyethylenelauryl ether, 399F
 Polypeptides, 70. *See also specific types, e.g.:*
 Proteins
 backbone conformations, **222–225**
 chemical synthesis of, **205–209**
 one gene-one polypeptide maxim, 26
 in protein sequencing, 169
 titration curves, 72, 73F
 Polypeptide hormones, 673T
 Polypeptide synthesis. *See also* Protein synthesis
 chain elongation, 1372–1373, 1373F, 1379–1388
 chain initiation, 1373–1379
 chain termination, 1391–1395
 chemical, **205–209**
 direction of, 1371–1373, 1372F
 summary of, 1365
 translational accuracy of, 1388–1391
 Polyproline, 224F
 Polyproline II helix, 228–229, 229F
 Polyproteins, HIV-1, 546
 Polyproteins, of HIV-1, 546F
 Polyprotic acids, **48–50**, 49F
 Polyribonucleotides, 1342
 Polyribosomes (polysomes), 154F, 1372, 1373F
 Polysaccharides, 15, 359, **365–366**. *See also specific polysaccharides*
 carbohydrate analysis, **366–367**
 disaccharides, **367**
 glycosaminoglycans, **370–373**
 glycosidic bonds in, **363–365**
 polymeric organization, 17F
 storage, **369–370**
 structural, **367–369**
 Polyserine, 205
 Polysomes, 154F, 1372, 1373F
 Polystyrene gels, 137
 Polytopic proteins, 402–403
 Poly(UAUC), 1343
 Polyubiquitin (PolyUb), 1411
 Polyunsaturated fatty acids, 387
 Polyvinylidene difluoride, *see* PVDF
 POLZ, *see* Pol ζ
 POM/CART cell type, 1099
 Pompe's disease, 666
 Popot, J.-L., 920
 P/O ratio, **831–833**, 833F
 Porcine somatotropin (pST), 119
 Porins, 403–404, 405F, 749–750, 824
 Porphobilinogen (PBG), 1048
 Porphobilinogen deaminase, 1048, 1053
 Porphobilinogen synthase (PBGs), 1048–1051, 1051F
 Porphyrins, 1056
 Porphyrin, 324, 818
 Porters, 745
 Porter, D., 812
 Porter, K., 9
 Position-Specific Iterated BLAST, *see* PSI-BLAST
 Position-specific score matrices, 202
 Positive allosteric effect, 348
 Positive-inside rule, 427
 Positively cooperative binding, 327
 Positive regulator, 1286
 Posttranslational transport, of proteins, 428, 428F
 Posttranscriptional modification, 97–98, 97F, **1301–1331**
 covalent modification, 1405
 mRNA processing, 1302–1327
 protein splicing, 1405–1408
 proteolytic cleavage, 1403–1404
 rRNA processing, 1328–1329
 tRNA processing, 1329–1331
 Posttranslational modification, 101, **1403–1408**
 and renaturation, 280–281
 role in secretory pathway, 422
 Posttranslational state, 1387–1388, 1387F
 POT1 (protection of telomeres 1), 1213
 Potassium channels, **752–755**, 753F, 754F
 Potassium ion, 45T, 1158
 Potassium ion channels, **752–755**, 753F, 754F
 Potatoes, 19T
 Poulos, T., 686
 Poulter, D., 979
 PP1, *see* Phosphoprotein phosphatase-1
 PPAR γ (peroxisome proliferator-activated receptor γ), 1104
 ppGpp, 1301
 PP_i, *see* Pyrophosphate
 P pili, 382
 PPI, *see* Peptidyl prolyl cis-trans isomerase
 PPM family, 722
 pppA(2'p5'A)_n, 1400
 PPP family, 722–725
 pppGpp, 1301
 (p)ppGpp, 1301
 P-protein, 1031
 PPRP, *see* 5-Phosphoribosyl- α -pyrophosphate
 PPT (phosphopantetheine transferase), 967
 PRA, *see* β -5-Phosphoribosylamine
 Prader-Willi syndrome (PWS), 1251
 Pravachol, 990, 991F
 Pravastatin, 990, 991F
 PRC, *see* Photosynthetic reaction center
 Prealbumin, 268, 268F, 269F, 677
 Prebiotic era, 29
 Precipitation, isoelectric, 134
 Precursor-product relationships, 574
 Preinitiation complex (PIC), 1376–1377
 Prelog, V., 76
 Pre-miRNAs, 1325, 1326F
 Pre-mRNAs, 1304–1305, 1312
 Prenylated proteins, 406–407, 407F
 Prenylation site, 406
 Prenyltransferase, 679, 978
 Preparative ultracentrifugation, **155–156**, 155F
 Prephenate, 1075
 Preprimosome, 1190
 Preprocollagen, 1404
 Preproinsulin, 1404
 Preproproteins, 1404
 Preproteins, 422, 1404
 Pre-replicative complex (Pre-RC), 1205–1207, 1206F
 Presequences, 422
 Presequence translocase-associated motor (PAM), 447
 Presqualene pyrophosphate, 979F, 980–981, 981F
 Presynaptic membrane, 440, 440F
 Pretranslocational state, 1387F, 1388
 Pre-tRNA introns, 1307T
 Pre-tRNAs, 1331
 PRF (Protein Research Foundation), 195T
pr gene (fruit fly), 25, 25F
 PriA helicase, 1191
 PriA protein, 1184T, **1185–1186**, 1190, 1190T, 1191
 Pribnow, D., 1266
 Pribnow box, 1266
 PriB protein, 1190, 1190T
 PriC protein, 1190, 1190T
 Priestley, J., 901
 Primaquine, 897–898
 Primary structure, 163, 289–290, 1345–1346.
 See also Nucleic acid sequencing;
 Protein sequencing
 Primary transcripts, 1301
 Primase, 101, 113F, 1176, **1188–1189**, 1190T
 Primers, 101–102, 103F, 116, 1176
 Primer strand, 1209
 Pri-miRNAs, 1325, 1325F
 Primordial atmosphere, 32
 Primosome, 1190–1193, 1190T
 Primosome assembly site (*pas*), 1190
 Prions, 313
 Prion diseases, **312–316**
 Prion hypothesis, 314–315
 PrionProtein (PrP), 313–315
 Prn-p, 313, 314
 Pro, *see* Proline
 Procarboxypeptidase A, 538
 Procarboxypeptidase B, 538
 Processive enzymes, 1177
 Processivity, of transcription, 1271–1272
 Prochiral atoms, 77
 Prochiral differentiation, 471F
 Prochymosin, 117F
 Procollagen, 1403–1404, 1403F–1405F
 ProCysRS, 1359
 Product inhibition studies, 500
 Proelastase, 538
 Proenzymes (zymogens), **537–538**
 Profiles, sequence alignment, 202
 Proflavin, 1340
 Progeria, 1211
 Progesterone, 681
 Progestins, 673T, 681, 991
 Proinsulin, 280–281, 280F
 Prokaryotae, 6

- Prokaryotes, **3–6**, 4F. *See also specific organisms*
 chain elongation, 1379–1388
 chain initiation, 1373–1376
 chain termination, 1391–1392, 1392F
 citric acid cycle, 789, 814–815
 DNA replication, 1173, **1190–1201**
 DNA size, 94T
 eukaryotic protein production in, 118
 evolution, 13F, 34
 fMet, 1373–1374
 genome sequencing, 176
 introns of, 1316
 mismatch repair, 1220
 mRNA posttranscriptional modification, 1302
 nucleotide excision repair, 1217
 ribosomes of, 1369–1371
 transcription control, **1283–1301**
 transformation by DNA, 85–86
 translational initiation, 1375–1376
 transposons of, 1236–1244
- Prokaryotic gene expression:
 mRNA lifetime, 101
 RNAP, 1265
 transcription, 96–97, 101, 1269
 translation, 101
- Proliferating cell nuclear antigen, *see* PCNA
- Proline:
 amino group, 67
 biosynthesis, 1071
 degradation, 1034
 genetic codes for, 100T, 1343T
 α helix/ β sheet propensity, 302T
 low α helix propensity, 304
 in native unfolded proteins, 283
 as nonessential amino acid, 1065T
 in PEST proteins, 1413
 Ramachandran diagram, 225
 side chains, 70, 264T
 specific rotation, 74
 structure and general properties, 68T
- Proline racemase, 516
- Prolyl 3-hydroxylase, 1405
- Prolyl 4-hydroxylase, 1405
- Prolyl hydroxylase, 236
- Promoters, 97, 571, 1266–1267, 1284
- Pronucleus, 121, 121F
- Proofreading, 1201
 DNA chain, 1177
 of synthesized proteins, 1390–1391
 of tRNA, 1355–1358
- 1, 2-Propanediol, 1018
- β Propeller, 433
- Propeptides, 1403–1404
- Prophase, 20F, 21F
- Prophospholipase A₂, 538
- Propionaldehyde, 1018
- Propionic acid, 32T
- Propionyl-CoA carboxylase, 952–953
- Propionyl-CoA carboxylase reaction, 953F
- Proportional counting, 572
- Propranolol, 680
- Proteins, 1403–1404
pro-R, 77, 77F
pro-S, 77, 77F
- Prostacyclins, 993, **995–1000**
- Prostacyclin I₂ (PGI₂), 997, 998
- Prostacyclin receptors, 689
- Prostacyclin synthase, 998
- Prostaglandins (PGs), 971, 993–995, 994F, 995F, **997–1000**
- Prostaglandin endoperoxide synthase, 997
- Prostaglandin H₂ synthase, 406, 997
- Prostaglandin receptors, 689
- Prostanoic acid, 993–994
- Prostate cancer, 1236
- Prosthetic group, 473
- Proteases, 101, 131, 1419–1420
- Protease A, 525T
- Protease B, 525T
- 20S Proteasome, 1411F, 1415, 1415F
- 26S Proteasome, 1411–1412, 1414
- Proteasomes, in ubiquitination, 1411–1412
- Protection of telomeres 1 (POT1), 1213
- Protective antigen (PA), anthrax, 715
- Proteins, 15. *See also related topics, e.g.:*
 Amino acids
 amino acid derivatives in, **78–79**, 80F
 amino acids of, 67–73, 68T–69T
 beta structures, **229–232**
 in biological processes, 67
 and buffers, 48
 chemical evolution of, 189–192, 191F
 and chemical synthesis of polypeptides, **206–209**
 in chromatin, 8
 conformational diseases, **309–316**
 crystal, 122
 cyclic symmetry, 268, 268F
 denatured, 57
 design of, 305–306
 dihedral symmetry, 268, 268F
 essential amino acids in, 1064
 evolution of, **192–196**, 196F, **316–318**
 fibrous, *see* Fibrous proteins
 functional groups of, 43
 fusion, 118
 globular, *see* Globular proteins
 helical structures, **225–229**
 helical symmetry, 269, 269F
 homologous, 189–192
 icosahedral symmetry, 268, 268F
 from inclusion bodies, 117
 and molecular cloning, **117–121**
 motifs, 249–251
 number of, 70
 octahedral (cubic) symmetry, 268, 268F
 one gene–one polypeptide maxim, 26
 organization of, 17F, 163–164, 281–282, 281F
 physical constants of, 153T
 polyproteins, 1404
 posttranslational modification and degradation of, 101
 primary structure, *see* Protein sequencing
 pseudosymmetric, 268
 for purification, 130
 quaternary structure, **266–271**, 267F
 roles of, 163
 secondary structure, **221–233**, 302–304
 solubilities of, **133–135**
 structures of, **230–233**
 subunit interactions, 267
 supersecondary structures, **249–251**
 symmetry, 267–270
 tertiary structure, **245–256**, 304–305
 tetrahedral symmetry, 268, 268F
 titration curves, 72, 72F
 in translation, **98–101**
 ubiquitin attachment to, 1410F
 α_1 -Proteinase inhibitor, 533
- Proteinase K, 1383
- Protein assays, **131–132**
- Protein C, 1317
- Protein-conducting channel (PCC), 424, 426
- Protein crystals, 134F
- Protein Data Bank (PDB), **256–257**, 256T, 259
- Protein degradation, **1408–1411**. *See also* Polyubiquitin; Ubiquitin
- Protein denaturation, 57, 221, 262, **265–266**
- Protein disulfide isomerase, *see* PDI
- Protein dynamics, **306–309**
- Protein families (Pfam), 256T, 258
- Protein folding, 537
 accessory proteins, **290–302**
 determinants, **281–284**
 endoplasmic reticulum, 427–428
 GroEL/ES system, **294–302**
 hierarchical nature of, 289
 landscape theory of, **287–289**, 288F
 pathways, **284–290**
 peptidyl prolyl cis-trans isomerases, **292**
 protein disulfide isomerases, 280, **290–292**, 290F, 291F
 and pulsed H/D exchange, 285–286
 and renaturation, 278–281
- Protein folding funnels, 287–289, 288F
- Protein folding problem, 278
- Protein G, 282
- Protein GB1, 282, 282F
- Protein growth factors, 671
- Protein Information Resource (PIR), 195T
- Protein Interfaces, Surfaces and Assemblies (PISA), 256T
- Protein isolation, **129–133**
- Protein kinases, 670, 973, 975
- Protein kinase A (PKA), 651–654
- Protein kinase B (PKB), 734, 737F
- Protein kinase C (PKC), 660, 698, 713, 727, 730–732
- Protein metabolism, 561F
- Protein phosphatases, **721–725**
- Protein phosphatase-2A, 699, 723F
- Protein purification, **129–156**
 chromatographic separations, **135–146**
 electrophoresis, **146–152**
 general strategy, 132–133
 and protein isolation, **129–133**
 and protein solubilities, **133–135**
 ultracentrifugation, **152–156**
- Protein renaturation, **278–281**
- Protein Research Foundation (PRF), 195T
- Protein sequence databanks, 195T
- Protein sequencing, **164–165**
 C-terminus identification, 165–168
 disulfide bond cleavage, 168–169
 disulfide bond position assignment, 172
 Edman degradation, 165, 167F, 171, 172, 174
 end group analysis, 165–168
 N-terminus identification, 165
 nucleic acid sequencing contrasted, 184–185
 peptide characterization and sequencing by mass spectrometry, **172–174**, 172F
 peptide cleavage reactions, **169–171**
 peptide fragments, ordering, 171
 peptide fragments, separation and purification of, 171
 peptide mapping, 174–175, 175F
 separation, purification, and characterization of polypeptide chains, 169
 sequence alignment, **194–203**
 sequence databases, **194–195**
 sequence determination, 171, 171F
- Protein Ser/Thr phosphatases, 722
- Protein solubilization, **130**
- Protein splicing, **1405–1408**
- Protein stability, **130–131**
 and denaturation, 265–266
 and disulfide bonds, 264–265
 electrostatic forces, 259–261
 hydrogen bonding, **261–262**
 hydrophobic forces, **262–264**
 thermostable proteins, 266

- Protein synthesis, 1260, 1362–1398. *See also related topics, e.g.:* Translation and antibiotics, 1395–1398 chain elongation, 1372–1373, **1379–1388** chain initiation, **1373–1379** chain termination, **1391–1395** direction of, 1371–1373 secretory pathway, **420–428** translational accuracy, 1388–1391 vesicle formation, **428–440** vesicle fusion, **440–445**
- Protein tyrosine kinases (PTKs), 690, **699–703**
- Protein tyrosine phosphatases (PTPs), 721
- Proteoglycans, **373–375**, 373T
- Proteoglycan subunit, 373, 375
- Proteolysis, limited, 170
- Proteome, 152, 185, 258
- Proteomics, 152, **576–578**, 577F
- Proteopedia, 256T, 257
- Protista, 12, 13F
- Protofilaments, keratin, 234F
- Protomers, 267
- Protons, 45–46, 45F, 45T
- Proton-motive force (pmf), 846
- Proton pump mechanism, 846–847, 850, 850F
- Proton-translocating ATP synthase, **852–859**
- Proton-translocating ATP synthase (Complex V), *see* F₁F₀-ATPase
- Proton wire, 800
- Proto-oncogenes, 705
- Protoplasts, 378
- Protoporphyrin IX, 316, 316F, **324** biosynthesis, 1053–1055 and electron-transport chain, 838
- Protoporphyrinogen IX, 1054
- Protoporphyrinogen oxidase, 1053–1055
- Protosterol, 982
- Protozoa, 13F, 185, 192, 1344T. *See also specific organisms*
- Pro-tRNA^{Pro}, 1359
- Proximal histidine, in hemoglobin, 332
- Proximity effects, enzyme catalysis by, **512–515**
- PrP (PrionProtein), 313–315
- PrP 27-30, 315
- Prp73 (peptide recognition particle), 1409
- PrP^C, 314–315
- PRPP, *see* 5-Phosphoribosyl- α -pyrophosphate
- PrP^{Sc}, 314–315
- Prusiner, S., 312
- PS I, *see* Photosystem I
- PS II, *see* Photosystem II
- PsbB, of photosystem, 916
- PsbC, of photosystem, 916
- PSBD, *see* Peripheral subunit-binding domain
- Pseudoglobulin, 133F
- Pseudorotation, 591
- Pseudosymmetric proteins, 268
- Pseudouridine, 1219, 1346, 1347F
- [PSI], 315
- PSI-BLAST (Position-Specific Iterated BLAST), **202–203**, 304
- D-Psicose, 361F
- P site (peptidyl site), 98F, 1373, 1385, 1387
- Psoriasis, 993
- pST (porcine somatotropin), 119
- PstI, 105T
- PT, *see* Pertussis toxin
- PTB (phosphotyrosine-binding) domain, 707
- PTC (phenylthiocarbamyl), 165
- PtdIns, *see* Phosphatidylinositol
- PtdIns-4,5-P₂, *see* Phosphatidylinositol-4,5-bisphosphate
- PTEN, 736
- Pteridine, 1043
- Pterins, 1043–1045
- Pterin-4a-carbinolamine, 1044
- Pterin-4a-carbinolamine dehydratase, 1044
- PTH, *see* Parathyroid hormone; Phenylthiohydantoin
- PTKs, *see* Protein tyrosine kinases
- PTPs (protein tyrosine phosphatases), 721
- PTS, *see* Phosphoenolpyruvate-dependent phosphotransferase system
- pUC18 cloning vector, 107, 107F
- Puckers, sugar-phosphate chain, 1152–1153, 1153F
- Pulmonary emphysema, 533
- Pulse-chase experiment, 1175
- Pulsed-field gel electrophoresis (PFGE), 158–159, 159F
- Pulsed H/D exchange, 284–286, 309
- Pulse labeling, 1175F
- Pumped protons, 843
- PurB, *see* Adenylosuccinate lyase
- PurC, *see* SAICAR synthetase
- PurE, 1111
- PurF, *see* Glutamine PRPP aminotransferase
- PurH, *see* AICAR transformylase
- Purification tables, 161
- Purine, **83**
- Purine nucleoside phosphorylase (PNP), 1130F, 1131
- Purine nucleotide cycle, 1132, 1133F
- Purine repressor (PurR), 1296
- Purine ribonucleotides, 1107–1108. *See also* Adenine; Guanine
- AMP synthesis, **1111–1113**, 1113F
- catabolism, **1130–1134**
- GMP synthesis, **1111–1113**, 1113F
- IMP synthesis, **1108–1111**, 1113F
- orientations of, 1152F
- and purine ring atoms, 1107F
- salvage, **1114**
- synthesis regulation, **1113–1114**
- Purity, 132
- PurJ, *see* IMP cyclohydrolase
- PurK, 1111
- PurL, *see* FGAM synthetase
- PurM, *see* AIR synthetase
- PurN, *see* GAR transformylase
- Puromycin, 424, 1376, 1382, 1382F, 1395, 1395T
- Purple membrane, 402
- Purple photosynthetic bacteria, 6, 7F, 13F, 403
- electron transport in, 909–913, 913F
- light-harvesting complexes, 906–909
- PVDF (polyvinylidene difluoride), 111, 171
- PvuII, 105T
- PWS (Prader–Willi syndrome), 1251
- Pycnodysostosis, 540
- Pyl (pyrrolysine), 1361–1362
- PylRS, 1362
- Pyran, 361
- Pyranoses, 361
- Pyridine nucleotides, 471F
- α -Pyridone, 508
- Pyridoxal-5'-phosphate (PLP), 511, 640, 1020
- Pyridoxal phosphate, 473T
- Pyridoxamine-5'-phosphate (PMP), 1020
- Pyridoxine, 474T, 1020
- Pyrimidine, **83**, 475–479
- Pyrimidine dimers, 1214–1215, 1214F
- Pyrimidine ribonucleotides, **736–738**, **1136**. *See also* Cytosine; Thymine; Uracil
- CTP synthesis, **1118–1119**
- sterically allowed orientations, 1152F
- synthesis regulation, **1118**
- UMP synthesis, **1114–1118**
- UTP synthesis, **1118–1119**
- Pyrobaculum aerophilum*, 1315
- Pyrococcus furiosus*, 114
- Pyrolobus fumarii*, 266
- Pyrolysine, 1361–1362
- Pyrophosphate (PP_i), 102F, 578, 1265
- Pyrophosphate cleavage, 582, 582F
- Pyrophosphate ion, 96, 96F
- 5-Pyrophosphomevalonate, 977
- Pyrophosphomevalonate decarboxylase, **977–978**, 978
- Pyrosequencing, 183, 184F
- Pyrrole-2-carboxylate, 516
- Pyrrole rings, 324
- Δ -1-Pyrroline-2-carboxylate, 516
- Δ ¹-Pyrroline-5-carboxylate, 1070F, 1071
- Pyrroline-5-carboxylate reductase, 1070F, 1071
- Pyrrolysine (Pyl), 1361–1362
- Pyruvamide, 617
- Pyruvate: alanine biosynthesis from, 1067F biosynthesis of, 561F in citric acid cycle, 766F, 790–792, 790F, 794–795, 816 degradation of amino acids to, 1030–1034 in Entner–Doudoroff pathway, 637F fermentation of, 594F, **614–619** in glycolysis, 593, 594F, 595, 596F and integration of pathways, 1090 and oxaloacetate, 872–876, 872F
- Pyruvate carboxylase, 818–819, 872–876, 874F, 875F
- Pyruvate decarboxylase (PDC), 616, 617F
- Pyruvate dehydrogenase (E1), 794–795, 798F, 799–800, 800F
- Pyruvate dehydrogenase kinase, 799, 804–805, 805F
- Pyruvate dehydrogenase multienzyme complex (PDC), **792–800**, 1111 coenzymes and prosthetic groups, 795T reactions of, 794F regulation, 804–805, 805F
- Pyruvate dehydrogenase phosphatase, 799, 805
- Pyruvate:ferredoxin oxidoreductase, 814–815
- Pyruvate kinase (PK), 581–582, 1089 in gluconeogenesis, 872 in glycolysis, 596F, **613–614**, 614F
- Pyruvate-phosphate dikinase, 936
- Pythagoras, 897
- PYY₃₋₃₆, 1099
- Q
- Q (plastoquinone), 915
- Q cycle, 848–849, 848F
- QFR (quinol–fumarate reductase), 840
- QH₂ (plastoquinol), 915
- QSAR, *see* Quantitative structure-activity relationships
- Q-SNAREs (SNAP receptors), 441, 442, 779, 780
- Quantitative structure-activity relationships (QSAR), 540, 540F
- Quantum yield, 912
- Quasi-equivalent subunits, 269
- Quaternary structure, proteins, 164, **266–271**, 267F
- Questran, 990
- Quiescence, 1202
- Quinine, 539, 1058
- Quinolate, 1137F, 1138
- Quinolate phosphoribosyltransferase, 1137F, 1138

- Quinol–fumarate reductase (QFR), 840
 Quinolone antibiotics, 1167, 1169–1170
 Quiocho, F., 1131
- R
 R5P, *see* Ribose-5-phosphate
 Rab5, 734
 Rab-GAP, 441
 Rab-GEF, 441
 Rab proteins, 406, 441–444
 Rac1, 727–728, 728F
 Racemic mixtures, 78
 Racker, E., 852, 860, 892
 Rack mechanism, 515
 RACKs, 730
 Rad50, 1224
 RAD51, 1230, 1236
 Radioactive counting, 149
 Radioactive decay, 572
 Radioimmunoassays, 130, 674
 Raf, 712–713
 Raffinose, 385
 Rafts, 411
 Ramachandran, G. N., 223
 Ramachandran diagram, **223–226**, 224F, 229
 Ramakrishnan, V., 1365, 1389, 1392, 1394
 Ran, 709
 Randle, P., 864
 Randle cycle, 864
 Random Bi Bi reactions, 498–500
 Random coil conformation, 90, 155, **230, 232**
 Random mechanism, 498
 Rao, Z., 838
 RAP1, 1213
 Rap1A, 713
 Rapamycin, 734, 737F
 Rapid equilibrium random Bi Bi reactions, 499, 500
 Rapoport, T., 424, 620
 RasGAP, 711
 Ras proteins, 407, 434, 688, 708–709
 Rats:
 carcinogenesis tests, 1224
 chromosome number, 19T
 genome sequencing, 177T
 liver cytoplasmic ribosomes, 1370T
 liver enzymes, 1408T
 liver membrane composition, 398T
 proteins for purification from, 130
 Rat1 exonuclease, 1304
 Rate constant, 483
 Rate-determining step, 487
 Rate equations, 483
 Ratner, S., 1025
 Rayment, I., 613, 874, 1238
 Rb, 1211
 RB69 pol, 1223
 RBD, *see* RNA-binding domain
 RBP1, 1318
 Rbx1, 1412–1413, 1413F
 RdRP (RNA-dependent RNA polymerase), 1324
 Reaction coordinate diagram, **485–486**, 485F
 Reaction kinetics, *see* Enzyme kinetics;
 Kinetics
 Reaction rates, non-enzymatic reactions, **483–484**
 Reactions, coupled, **60–61**
 Reactive oxygen species (ROS), 325, 840, 865
 Reading frames, 101, 101F, 1342F
 Reads, 181
 Rearrangement reactions, **567**
 RecA, 1221, 1222, 1239
 and recombination in *E. coli*, **1228–1230**, 1229F, 1230F
 and recombination repair, 1234
recA gene, 1221
 RecBCD, 1230–1231, 1230F, 1231F, 1235
recB gene, 1230
recC gene, 1230
recD gene, 1230
 Receptors, 660
 hormone binding, 674–675
 target of drug design, 539
 Receptor-mediated endocytosis, 454
 Receptor tyrosine kinases (RTKs), 293, **699–703**
 Recessive traits, 20–22
 RecG, 1234
 RecJ, 1220
 Recognition helix, 1288
 Recognition sites, Type II restriction enzymes, 105, 105T
 Recombinant DNA, 104, 109F, 110F, 621. *See also* Molecular cloning
 Recombinant proteins, 119
 Recombinases, 1239
 Recombination, 24, **1225–1246**
 chromosomal rearrangement by, 1242F
 homologous, **1225–1236**, 1227F
 site-specific, 1239–1240, **1242–1246**
 transposition, **1236–1246**
 viruses, 27–28, 28F
 Recombination repair, 1222, **1234–1236**, 1234F, 1235F
 Recommended names, enzymes, 479
 Red algae, 13F
 Redox loop mechanism, 847–849, 847F
 Redox reactions, 583. *See also* Oxidation–reduction reactions
 Red tide, 777, 939
 Reducing agent, 584
 Reducing atmosphere, 32
 Reducing sugars, 364
 Reductant, 584
 Reduction, 583. *See also* Oxidation–reduction reactions
 Reduction potentials, 585, 585T
 Reductive pentose phosphate cycle, 927. *See also* Calvin cycle
 Reed, G., 613
 Reed, L., 792, 798
 Rees, D., 910, 1080
re face, 77, 77F
 Refsum's disease, 958
 REG, 1418–1419
 REG α , 1418–1419
 REG β , 1418
 Reichard, P., 1119, 1122
 Reichert, E., 323
 RelA (stringent factor), 1301
relA gene, 1301
 Relatedness odds, 198
 Relatedness odds matrix, 198
 Related-to-ubiquitin-1 (RUB1), 1421
 Relative elution volume, in gel filtration chromatography, 138
 Relaxed circles, 1160
 Relaxed control, 107, 1301
 Release factors, 682, 1375T. *See also* RF-1; RF-2; RF-3
 Release-inhibiting factors, 682
 Remington, J., 766, 806, 807
 Remnant receptor, 454
 Renaturation:
 of DNA, 93, 93F
 of proteins, *see* Protein renaturation
 Renin, 547, 547F
 Reperfusion injury, 325
 Repetitive sequences, 181
 Repetitive sequences, ultracentrifugation of nucleic acids, 159
 Rep helicase, **1183–1186**, 1191–1193
 Replica DNAs, 1174F
 Replica plating, 26, 26F
 Replication, *see* DNA replication
 Replication bubbles, 1173–1174, 1173F
 Replication eyes, 1173–1174, 1173F, 1176F
 Replication factor C, *see* RFC
 Replication forks, 102–103, **1173–1174**
 in *E. coli* replication, 1199
 eukaryotes, 1206
 in recombination repair, 1234–1235, 1234F, 1235F
 Replication fork collapse, 1222
 Replication origin, 106, **1174**, 1205–1206
 Replication protein A (RPA), 1206
 Replicative forms, *see* RF; RFI; RFII
 Replicative transposition, 1237, 1239, 1239F
 Replicative transposons, 1242
 Replicons, 1205, 1226
 Replisome, 1193F, 1194, 1196, 1196F
 Reporter genes, 120–121, 120F, 571
 Rep protein, 1184T
 Repressors, 96
 RER, *see* Rough endoplasmic reticulum
 Research articles, reading of, 35–36
 Resequencing, 184
 Resins, 137–138, 207–208
 Resistin, 1104
 Resolvase, 1239–1241, 1241F
 Resonance energy transfer, 905
 Respiration, 9, 34, 323
 Respiratory chain, 823
 Respiratory distress syndrome, 1005
 Restart primosome, 1235
 Restriction endonucleases, **104–106**, 105F
 digests from, 106F
 for gene manipulation, 109
 use in nucleic acid sequencing, 176
 Restriction enzymes, **104**, 105T
 Restriction-fragment length polymorphisms (RFLPs), 106, 106F, 107F
 Restriction maps, 107F
 Restriction-modification systems, 104
 Restrictive conditions, 27
 Retaining β -glycosidases, 524
 Reticulocytes, 111–112, 1056
 Retinal, 123, 402, 402F, 689, 850–851, 976
 Retinol, 252
 Retinol binding protein, 252, 252F, 310
 Retrograde transport, 428
 Retrotranslocation, 428
 Retrotransposons, 1244–1246
 Retroviruses, 116, 545, 1207, 1245–1246, 1245F
 Reverse genetics, 185
 Reverse gyrase, 1163
 Reverse-phase chromatography (RPC), 132T, 145, 171, 172
 Reverse transcriptase, 95F, 116, 545, **1207–1209**, 1208F
 Reverse transcriptase inhibitors, 546
 Reverse translation, 313
 Reverse turns, **232**, 233F, 246, 304
 Reversible processes, 56–57
 Reversible reactions, **491–492**, 501–502
 Reznikoff, W. S., 1237, 1238
 RF (replicative form), 1190, 1266
 RF-1 (release factor), 1375T, 1391–1394, 1393F
 RF-2 (release factor), 1375T, 1391–1394
 RF-3 (release factor), 1375T, 1392

- RFC (replication factor C), 1204–1205, 1204F
 RF I (replicative form), 1190, 1191, 1191F
 RF II (replicative form), 1190
 RFLPs, *see* Restriction-fragment length polymorphisms
 R form (*RS* system), 76–77
 R Groups, amino acids, 70
 RGS proteins, 692
rhI gene, 1243
 L-Rhamnose, 365
 Rh (Rhesus) blood group system, 414–415
 Rheumatoid arthritis, 1409
Rhizobium, 1080F
 Rho13N, 1276F
 Rhodopsin, 163, 689
 Rho factor, 1275–1276, 1276F
 Rho proteins, 688, 709, 1365
 Ribitol, 364
 Riboflavin, 474T, 565F, 1138
 Ribonuclease A, *see* RNase A
 Ribonuclease B, *see* RNase B
 Ribonuclease T1, 176
 Ribonucleic acid, *see* RNA
 Ribonucleoproteins, 1145
 Ribonucleotides, **82**, 82F
 Ribonucleotide reductase (RNR), 844, 1119–1126
 D-Ribose, 19, 82, 360F, 361
 Ribose phosphate isomerase, 929
 Ribose phosphate pyrophosphokinase, 1108, 1109F, 1111
 Ribose-5-phosphate (R5P):
 in AMP/GMP synthesis, 1112F
 in Calvin cycle, 929
 in IMP synthesis, 1108
 in pentose phosphate cycle, 892–894
 Ribosomal recycling factor, *see* RRF
 Ribosomal RNA, *see* rRNA
 5S Ribosomal RNA, 176
 70S Ribosome, 1363T, 1369F, 1375
 Ribosomes, 1145, 1338. *See also* Protein synthesis
 architecture, 1366–1368
 binding sites, 1368
 of *E. coli*, 367F, 1363F–1366F
 of eukaryotes, 7F, 9, 1369–1371
 of prokaryotes, 4, 4F
 reading direction in, 1342–1343, 1372
 as ribozyme, 1383–1384
 RNA synthesis regulation, 1301
 sedimentation coefficient, 154F
 self-assembly of, 1365
 structure, 1363–1371
 synthesis in secretory pathway, 421F
 translation by, 98–101, 1363–1398
 vesicle formation, 428–440
 vesicle fusion, 440–445
 Riboswitches, 1299–1301, 1300F, 1318–1319, 1320F
 Ribothymidine (T), 1347F
 Ribozymes, 82, 1078
 and Group I introns, 1308–1309
 hammerhead, **1310–1311**, 1311F
 ribosomes as, 1383–1384
 D-Ribulose, 359, 361F
 Ribulose-5-phosphate epimerase, 894, 895F
 Ribulose-5-phosphate isomerase, 894, 895F
 Ribulose-5-phosphate (Ru5P), 892–895, 895F, 927
 Ribulose biphosphate carboxylase activase, 931, 933
 Ribulose-1,5-bisphosphate carboxylase-oxygenase, *see* RuBisCO
 Ribulose biphosphate carboxylase (RuBP carboxylase), **929–931**, 930F
 Ribulose-1,5-bisphosphate (RuBP), 927
 Rice, 122, 122F, 177T
 Rich, A., 236, 1149–1151, 1155, 1323, 1346, 1372
 Richter, J., 1402
 Ricin, 1395T
 Rickets, 677
Rickettsia, 4F
Rickettsia prowazeki, 177T
 Rieske, J., 835
 Rieske iron-sulfur proteins, 835
 Rifampicin, 1176, 1269
 Rifamycin B, 1269, 1395
 Right-handed helix, 224F, 225F, 227F
rIIA complementation group, 28
rIIB cistron, 1340
rIIB complementation group, 28
 Rilling, H., 979
 Ringe, D., 308, 434
 RING finger, 1410
 RISC (RNA-induced silencing complex), 1324
 Risedronate, 679F
 Ritonavir, 550F, 551
 Rittenberg, D., 574, 961, 1048
 RK (HMG-CoA reductase kinase), 989
 RMM (RNA-recognition motif), 1365
 RNA-11, 1151
 16S RNA, 159
 23S RNA, 1329F
 45S RNA, 1328
 RNA (ribonucleic acid), 4, 1145. *See also* related topics, *e.g.*: Translation
 and central dogma of molecular biology, 95, 1260
 chemical structure, **85**
 on DNA chips, 213
 in DNA replication, 101–102
 and early evolution, 33–34
 fractionation, 156–159
 hybridization, 93
 messenger, *see* mRNA [messenger RNA]
 metabolite-sensing, 1299–1301
 modes of growth for, 1270F
 Northern blot for, 113
 PCR amplification, 116
 ribosomal, *see* rRNA [ribosomal RNA]
 synthesis of, 95–98
 transcript editing, 185
 in transcription, 1260–1265
 transfer, *see* tRNA [transfer RNA]
 translation of, 98–101
 zonal ultracentrifugation, 159
 RNAase D, 1328
 RNAase M5, 1328
 RNAase M16, 1328
 RNAase M23, 1328
 RNA-binding domain (RBD), 1303. *See also* RRM (RNA recognition motif)
 RNA-dependent RNA ATPases, 1313F
 RNA-dependent RNA helicases, 1313F
 RNA-dependent RNA polymerase (RdRP), 1324
 RNA-directed DNA polymerase, 95F, 116, 1207–1208. *See also* Reverse transcriptase
 RNA-directed RNA polymerase, 95F
 RNA-DNA hybrid helix, 96, 1151, 1151F, 1207
 RNA editing, 1320, 1322–1323
 RNAi, *see* RNA interference
 RNA-induced silencing complex (RISC), 1324
 RNA interference (RNAi), 1145, **1323–1326**, 1323F
 RNA ligase, 1322
 RNAP (RNA polymerase), 96F, **1265–1283**
 and AraC, 1292–1294
 of bacteriophage M13, 1190
 in catabolite repression, 1286
 chain elongation, 1270–1272, 1270F
 chain initiation, 1267–1269
 chain termination, 1271F, 1273–1275
 eukaryotic, 1276–1283, 1277T
 and intercalating agents, 1272
 and *lac* repressor, 1285
 in replication, 1176
 RNA-directed, 95F
 and stringent response, 1301
 structure, 1268, 1268F–1269F
 template binding, 1266–1267, 1266F
 of *Thermus aquaticus*, 1268, 1269F
 of *Thermus thermophilus*, 1268, 1268F–1269F
 in transcription, 95–96, 1265–1283
 transcription cycle and translocation mechanism of, 1280F
 RNAP A, *see* RNAP I
 RNAP B, *see* RNAP II
 RNAP C, *see* RNAP III
 RNAP core enzyme, 1265, 1267, 1269
 RNAP holoenzyme, **1265–1266**
 chain elongation, 1270–1272, 1270F, 1271F
 chain initiation, 1267–1269
 chain termination, 1271F, 1273–1275
 and *lac* repressor, 1285
 and template binding, 1266–1267, 1266F
 RNAP I (RNA polymerase I) (Pol I), 1276, 1280–1282, 1408T
 RNAP II (RNA polymerase II) (Pol II), **1276–1283**
 and amatoxins, 1280
 error correction by, 1281, 1281F
 and mRNA capping, 1302
 and splicing factors, 1314
 structure of yeast, 1277–1280, 1278F
 RNAP II elongation complex, 1279F
 RNAP III (RNA polymerase III) (Pol III), 1280, 1281, 1283
 RNA polymerase, *see* RNAP
 RNA polymerase I, *see* RNAP I
 RNA polymerase II, *see* RNAP II
 RNA polymerase III, *see* RNAP III
 RNA primers, 101–102, 103F, **1176**
 of bacteriophage M13, 1190
 in *E. coli* replication, 1193F
 eukaryotic, 1207
 Pol I excises, 1181, 1187
 RNA-recognition motif, *see* RRM
 RNase, for nucleic acid fractionation, 157
 RNase III, 1324, 1328
 RNase A (ribonuclease A), 63, 176, 470
 acid-base catalytic mechanism, 508–510, 509F
 denaturation of, 265F, 266
 folding rate, 284, 381
 isoelectric point, 134T
 physical constants, 153T
 renaturation, 278–281, 279F
 state of, 308
 titration curve, 73F
 RNase B (ribonuclease B), **380–381**, 380F
 RNase E, 1328
 RNase F, 1328
 RNase H, 1151, 1207–1209
 RNase H1, 1207
 RNase L, 1400
 RNase P, 1328
 RNA sequencing, 176, 179
 RNA triphosphatase, 1302
 RNA world, 33–34, 1126
 RNR, *see* Ribonucleotide reductase

- Roach, P., 646
 Roberts, R., 1248, 1304
 Robison, R., 595
 Rodbell, M., 690
 Rodnina, M., 1384
 Rofecoxib, 999–1000
 Rolling circle replication, 1191–1193, 1192F
 Rooted trees, 203F, 204
 Rop protein, 282–283, 283F
 ROS, *see* Reactive oxygen species
 Rosbash, M., 1306
 Rose, G., 262, 281, 282, 304
 Rose, I., 1119
 Roseman, S., 765, 766
 Rosetta algorithm, 305, 306
 Rossman, M., 256, 615
 Rossman fold, 256
 Rotamases, 292
 Rotamers, 306
 Rotation angles, 222–225
 Rotation symmetry, protein, 268
 Rotenone, 831
 Rothman, J., 419, 442, 888
 Rough endoplasmic reticulum (RER), 7F, 9
 metabolic functions, 562T
 secretory pathway in, 420–424
 vesicle formation, 428–440
 vesicle fusion, 440–445
 Round-up, 1075
 Roundworms, trans-splicing in, 1320
 Rous, P., 704
 Rous sarcoma virus (RSV), 704
 RPA (replication protein A), 1206
 RPC, *see* Reverse-phase chromatography
 RPE65 gene, 123
 Rpn11, 1418
 Rpr4, 1327
 Rpr6, 1327
 Rpr40, 1327
 Rpr41, 1327
 Rpr42, 1327
 Rpr43, 1327
 Rpr44, 1327
 Rpr45, 1327
 Rpr46, 1327
 Rpt5, 1417
 RRF (ribosomal recycling factor), 1375T,
 1392, 1394, 1394F
 RRM (RNA recognition motif), 1303–1304,
 1304F, 1365
 5.8S rRNA, 1328, **1370**
 5S rRNA, 1301, 1328, 1364, **1370**
 16S rRNA, 1328, 1364–1366, 1370F
 base pairing with rRNA, 1374–1375
 and stringent response, 1301
 18S rRNA, 1328, **1370**
 23S rRNA, 1301, 1328, 1364, 1366
 28S rRNA, 1328, **1370**
 30S rRNA, **1370**
 40S rRNA, 1370T
 50S rRNA, **1370**
 60S rRNA, 1370T
 80S rRNA, 1370T, 1371, 1371F
 rRNA (ribosomal RNA), 1260. *See also*
 Ribosomes
 methylation, 1328
 posttranscriptional modification,
 1328–1329, 1328F
 in protein synthesis, 98
 structure of, 213
 zonal ultracentrifugation, 159
 RS75091, 1001
 R-SNAREs (SNAP receptors), 441, 442,
 779, 780
 RS system, 76–77
 R state (oxyHb quaternary conformation),
 333–334, 336–339, 336F, 337F
 and hemoglobin cooperativity,
 352–353
 and sequential model of allostereism, 351
 and symmetry model of allostereism,
 349–351
 R state, ATCase, 476–479, 477F
 RSV (Rous sarcoma virus), 704
 RTKs, *see* Receptor tyrosine kinases
 Rtt103 protein, 1304
 R-type pneumococci, 86, 86F
 Ru5P, *see* Ribulose-5-phosphate
 RUB1 (related-to-ubiquitin-1), 1421
 Ruben, S., 813, 903
 RuBisCo (ribulose-1,5-bisphosphate
 carboxylase-oxygenase), 299–300,
 934–935, 934F
 RuBP (ribulose-1,5-bisphosphate), 927
 RuBP carboxylase, *see* Ribulose
 bisphosphate carboxylase
 Rubredoxin, 135F
 Running gel, in disc electrophoresis, 148
 Rupley, J., 520
 Rutter, W., 530
 RuvA, 1231–1233, 1232F, 1234
 RuvAB, 1231, 1234, 1235
 RuvABC, 1230–1234
 RuvABC resolvosome, 1234
 RuvB, 1231–1234
 RuvC, 1233, 1234
 Rye, H., 299
 S
 S, *see* Entropy
 S1P, *see* Site-1 protease
 S2P (site-2 protease), 988
 s⁴U (4-thiouridine), 1347F
 S6', 1417
 S7P, *see* Sedoheptulose-7-phosphate
 S20/L26, 1364
 Sabatini, D., 420
 Sac1, 736
 Saccharides, **359**. *See also* Glycoproteins;
 Monosaccharides; Polysaccharides
 Saccharomyces cerevisiae (Baker's yeast):
 Cdc6, 1206–1207
 genome sequencing, 177T, 182
 mitochondrial deviations from ideal, 1344T
 replication origins, 1205
 replication studies, 1202
 RNAP II structure, 1277–1280, 1278F
 RNAP subunits, 1277T
 as source of proteins for purification, 130
 topoisomerase II, 1167–1168, 1168F
 Saccharopine, 1040
 Sacchetini, J., 944, 1407
 Saenger, W., 916, 922
 Saibil, H., 297
 SAICAR, *see* 5-Aminoimidazole-4-(N-
 succinylcarboxamide) ribotide
 SAICAR synthetase (PurC), 1109F, 1111
 Salamanders, 14F
 Sall1, 105T
 Sali, A., 1371
 Salmine, 134T
Salmonella typhimurium, 1224, 1243
 Salts:
 dissolution in water, 42–43
 and protein denaturation, 265–266
 protein solubilities and concentrations of,
 133–134, 133F
 Saltatory conduction, 777
 Salt bridges, 259–260, 262, 339
 Salting in, 132T, 133–134
 Salting out, 132T, 134
 Salvage pathways, **1114**
 SAM (S-adenosylmethionine), 80, 80F,
 1004, 1034
 and Dam/Dcm MTases, 1247, 1247F
 as methylating agent, 1062, 1214F, 1218
 met repressor complexed with, 1290–1291,
 1291F, 1297
 and mRNA capping, 1302
 rRNA methylation, 1328
 Sam35, 449
 Sam37, 449
 Sam50, 449
 SAM complex, 448–449
 Samuelson, B., 994
 Sancar, A., 1217
 Sandhoff's disease, 1013T
 Sanger, F., 164, 165, 176, 1344
 Sanger method, of nucleic acid sequencing,
 176–180, 184
 Santi, D., 1127, 1247
 SAP-A, 1011
 SAP-B, 1011
 SAP-C, 1011
 SAP-D, 1011
 Saposins, 1011
 SAPs (sphingolipid activator proteins), 1011
 Saquinavir, 550F, 551
 Sar1, 430
 Sar1p, 437
 α-Sarcin, 1395T
 Sarcomas, 704
 Sarcoplasmic reticulum (SR), 761, 763
 Sarcosine, 32T
 Sareste, M., 708
 Sarin, 782
 SARs (structure–activity relationships), 540
 SASPs (small acid-soluble spore
 proteins), 1149
 Satellite bands, 159
 Sattler, M., 1314
 Saturated enzymes, 489
 Saturated fatty acids, 387–388, 387T
 Saturation function, 747
 Saturation kinetics, 747
 Sax, M., 616
 Saxitoxin, 777
 Sazanov, L., 835
 SBPase, *see* Sedoheptulose bisphosphatase
 SCA (spinocerebellar ataxia), 1252
 Scaffold-attachment regions, *see* SARs
 Scaffold proteins, 713–714
 Scalar protons, 843
 Scanning microcalorimeter, 59
 SCAP, *see* SREBP cleavage-activating
 protein
 Scatchard, G., 674
 Scatchard plot, 674
 Scavenger Receptor Class B type I
 (SR-BI), 456
 Scavenger receptors, 457
 SCF^{Skp2}, 1412, 1413F
 SCF complexes, 1412
 Schachman, H., 475
 Schaftingen, E., 663
 Schally, A., 683
 Schatz, G., 445
 Schiff base, 510, 568, 569F, 1020–1021
 Schiffer, M., 910
 Schimmel, P., 1351, 1356
 Schimmel, P. R., 1329
 Schindelin, H., 291
 Schirmer, H., 803
 Schirmer, T., 749
Schistosoma mansoni, 1310–1311, 1311F

- Schizosaccharomyces pombe*, 1202, 1206–1207
- Schleiden, M., 3
- Schleif, R., 1292, 1293
- Schlessinger, J., 729
- Schoenheimer, R., 1408
- Schofield, C., 534
- Schulman, L., 1351
- Schultz, S., 1212
- Schulz, G., 403, 628, 803, 983
- Schwann, T., 3
- Schwann cell, 778F
- SCID, *see* Severe combined immunodeficiency disease
- SCID-X1, 123
- SciFinder Scholar, 35
- Scintillation counter, 149
- SCIPs, 735
- Scissile peptide bond, 169
- SCOP, *see* Structural Classification of Proteins
- Scorpion venom, 777
- Scott, W., 1310
- Scrapie, 312–315, 313F
- Screens, for drugs, 539
- Scrunching, 1268
- Scurvy, 236, 364
- SDS (sodium dodecyl sulfate), 150, 169, 171, 399F
- SDS-PAGE (polyacrylamide gel electrophoresis), 150, 151F, 169, 411F. *See also* PAGE (polyacrylamide gel electrophoresis)
- Sec (selenocysteine), 1361
- Sec1, 441
- Sec7, 435
- Sec12p, 437
- Sec13/31, 430, 438–439, 438F
- Sec23/24, 430
- Sec61, 424
- Sec62/Sec63 complex, 428
- SecA, 428
- SecB, 428
- Secondary lysosome, 455F
- Secondary structure, 163, **221–233**
helical, 225–229, 225F
nonrepetitive, 230, 232
peptide group in, 221–225
predicting, for proteins, **302–304**
proteins, **221–233**
tRNA, 1345–1346, 1346F
- Second law of thermodynamics, **54–57**
- Second messengers, 661, **725–727**
- Second-order rate equation, 484
- Second-order reactions, 483, 484F
- Secretory proteins, 421F
- β -Secretase, 312, 547
- γ -Secretase, 312
- Secretin, 673T, 675
- Secretory pathway, **420–428**
- Secretory vesicles, 429F, 1405
- SecY, 424–425, 425F
- SeCys (selenocysteine), 1361
- Sedimentation, **152–153**
- Sedimentation coefficient, 153, 154F
- Sedoheptulose-7-phosphate (S7P), 636, 894
- Sedoheptulose biphosphatase (SBPase), 929, 933F
- Seeburger, P., 383
- Seed sequence, 1325
- Séguin, A., 823
- SELB, 1361
- Selectable markers, 111
- Selenocysteine (Sec) (SeCys), 1361
- SELEX (Systematic Evolution of Ligands by EXponential enrichment), **213–214**
- Self-assembly, 17, 278, 302
- Self-compartmentalized proteases, 1419–1420
- Self organization, 29, 30F
- Self-splicing genes, 1306–1308
- Sem-5, 709
- Semiconservative replication, 90
- Semiconservative replication, of DNA, **1173–1174**
- Semidiscontinuous replication, of DNA, **1175–1176**, 1175F
- Semi-invariant position, 1346
- Sendai virus, 408, 409F
- Senebier, J., 901
- Senescence, 703, 1210
- Sense RNA, 1323
- Sense strand, 203, **1266**, 1267F
- Sephadex gels, 139
- Sephadex gels, 139
- Septic shock, 688
- seqA* gene, 1196
- SeqA protein, 1196
- Sequence databases, 194–195
- Sequence-tagged connectors (STCs), 181
- Sequence-tagged sites (STSs), 181
- Sequencing, *see* Nucleic acid sequencing; Protein sequencing
- Sequencing gel, 177–178, 178F, 179F
- Sequential model, of allosteric interactions, 351–352
- Sequential reactions, 498–501, 500F
- Sequestration, 1195
- SER, *see* Smooth endoplasmic reticulum
- Ser, *see* Serine
- SERCA complex, 762–764, 762F, 763F
- Series-5 leukotrienes, 1003
- Serine:
amino group, 208F
biosynthesis, 1071–1072
degradation, 1030–1034
genetic codes for, 100T, 1343T
in globular proteins, 246–247
in glycerophospholipids, 389T
half-life, 1413T
 α helix/ β sheet propensity, 302T
inserted by *E. coli* nonsense suppressor, 1362T
in native unfolded proteins, 283
as nonessential amino acid, 1065T
in PEST proteins, 1413
side chains, 71, 208F, 264T
structure and general properties, 69T
- Serine carboxypeptidase II, 531, 531F
- Serine dehydratase, 1031, 1408T
- Serine hydroxymethyltransferase, 1031, 1033–1034, 1129
- Serine palmitoyltransferase, 1008
- Serine proteases, 525T
catalytic mechanism, **531–537**, 532F
evolutionary relationships among, 530–531
kinetics and catalytic groups, **525–527**
specificity pockets, 529F
transition state stabilization, 534F
X-ray structures, **527–531**
zymogens, **537–538**
- Serine recombinase, 1239
- Serotonin, **783**, 1046, 1059
- Serotonin receptors, 689
- Serpentine receptors, 689
- SerRS, 1351
- Serum, disc electrophoresis of, 149F
- Serum albumin, 134T, 140F, 944–945, 945F
- Serum albumin C, 133F
- Serum albumin dimer, 140F
- Seryl-adenylate, 1358
- Severe combined immunodeficiency disease (SCID), 122, 123, 1132
- Sex chromosomes, 22–23
- sex-lethal (sxl)* gene (*Drosophila melanogaster*), 1318
- Sex linked genes, 24
- SF1 (splicing factor 1), 1312
- S* form (*RS* system), 76–77
- SH1 domains, 706
- SH2-containing inositol- 5-phosphatases (SHIPs), 735
- SH2 domains, 706–707, 1317
- SH3 domains, 708, 1317
- Sharon, N., 523
- Sharp, K., 259
- Sharp, P., 1304, 1306
- Shc, 707, 709–710
- Shear degradation, DNA, 95
- Sheep, scrapie in, 312–315
- Shelterin, 1213
- Shemin, D., 574, 1048
- Shi, Y., 722
- Shimomura, O., 120
- Shine, J., 1374
- Shine–Dalgarno sequences, 1300, 1301, 1374–1375, 1398
- SHIP2, 735
- Shipley, G., 696
- SHIPs (SH2-containing inositol- 5-phosphatases), 735
- Shirakawa, M., 1250
- Shoelson, S., 721
- Shoolingin-Jordan, P., 1053
- Short, strong hydrogen bonds, 536
- Short tandem repeats (STRs), 115–116
- Short-term regulation, of fatty acid metabolism, 973
- Shotgun cloning, 113
- Shotgun sequencing, 181
- Shotton, D., 529
- SHP-2, 721–722
- Shulman, G., 1103
- Shuman, S., 1188
- Shuttle vectors, 118
- Sialic acid, 1010
- Sialic acids, 365, 392F. *See also* NANA
- Sialidase, 381
- Sickle-cell anemia, 185–188, **343–347**
gene therapy, 123
Southern blot for diagnosis or prenatal detection, 112–113
- Sickle-cell hemoglobin, 81. *See also* Hemoglobin S
- Sickle-cell trait, 187–188
- Side chains, of amino acids, 70–71, 208F, 264T, 511
- SIDS (sudden infant death syndrome), 948
- si* face, 77, 77F
- Sigler, P., 294, 692, 729, 942, 1288
- σ^{32} , 1284
- σ^{54} , 1284
- σ^{gp28} , 1284
- $\sigma^{gp33/34}$, 1284
- σ^{70} , 1265, 1284
- σ factors, 1265, 1266, 1284
- σ -Replication, 1191–1193, 1192F
- Sigmoidal shape, oxygen-binding curve, 326, 326F, 339
- Signal-anchor sequence, 426
- Signal-gated channels, 772
- Signal peptidase, 422, 1404
- Signal peptides, 420, 1404

- Signal recognition particle, *see* SRP
Signal sequence, 117
Signal transducers and activators of transcription (STATS), 718
Signal transduction, 671, 1099. *See also related topics, e.g.*: Hormones
Sildenafil, 699, 743
Silica, 138, 144, 145
Silica gel, 144
Silicon, 31
Silicones, 31
Silk, 233F
Silver stain, 149
Simian sarcoma virus, 705
Simian virus 40, *see* SV40
Simmons, D., 1000
Simon, M., 1243
Simple sugars, 359
Simple transposition, 1237
Simple triacylglycerols, 388
Simvastatin, 990, 991F
Singer, J., 408
Single blind tests, 542
Single-displacement reactions, 498, 501
Single nucleotide polymorphisms (SNPs), 184, 213
Single-pass transmembrane proteins, 426
Single-strand binding protein, *see* SSB
Single-stranded DNA, *see* ssDNA
Single-strand nicks, 1230, 1235F
Single-tailed lipids, 394, 394F
Sinning, I., 424
siRNAs (small interfering RNAs), 1323–1324
Site-1 protease (S1P), 988, 989
Site-2 protease (S2P), 988
Site-directed mutagenesis, 119–120
Site-specific recombination, 1237, 1239–1240, 1242–1246
 β -Sitosterol, 393
60S subunit (ribosome), 1370T, 1371
Size exclusion chromatography, 138
Sjöstrand, F., 9
Skeletal muscle, 1091–1092
Skin, 16F, 235, 238F, 240T
Skp1, 1412–1413, 1412F, 1413F
Skp2, 1412–1413, 1412F
Slab gel electrophoresis, 148F. *See also* Gel electrophoresis
Slack, R., 936
Slater, E., 845
Slicer, 1324
Sliding clamp, Pol III, 1182–1183, 1183F, 1196–1198
Slime molds, 7F, 13F
Slow reacting substances of anaphylaxis (SRS-A), 1000
Slow-twitch muscle fibers, 619
SL (spliced leader) RNA, 1320
Small acid-soluble spore proteins (SASPs), 1149
Small interfering RNAs (siRNAs), **1323–1324**
Small nuclear ribonucleoproteins, *see* snRNPs
Small nuclear RNAs, *see* snRNAs
Small nucleolar RNAs, *see* snoRNAs
Small ubiquitin-related modifier (SUMO), 1421
Sm core domain, 1315–1316
Smith, C., 158
Smith, E., 189
Smith, H., 105, 181
Smith, J., 920
Smith, M., 119
Smith, T., 200, 1023
Smith–Waterman alignment algorithm, 201
Smoking, 458
Smooth endoplasmic reticulum (SER), 7F, 9, 562T
SM proteins, 441
Sm proteins, 1314, 1315F
Sm RNA motif, 1314
S_N2 reaction, 514, 514F
Snake venom, 781, 1017
Snake venom phosphodiesterase, 176
SNAP-25, 441, 441F, 443, 444
SNAP receptors (SNAREs), 441–445, 443F
SNAPs, *see* Soluble NSF attachment proteins
SNAREs, *see* SNAP receptors
Snell, E., 1021
Snorkeling, 406
snoRNAs, 1329
snoRNPs, 1329
SNPs, *see* Single nucleotide polymorphisms
snRNAs, **1311–1312**
snRNPs (small nuclear ribonucleoproteins), **1312**, 1314
Snu114, 1313F
SOD, *see* Superoxide dismutase
Sodium azide, 131
Sodium channels, 772, 776–777
Sodium cholate, 399F
Sodium deoxycholate, 399F
Sodium dodecyl sulfate, *see* SDS
Sodium ion, 45T, 1158
Solid phase peptide synthesis (SPPS), 206, 206F
SOLiD system, 184
Söll, D., 1358
Solubility, protein, **132–135**
Solubilization, protein, **130**
Soluble NSF attachment proteins (SNAPs), 441, 444
Solution methods, for nucleic acid fractionation, **156–157**
Solvated ions, 43
Solvents:
 dielectric constants and dipole moments, 43T
 water and nonpolar, 262–264, 263T
 water as, 42–44
Somatic cells, 19, 20
Somatomedins, 673T, 683
Somatostatin, 673T, 675, 683
Somatotropin, 119, 673T, 683
Sondek, J., 728
Sonenberg, N., 1378
Sonication, 95, 130, 395
D-Sorbose, 361F
Sorensen, S., 47
Soret bands, 838
Sorting sequence, of LDL receptors, 457
Sos, 709–711
SOS box, 1221
SOS repair, 1222–1223
SOS response, 1181, 1221–1223, 1221F, 1234
Southern, E., 111
Southern blotting (Southern transfer technique), **111–113**, 112F, 149, 1207–1208
Sowadski, J., 653
Spacer gel, 148
Spacer groups, 142
Special pair, in photosynthesis, 910–912, 913F
Specific rotation, 74
Spectrin, 412, 413F
Sperm cells, 12F, 1211
Sperm whale myoglobin, *see* Myoglobin
SPGA (*Streptomyces griseus* protease A), 530–531
S phase, **1202**, 1205, 1207
Spheroplasts, 378
Sphinganine, 1009
Sphingoglycolipids, 391, 1004, **1008–1013**, 1009F
Sphingolipids, **390–392**, 395, 1004F
Sphingolipid activator proteins (SAPs), 1011
Sphingolipid storage diseases, 392, 1011, 1013
Sphingomyelins, 390–391, 391F, 398T, 1008, 1008F
Sphingophospholipids, 390–391, 1004, **1008–1009**
Sphingosine, 390, 391F, 392F
Spiegelman, S., 1264–1265
Spina bifida, 1035
Spinocerebellar ataxia (SCA), 1252
Spirilla, 4
Spirillum, 4F
Spirochetes, 4F
Spleen phosphodiesterase, 176
Spliced leader (SL) RNA, 1320
Spliceosomes, 1308, **1312–1313**, 1312F, 1313F
 AU-AC, 1319
 structures, 1314–1316, 1316F
Splicing, *see* Gene splicing
Splicing factor 1 (SF1), 1312
Sponges, 13F
Spontaneity, 52, 57–58, 57T
Spontaneous processes, 52, 57–58, 57T
Spores, **4**, 117, 1149, 1284
Sporulation, 1149
SPPS, *see* Solid phase peptide synthesis
SQS, *see* Squalene synthase
Squalene, 975, 975F, 983F
 cyclization, 982–983
 formation, **978–982**, 979F
Squalene epoxidase, 982
Squalene-hopene cyclase, 406, 983
Squalene synthase (SQS), 978, 982F
SR, *see* Sarcoplasmic reticulum; SRP receptor
SR α , 423
SR β , 423
SR1 mutant, 299–300
SRA domain, 1250
SR-BI (Scavenger Receptor Class B type I), 456
Src, 244F, 706–707, 715
Src family, 715
Src homology domains, *see* SH 1 domains; SH2 domains; SH3 domains
SRE (sterol regulatory element), 987
SREBP, *see* Sterol regulatory element binding protein
SREBP cleavage-activating protein (SCAP), 987–989
SRP (signal recognition particle), 420–424, 421F, 423F, **1404**
SRP9, 422
SRP14, 422
SRP19, 422
SRP54, 422
SRP68, 422
SRP72, 422
SRP receptor (SR), 420–421, 421F, 423
SR proteins, 1314
SRS-A (slow reacting substances of anaphylaxis), 1000
SSB (single-strand binding protein), 1183–1184, 1184F, 1184T, **1187**, 1187F, 1195
(SSB)₃₅, 1187
(SSB)₆₅, 1187
ssDNA (single-stranded DNA), 1180, 1185, 1187

- Stabilization, protein, **130–131**
 Stacked-X conformation, 1227F
 Stacking associations, in tRNAs, 1348–1349
 Stacking gel, 148
 Stadtman, E., 1068
 Stadtman, T., 1361
 Staggered conformation, 222, 223F
 Stahl, F., 90, 1173
 Staining, 149, 158
 Standard free energy changes, **59–60**
 Standard redox potential, 584, 585T
 Standard state, 58–60
 Stanley, C., 1023
 Staphylococcal nuclease, 143F
Staphylococcus, 4F
 Starch, 359, **369–370**, 932F
 Starch-branching enzyme, 931
 Starch synthase, 645, 931
 Stark, H., 1315–1316
 Starvation, 871, 973, 1101
 State, of a system, 53, 56
 State functions, 53, 54
 Statins, 990–991
 Stationary phase, 135
 Statistical factors, 348
 STATS (signal transducers and activators of transcription), 718
 Stavudine, 1208
 STCs (sequence-tagged connectors), 181
 Ste5p, 713–714
 Steady state, 488–490, 588
 Stearic acid, 386, 387F, 387T, 392F
 1-Stearoyl-2-oleoyl-3-phosphatidylcholine, 390F
 Steatorrhea, 943
 Steitz, J., 1311, 1329, 1356
 Steitz, T., 597, 968, 1177, 1178, 1208, 1229, 1240, 1286, 1353, 1366, 1375, 1383
 Stem cells, 121
 Step-wise elution, 136–137, 136F
 Stercobilin, 1056, 1057
 Stereoelectronic assistance, 514–515
 Stereoelectronic control, 514
 Stereoisomers, 75
 Stereo pair, 271
 Stereo pictures, 271, 271F
 Stereospecificity, enzymes, **470–472**
 Stereospecific numbering, 389F
 Steric interference, polypeptides, 222–225, 223F
 Steroid hormone receptors, 291–293
 Steroid hormones, 392, 393, 673T, **680–682**, 976
 biosynthesis, **991–993**, 992F
 Sterol, 392
 Sterol regulatory element (SRE), 987
 Sterol regulatory element binding protein (SREBP), 988, 988F, 989
 Sterol-sensing domain, 987
 Steven, A., 436
 Stevens, R., 404
 Sticky ends, 105, 117–118
 Stigmasterol, 393
 Stigmatellin, 849
 Stöffler, G., 1365
 Stokes equation, 155
 Stokes radius, 155
 Stomata, 904
 Stoops, J., 798
 Stop codons, 99, 100T, 1343
 Stopped-flow device, 284, 284F
 Stop-transfer anchor sequence, 426
 Storage polysaccharides, **369–370**
 Stout, D., 808
 Strain, lysozyme catalytic mechanism and, 522–523
 Strand passage mechanism, 1163–1165, 1164F
 Streptavidin, 298, 857–858, 873
Streptomyces alboniger, 1382
Streptomyces antibioticus, 1272
Streptomyces griseus protease A (SPGA), 530–531
Streptomyces mediterranei, 1269
 Streptomycin, 1263F, 1388, **1395**, 1395T, 1396F, **1397**
 Streptomycin-resistant mutants, **1395**, **1397**
 Stringent control, 107, 1301
 Stringent factor, *see* RelA
 Stringent response, 1301, 1397
 Stroke, 865
 Stroma, 11–12, 902
 Stromal lamellae, 902
 Strong acids, 46–47
 Strong bases, 47–48, 48F
 Stroud, R., 529, 817
 STRs (short tandem repeats), 115–116
 Structural Classification of Proteins (SCOP), 256T, 258
 Structural genes, 117, 203, 1262
 Structural genomics project, 258–259
 Structural polysaccharides, **367–369**
 Structure-activity relationships (SARs), 540
 Structure-based drug design, 541
 STSs (sequence-tagged sites), 181
 Stubbe, J., 1119
 Stueher, D., 686
 Sturtevant, A., 24
 S-type pneumococci, 86, 86F
su1 nonsense suppressor, 1362T
su2 nonsense suppressor, 1362T
su3 nonsense suppressor, 1362T
su4 nonsense suppressor, 1362T
su5 nonsense suppressor, 1362T
su6 nonsense suppressor, 1362T
su7 nonsense suppressor, 1362T
 Sublactam, 378
 Submitochondrial particles, 852
 Substantia nigra, 1060
 Substituents, of prochiral centers, 77
 Substrates, 58, 348, 469, 1128
 Substrate cycles, 624, 628–629
 Substrate-level phosphorylation, 582
 Substrate specificity, **470–473**, 470F
 Subtilisin, 119, 525T, 531, 531F, 534
 Subunits, protein:
 composition, 270–271
 interactions, 266, 267
 and nucleic acid subunits, 164
 Subunit IV, of cytochrome *b*, 920
 Succinate, 493, 791, **811**, 947
 Succinate dehydrogenase, *see* Complex II
 Succinate thiokinase, 810
 Succinic acid, 32T, 49
 Succinylcholine, 782
 Succinyl-CoA, 567, 956
 from amino acids, 1034–1039
 in citric acid cycle, 766F, 789, **810–811**, 811F
 in heme biosynthesis, 1048
 Succinyl-CoA synthetase, 791, **810–811**, 811F
 Succinyl-phosphate, 810
 Suck, D., 1233
 Sucrose, 370
 Sucrose (table sugar), 144, 265, **367**, 367F, 488, 932F
 Sucrose-6-phosphate, 932
 Sucrose-phosphate phosphatase, 932
 Sucrose-phosphate synthase, 932
 Sucrose phosphorylase, 501
 Sudden infant death syndrome (SIDS), 948
 Sugar-phosphate chain conformation, 1152–1154, 1152F, 1153F
 Sugars, 15, **359**. *See also* Monosaccharides;
 Polysaccharides
 synthesis in prebiotic conditions, 33
 Suicide substrates, 1128
 Sulfanilamide, 1064
 Sulfate ion, 45T
 Sulfate-reducing bacteria, 6
 Sulfatides, 391, 1008, 1010, 1010F
 Sulfite reductase, 934, 1072
Sulfolobus solfataricus, 1222, 1222F
 Sulfonamides, 1064, 1111
 Sulfoquinovosyl diacylglycerol, 902
 Sulfuric acid, 46
 Sulston, J., 181
 Sumner, J., 132, 470
 SUMO (small ubiquitin-related modifier), 1421
 Sundaralingam, M., 1153
 Sup35 protein, 315–316
 Superacids, 511
 Supercoiled DNA, **1158–1170**, 1160F, 1270–1271
 measurements of supercoiling, 1160–1162
 superhelix topology, **1158–1160**
 topoisomerases, **1162–1170**
 Superhelix, 433, 1158–1160
 Superhelix density, 1162
 Superoxide dismutase (SOD), 489T, 491, 491F, 866
 Superoxide ion, 325, 341
 Superoxide radical, 491
 Superrepressed mutants, 1336
 Supersecondary structures, **249–251**
 Supertwisting, 1158
 Suppressors, 1340
 Suppressor tRNAs, 1362
 Supramolecular assemblies, 15, 16F
 Surface-active molecules, 51
 Surface hydrophobicity, 145
 Surface labeling, 400
 Surfactants, 51
 Surroundings, 52
 Sutherland, E., 661, 722
 Sutton, W., 22
 SV40 (Simian virus 40):
 enhancers, 1282–1283
 GC boxes, 1282
 large-T antigen, 1211
 replication studies, 1202
 supercoiling, 1162, 1162F
 Svedberg, T., 152
 Svedbergs (unit), 153
 Swiss-Pdb Viewer, 256T, 257
 SWISS-PROT, 195, 203
 Swiss-Prot Protein Knowledgebase, 195T
 Swiss roll barrel, 252, 252F
xlx (*sex-lethal*) gene (*Drosophila melanogaster*), 1318
 SXL protein, 1318
 SYBR Safe, 158
 Symmetry, proteins, 267–270
 Symmetry model, of allosteric interactions, 349–351
 Symport, 758, 758F
 Synapses, 440, 440F, 527, **778**
 Synaptic cleft, 440, 440F, 778
 Synaptic complex, 1237
 Synaptic vesicles, 440, 441F, 779, 780
 Synaptobrevin, 441, 441F, 444
 Synaptotagmin1, 736
 Synaptosomes, 440, 779, 1241F
 Synaptotagmin I, 779

- Synchrotrons, 241
 Syn conformation, 1152F
Synechocystis sp., 177T
 Synge, R., 144
 Synonyms, in genetic code, 99, 1343
 Syntaxin, 433F, 441, 441F, 443, 444
 2,5A synthetase ([2',5']-oligoadenylate synthetase), 1400
 Syphilis, arsenicals for, 799
 SYPRO dyes, 149
 Systematic Evolution of Ligands by EXponential enrichment (SELEX), **213–214**
 Systematic names, enzymes, 479
 Systemic lupus erythematosus, 1204, 1312
 Systems, 52–53
 Systems biology, **576–578**, 576F
 Szent-Györgyi, A., 791
 Szostak, J., 1210
- T**
 T (ribothymidine), 1347F
 T1 G6P translocase, 665F
 T2 transporter, 665F
 T3 transporter, 665F
 T4 Endonuclease VII, 1233–1234, 1233F
 T4 Lysozyme, 282, 304
 T7 gene 4 helicase/primase, 1184, 1184F, 1188
 T7 gp4, 1184, 1184F
 Tabun, 782
 Tacrolimus, 724
 Tagamet, 764
 D-Tagatose, 361F
 Tail spike protein, 289–290
 Tainer, J., 686, 1126, 1219
 D-Talose, 360F
 Tandem mass spectrometry (MS/MS), 173–175, 174F, 175F
 Tangier disease, 458
 Taq DNA polymerase, 114, 179
 TaqI, 105T
 Taq RNAP, 1268, 1269, 1269F
 T arm, 1346
 Tarui's disease, 667
 TATA box, 1282F
 Tatum, E., 26, 570, 1262
 Tau protein, 312
 Taurine conjugates, 993, 993F
 Taxonomy, 6, 12, 189
 Taylor, S., 653, 654
 Tay–Sachs disease, 123, 392, **1011**, **1013**, 1013F
 TBSV (tomato bushy stunt virus), 277
 T ϕ C arm, 1346
 TC10, 738
 TCA (tricarboxylic acid) cycle, 789. *See also* Citric acid cycle
 T cell receptor, 724
 T cells, 123, 292–293, 671
 TCR (transcription-coupled repair), 1217
 TD₅₀, 539
 TDF (testes-determining factor), 682
 TE (palmitoyl thioesterase), 965
 TEBP (telomere end-binding protein), 1212–1213, 1212F
 Teeth, 235
 Teichoic acids, 378, 378F
 Telomerase, **1209–1213**
 Telomere end-binding protein, *see* TEBP
 Telomere repeat-binding factor 1 (TRF1), 1213
 Telomere repeat-binding factor 2 (TRF2), 1213
 Telomeres, 109, **1209–1213**
 Telomeric T-loops, 1213, 1213F
 Telophase, 20F, 21F
 Temin, H., 545, 1207
- Temperature:
 denaturation, 57
 and entropy, 56F
 and lipid bilayer fluidity, **397–399**
 Temperature-jump, 284
 Template binding, RNAP, 1266–1267, 1266F
 Template strand, 96, 102F
 Tendons, 232, 233, 235, 240T
 Tensin, 736
 TER, 1210
TerA, 1199
TerB, 1199
TerC, 1199
TerD, 1199
TerE, 1199
TerF, 1199
TerG, 1199
TerH, 1199
TerI, 1199
TerJ, 1199
 Terminal deoxynucleotidyl transferase, 109, 109F
 Terminal desaturases, 970–971
 Terminal transferase, 109, 109F
 Terminal uridylyltransferase (TUase), 1322
 Termites, 369
 Termolecular reactions, 483
 Terpenoids, 976–977
Ter sites, 1199, 1206
 TERT (telomerase subunit), 1210, 1211, 1211F
 Tertiary structure, 163
 α/β barrels, 252, 254
 domains, 247–249, 251–253, 253F
 globular proteins, 245–256
 α helices and β sheets, 246
 open β sheets, 254–256
 predicting, for proteins, 304–305
 and protein folding, 287
 side chain polarity, 246–247
 supersecondary structures, 249–251
 tRNA, 1348–1349
 Testes, 672F
 Testes-determining factor (TDF), 682
 Testicular feminization, 681
 Testosterone, 681
 Tetanus, 442
 Tethering factors, 441
 Tetracycline, 128, 1395T, 1396F, **1397**
 Tetracycline-resistant bacterial strains, 1397
 Tetrahedral intermediate, 531–533
 Tetrahedral symmetry, proteins, 268, 268F
 5,6,7,8-Tetrahydrobiopterin, *see* BH₄
 Tetrahydrofolate, 473T, 492
 Tetrahydrofolate (THF), **1062–1064**
 Tetrahydrofuran-2-carboxylate, 516
Tetrahymena thermophila:
 Group I introns, 1307–1310, 1307F, 1309F, 1310F
 telomerase, 1209–1210
 Tetraloop, 1308
 2,3,4,6-*O*-Tetramethyl- α -D-glucose, 508
 Tetramethyl-*p*-phenylenediamine (TMPD), 831
 Tetranucleotide hypothesis, 85
 Tetrapeptides, 73F
 Tetraubiquitin, 1411F
 Tetrazole, 211
 Tetradotoxin, 777
 TeTx, 442
 TFIIF, 1218
 TFIIS protein, 1281–1282
 TG, *see* Thapsigargin
 TGN, *see* Trans Golgi network
- Thalassemias, 219, 342
 Thalidomide, 78, 78F
 Thapsigargin (TG), 763, 763F
 ThDP (thiamin diphosphate), 616
 Theoretical plate, in chromatography, 135
 Therapeutic index, 539
 Thermal stability, proteins, 266
Thermatoga maritima, 1394F
 Thermoacidophiles, 6
 Thermocycler, 114
 Thermodynamics, **52–61**. *See also* Equilibrium
 chemical equilibria, 58–61
 defined, 52
 electron-transport chain, **828–829**
 first law, **52–54**
 free energy, **57–58**, 61
 glycogen metabolism, 643–644
 of life, **586–589**
 of membrane transport, **744–745**
 of phosphate compounds, **578–583**
 second law, **54–57**
 transition state, 486
 units and constants, 53T
 Thermogenesis, 629, 860–861, **1099–1001**
 Thermogenin, 861, 1101
 Thermolysin, 169T
Thermoplasma acidophilum, 1415, 1415F
Thermoproteus, 7F
 Thermosomes, 301
 Thermostable proteins, 266
Thermus aquaticus, 179, 466
 DNA polymerase I (Klentaq1), 1178–1180
 EF-Tu, 1381F
 in PCR, 114
 RNAP, 1268, 1269, 1269F
Thermus thermophilus:
 30S subunit, 1389–1390
 Argonaute, 1324, 1325F
 EF-G complex with GDP, 1385–1386, 1386F
 proteinase K, 1383
 ribosomal complex, 1384, 1392–1394, 1393F, 1394F
 ribosomal subunits, 1366–1368, 1371, 1386F
 RNAP, 1268, 1268F–1269F
 RuvB, 1231–1233, 1232F
 θ replication, 1174, 1175F
 θ structures, 1174
 THF, *see* Tetrahydrofolate
 Thiamin diphosphate (ThDP), 616
 Thiamine, 474T, 618
 Thiamine pyrophosphate, *see* TPP
 Thiazolidinediones (TZDs), 1103–1104
 Thiazolinone, 165
 Thiazolium ring, 616
thi box, 1300
 Thin layer chromatography (TLC), 145
 Thiogalactoside transacetylase, 1261
 Thiohemiacetal, 608
 Thiokinases, 945
 Thiolase, 947, 958, 976
 Thiolase reaction, 949–950
 Thioredoxin (Trx), 291, 933–934, 934F, 1124
 Thioredoxin reductase (TrxR), 1125
 4-Thiouridine (s⁴U), 1347F
 30S subunit (ribosome), 363, 1363T, 1368, 1368F, 1369F, **1370**
 path of mRNA through, 1375, 1376F
 Thirumalai, D., 300
 Thr, *see* Threonine
 Thr-AMS, 1358
 Threading (fold recognition), 305

- 3_{10} Helix, 224F, 226, 228
 3' end, of nucleic acids, 84
 3.6_{13} Helix, *see* α helix
 Threonine:
 biosynthesis, 1072–1073, 1075
 degradation, 1030–1034
 as essential amino acid, 1065T
 genetic codes for, 100T, 1343T
 in globular proteins, 246–247
 half-life, 1413T
 α helix/ β sheet propensity, 302T
 PEST proteins rich in, 1413
 side chains, 71, 264T
 stereoisomers, 75–76, 76F, 77F
 structure and general properties, 69T
 D-Threonine, 75, 76, 76F
 L-Threonine, 75, 76, 76F
 (2S,3R)-Threonine, 76, 77F
 Threonine dehydrogenase, 1034
 Threonyl adenylate, 1357
 D-Threose, 360F
 Thrombin, 525T, 735
 Thromboxanes, 993, **995–1000**
 Thromboxane A_2 (Tx A_2), 998
 Thromboxane receptors, 689
 Thromboxane synthase, 998
thr operon, 1299T
 ThrRS, 1358
 Thr-tRNA^{Thr}, 1358
 Thy, *see* Thymine
 Thylakoids, 12, 902, 916F, 926, 926F
 Thymidylate synthase (TS), 1062, 1126–1128
 Thymidylate synthesis, 1126–1130
 Thymine, 18, **83**, 83T, 1177. *See also* Watson–Crick base pairs
 origin, **1126–1130**
 and point mutation generation, 1339–1340
 in pyrimidine catabolism, 1136F
 tautomeric forms, 88F
 Thymine dimer, 1214–1215, 1214F
 Thyroid, 672F
 Thyroid hormones, **676–677**
 Thyroid hormone deiodinases, 1361
 Thyroid hormone receptor, 677
 Thyroid hormone response element (TRE), 879
 Thyroid-stimulating hormone (TSH), 683
 Thyroperoxidase (TPO), 676
 Thyrotropin, 673T, 683
 Thyrotropin-releasing factor (TRF), 673T, 683
 Thyroxine, 80, 80F, 310, 673T, 676–677
 TIM (triose phosphate isomerase) (TPI):
 in Calvin cycle, 929
 of chicken muscle, 231F, 252, 254F
 in glycolysis, 596F, **603–606**, 605F
 Tim9, 448
 Tim10, 448
 Tim12, 448
 Tim14, 447
 Tim16, 447
 Tim17, 447
 Tim18, 448
 Tim21, 447
 Tim22, 448
 Tim23, 446–448
 Tim44, 447
 Tim50, 447
 Tim54, 448
 TIM barrel, 252, 254F, 300
 TIM proteins, 445–449
 TIN2, 1213
 Tiselius, A., 146
 Tissues, 16F
 Tissue culture, 575
 Tissue regeneration, 1163
 Tissue slices, 575
 Tissue-type plasminogen activator (t-PA), recombinant, 119
 Titin, 1305
 Titration curves, **47–48**, 47F, 48F
 of proteins and polypeptides, 72, 72F, 73F
 TLC (thin layer chromatography), 145
 T-loops, telomeric, 1213, 1213F
 TLS (translesion synthesis), 1222
 T_m , *see* Melting temperature
 TMPD (tetramethyl-*p*-phenylenediamine), 831
 TM proteins, *see* Transmembrane proteins
 Tn3, 1237, 1239
 Tn5, 1237–1239
 Tn5 transposase, 1237–1239, 1238F
 TNBS (trinitrobenzenesulfonic acid), 419, 419F
 TNF- α , *see* Tumor necrosis factor- α
 TNFs, *see* Tumor necrosis factors
 TnpA, 1237
tnpA gene, 1237
 TnpR, 1237, 1239
tnpR gene, 1237
 Toads, 1409
 Tob35, 449
 Tob55, 449
 TOB complex, 448, 449
 Todd, A., 84
 Tollen's reagent, 364
 Toluene, 130
 Tom5, 446
 Tom6, 446
 Tom7, 446
 Tom20, 446, 447F
 Tom22, 446
 Tom37, 449
 Tom38, 449
 Tom40, 446
 Tom55, 449
 Tom70, 446
 Tomato bushy stunt virus (TBSV), 277
 TOM complex, 446, 447
 TOM core complex, 446, 447, 447F
 TOM proteins, 445–447
 Tong, L., 604
 Tonks, N., 721
 Top 7 protein, 306, 306F
 Topogenesis, 427
 Topoisomerases, **1162–1170**
 Topoisomerase I, 1165–1166, 1165F
 Topoisomerase II, 1163, 1166–1169, 1169F
 Topoisomerase III, 1163, 1164F
 Topoisomerase IV, 1166
 Topoisomerase V, 1166
 Topoisomerase VI, 1166
 Topoisomerase inhibitors, 1169–1170
 Topologically bound polynucleotide strands, 1159F
 Topological switch point, 255
 Topology:
 of integral proteins, 406
 polypeptide strands, 230
 Toprim fold, 1189
 TORC2, 1096
 Toroidal helix, 1160, 1160F
 Torpedo model, 1304
 Torsion angles, 222–225
 Tosyl-L-phenylalanine chloromethyl ketone, *see* TPCK
Toxoplasma gondii, 1116
 Toxoplasmosis, 1116
 Toyoshima, C., 760, 763
 t-PA, recombinant, 119
 TPCK (tosyl-L-phenylalanine chloromethyl ketone), 527, 527F
 TPI (triose phosphate isomerase), *see* TIM
 TPO (thyroperoxidase), 676
 TPP (thiamine pyrophosphate), 473T, 511, 795, 795T
 in alcoholic fermentation, 616, 616F
 synthesis of, 1300, 1319, 1320F
 TPPI, 1213
 T-protein, 1032
 TR (telomerase subunit), 1211
tra-2 (transformer-2) gene (*Drosophila melanogaster*), 1318
 TRA2 protein, 1318
 TRAM (translocating chain-associated membrane protein), 426
 Trans-acting factors, 1264
 Transaldolase, 894, 896–897, 896F
 Transaminases, 498, 1020–1023
 Transamination, 935, **1020–1023**
 Trans cisternae, 428, 429F
 Transcobalamins, 957
Trans configuration gene mutations, 28
 Transcortin, 681
 Transcription, 9, 19, **95–98**, 1145, **1260–1333**.
 See also Posttranscriptional modification; RNAP
 DNA replication vs., 1173
 monitoring, 120–121
 posttranscriptional modification, 1301–1331
 prokaryotic control of, 1283–1301
 proportion of genome transcribed, 182
 RNA in, 1260–1265
 RNAP in, 1265–1283
 speed and accuracy, 1271–1272
 Transcription bubble, 96, 96F, 1267, 1270–1271
 Transcription-coupled repair (TCR), 1217
 Transcription factors, 96, 572
 Transcription repair coupling factor (TRCF), 1218
 Transcriptome, 213
 Transcriptomics, **576**
 Transducin (G α), 691, 693F
 Transduction, 1225
 Transfection, 87
 Transferase reactions, 497–498
 Transferases, 479T
 Transferrin, 140F, 1056
 Transfer RNA, *see* tRNA
 Transformation, 86, 110–111, 704
 Transformation competent cells, 108
transformer-2 (*tra-2*) gene (*Drosophila melanogaster*), 1318
transformer (*tra*) pre-mRNA (*Drosophila melanogaster*), 1318
 Transforming principle, DNA as, 85–86
 Transgenes, 121
 Transgenic organisms, 86, 86F, **121–122**, 570–572
 Trans Golgi network (TGN), 428, 429F
 Transient phase, 488
 Transimination, 1022
 Transitions, 1339
 Transition state, **485–486**, **515–516**
 Transition state analogs, 516
 Transition state diagram, 485–486, 485F, 487F
 Transition state theory, **484–487**
 Transition temperature, 397
 Transketolase, 894–896, 895F, 929
 Translation, 19, 95, **98–101**, 98F, 1145. *See also* Genetic code; Ribosomes
 accuracy of, 1388–1391
 and antibiotics, 1395

- Translation, (Contd.)
control of eukaryotic, 1398–1402
defined, **1338**
E. coli initiation sequences, 1375F
genetic code, **1338–1345**
initiation in *E. coli*, 1376F
posttranslational modification, **1403–1408**
protein degradation, 1408–1421
ribosomes and polypeptide synthesis, 1362–1398
tRNA aminoacylation, **1345–1362**
Translational coupling, 1398
Translesion synthesis (TLS), 1222
Translocating chain-associated membrane protein (TRAM), 426
Translocation, 1379, **1387–1388**, 1387F
Translocators, 745
Translocon, 420, 426–427, **1404**
Translocon-associated membrane protein (TRAP), 425F, 426
Transmembrane helices, 426–427, 426F
Transmembrane (TM) proteins, 251, **400–404**, **426–427**, 427F
Transmissible spongiform encephalopathy (TSE), 309, 312
Transmission coefficient, 486
Transpeptidation, 1379, **1382–1384**
Transplantation, transgenic organisms for, 121–122
Transporters, 745
Transport proteins, 744, 745. *See also* Membrane transport
Transposable elements, 1236
Transposase, 1236
Transposition, **1236–1246**
Transposons, **1236–1246**
Trans-Schiffization, 1022
Trans-SNARE complex, 442
Trans-splicing, 1319–1320, 1321F
Transthyretin, 268, 268F, 269F, 310
Transverse diffusion, 396
Transversion, 1339
TRAP, *see* Translocon-associated membrane protein
tra (transformer) pre-mRNA (*Drosophila melanogaster*), 1318
TRA protein, 1318
Traps, optical, 1273–1274
Trastuzumab, 119–120
TRCF (transcription repair coupling factor), 1218
β-TrCP, 1414
TRE, *see* Thyroid hormone response element
TRF, *see* Thyrotropin-releasing factor
TRF1 (telomere repeat-binding factor 1), 1213
TRF2 (telomere repeat-binding factor 2), 1213
Triacylglycerol lipase, 941, 1089–1090
Triacylglycerols, **388–389**, 940. *See also* Fatty acids; Lipids
and cholesterol biosynthesis, 986
and dietary EPA, 1003
and liver, 1094
synthesis, **971–973**, 972F
transport in blood, 452F, 973
Triad family, 1066
Tricarboxylate transport system, 968
Tricarboxylic acid (TCA) cycle, *See* Citric acid cycle
TRiC chaperonins, 301–302, 301F
Trichloroacetic acid, 211
Tricorn protease, 1420, 1420F
Triggered conformational changes, 307
Trigger factor, 293
Triglycerides, **388–389**, 940
Triglycerols, 940
Triiodothyronine, 673T, 676
Trimethoprim, 1129
N,N,N-Trimethylalanine, 79F
ε-N,N,N-Trimethyllysine, 79F
Trinitrobenzenesulfonic acid, *see* TNBS
Trinucleotide repeat expansions, 1251–1252
Triolein, 388
Trioleoylglycerol, 388
Trioses, 360F
Triose phosphate isomerase, 231F, *see* TIM
Tripeptides, 70
Triple binding assays, 1342
Triplet codons, 1340–1341
Tris(2,3-dibromopropyl) phosphate, 1225
Triskelions, 430F, 431
Tristearin, 388
Tristearoylglycerol, 388
Triton X-20, 399F
Triton X-100, 399F, 411
tRNA (transfer RNA), 1145, 1260, 1338
aminoacylation, **1345–1362**
bases of, 85
cloverleaf form, 98F
isoaccepting, 1351
modified bases, 1346, 1347F
posttranscriptional modification, **1329–1331**
primary structure, **1345–1346**
role in gene expression, 95F
role in protein synthesis, 98–101
secondary structure, **1345–1346**, 1346F
sedimentation coefficients, 154F
sequencing, 176
structure and function of, 213
tertiary structure, 1348–1349
tRNA^{Ala}, 176, 1345, 1351F, 1352, 1352F
tRNA^{Arg}, 1352
tRNA^{Asp}, 1349, 1351F, 1354–1355, 1354F, 1355F
tRNA^{Cys}, 1352
tRNA^{Gln}, 1351F, 1352–1354, 1353F, 1355F
tRNA^{Ile}, 1352, 1355–1358, 1356F, 1357F
tRNA^{Met}, 1374, 1374F
tRNA^{Met}, 1374
tRNA^{Phe}, 1346, 1346F, 1348, 1352
tRNA^{Pyl}, 1362
tRNA^{Sec}, 1361
tRNA^{Ser}, 1351F
tRNA^{Tyr}, 1331
tRNA^{Val}, 1356
Trophic hormones, 682
Tropocollagen, 240
Tropomodulin, 412F–413F
Tropomyosin, 134T, 412F–413F
α-Tropomyosin, 1317, 1317F
Trout, 1409
Trp, *see* Tryptophan
trpL sequence, 1297–1299, 1297F–1299F
trp operon, 1296–1299, 1297F–1299F, 1299T
trp repressor, 1288, 1290, 1290F
Trx, *see* Thioredoxin
TrxR (thioredoxin reductase), 1125
Trypanosoma brucei, 1418
Trypanosomiasis, arsenicals for, 799
Trypanosomes, 1320
Trypsin, 470, 525, 525T, 529T
catalytic mechanism, 533, 533F
cytochrome *b₅* cleavage, 401
gene duplication, 194
proenzymes, 537, 537F
specificity, 169–170, 169T
X-ray structure, 528F, 529
Trypsinogen, 537, 537F
Tryptophan:
biosynthesis, 1075–1078, 1297
degradation, 1041–1042
as essential amino acid, 1065T
and fluorescence resonance energy transfer, 286
genetic codes for, 100T, 1343T
in globular proteins, 246–247
α helix/β sheet propensity, 302T
inserted by *E. coli* nonsense suppressor, 1362T
in native unfolded proteins, 283
nicotinamide coenzyme from, 1137F, 1138
side chains, 70–71, 264T
structure and general properties, 68T
Tryptophan hydroxylase, 1045, 1059
Tryptophan synthase, 1075–1078
Tryptophanyl-tRNA^{Trp}, 1298, 1299F
TS, *see* Thymidylate synthase
TSE, *see* Transmissible spongiform encephalopathy
T-segment, of DNA, 1169
TSH (thyroid-stimulating hormone), 683
Tsien, R., 121
t-SNAREs (SNAP receptors), 441
T state (deoxyHb quaternary conformation), 333–334, 336–339, 336F, 337F
and hemoglobin cooperativity, 352–353
and sequential model of allostery, 351
and symmetry model of allostery, 349–351
T state, ATCase, 476–479, 477F
Tsukihara, T., 416, 1417
Tswett, M., 135
d-Tubocurarine, 781
Tubulin, 10, 10F, 269
Tubulin α, 301
Tubulin β, 301
Tumor necrosis factor-α (TNF-α), 715, 1096, 1414
Tumor necrosis factors (TNFs), 715, 717
Tumor promoters, 730–731
Tumor suppressors, 736, 1414
Tumor viruses, 704–705, 1163
Tunicamycin, 888, 889F
Tunicates, 368
Turkeys, 19T
Turner's syndrome, 682
Turnover number, 490
tus gene, 1199
Tus protein, 1199, 1199F, 1206
TUTase (terminal uridylyltransferase), 1322
Tweezers, optical, 1274, 1274F
Twilight zone, 196
Twin-bulb apparatus, 54, 55F, 56
Twintrons, 1307T
Twist, of superhelix, 1158–1159, 1159F
Twitchin kinase, 658
2,2₇ Ribbon, 224F, 226, 228
Two-dimensional (2D) gel electrophoresis, **152**, 152F, 175
Two-dimensional NMR spectroscopy, **243–244**, 285–286
Two-dimensional paper chromatography, 144–145, 145F
Two-hybrid system, 705
TxA₂ (thromboxane A₂), 998
Ty1, 1245
TYA, 1246
TYB, 1246
Tyk2, 718
Type 0 glycogen storage disease, 668

- Type IA topoisomerases, **1162–1165**, 1163F, 1164F
- Type IB topoisomerases, 1162, **1165–1166**, 1165F
- Type IC topoisomerases, 1162
- Type 1 diabetes, 310, 1102, 1400
- Type I β bends, 232, 233F
- Type I glycogen storage disease, 661, 666
- Type I restriction endonucleases, 104–105
- Type I TM proteins, 426
- Type I topoisomerases, **1163–1166**
- Type IIA topoisomerases, 1163
- Type IIB topoisomerases, 1163
- Type 2 diabetes, 310, 1102–1103
- Type II β bends, 232, 233F
- Type II glycogen storage disease, 666
- Type II restriction endonucleases, 105, 105T
- Type II TM proteins, 426, 427F
- Type II topoisomerase inhibitors, 1169–1170
- Type II topoisomerases, 1163, **1166–1170**, 1175
- Type III glycogen storage disease, 667
- Type III restriction endonucleases, 104–105
- Type III TM proteins, 426, 427F
- Type IV glycogen storage disease, 667
- Type IV restriction endonucleases, 105
- Type IV TM proteins, 426–427
- Type V glycogen storage disease, 667
- Type VI glycogen storage disease, 667
- Type VII glycogen storage disease, 667
- Type VIII glycogen storage disease, 667
- Type IX glycogen storage disease, 667
- Type A blood, 22, **415**
- Type AB blood, 22, **415**
- Type B blood, 22, **415**
- Type O blood, 22, **415**
- Type α interferon, 1399
- Type β interferon, 1399
- Type γ interferon, 1399
- Tyr, *see* Tyrosine
- Tyrosine:
- aromatic ring flipping and protein core mobility, 308–309
 - biosynthesis, 1075–1078
 - degradation, 1043–1047
 - and *E. coli* nonsense suppressor, 1362T
 - and fluorescence resonance energy transfer, 286
 - genetic codes for, 100T, 1343T
 - in globular proteins, 246–247
 - half-life, 1413T
 - α helix/ β sheet propensity, 302T
 - in native unfolded proteins, 283
 - in neurotransmitter synthesis, 1059–1060
 - as nonessential amino acid, 1065T
 - side chains, 71, 264T
 - structure and general properties, 69T
- Tyrosine aminotransferase, 1408T
- Tyrosine hydroxylase, 1045, 1059
- Tyrosine kinase-based signaling, 699
- binding modules, adaptors, GEFs, and GAPs, **705–711**
 - and cancer, **703–705**
 - MAP-kinase signaling cascades, **712–714**
 - protein phosphatases, **721–725**
 - tyrosine kinase-associated receptors, **699–703**, **715–720**
- Tyrosine recombinase, 1239
- Tyvelose, 379F
- TZDs (thiazolidinediones), 1103–1104
- U
- U1-70K, 1315
- U1-A, 1315, 1316
- U1-C, 1315
- U1-snRNA, 1312, 1315–1316
- U1-snRNP, 1312, 1315–1316, 1316F
- U2-snRNA, 1312
- U2-snRNP, 1312
- U4atac-U6atac, 1319
- U4-snRNA, 1312
- U4-U6-snRNP, 1312
- U5, 1319
- U5-snRNP, 1312
- U6-snRNA, 1312
- U6-snRNP, 1312
- U11, 1319
- U12, 1319
- UAA (codon), 1343, 1362, 1362T
- UAG (codon), 1343, 1362, 1362T
- UbcH7, 1412–1413, 1412F
- UBDs (ubiquitin-binding domains), 1420
- Ubiquinol, 836F
- Ubiquinone, *see* Coenzyme Q
- Ubiquitin, 989, 1404, **1410–1421**, 1410F. *See also* Polyubiquitin
- Ubiquitin-activating enzyme (E1), 1410
- Ubiquitination, 1414–1421
- Ubiquitination signals, 1410
- Ubiquitin-binding domains (UBDs), 1420
- Ubiquitin-conjugating enzyme (E2), 1410–1421
- Ubiquitinlike modifiers (Ubls), 1421
- Ubiquitin-protein ligase (E3), 1410–1421, 1410F
- Ubisemiquinone, 836F
- Ubls (ubiquitinlike modifiers), 1421
- Ubr1, 1413
- UCP, *see* Uncoupling protein
- UCP1, 1100
- UCP2, 862, 1101
- UCP3, 862, 1101
- UDG (uracil–DNA glycosylase), 1218–1219, 1219F
- UDPG, *see* UDP-glucose
- UDP–galactose, 631
- UDP–galactose-4-epimerase, 632
- UDP–glucose (UDPG), 631, 644
- UDP–glucose:glycoprotein glucosyltransferase (GT), 886
- UDP-glucose pyrophosphorylase, **644**
- 3'-U-exo (3'-U-exonuclease), 1322
- UGA (codon), 1343, 1362, 1362T
- UGA-1 nonsense suppressor, 1362T
- UGA-2 nonsense suppressor, 1362T
- Uhlenbeck, O., 1351
- UHRF1 protein, 1250, 1250F
- Ultracentrifugation, 132T, **152–156**, 159
- Ultrafiltration, 117, 132T, 141
- Umami, 1064
- UMP (uridine monophosphate), 83T, **1114–1118**, 1136F
- umuC* gene, 1222
- UmuD, 1222
- UmuD'₂C, 1222
- umuD* gene, 1222
- Uncompetitive inhibition, **495**, 495F, 502
- Uncoupling protein (UCP), 861–862, 1100–1101
- Unexpressed DNA, 1304–1305, 1316–1317
- UNG (uracil *N*-glycosylase), 1218
- ung E. coli* mutants, 1218–1219
- Unidirectional replication, 1174, 1175F
- Uniform resource locator (URL), 194
- Unimolecular reactions, 483
- Uniport, 758, 758F
- Unit cells, 270
- Unit evolutionary period, 190
- Universal donors (blood), 466
- Universal recipients (blood), 466
- Unrooted trees, 203F, 204
- Unsaturated fatty acids, 386–388, 387T, **950–952**, 950F
- Unwin, N., 402, 781
- uORFs (upstream open reading frame), 1400–1401
- Up-and-down β Barrels, 251–252
- UP elements, *see* Upstream promoter elements
- Up mutations, 1266
- Upstream open reading frame (uORFs), 1400–1401
- Upstream promoter elements (UP elements), 1266, 1282
- Ura, *see* Uracil
- Uracil, 19, **83**, 83T. *See also* Watson-Crick base pairs
- and genetic code, 100T, 1343T
 - and mutations, 1218–1219, 1339–1340
 - in pyrimidine catabolism, 1136F
 - in tRNAs, 1347F
- Uracil–DNA glycosylase, *see* UDG
- Uracil *N*-glycosylase (UNG), 1218
- Urate oxidase, 1134
- URE2* gene (yeast), 315
- Ure2p, 315
- Urea, 1025
- in Miller–Urey experiments, 32T
 - in protein sequencing, 169, 171
 - for renaturation of proteins, 117
 - in stopped-flow apparatus, 284
 - from uric acid breakdown, 1135F
- Urea cycle, 791
- arginase, **1025–1029**
 - argininosuccinase, **1028**
 - argininosuccinate synthetase, **1028**
 - carbamoyl phosphate synthetase, **1025–1028**
 - ornithine transcarbamoylase, **1028**
 - regulation of, 1028–1029
- Urease, 132, 140F, 323, 470, 489T
- β -Ureidoisobutyrate, 1136F
- β -Ureidopropionase, 1136F
- β -Ureidopropionate, 1136F
- Ureotelic organism, 1025
- Urey, H., 32–33
- Uric acid, 1025, 1107, **1134–1135**
- Uricotelic organism, 1025
- Uridine, 83T, 1136F
- Uridine diphosphate glucose (UDP-glucose), 644
- Uridine monophosphate, *see* UMP
- Uridine phosphorylase, 1136F
- Uridine triphosphate, *see* UTP
- Uridylic acid, *see* UMP
- Uridyltransferase, 1071
- Urine, 1095
- Urkingdoms, 6
- URL (uniform resource locator), 194
- Urobilin, 1056, 1057
- Urobilinogen, 1056, 1057
- Urochordates, 13F
- Uronic acids, 364
- Uroporphyrinogen decarboxylase, 1053, 1054
- Uroporphyrinogen III, 1053, 1054
- Uroporphyrinogen III synthase, 1052–1054
- Uroporphyrinogen synthase, 1053
- UTP (uridine triphosphate), 96, **1118–1119**, 1265
- UV absorbance spectra, 90, 92, 92F, 285F
- UV absorption, gel electrophoresis and, 149
- UvrABC endonuclease, 1217
- UV radiation, 32, 104, 1214
- uvrA* gene, 1217

- UvrA protein, 1217
uvrB gene, 1217
 UvrB protein, 1217
uvrC gene, 1217
 UvrC protein, 1217
 UvrD protein, 1217, 1220
 Uyeda, K., 663
- V
 V_{\max} (maximal velocity), 489
 Vaccines, 205
 Vacuoles, 7F, 11, 11F
 Vagelos, R., 961
 Val, *see* Valine
 Val-AMS (5'-O'-[N-(L-valyl)sulfamoyl]adenosine), 1356–1357
 Valine:
 and α -amino- β -chlorobutyrate, 1408
 biosynthesis, 1075
 degradation, 1034–1039
 as essential amino acid, 1065T
 genetic codes for, 100T, 1343T
 in globular proteins, 246
 half-life, 1413T
 α helix/ β sheet propensity, 302T
 in native unfolded proteins, 283
 side chains, 70, 264T
 structure and general properties, 68T
 Valinomycin, 79, 748, 749F
 ValRS, 1356–1357
 Valyl-adenylate, 1356–1357
 5'-O'-[N-(L-valyl)sulfamoyl]adenosine (Val-AMS), 1356–1357
 VAMP (Vesicle Associated Membrane Protein), 441
 Vanadate, 758
 van der Waals distance, 41, 224F
 van der Waals forces, 260
 Van Duyne, G., 1244
 Vane, J., 994
 van Helmont, J.-B., 901
 van Leeuwenhoek, A., 4
 van Niel, C., 903
 Van Roey, P., 252
 van't Hoff plot, 59
 Variable arm, 1346
 Variant surface glycoprotein (VSG), 892
 Varmus, H., 705
 Varshavsky, A., 1413
 Vasopressin, 673T, 683, 784
 Vassilyev, D., 1268
 VAST (Vector Alignment Search Tool), 256T, 258
 vCJD (new variant Creutzfeldt-Jakob disease), 315
 V(D)J recombination, 1223
 Vector Alignment Search Tool, *see* VAST
 Vectorial nature, of active transport, 760
 Vectorial protons, 843
 Vectors:
 cloning, 104, **106–109**
 shuttle, 118
 Vegetative cell, 1284
 Velocity, of reactions, 483, 488, 489F
 Vennesland, B., 470, 471
 Venom, *see* Snake venom
 Venter, C., 176, 181, 182
v-erbB oncogene, 705
 Verdine, G., 1216
 Versican, 373T
 Vertebrates, 13F. *See also specific types*
 collagen of, 235
 introns of, 1316
 open reading frames for, 182
 rRNA methylation sites of, 1328–1329
- Very low density lipoproteins, *see* VLDL
 Vesicle Associated Membrane Protein (VAMP), 441
 Vesicle formation, **428–440**
 Vesicle fusion, 430, **440–445**
 Vesicular stomatitis virus (VSV), 885
v-fos proto-oncogene, 705
vg gene (fruit fly), 25F
 Viagra, 699, 743
Vibrio cholerae, 576
 Villafranca, E., 724
 Villafranca, J., 1128
 Vimentin, 10F
 Vinograd, J., 1160
 Vioxx, 543, 999–1000
 Viral strand, bacteriophage M13, 1190
 Virions, 545
 Virus-based cloning vectors, 108
 Viruses, 3. *See also specific viruses*
 budding of, 466
 and cancer, 704–705
 DNA size, 94T
 in gene therapy, 122
 genetics of, 26–28, 27F, 28F
 life cycle, 27F
 RNA and DNA, 85
 and RNAi, 1324–1325
 and RNA polymerases, 96
 sedimentation coefficients, 154F
 vaccines for, 205
 Viscosity, 155
 Vitalism, 587
 Vitamins, 474, 474T, 993
 Vitamin A, 122, 252, 474, 943. *See also* Retinol
 Vitamin B₁, 474T, 618
 Vitamin B₂, 474T, 565F
 Vitamin B₆, 474T, 640, 1020
 Vitamin B₁₂, 474T, 956–957
 Vitamin C (ascorbic acid), 236, **364–365**, 364F
 Vitamin D, 474, 673T, **677–679**, 679F, 943
 Vitamin D₂, 678
 Vitamin D₃, 677–678
 Vitamin D-binding protein, 678
 Vitamin D intoxicification, 678
 Vitamin E, 866, 943
 Vitamin K, 943
 Vitamin K₁, 922
 Vitamin K₂, 910
 Vitravene (Fomivirsen), 1403
v-Jun proto-oncogene, 705
 VLDL (very low density lipoproteins), 449, 456, 944
 and apoB-100, 1322
 and atherosclerosis, 458
 degradation, 452
 formation, 986
 properties, 449T
 transport in blood, 973
 Void volume, in gel filtration chromatography, 138
 Voltage-gated ion channels, **771–775**, 772F, 779
 von Euler, U., 993
 von Gierke's disease, 666, 1135
 von Liebig, J., 470
v-Ras proto-oncogene, 705
 VSG (variant surface glycoprotein), 892
v-sis oncogene, 705
 v-SNAREs (SNAP receptors), 441
v-Src protein, 704–705
 VSV (vesicular stomatitis virus), 885
 VSV G-protein, 885, 887F
 V-type ATPases, 758
- W
 Wagner, G., 1216, 1378
 Wakil, S., 961
 Waksman, G., 1178, 1186
 Waksman, S., 1395
 Walker, J., 853, 857, 865
 Walker A motif, 855
 Walker B motif, 855
 Walsh, C., 562
 Walz, T., 431
 Wang, A., 1149
 Wang, J., 1162
 Warburg, O., 575, 595, 823, 864, 892
 Warfarin, 543F
 Warshel, A., 523
 Water, **40–45**
 activity of, 60
 dielectric constant and dipole moment, 43T
 in glycerophospholipids, 389T
 ionization constant, 47
 and nitrogen excretion, 1134
 and nonpolar solvents, 262–264, 263T
 proton mobility, 44–45
 reactant in Miller–Urey experiments, 32, 33
 solvent properties, **42–44**
 structure and interactions, **40–42**, 40F–42F
 Waterman, M., 200
 Water-oxidizing center (WOC), 916
 Water-soluble vitamins, 474
 Watson, H., 529
 Watson, J., 88, 182, 1146, 1173, 1363
 Watson–Crick base pairs, 89–90, 89F, 104, 1145–1146, **1154–1156**
 and DNA polymerase I, 1178–1180
 electronic complementarity, **1155–1156**
 geometric complementarity, **1154–1155**
 and Pol I, 1178–1180
 Watson–Crick structure:
 of B-DNA, **88–90**
 real DNA vs., 1146–1148
 Waxes, 387
 WD40 service motif, 433
 WD repeat, 987
 Weak acids, 46–48, 48F
 Weber, P., 686
 Web of Science, 35
 Weinberg, R., 1211
 Weis, W., 443, 444
 Weismann, A., 19
 Weiss, S., 1265
 Westbrook, E., 696
 Westerhoff, H., 863
 Western blot, 149
 Westheimer, F., 470, 471
 WGSA, *see* Whole genome shotgun sequencing
 Whelan, W., 645
wh gene (fruit fly), 24, 25, 25F
 Whole genome shotgun sequencing (WGSA), 180F, 181
 Wigley, D., 1231
 Wikipedia, 35
 Wikström, M., 844
 Wild type, 23–24
 Williams, C., 803, 1125
 Williams, J., 606
 Williams, L., 1148
 Williams, R., 728, 733
 Wilson, K., 1112
 Winged helix motif, 1291
 Withers, S., 524
 Wittinghofer, A., 711
 Wittmann, H. -G., 1365
 Wittmann-Liebold, B., 1365

- Wlodawer, A., 549
 Wobble pairing, 1360–1361, 1360F, 1360T
 WOC (water-oxidizing center), 916
 Woese, C., 6, 8
 Wolberger, C., 1293
 Wolcott–Rallison syndrome, 1400
 Wolfenden, R., 515, 1384
 Wolman's disease, 466
 Wolynes, P., 287
 Woodward, R. B., 975
 Wool, 233, 235
 Work, 53–54, 57–58
 World Wide Web, 195T, 256T
 Writhing number, of superhelix, 1159–1160, 1159F
 Wunsch, C., 199
 Wüthrich, K., 243, 314
 WW domain, 708
 Wyman, J., 349
- X**
 Xanthine, 1112, 1130F
 Xanthine dehydrogenase, 1133
 Xanthine oxidase (XO), 1130F, 1132–1133
 Xanthomas, 457
 Xanthosine, 1130F
 Xanthosine monophosphate, *see* XMP
 X chromosome, 22–23
 Xenobiotics, 542
Xenopus borealis, 1283
Xenopus laevis, 1163
 Xenotransplantation, 121–122
 XerC, 1243
 XerD, 1243
 Xeroderma pigmentosum (XP), 1217–1218, 1223, 1224
 X-gal (5-bromo-4-chloro-3-indolyl- β -D-galactoside), 110
 XhoI, 105T
 X-linked phosphorylase kinase deficiency, 667
 XMP (xanthosine monophosphate), 1112, 1130F
 XO, *see* Xanthine oxidase
 XP, *see* Xeroderma pigmentosum
 XPA, 1217
 XPB, 1217, 1218
 XPC, 1217
 XPD, 1217, 1218
 XPE, 1217
- XPF, 1217
 XPG, 1217, 1218
 XPV, 1217
 X-ray crystallography:
 and double helix of DNA, 88, 88F
 of enzyme–substrate complexes, 470
 interpretation of, 241–245
 and NMR, 244
 protein dynamics studies, 306
 Xrcc4, 1223–1224
 Xrn1 exonuclease, 1327
 Xrn2 exonuclease, 1304
 Xu, W., 722
 Xu5P, *see* Xylulose-5-phosphate
 Xylitol, 365
 XylNAc residue (*N*-acetylxylosamine), 523
 Xylose, 597–598
 D-Xylose, 360F, 361
 D-Xylulose, 361
 Xylulose-5-phosphate (Xu5P), 892–894, 929
- Y**
 YACs (yeast artificial chromosomes), 108–109, 113, 114, 180–181
 YADH, *see* Yeast alcohol dehydrogenase
 Yalow, R., 674
 Yang, W., 1222
 Yanofsky, C., 1296, 1298, 1337
 Yarus, M., 1383
 Y chromosome, 23
 Yeast, 13F. *See also* *Saccharomyces cerevisiae* (Baker's yeast)
 20S proteasome, 1416F–1417F
 chromosome number, 19T
 cloning of, in host organism, 104. *See also* YACs [yeast artificial chromosomes]
 DNA size, 94T
 eEF1A-eEF1Bb, 1389F
 exon splicing, 1305–1306
 fermentation, 593–594, 616–619
 GCN2, 1400–1401
 genome sequencing, 176, 177T, 182
 introns in, 1316
 prions in, 315–316
 protein disulfide isomerase, 291–292, 291F
 RAD51, 1230
 Rpn11, 1418
 80S rRNA, 1371F
 rRNA methylation sites, 1328–1329
- shuttle vectors, 118
 snoRNAs, 1329
 transposons, 1244
 tRNA^{Ala}, 1345F, 1346
 tRNA^{Asp}, 1349
 tRNA^{Phe}, 1346, 1346F, 1348
 vesicle fusion, 440
 Yeast alanine tRNA, 176
 Yeast alcohol dehydrogenase (YADH), 618, 619
 geometric specificity, 472–473
 molecular mass, 140F
 stereospecificity, 470–472
 Yeast artificial chromosomes, *see* YACs
 Yellow mosaic virus protein, 153T
Yersinia pestis, 1420–1421
 Y⁺ gene, 1261–1262, 1264
 Ylid, 616
 -yl suffix, 73
 Yokoyama, S., 1355–1357
 Yonath, A., 1365, 1366, 1376
 Yonetani, T., 354
 YopJ, 1420
 Yoshida, M., 857
 Yoshikawa, S., 841
 Young, W., 594
- Z**
 Z α , 1150–1151, 1150F
 Zalcitabine, 1208
 Zamecnik, P., 1345, 1362
 Zamore, Phillip, 1323
 ZAP-70, 1412, 1412F
 Z-DNA, 1146F, 1147F, 1148T, **1149–1151**
 Zero order reactions, 488
 Z⁺ gene, 1261–1262, 1264
 Zidovudine, *see* 3'-Azido-3'-deoxythymidine
 α Zigzag, 433
 Zimm, B., 94
 Zinc, 473, 511–513
 Zinc fingers, 1402
 Zipping, 443F
 Zocor, 990, 991F
 Zonal ultracentrifugation, 155, 156F, 159
 Zone electrophoresis, 146
 Z-scheme, 914, 915F, 917F
 Zwitterions, 67F, 70
 Zygote, 20
 Zymase, 594
 Zymogens, **537–538**